Conditions: ANCA-Associated Vasculitis
Keywords: ANCA-associated vasculitis complement vasculitis C5aR avacopan CCX168 MPA GPA
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 331
Healthy volunteers: no

Brief summary:
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab.

Detailed description:
Complement 5a and its receptor C5aR (CD88) are involved in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

This is a randomized, double-blind, active-controlled Phase 3 study to evaluate the safety and efficacy of the orally-administered, selective C5aR inhibitor CCX168 (avacopan) in inducing and sustaining remission in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treated concomitantly with Rituximab or Cyclophosphamide/Azathioprine.

Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.

Arms:
arm 1: Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone. arm 2: Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.

Interventions: intervention 1: Avacopan intervention 2: Prednisone intervention 3: Cyclophosphamide intervention 4: Rituximab intervention 5: Azathioprine
Intervention descriptions: intervention 1: Avacopan 30 mg twice daily orally for 52 weeks (364 days):

\- Three 10 mg avacopan capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.

Oral prednisone-matching placebo tapering regimen over 20 weeks (140 days):

* Prednisone-matching placebo capsules equivalent to 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to a protocol-specified schedule.
* Adolescents who weighed ≤37 kg started at a prednisone-matching placebo dose of 30 mg per day. intervention 2: Avacopan-matching placebo twice daily orally for 52 weeks (364 days):

\- Three avacopan-matching placebo capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.

Oral prednisone tapering regimen over 20 weeks (140 days):

* Prednisone 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to the protocol-specified schedule.
* Adolescents who weighed ≤37 kg started at a prednisone dose of 30 mg per day. intervention 3: Orally or intravenously administered intervention 4: Intravenously administered intervention 5: Orally administered

Protocol document:
Prot_000.pdf: 
CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 1 of 135 
PROTOCOL 
Protocol Amendment 4.0 
 
TITLE PAGE 
Study Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study 
to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in 
Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-
Associated Vasculitis Treated Concomitantly with Rituximab or 
Cyclophosphamide/Azathioprine 
Protocol Number: CL010_168 
Investigational Product: Complement 5a Receptor Antagonist CCX168 (INN/USAN 
avacopan) 
Indication: ANCA-Associated Vasculitis 
Sponsor: ChemoCentryx, Inc. 
Development Phase: 3 
IND number 120784 
EudraCT number 2016-001121-14 
Sponsor's Responsible 
Medical Officer: 
 
ChemoCentryx, Inc. 
 
Sponsor Signatory: 
Approval Date: 28 November 2016  
21 June 2017—Protocol Amendment 1.0 
15 June 2018 – Protocol Amendment 2.0 
18 Jan 2019 – Protocol Amendment 4.0 
Confidential 
The information contained herein is the property of the Sponsor and may not be reproduced, 
published, or disclosed to others without written authorization of the Sponsor. 
This study will be conducted according to the principles of Good Clinical Practice as described 
in International Council for Harmonisation guidelines, including the archiving of essential 
documents. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 2 of 135 
INVESTIGATOR SIGNATORY PAGE 
Protocol Number: CL010_168 
Protocol Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the 
Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic 
Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or 
Cyclophosphamide/Azathioprine 
I agree: 
• to assume responsibility for the proper conduct of the study at this site. 
• to conduct the study in compliance with this protocol, any future amendments, and with 
any other study conduct procedures provided by ChemoCentryx, Inc. 
• not to implement any deviations from or changes to the protocol without agreement from 
the sponsor and prior review and written approval from the Institutional Review Board 
(IRB)/Ethics Committee (EC), except where necessary to eliminate an immediate hazard 
to the patients, or for administrative aspects of the study (where permitted by all 
applicable regulatory requirements). 
• that I am thoroughly familiar with the appropriate use of the investigational drug(s), as 
described in this protocol, and any other information provided by the sponsor including, 
but not limited to the following: the current version of the Investigator’s Brochure 
prepared by ChemoCentryx, Inc. and approved product label, if applicable. 
• that I am aware of and will comply with current ICH/FDA good clinical practices 
guidelines (GCP) and all regulatory requirements. 
• to ensure that all persons assisting me with the study are adequately informed about the 
investigational drug(s) and their study-related duties and function as described in the 
protocol. 
__________________________________      
 
 ___________________ 
Principal Investigator  
 
 
 
 
 
 
 
Date 
 
__________________________________ 
Printed Name 
Address*_____________________________________________________________ 
____________________________________________________________________ 
Phone Number* ___________________________________________ 
* If the address or phone number needs to be changed during the course of the study, this will be 
done by the Investigator, with written notification to the Sponsor, and will not require (a) 
protocol amendment(s). 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 3 of 135 
SPONSOR CONTACT INFORMATION 
Protocol Number: CL010_168 
Protocol Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the 
Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic 
Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or 
Cyclophosphamide/Azathioprine 
 
Medical Officer 
 
 
Clinical  
 
 
 
Operations  
 
 
Manager  
 
 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 4 of 135 
SPONSOR SIGNATURE FOR APPROVAL 
Protocol Number: CL010_168 
Protocol Title:  A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the 
Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic 
Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or 
Cyclophosphamide/Azathioprine 
  
 
 
 
____________________________________ 
 
______________________ 
 
 
Date 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 5 of 135 
PROTOCOL AMENDMENT 4.0: SUMMARY OF CHANGES 
1. The protocol Title Page was updated with the new amendment number and date. 
2. Study period in Synopsis has been updated to add details for clarity. 
3. Efficacy Assessments no.4 has been updated to deleted “first morning” in First morning 
urinary albumin:creatinine ratio (UACR) in Study Synopsis to correct error in original, 
random void is acceptable and first morning void is not necessary. 
4. To be consistent with section 6.1 Screening and Enrollment, record the Results from 
histology of renal biopsies performed within 4 weeks prior to Day 1 has been corrected to 
prior to Screening in Synopsis, Time and Events Table and Section 3.4. 
5. The definition of ITT population and treatment failures were amended to align with 
definition in the Statistical Analysis Plan in the following sections: Synopsis, 8.1.1.
 
Intent-to-Treat Population, 8.2.2. Secondary Endpoints, 8.6.5. Efficacy Analyses 
6. The Time & Events Table was updated to add Hematology for study weeks 23, 29, 35, 42 
and 48 
7. Section 4.4 Removal of Patients from Therapy of Assessment was updated to 
a. Add language on pausing for Grade 2 neutropenia and also provided further details on 
transaminase elevations that were in the previously issued (June 2018) safety 
notification letter. 
8. The blood samples will be collected for shipment to the central laboratory for hematology 
was added in the following Sections: 6.16 Study Week 23; 6.18 Study Week 29; 6.20 
Study Week 35; 6.22 Study Week 42; 6.24 Study Week 48 
9. Section 7.2.4.6 Laboratory Abnormalities was updated to incorporate recommendations 
of the DMC and rules for pausing administration of blinded study drug. 
10. Based on DMC review of unblinded safety data from all completed and ongoing studies 
of CCX168, Section 12.14.2 Clinical Evaluation was updated. 
11. Benefit/Risk reference to IB added. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 6 of 135 
TABLE OF CONTENTS 
INVESTIGATOR SIGNATORY PAGE .........................................................................................2 
SPONSOR CONTACT INFORMATION .......................................................................................3 
SPONSOR SIGNATURE FOR APPROVAL .................................................................................4 
PROTOCOL AMENDMENT 4.0: SUMMARY OF CHANGES ...................................................5 
TABLE OF CONTENTS .................................................................................................................6 
STUDY SYNOPSIS ......................................................................................................................12 
TIME AND EVENTS TABLE: PLEASE REFER TO BOTTOM OF THIS TABLE FOR 
TABLE FOOTNOTES. ..............................................................................................31 
LIST OF ABBREVIATIONS AND ACRONYMS ......................................................................36 
1. 
INTRODUCTION ......................................................................................................38 
1.1. 
Background Information .............................................................................................38 
1.2. 
Rationale for the Study ...............................................................................................41 
2. 
OBJECTIVES .............................................................................................................41 
2.1. 
Primary Objective .......................................................................................................41 
2.2. 
Secondary Objectives .................................................................................................41 
3. 
STUDY DESIGN .......................................................................................................42 
3.1. 
Stratification ...............................................................................................................42 
3.2. 
Randomization ............................................................................................................43 
3.3. 
Study Treatments ........................................................................................................43 
3.4. 
Study Visits and Procedures .......................................................................................45 
4. 
STUDY POPULATION .............................................................................................46 
4.1. 
Size of the Population .................................................................................................46 
4.2. 
Inclusion Criteria ........................................................................................................46 
4.3. 
Exclusion Criteria .......................................................................................................47 
4.4. 
Removal of Patients from Therapy of Assessment.....................................................49 
5. 
STUDY MEDICATION/TREATMENT ...................................................................51 
5.1. 
Product Characteristics ...............................................................................................51 
5.2. 
Randomization and Method of Treatment Assignment ..............................................52 
5.3. 
Doses and Regimens ...................................................................................................52 
5.4. 
Rationale for Dose Selection ......................................................................................54 
5.5. 
Drug Supply ................................................................................................................55 
5.5.1. 
Packaging and Labeling ..............................................................................................55 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 7 of 135 
5.5.2. 
Storage ........................................................................................................................55 
5.6. 
Blinding ......................................................................................................................55 
5.7. 
Drug Accountability ...................................................................................................56 
5.8. 
Treatment Compliance ................................................................................................56 
5.9. 
Concomitant Medications and Restrictions ................................................................56 
6. 
STUDY PROCEDURES ............................................................................................57 
6.1. 
Screening and Enrollment ...........................................................................................57 
6.2. 
Study Day 1 ................................................................................................................59 
6.3. 
Study Week 1 (Day 8) ................................................................................................61 
6.4. 
Study Week 2 (Day 15) ..............................................................................................62 
6.5. 
Study Week 3 (Day 22) ..............................................................................................64 
6.6. 
Study Week 4 (Day 29) ..............................................................................................65 
6.7. 
Study Week 6 (Day 43) ..............................................................................................66 
6.8. 
Study Week 7 (Day 50) ..............................................................................................66 
6.9. 
Study Week 8 (Day 57) ..............................................................................................68 
6.10. 
Study Week 10 (Day 71) ............................................................................................68 
6.11. 
Study Week 13 (Day 92) ............................................................................................69 
6.12. 
Study Week 14 (Day 99) ............................................................................................71 
6.13. 
Study Week 15 (Day 106) ..........................................................................................71 
6.14. 
Study Week 16 (Day 113) ..........................................................................................71 
6.15. 
Study Week 20 (Day 141) ..........................................................................................72 
6.16. 
Study Week 23 (Day 162) ..........................................................................................73 
6.17. 
Study Week 26 (Day 183) ..........................................................................................73 
6.18. 
Study Week 29 (Day 204) ..........................................................................................74 
6.19. 
Study Week 32 (Day 225) ..........................................................................................75 
6.20. 
Study Week 35 (Day 246) ..........................................................................................76 
6.21. 
Study Week 39 (Day 274) ..........................................................................................76 
6.22. 
Study Week 42 (Day 295) ..........................................................................................77 
6.23. 
Study Week 45 (Day 316) ..........................................................................................77 
6.24. 
Study Week 48 (Day 337) ..........................................................................................78 
6.25. 
Study Week 52 (Day 365) ..........................................................................................79 
6.26. 
Study Week 60 (Day 421) ..........................................................................................80 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 8 of 135 
6.27. 
Early Termination Visit ..............................................................................................80 
7. 
STUDY ASSESSMENTS ..........................................................................................81 
7.1. 
Efficacy Assessments .................................................................................................81 
7.1.1. 
BVAS ..........................................................................................................................81 
7.1.2. 
Urinary Measurements ................................................................................................81 
7.1.3. 
Estimated Glomerular Filtration Rate .........................................................................82 
7.1.4. 
Health-Related Quality of Life Assessments ..............................................................82 
7.1.5. 
Vasculitis Damage Index (VDI) .................................................................................83 
7.1.6. 
Disease Relapse ..........................................................................................................83 
7.1.7. 
Renal Histology ..........................................................................................................83 
7.2. 
Safety Assessments .....................................................................................................83 
7.2.1. 
Physical Examinations, Vital Signs, and ECGs..........................................................83 
7.2.2. 
Clinical Safety Laboratory Assessments ....................................................................84 
7.2.3. 
Anti-Neutrophil Cytoplasmic Antibody (ANCA) Assessments .................................85 
7.2.4. 
Adverse Events ...........................................................................................................85 
7.2.4.1. 
Adverse Event Severity Assessment ..........................................................................85 
7.2.4.2. 
Causality Assessment .................................................................................................86 
7.2.4.3. 
Serious Adverse Events ..............................................................................................86 
7.2.4.4. 
Infections ....................................................................................................................87 
7.2.4.5. 
SARs and SUSARs .....................................................................................................87 
7.2.4.6. 
Laboratory Abnormalities ...........................................................................................88 
7.2.4.7. 
Pregnancies .................................................................................................................89 
7.2.5. 
Serious Adverse Event Reporting ...............................................................................89 
7.3. 
Pharmacokinetic Assessments ....................................................................................90 
7.4. 
Pharmacodynamic Assessments .................................................................................90 
7.5. 
Study Completion and Withdrawal ............................................................................90 
7.6. 
Data Monitoring Committee .......................................................................................91 
8. 
STATISTICS ..............................................................................................................91 
8.1. 
Patient Populations .....................................................................................................91 
8.1.1. 
Intent-to-Treat Population ..........................................................................................91 
8.1.2. 
Per Protocol Population ..............................................................................................91 
8.1.3. 
Safety Population ........................................................................................................91 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 9 of 135 
8.2. 
Efficacy Endpoints ......................................................................................................92 
8.2.1. 
Primary Endpoints ......................................................................................................92 
8.2.2. 
Secondary Endpoints ..................................................................................................92 
8.3. 
Safety Endpoints .........................................................................................................92 
8.4. 
Pharmacokinetic Endpoints ........................................................................................93 
8.5. 
Pharmacodynamic Endpoints .....................................................................................93 
8.6. 
Statistical Analysis Methodology ...............................................................................93 
8.6.1. 
Patient Disposition ......................................................................................................94 
8.6.2. 
Demographics and Baseline Characteristics ...............................................................94 
8.6.3. 
Prior and Concomitant Medications ...........................................................................94 
8.6.4. 
Study Drug Exposure and Compliance .......................................................................94 
8.6.5. 
Efficacy Analyses .......................................................................................................94 
8.6.6. 
Handling of Missing Data ...........................................................................................97 
8.6.7. 
Covariates and Subgroups ..........................................................................................97 
8.6.8. 
Safety Analyses ..........................................................................................................98 
8.6.9. 
Pharmacokinetic and Pharmacodynamic Marker Analysis ........................................99 
8.7. 
Sample Size Justification ............................................................................................99 
8.8. 
Interim Analysis ..........................................................................................................99 
8.9. 
Protocol Deviations ..................................................................................................100 
9. 
STUDY COMPLETION AND TERMINATION ....................................................100 
9.1. 
Study Completion .....................................................................................................100 
9.2. 
Study Termination ....................................................................................................100 
10. 
REGULATORY AND ADMINISTRATIVE REQUIREMENTS ..........................100 
10.1. 
Investigator Responsibilities .....................................................................................100 
10.2. 
Institutional Review Board or Ethics Committee .....................................................100 
10.3. 
Informed Consent .....................................................................................................101 
10.4. 
Protocol Modifications .............................................................................................101 
10.5. 
Regulatory Documentation .......................................................................................101 
10.6. 
Patient Identification Register ..................................................................................102 
10.7. 
Record Retention ......................................................................................................102 
10.8. 
Case Report Form Completion .................................................................................102 
10.9. 
Monitoring ................................................................................................................102 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 10 of 135 
10.10. 
On-site Visits and Audits ..........................................................................................103 
10.11. 
Use of Information and Publication ..........................................................................103 
11. 
REFERENCES .........................................................................................................104 
12. 
APPENDICES ..........................................................................................................105 
12.1. 
Statement of Obligations of Sponsor, Monitor, and Clinical Investigator ...............105 
12.2. 
Informed Consent Form ............................................................................................107 
12.3. 
Birmingham Vasculitis Activity Score (BVAS) Version 3 ......................................108 
12.3.1. 
Instructions ...............................................................................................................108 
12.3.2. 
AAV Organ Systems and Activity Items in BVAS ..................................................108 
12.3.3. 
Scoring of BVAS ......................................................................................................111 
12.4. 
Vasculitis Damage Index ..........................................................................................112 
12.4.1. 
Instructions ...............................................................................................................112 
12.4.2. 
AAV Organ Systems in VDI ....................................................................................112 
12.4.3. 
Scoring of VDI .........................................................................................................114 
12.5. 
Glucocorticoid Toxicity Index (GTI) .......................................................................114 
12.5.1. 
Definitions of Items Comprising the GTI .................................................................116 
12.5.2. 
Definitions of Specific List Items .............................................................................121 
12.6. 
Prednisone Dose Schedule ........................................................................................122 
12.6.1. 
Study-Supplied Prednisone .......................................................................................122 
12.6.2. 
Non-Study Supplied Glucocorticoid Use .................................................................123 
12.6.2.1. 
Prior to the Screening Period ....................................................................................124 
12.6.2.2. 
During the Screening Period .....................................................................................124 
12.6.2.3. 
During the Treatment Period ....................................................................................124 
12.7. 
Cyclophosphamide and Azathioprine Dosing ..........................................................125 
12.7.1. 
Cyclophosphamide Dosing .......................................................................................125 
12.7.2. 
Azathioprine and Mycophenolate Dosing ................................................................127 
12.8. 
Rituximab Dosing .....................................................................................................127 
12.9. 
Adverse Events Reported with Cyclophosphamide .................................................127 
12.10. 
Adverse Events Reported with Glucocorticoid Use .................................................128 
12.11. 
Adverse Events Reported with Rituximab Use ........................................................130 
12.12. 
Adverse Events Reported with Azathioprine Use ....................................................130 
12.13. 
Adverse Events Reported with Mycophenolate Mofetil Use ...................................130 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 11 of 135 
12.14. 
Benefit-Risk Assessment ..........................................................................................131 
12.14.1. 
Nonclinical Evaluation .............................................................................................131 
12.14.2. 
Clinical Evaluation ...................................................................................................132 
12.14.3. 
Pediatric Testing .......................................................................................................133 
 
LIST OF TABLES 
Table 1: 
CCX168/Placebo, Prednisone/Placebo, and Cyclophosphamide/Azathioprine 
or Rituximab Treatments for the Two Study Groups .................................................43 
Table 2: 
CCX168/Placebo Starting Dose and Dose Adjustments Based on CCX168 
Plasma Exposure in Adolescents ................................................................................44 
Table 3: 
The Glucocorticoid Toxicity Index ..........................................................................115 
Table 4: 
Severity of Glucocorticoid Toxicity in the Skin .......................................................119 
Table 5: 
Severity of Neuropsychiatric Glucocorticoid Toxicity .............................................120 
Table 6: 
Prednisone/Matching Placebo Schedule for the Control Group ...............................122 
Table 7: 
Prednisone/Matching Placebo Dosing by Study Day ...............................................123 
Table 8: 
Dose (mg/kg) for Oral or IV Cyclophosphamide Based on Age and eGFR ............126 
 
LIST OF FIGURES 
Figure 1: 
Study Schema .............................................................................................................30 
 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 12 of 135 
STUDY SYNOPSIS 
Name of Sponsor 
ChemoCentryx, Inc. 
Name of Active Ingredient 
CCX168 (avacopan) 
Study number: 
CL010_168 
Title 
A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and 
Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody 
(ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or 
Cyclophosphamide/Azathioprine 
Investigators 
Several 
Study centers 
Multi-center 
Study period 
Individuals participate for up to 60 
weeks, 52 week treatment period 
and 8 week followup period 
Phase of development 
Phase 3 
Objectives 
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain 
remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, 
or in combination with rituximab. Disease remission is defined as achieving a Birmingham 
Vasculitis Activity Score (BVAS) of 0 and not taking glucocorticoids for treatment of AAV 
within 4 weeks prior to Week 26. Sustained remission is defined as remission at Week 26 
without relapse to Week 52 (BVAS of 0 and not taking glucocorticoids for treatment of AAV 
within 4 weeks prior to Week 52). 
The secondary objectives of this study include: 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 13 of 135 
1. Evaluation of the glucocorticoid-induced toxicity in the CCX168 plus rituximab or 
cyclophosphamide/azathioprine group, compared to prednisone plus rituximab or 
cyclophosphamide/azathioprine, based on the Glucocorticoid Toxicity Index (GTI; 
Miloslavsky et al, 2016); 
2. Evaluation of rapidity of response in the CCX168 plus rituximab or 
cyclophosphamide/azathioprine group, compared to prednisone plus rituximab or 
cyclophosphamide/azathioprine, based on remission (BVAS of 0) at Week 4; 
3. Evaluation of the safety of CCX168 plus rituximab or cyclophosphamide/azathioprine, 
compared to prednisone plus rituximab or cyclophosphamide/azathioprine based on the 
incidence of adverse events and changes in vital signs, physical examinations, clinical 
laboratory tests, and electrocardiograms (ECGs) in these patients; 
4. Assessment of health-related quality-of-life changes based on the Short Form-36 version 2 
(SF-36 v2) and the EuroQOL-5D-5L (EQ-5D-5L) with CCX168 plus rituximab or 
cyclophosphamide/azathioprine, compared to prednisone plus rituximab or 
cyclophosphamide/azathioprine; 
5. Assessment of changes in parameters of renal disease including estimated glomerular 
filtration rate (eGFR), albuminuria, and urinary excretion of monocyte chemoattractant 
protein-1 (MCP-1) in patients with active renal disease at baseline with CCX168 plus 
rituximab or cyclophosphamide/azathioprine, compared to prednisone plus rituximab or 
cyclophosphamide/azathioprine; 
6. Assessment of changes in cumulative organ damage based on the Vasculitis Damage Index 
(VDI) with CCX168 plus rituximab or cyclophosphamide/azathioprine, compared to 
prednisone plus rituximab or cyclophosphamide/azathioprine; 
7. Assessment of changes in markers of pharmacodynamics in plasma and urine with CCX168 
plus rituximab or cyclophosphamide/azathioprine, compared to prednisone plus rituximab 
or cyclophosphamide/azathioprine; 
8. Evaluation of the pharmacokinetic profile of CCX168 in patients with AAV. 
Methodology 
Standard therapy for patients with AAV, including granulomatosis with polyangiitis (GPA) and 
microscopic polyangiitis (MPA), includes cyclophosphamide followed by azathioprine, or 
rituximab, plus a tapering schedule of oral glucocorticoids. Severe disease may warrant the 
addition of IV glucocorticoids and/or plasma exchange. Glucocorticoid use in these patients is 
associated with an increased risk of serious adverse events such as infections.  
Based on compelling results from both preclinical studies in a mouse model of AAV and Phase 
2 clinical trial results, CCX168 has the potential to be an effective therapy for this disease that 
will also allow for glucocorticoid sparing or elimination. Hence, the clinical hypothesis of the 
trial is to test whether CCX168 is effective in inducing and then sustaining remission in patients 
with AAV who are also treated with either cyclophosphamide/azathioprine or rituximab.  
This hypothesis will be tested in a randomized, double-blind, double-dummy, active-controlled, 
Phase 3 clinical trial in approximately 300 patients with newly diagnosed or relapsing AAV. 
To obtain balance across treatment groups, eligible patients will be stratified based on the 
following factors: 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 14 of 135 
1. One of the following treatment regimens: 
a. IV rituximab 
b. IV cyclophosphamide followed by oral azathioprine 
c. Oral cyclophosphamide followed by oral azathioprine 
2. Positive test for proteinase-3 (PR3) vs. myeloperoxidase (MPO) ANCA at diagnosis  
3. Newly-diagnosed vs. relapsing disease 
After stratification, patients will be randomized, using an interactive response technology (IRT) 
system and a minimization algorithm, in a 1:1 ratio to one of two treatment groups: 
Group A: CCX168-matching placebo plus cyclophosphamide/azathioprine or rituximab plus 
full starting dose of prednisone; 
Group B: CCX168 plus cyclophosphamide/azathioprine or rituximab plus placebo prednisone. 
Treatments for each group are shown below: 
Group 
CCX168 
Active 
CCX168-
Matching 
Placebo 
Prednisone Active 
Prednisone-
Matching 
Placebo 
Cyclophosphamide 
(CYC)/azathioprine or 
Rituximab (RTX) 
A 
None 
3 Placebo 
capsules 
orally 
twice daily 
60 mg starting dose 
(or 45 mg for 
patients <55 kg) 
with standard 
tapering schedule; 
Adolescents who 
weigh ≤37 kg will 
start at a prednisone 
dose of 30 mg per 
day. 
None 
CYC: 15 mg/kg IV up to 1.2 g 
maximum every 2 to 3 weeks for 
13 weeks, followed by 
azathioprine 1 mg/kg/day starting 
at Week 15, with titration up to 2 
mg/kg/day 
or  
CYC 2 mg/kg/day orally for 14 
weeks, followed by azathioprine 
1 mg/kg/day starting at Week 15, 
with titration up to 2 mg/kg/day 
or 
RTX: 375 mg/m2 IV weekly x 4 
infusions. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 15 of 135 
B 
3 x 10 mg 
CCX168 
capsules 
orally twice 
daily 
None 
None 
Placebo 
capsules 
CYC: 15 mg/kg IV up to 1.2 g 
maximum every 2 to 3 weeks for 
13 weeks, followed by 
azathioprine 1 mg/kg/day starting 
at Week 15, with titration up to 2 
mg/kg/day  
or  
CYC 2 mg/kg/day orally for 14 
weeks, followed by azathioprine 
1 mg/kg/day starting at Week 15, 
with titration up to 2 mg/kg/day  
or 
RTX: 375 mg/m2 IV weekly x 4 
infusions. 
The selection of IV cyclophosphamide, oral cyclophosphamide, or IV rituximab is at the 
discretion of the Investigator. The treatment period is 52 weeks (364 days), followed by an 8-
week (56 days) follow-up period. 
Study drug and other medication for vasculitis will be taken as follows by study patients: 
Group A (control group): 
• Three CCX168-matching placebo capsules in the morning, preferably with food, and 3 
in the evening, preferably with food, approximately 12 hours after the morning dose, 
daily for 52 weeks (364 days).  
• Prednisone 60 mg orally per day if the patient's body weight is ≥55 kg, or 45 mg per day 
if the patient's body weight is <55 kg, starting on Day 1 with tapering according to the 
protocol-specified schedule. Adolescents who weigh ≤37 kg will start at a prednisone 
dose of 30 mg per day. 
• If a patient is in the IV cyclophosphamide stratum, cyclophosphamide 15 mg/kg IV up 
to a maximum of 1.2 g will be given on Day 1 and also at the Week 2, 4, 7, 10, and 13 
study visits. The IV cyclophosphamide dose will be adjusted based on the patient’s age, 
eGFR, and WBC count according to protocol-specified criteria. Starting at Week 15, all 
patients will receive oral azathioprine at a starting dose of 1 mg/kg/day, with titration up 
to a target dose of 2 mg/kg/day at 2 weeks. If azathioprine is not tolerated, 
mycophenolate mofetil at a target dose of 2 g/day may be given. If mycophenolate 
mofetil is not tolerated or not available, enteric coated mycophenolate sodium may be 
given at a target dose of 1440 mg/day. 
• If a patient is in the oral cyclophosphamide stratum, cyclophosphamide 2 mg/kg/day 
(maximum 200 mg/day) will be given orally starting on Day 1 and continuing up to the 
day before Week 15. The cyclophosphamide dose will be adjusted based on the patient’s 
age, eGFR, and WBC count according to protocol-specified criteria. Starting at Week 
15, all patients will receive oral azathioprine at a starting dose of 1 mg/kg/day, with 
titration up to a target dose of 2 mg/kg/day at 2 weeks. If azathioprine is not tolerated, 
mycophenolate mofetil at a target dose of 2 g/day may be given. If mycophenolate 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 16 of 135 
mofetil is not tolerated or not available, enteric coated mycophenolate sodium may be 
given at a target dose of 1,440 mg/day. 
• If in the rituximab stratum, rituximab IV will be given on Day 1, and then Weeks 1, 2, 
and 3 at a dose of 375 mg/m2 at each visit for a total of 4 weekly infusions.  
Group B (CCX168): 
• Three 10 mg CCX168 capsules in the morning, preferably with food, and 3 capsules in 
the evening, preferably with food, approximately 12 hours after the morning dose, daily 
for 52 weeks (364 days). 
• Prednisone-matching placebo capsules equivalent to 60 mg orally per day if the patient's 
body weight is ≥55 kg, or 45 mg per day if the patient's body weight is <55 kg, starting 
on Day 1 with tapering according to a protocol-specified schedule. Adolescents who 
weigh ≤37 kg will start at a prednisone-matching placebo dose of 30 mg per day. 
• If a patient is in the IV cyclophosphamide stratum, cyclophosphamide 15 mg/kg IV up 
to a maximum of 1.2 g will be given on Day 1 and also at the Week 2, 4, 7, 10, and 13 
study visits. The cyclophosphamide dose will be adjusted based on the patient’s age, 
eGFR, and WBC count according to protocol-specified criteria. Starting at Week 15, all 
patients will receive oral azathioprine at a starting dose of 1 mg/kg/day, with titration up 
to a target dose of 2 mg/kg/day at 2 weeks. If azathioprine is not tolerated, 
mycophenolate mofetil at a target dose of 2 g/day may be given. If mycophenolate 
mofetil is not tolerated or not available, enteric coated mycophenolate sodium may be 
given at a target dose of 1,440 mg/day. 
• If a patient is in the oral cyclophosphamide stratum, cyclophosphamide 2 mg/kg/day 
(maximum 200 mg/day) will be given orally starting on Day 1 and continuing up to the 
day before the Week 15 study visit. The cyclophosphamide dose will be adjusted based 
on the patient’s age, eGFR, and WBC count according to protocol-specified criteria. 
Starting at Week 15, all patients will receive oral azathioprine at a starting dose of 1 
mg/kg/day, with titration up to a target dose of 2 mg/kg/day at 2 weeks. If azathioprine 
is not tolerated, mycophenolate mofetil at a target dose of 2 g/day may be given. If 
mycophenolate mofetil is not tolerated or not available, enteric coated mycophenolate 
sodium may be given at a target dose of 1,440 mg/day. 
• If in the rituximab stratum, rituximab IV will be given on Day 1, and then Weeks 1, 2, 
and 3 at a dose of 375 mg/m2 at each visit for a total of 4 weekly infusions. 
Patients with severe AAV will be allowed to receive up to 3 g IV methylprednisolone during 
the 4-week period prior to screening for the study. Patients with active AAV will also be 
allowed to receive oral glucocorticoids during the 6 weeks prior to screening for the study. 
Patients will not be considered for screening if they have received continuous treatment with 
moderate or high dose glucocorticoids, defined as  more than 10 mg prednisone or equivalent,  
for more than 6 weeks prior to screening for the study. 
For study centers where enrollment of adolescents (12 to 17 years old) is approved, CCX168 or 
placebo dosing will initially be given based on the body weight at screening and the dose will 
be adjusted based on CCX168 plasma levels as shown in the table below. 
Only in 12 to 17 year old patients, blood samples will be taken pre-dosing and at Hours 0.5, 1, 
2, 3, 4, and 6 after the first CCX168 dose on Day 1 and plasma samples will be sent for 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 17 of 135 
expeditious measurement of CCX168 and CCX168-M1 in these patients. Dose adjustments will 
be made based on AUC0-6 as shown in the table. These AUC0-6 thresholds are based on the 
mean CCX168 plasma exposure (525 ng•hr/mL) and one standard deviation (174 ng•hr/mL) 
above or below the mean in adult patients from Phase 2 study CL002_168 in AAV. In order to 
maintain the blind, some patients on placebo will also be instructed to modify the number of 
placebo capsules taken. 
Body weight 
Initial CCX168/placebo dose 
CCX168 Plasma AUC0-6 
(ng•hr/mL) on Day 1 
CCX168 Dose 
Adjustment 
<40 kg (88 lb) 
10 mg (1 capsule) twice daily 
≥351  
None 
 
 
<351  
Increase dose to 20 mg 
(2 capsules) twice daily 
40-55 kg (88-121 lb) 
20 mg (2 capsules) twice daily 
351 to 699 
None 
 
 
<351 
Increase dose to 30 mg 
(3 capsules) twice daily 
 
 
>699 
Decrease dose to 10 mg 
(1 capsule) twice daily 
>55 kg (121 lb) 
30 mg (3 capsules) twice daily 
≤699 
None 
 
 
>699 
Decrease dose to 20 mg 
(2 capsules) twice daily 
Extra glucocorticoid treatment, i.e., that not provided as study medication, must be avoided as 
much as possible during the study. However, patients who experience a relapse of their AAV 
during the study may be treated with IV glucocorticoids (typically 0.5 to 1 g 
methylprednisolone per day for 3 days) and/or oral glucocorticoids, tapered according to the 
patient’s condition. A relapse is defined as worsening of disease, after having previously 
achieved remission at Week 26 (BVAS = 0 and having received no glucocorticoids for 
treatment of vasculitis for 4 weeks), that involves: 
• one or more major item in the BVAS, or 
• three or more minor items in the BVAS, or 
• one or two minor items in the BVAS recorded at two consecutive study visits. 
These patients may continue study drug treatment and should continue in the study. 
Patients who experience worsening of disease during the study that involves a major item in the 
BVAS may be treated with IV glucocorticoids (typically 0.5 to 1 g methylprednisolone per day 
for 3 days) and/or oral glucocorticoids, tapered according to the patient’s condition. Worsening 
not involving a major item in the BVAS may be treated with a short burst (i.e., not more than 2 
weeks) of oral glucocorticoids, at a maximum dose of 20 mg prednisone equivalent. Patients 
experiencing worsening of disease may continue study drug treatment and should continue in 
the study. 
Patients who have one or more major items in the BVAS before study entry, and who do not 
show an improvement or stabilization of these items within the first 4 weeks of the study, may 
receive additional IV or oral glucocorticoids, tapered according to the patient’s condition. If the 
Investigator considers giving other medications, such as additional rituximab or 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 18 of 135 
cyclophosphamide treatment, these should be discussed with the Medical Monitor. These 
patients may continue study drug treatment and should continue in the study. 
Patients need to receive prophylactic therapy according to local practice during the course of the 
study. This includes prophylaxis against Pneumocystis jirovecii (formerly carinii) infections 
(sulfamethoxazole 400 mg-trimethoprim 80 mg daily or sulfamethoxazole 800 mg-
trimethoprim 160 mg every second day; if allergic, dapsone, atovaquone, or pentamidine may 
be used according to local practice), osteoporosis, nausea, and therapy for gastroprotection. 
All patients will visit the study center during the screening period, and, if eligible, on Day 1 and 
Weeks 1, 2, 3, 4, 7, 10, 13, 16, 20, 23, 26, 29, 32, 35, 39, 42, 45, 48, 52, and 60. 
CCX168/placebo will be taken orally in the morning, preferably with food, and in the evening 
(approximately 12 hours after the morning dose), preferably with food. 
The screening period will be kept as short as possible in order not to delay initiation of 
treatment. The screening period must not exceed 14 days. Screening procedures will include 
written informed consent, collecting demographic data, medical history, medication history, 
physical examination and vital signs, serum chemistry tests, hematology tests, serum pregnancy 
test (in women of childbearing potential: have experienced menarche and who is not 
permanently sterile or postmenopausal; postmenopausal is defined as 12 consecutive months 
with no menses without an alternative medical cause), urinalysis (including hematuria and 
albuminuria), 12-lead ECG, a test to exclude tuberculosis (interferon γ release assay [IGRA], 
tuberculin purified protein derivative [PPD] skin test, or chest radiography [X rays or CT scan]) 
if not done within 6 weeks prior to screening, viral screening (if not done within 6 weeks prior 
to screening), serology (anti-nuclear antibodies [ANA], anti-glomerular basement membrane 
[GBM] antibodies, IgG, IgM, and IgA) and complement (C3 and C4) measurements (if not 
done within the previous 12 months), estimated glomerular filtration rate (eGFR) based on 
serum creatinine, ANCA measurement (anti-PR3 and anti-MPO, if not done previously), and 
BVAS and VDI assessment. The BVAS version 3 will be used in this study (Mukhtyar et al, 
2009; Suppiah et al, 2011).  
To expedite the screening process, blood and urine tests may be done at the local laboratories 
for the Screening visit. Laboratory results from the local laboratories obtained within 72 hours 
of screening are acceptable in order to avoid unnecessary blood draws. Results from histology 
of renal biopsies (if performed within 4 weeks prior to Screening) will be recorded on standard 
histology forms. 
Eligible patients must be ANCA-positive (having tested positive for antibodies to PR3 or MPO 
by ELISA or ALBIA, either at the time of enrollment or in the past) and must have at least one 
“major” item, or at least 3 minor items, or at least the two renal items of proteinuria and 
hematuria in the BVAS. Care must be taken to ensure that the renal items are due to vasculitis 
activity and not other factors such as menses or cyclophosphamide-related cystitis. If a patient 
has “other” items, not specified in the BVAS, these need to be discussed with the Medical 
Monitor before enrollment. 
Eligible patients will visit the study center on Day 1, after an overnight fast of at least 9 hours, 
for physical examination and vital signs, serum chemistry tests (including HbA1c and LDL 
cholesterol), hematology tests, serum pregnancy test (in women of childbearing potential), 
urinalysis (including hematuria, urinary albumin:creatinine ratio [UACR], and MCP-


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 19 of 135 
1:creatinine ratio assessment), eGFR, ANCA measurement (anti-PR3 and anti-MPO ELISA), 
SF-36 v2 and EQ-5D-5L assessment, Glucocorticoid Toxicity Index (GTI) baseline assessment, 
baseline pharmacokinetic (PK) and pharmacodynamic (PD) blood sample collection, saliva 
sample collection, stratification and randomization. Medication will be administered (IV) and 
dispensed (for oral medications). The patients will take the first dose of CCX168 or placebo, 
and prednisone or placebo while at the study center. A patient could be kept overnight in the 
hospital on Day 1, if necessary, based on the patient’s clinical condition. This hospital stay may 
be extended, if the patient’s condition demands it, and this hospital stay would not be 
considered a serious adverse event (SAE), unless other SAE criteria are met. 
Twice daily dosing of CCX168 or placebo will continue for 364 days. At post-Day 1 study 
visits, study medication will be administered according to the protocol schedule, and blood and 
urine samples will be collected for safety and efficacy and PK/PD measurements. BVAS 
assessments will be made at Screening and Weeks 4, 10, 16, 26, 39, 52, and 60. VDI 
assessments will be made at Screening and Weeks 26, 52, and 60. SF-36 v2 and EQ-5D-5L will 
be completed on Day 1 and Weeks 4, 10, 16, 26, 39, 52, and 60. GTI assessments will be done 
on Day 1 and at Weeks 13 and 26. If a patient consents, renal biopsy for histology will be 
performed at Week 52. Physical examinations, vital sign assessments, and ECG measurements 
will be performed throughout the study. Concomitant medication and adverse event assessments 
will be made at every study visit. 
Patients will be discharged from the study when all the Study Week 60 visit procedures have 
been completed. Each patient's condition will be evaluated by the Investigator at the end of the 
clinical trial (Week 60) and appropriate standard of care medical treatment will be provided to 
all patients as needed. 
To the extent possible, any adverse events that are deemed study drug-related and are ongoing 
at discharge will be followed to resolution or until a determination is made that the unresolved 
event is stable. 
Number of Patients 
Approximately 300 patients with AAV will be randomized for this study. Patients who drop out 
of the study prematurely will not be replaced. 
Main Criteria for Inclusion 
1. Clinical diagnosis of granulomatosis with polyangiitis (Wegener's) or microscopic 
polyangiitis, consistent with Chapel-Hill Consensus Conference definitions (Jennette et al, 
2013); 
2. Aged at least 18 years, with newly-diagnosed or relapsed AAV where treatment with 
cyclophosphamide or rituximab is needed; where approved, adolescents (12 to 17 years old) 
may be enrolled; female patients of childbearing potential may participate if adequate 
contraception is used during the study, and for at least 6 months after the last 
cyclophosphamide dose (if receiving cyclophosphamide) and at least 12 months after the 
last rituximab dose (if receiving rituximab); male patients with partners of childbearing 
potential may participate in the study if they had a vasectomy at least 6 months prior to 
randomization or if adequate contraception is used during the study, and for at least 6 
months after the last cyclophosphamide dose (if receiving cyclophosphamide) and at least 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 20 of 135 
12 months after the last rituximab dose (if receiving rituximab); Adequate contraception is 
defined as resulting in a failure rate of less than 1% per year (combined estrogen and 
progestogen [oral, intravaginal, or transdermal], or progestogen-only hormonal 
contraception [oral, injectable, or implantable], intra-uterine device, intra-uterine hormone 
releasing system, bilateral tubal occlusion, vasectomized partner, or true [absolute] sexual 
abstinence, i.e., in line with the preferred and usual lifestyle of the patient); for patients who 
will be receiving mycophenolate instead of azathioprine, a second form of birth control 
must be used if the first form of birth control is hormonal contraception, such as 
progestogen-only hormonal contraception, because mycophenolate reduces blood levels of 
the hormones in the oral contraceptive pill and could theoretically reduce its effectiveness; 
sperm donation for at least 6 months after the last cyclophosphamide dose (if receiving 
cyclophosphamide), and at least 12 months after the last rituximab dose (if receiving 
rituximab), must not be performed. 
3. Positive test for anti-PR3 or anti-MPO (current or historic) antibodies; 
4. At least one major item, or at least 3 minor items, or at least the 2 renal items of proteinuria 
and hematuria in the BVAS; care must be taken to ensure that the renal items are due to 
vasculitis activity and not other factors such as menses or cyclophosphamide-related 
cystitis; if a patient has “other” items, not specified in the BVAS, these need to be discussed 
with the Medical Monitor before enrollment. 
5. Estimated glomerular filtration rate ≥15 mL/minute/1.73 m2 (using MDRD method for 
adults, and modified Schwartz equation for adolescents) at screening; 
6. Willing and able to give written Informed Consent and to comply with the requirements of 
the study protocol; written Informed Consent should be obtained from the legal guardian in 
accordance with regional laws or regulations for patients 12 to 17 years of age, and 
7. Judged by the investigator to be otherwise fit for the study, based on medical history, 
physical examination (including electrocardiogram [ECG]), and clinical laboratory 
assessments. Patients with clinical laboratory values that are outside of normal limits (other 
than those specified in the Exclusion Criteria) and/or with other abnormal clinical findings 
that are judged by the Investigator not to compromise patient participation in the study, may 
be entered into the study. 
Main Criteria for Exclusion 
1. Pregnant or breast-feeding; 
2. Alveolar hemorrhage requiring invasive pulmonary ventilation support anticipated to last 
beyond the screening period of the study; 
3. Any other known multi-system autoimmune disease including eosinophilic granulomatosis 
with polyangiitis (Churg-Strauss), systemic lupus erythematosus, IgA vasculitis (Henoch-
Schönlein), rheumatoid vasculitis, Sjögren's syndrome, anti-glomerular basement membrane 
disease, or cryoglobulinemic vasculitis; 
4. Required dialysis or plasma exchange within 12 weeks prior to screening; 
5. Have had a kidney transplant; 
6. Received cyclophosphamide within 12 weeks prior to screening; if on azathioprine, 
mycophenolate, or methotrexate at the time of screening, these drugs must be withdrawn 
prior to receiving the cyclophosphamide or rituximab dose on Day 1; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 21 of 135 
7. Received intravenous glucocorticoids, >3000 mg methylprednisolone equivalent, within 4 
weeks prior to screening; 
8. Have been taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone-
equivalent for more than 6 weeks continuously prior to the screening visit; 
9. Received rituximab or other B-cell antibody within 52 weeks of screening or 26 weeks 
provided B cell reconstitution has occurred (i.e., CD19 count > 0.01x109/L); received anti-
TNF treatment, abatacept, alemtuzumab, IVIg,  belimumab, tocilizumab, or eculizumab 
within 12 weeks prior to screening; immunosuppressive drugs not listed here must be 
discussed with the Medical Monitor; 
10. Currently taking a strong inducer of the cytochrome P450 3A4 (CYP3A4) enzyme, such as 
carbamazepine, phenobarbital, phenytoin, rifampin, or St. John’s wort; 
11. Any of the following within 12 weeks prior to screening: symptomatic congestive heart 
failure requiring prescription medication, unstable angina (unless successfully treated with 
stent or bypass surgery), clinically significant cardiac arrhythmia, myocardial infarction or 
stroke; 
12. History or presence of any form of cancer within the 5 years prior to screening, with the 
exception of excised basal cell or squamous cell carcinoma of the skin, or carcinoma in situ 
such as cervical or breast carcinoma in situ that has been excised or resected completely and 
is without evidence of local recurrence or metastasis; 
13. Evidence of tuberculosis based on interferon γ release assay (IGRA), tuberculin purified 
protein derivative (PPD) skin test, or chest radiography done at screening or within 6 weeks 
prior to screening; 
14. HBV, HCV, or HIV viral screening test showing evidence of active or chronic viral 
infection done at screening or within 6 weeks prior to screening; 
15. Received a live vaccine within 4 weeks prior to screening; 
16. WBC count less than 3500/μL, or neutrophil count less than 1500/μL, or lymphocyte count 
less than 500/µL before start of dosing; 
17. Evidence of hepatic disease: AST, ALT, alkaline phosphatase, or bilirubin > 3 times the 
upper limit of normal before start of dosing; 
18. Clinically significant abnormal ECG during screening, e.g., QTcF greater than 450 msec; 
19. Known hypersensitivity to CCX168 or inactive ingredients of the CCX168 capsules 
, cyclophosphamide or its 
metabolites (for patients scheduled to receive cyclophosphamide), or known Type I 
hypersensitivity or anaphylactic reactions to murine proteins, Chinese Hamster Ovary cell 
proteins, or to any component of rituximab (for patients scheduled to receive rituximab), or 
any contraindications or hypersensitivity to the use of azathioprine, cyclophosphamide, 
mycophenolate, or prednisone, or excipients, where applicable, as per the local prescribing 
information; for patients who will receive azathioprine, concomitant use with allopurinol is 
contraindicated; 
20. For patients scheduled to receive cyclophosphamide treatment, urinary outflow obstruction, 
active infection (especially varicella zoster infection), or platelet count <50,000/μL before 
start of dosing; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 22 of 135 
21. Participated in any clinical study of an investigational product within 30 days prior to 
screening or within 5 half-lives after taking the last dose;  
22. Participated previously in a CCX168 study; and 
23. History or presence of any medical condition or disease which, in the opinion of the 
Investigator, may place the patient at unacceptable risk for study participation. 
Test Product 
Group B will be the test group. Patients in this group will receive active CCX168 (avacopan) 
capsules. CCX168 will be administered orally via hard gelatin capsules containing 10 mg 
CCX168. The CCX168 capsules will be supplied to the study centers in plastic bottles 
containing 180 capsules. 
Patients in Group B will receive one bottle of CCX168 capsules on Day 1 and Weeks 4, 7, 10, 
and 13, and two bottles at the Week 16, 20, 26, 32, 39, and 45 visits. Patients will be asked to 
take 3 CCX168 capsules orally every morning, preferably with food, and 3 capsules every 
evening, preferably with food, approximately 12 hours after the morning dose, as instructed. 
Study medication will be taken for 364 days continuously. Capsules will be taken orally with 
water. CCX168 and placebo bottles and capsules will be identical in appearance. 
Patients in Group B will also take prednisone-matching placebo capsules orally according to the 
protocol-specified schedule. 
Reference Therapy, Dose and Mode of Administration 
Group A will be the control group. Patients in this group will receive CCX168-matching 
placebo capsules. Placebo will be administered orally via hard gelatin capsules containing only 
inactive ingredients. Placebo capsules will be supplied to the study centers in plastic bottles 
containing 180 capsules. 
Patients in Group A will receive one bottle of CCX168-matching placebo capsules on Day 1 
and Weeks 4, 7, 10, and 13, and two bottles at the Week 16, 20, 26, 32, 39, and 45 visits. 
Patients will be asked to take 3 CCX168-matching placebo capsules orally every morning, 
preferably with food, and 3 capsules every evening, preferably with food, approximately 12 
hours after the morning dose, as instructed. Study medication will be taken for 364 days 
continuously. Capsules will be taken orally with water. Placebo and CCX168 bottles and 
capsules will be identical in appearance. 
Patients in Group A will also take prednisone capsules according to the protocol-specified 
tapering schedule. 
Prednisone or prednisone-matching placebo will be given as tablets, over-encapsulated with 
hard gelatin capsules in order to maintain the blind. Two dose strengths of prednisone capsules 
will be provided, 20 mg and 5 mg. Placebo for prednisone will be given as matching hard 
gelatin capsules with placebo tablets. 
Oral or IV cyclophosphamide, azathioprine (or mycophenolate, if needed), and rituximab will 
be prescribed and provided by the study centers.  


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 23 of 135 
Duration of Treatment and Observation  
Patients will be screened within a period not to exceed 14 days prior to Study Day 1 (the first 
day of dosing). The treatment period is 364 days and all patients will be followed for 56 days 
after the treatment period. 
To the extent possible, any adverse events that are deemed study drug-related and are ongoing 
at discharge will be followed to resolution or until a determination is made that the unresolved 
event is stable. The patient’s condition will be evaluated by the Investigator at the end of the 
clinical trial and appropriate standard of care medical treatment will be provided to all patients 
as needed. 
Safety and Other Assessments 
Safety assessments include adverse events, physical examination abnormalities, vital signs, and 
clinical laboratory tests (including blood chemistry, hematology, and urinalysis), the 
glucocorticoid toxicity index, and ECGs. Anti-MPO and anti-PR3 antibody levels will be 
measured over the course of the study. 
Efficacy Assessments 
Efficacy assessments include: 
1. BVAS; 
2. SF-36 v2 and EQ-5D-5L measurements; 
3. Disease relapse events; 
4. Urinary albumin:creatinine ratio (UACR); 
5. eGFR by MDRD serum creatinine-based formula for adults, and modified Schwartz 
equation for adolescents; 
6. Urinary MCP-1:creatinine ratio, and 
7. VDI. 
Pharmacokinetic Assessments 
Concentrations of CCX168 and significant metabolites will be determined in plasma from blood 
collected on Day 1 (pre-dose baseline), Weeks 1, 2, 4, 7, 13, 26, 39, and 52 in all patients. Only 
for patients 12 to 17 years of age, CCX168 and metabolites will also be measured at Hours 0.5, 
1, 2, 3, 4, and 6 after the first dose on Day 1. Samples from adolescent patients will be assayed 
expeditiously and CCX168 dose adjustments will be made, if necessary. 
Pharmacodynamic Assessments 
Plasma samples will be collected on Day 1 (pre-dose baseline), and Weeks 1, 2, 4, 13, 26, 39, 
52, and 60 for pharmacodynamic marker measurements, including, for example, cystatin C, 
complement fragments, and inflammatory cytokine and chemokine levels. The PK plasma 
samples may also be used for these pharmacodynamic marker measurements. 
Blood samples collected may be used for lymphocyte subtype counts, as well as for DNA and 
other biomarker assessments by RNA analysis. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 24 of 135 
Urine samples will be collected on Day 1 (pre-dose baseline), and Weeks 1, 2, 4, 13, 26, 39, 52, 
and 60 for biomarker assessments including, for example, complement fragments, inflammatory 
chemokine and cytokine levels. 
A saliva sample will be collected on Day 1 from patients who have provided Informed Consent 
for assessment of genetic markers of ANCA disease as well as the complement pathway. 
Statistical Methods 
Demographics and Baseline Characteristics 
All patient baseline characteristics and demographic data, i.e., age, sex, race, ethnicity, weight, 
height, body mass index, anti-PR3 and anti-MPO status, GPA vs. MPA disease type, newly-
diagnosed vs. relapsing disease, IV cyclophosphamide vs. oral cyclophosphamide vs. IV 
rituximab use, vasculitis disease duration (from time of diagnosis), BVAS, VDI, SF-36 v2, EQ-
5D-5L, GTI, eGFR, hematuria status, UACR, and urinary MCP-1:creatinine ratio will be listed 
and summarized by treatment group. 
Glomerular histopathology (if biopsy was taken), physical examination abnormalities, medical 
history, previous and concomitant medications (including vasculitis medication use) at study 
entry will be listed and summarized by treatment group. 
Efficacy Analysis 
The primary efficacy endpoints are: 
1. The proportion of patients achieving disease remission at Week 26, defined as a BVAS 
score of 0 and not taking glucocorticoids for treatment of AAV within 4 weeks prior to 
Week 26. 
2. The proportion of patients achieving sustained disease remission, defined as remission at 
Week 26 without relapse to Week 52 (BVAS of 0 and not taking glucocorticoids for 
treatment of AAV within 4 weeks prior to Week 52). 
Secondary endpoints include: 
1. Glucocorticoid-induced toxicity as measured by change from baseline over the first 26 
weeks in the glucocorticoid toxicity index; 
2. Early remission, defined as BVAS of 0 at Week 4; 
3. Change from baseline over 52 weeks in health-related quality-of-life as measured by the 
domains and component scores of the SF-36 v2 and EQ-5D-5L visual analogue scale (VAS) 
and index; 
4. Proportion of patients and time to experiencing a relapse; relapse is defined as occurrence of 
at least one major item in the BVAS, or three or more minor items in the BVAS, or one or 
two minor items in the BVAS at two consecutive visits, after having previously achieved 
remission at Week 26 (BVAS = 0 and having received no glucocorticoids for treatment of 
vasculitis for 4 weeks); 
5. In patients with renal disease at baseline (based in the BVAS renal component), the change 
in eGFR from baseline over 52 weeks; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 25 of 135 
6. In patients with renal disease at baseline (based in the BVAS renal component), the percent 
change in UACR from baseline over 52 weeks; 
7. In patients with renal disease at baseline (based in the BVAS renal component), the percent 
change in urinary MCP-1:creatinine ratio from baseline over 52 weeks; 
8. Change in the VDI from baseline over 52 weeks. 
Summary statistics will be calculated for each of the endpoints. For categorical endpoints, 
numbers and percentages will be calculated. For continuous variables, numbers, means, 
medians, ranges, standard deviations, and standard error of means will be calculated. Geometric 
means will be calculated for data that are typically not normally distributed, e.g., UACR and 
urinary MCP-1:creatinine ratio. 
Results will be presented by treatment group. Results will be presented by stratum for each of 
the three stratification factors, IV rituximab vs. IV cyclophosphamide vs. oral 
cyclophosphamide use, anti-PR3 vs. anti-MPO positive ANCA, and newly-diagnosed vs. 
relapsing patients, as well as GPA vs. MPA. Results will be presented for patients with renal 
AAV and those without renal AAV at baseline, as well as those who received IV 
glucocorticoids upfront compared to those who did not. Data will also be presented by 
geographic distribution, sex, age group, race, and ethnicity for at least the primary endpoints. 
The overall efficacy hypothesis in this study is that CCX168 treatment will be effective in 
treatment of patients with AAV based on inducing and then sustaining remission without 
requiring chronic oral prednisone treatment. 
For the two primary efficacy endpoints, the proportion of patients achieving disease remission 
at Week 26 and sustained disease remission at Week 52, and the two-sided 95% confidence 
intervals for the difference in proportions (CCX168 minus control) will be estimated for the 
comparison between the CCX168 group and the control group. 
The proportion of patients achieving disease remission at Week 26 will be calculated as the 
number of patients with a BVAS of 0 during the 4-week period preceding the Week 26 visit, 
and having not received any glucocorticoid treatment for AAV during the 4-week period 
preceding and including the Week 26 visit, divided by the total number of patients randomized 
to the particular treatment group and who received at least 1 dose of blinded study drug. 
The proportion of patients achieving sustained disease remission at Week 52 will be calculated 
as the number of patients who achieved remission at Week 26 (with a BVAS of 0 during the 4-
week period preceding the Week 26 visit, and having not received any glucocorticoid treatment 
for AAV during the 4-week period preceding and including the Week 26 visit) AND who have 
also achieved remission at Week 52 (with a BVAS of 0 during the 4 week-period preceding the 
Week 52 visit, and having not received any glucocorticoid treatment for treatment of AAV 
during the 4-week period preceding and including the Week 52 visit), divided by the total 
number of patients randomized to the particular treatment group and who received at least 1 
dose of blinded study drug. Patients who relapse after Week 26 and before Week 52 will be 
considered treatment failures for the sustained remission analysis at Week 52. 
The following hypotheses will be tested for the first primary efficacy endpoint: 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 26 of 135 
• The non-inferiority null hypothesis (H10) is that the CCX168 group is inferior to the 
control group when comparing the remission rate based on BVAS at Week 26. 
• The non-inferiority alternative hypothesis (H11) is that the CCX168 group is not inferior 
to the control group when comparing the remission rate at Week 26. 
• The superiority null hypothesis (H20) is that the CCX168 group is not different from the 
control group when comparing the remission rate at Week 26. 
• The superiority alternative hypothesis (H21) is that the CCX168 group is superior to the 
control group when comparing the remission rate at Week 26. 
The following hypotheses will be tested for the second primary efficacy endpoint: 
• The non-inferiority null hypothesis (H30) is that the CCX168 group is inferior to the 
control group when comparing the sustained remission rate based on remission at Week 
26 without relapse to Week 52. 
• The non-inferiority alternative hypothesis (H31) is that the CCX168 group is not inferior 
to the control group when comparing the sustained remission rate based on remission at 
Week 26 without relapse to Week 52. 
• The superiority null hypothesis (H40) is that the CCX168 group is not different from the 
control group when comparing the sustained remission rate based on remission at Week 
26 without relapse to Week 52. 
• The superiority alternative hypothesis (H41) is that the CCX168 group is superior to the 
control group when comparing the sustained remission rate at Week 26 without relapse 
to Week 52. 
The two primary endpoints will be tested sequentially using a gatekeeping procedure to 
preserve the Type I error rate at 0.05. The sequence of testing will be as follows: 
1. Test for non-inferiority (H10) of the CCX168 group compared to the control group 
regarding remission at Week 26; if the p-value for non-inferiority is < 0.05, proceed to step 
2; 
2. Test for non-inferiority (H30) of the CCX168 group compared to the control group 
regarding sustained remission at Week 52; if the p-value for non-inferiority is <0.05, 
proceed to the step 3; 
3. Test for superiority (H40) of the CCX168 group compared to the control group regarding 
sustained remission at Week 52; if the p-value for superiority is <0.05, proceed to step 4; 
4. Test for superiority (H20) of the CCX168 group compared to the control group regarding 
remission at Week 26. 
For the non-inferiority test of the first primary efficacy endpoint, if the lower bound of the 95% 
confidence interval is greater than -0.20 (i.e., P <0.05 for the non-inferiority test) and the 
control group disease remission rate is at least 40% at Week 26, the CCX168 group will be 
considered not inferior to the control group. For the superiority test, if the lower bound of the 
95% confidence interval is greater than 0.0 (i.e., P <0.05 for the superiority test), the CCX168 
group will be considered superior to the control group in achieving the disease remission at 
Week 26. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 27 of 135 
For the second primary endpoint, the proportion of patients in disease remission at Week 26 
without relapse to Week 52, and the two-sided 95% confidence interval for the difference in 
proportion (CCX168 minus control) will be estimated for the comparison between the CCX168 
group and the control group. For the non-inferiority test of the second primary endpoint, if the 
lower bound of the 95% confidence interval is greater than -0.20 (i.e., P <0.05 for the non-
inferiority test), the CCX168 group will be considered not inferior to the control group. For the 
superiority test, if the lower bound of the 95% confidence interval is greater than 0.0 (i.e., P 
<0.05 for the superiority test), the CCX168 group will be considered superior to the control 
group in achieving the disease remission at Week 26 without relapse to Week 52. 
5. Patients who relapse after Week 26 and before Week 52 will be considered treatment 
failures for the sustained remission analysis at Week 52. A relapse is defined as worsening 
of disease that involves one or more major items, or three or more minor items in the 
BVAS, or one or two minor items in the BVAS recorded at two consecutive visits, after 
having previously achieved remission at Week 26 (BVAS = 0 and having received no 
glucocorticoids for treatment of vasculitis for 4 weeks). 
The stratified Newcombe hybrid-score method will be used to calculate the confidence intervals 
for the common difference in proportions. 
Binary variables of the secondary efficacy endpoints, the proportion of patients with early 
remission (Week 4) and the proportion of patients with relapse events, will be analyzed 
similarly to the primary efficacy endpoints. 
If there are a sufficient number of relapse events, time from remission to relapse will be 
analyzed by Kaplan Meier methodology and log rank testing of the differences between 
treatment groups. 
Continuous variables of the secondary efficacy endpoints will be analyzed using a mixed effects 
model for repeated measures (MMRM) with treatment group, visit, treatment-by-visit 
interaction, and randomization strata (IV rituximab, IV or oral cyclophosphamide, anti-PR3 or 
anti-MPO ANCA, and newly-diagnosed AAV or relapsed AAV) as factors, and baseline as 
covariate. Patients will be considered as repeated measure units over visits. Point estimates and 
corresponding 95% confidence intervals will be estimated for the difference between the 
CCX168 group and the control group across 52 weeks using simple contrast from the model. 
Continuous variables include change and/or percent change from baseline in GTI, eGFR, 
UACR, urinary MCP-1:creatinine ratio, SF-36 v2 (domains and component scores) and EQ-5D-
5L VAS and index, VDI, and pharmacodynamics markers. Data that are not normally 
distributed, e.g., UACR will be log-transformed before analysis. 
The Week 60 follow-up data will be summarized with no formal statistical testing. 
All statistical testing will be two-sided, with the type I error rate at α=0.05. 
The efficacy analyses will be performed in the intent-to-treat (ITT) and per protocol (PP) 
populations. All patients who are randomized and who received at least 1 dose of study drug 
will be included in the ITT population. Efficacy analysis in the ITT population will be 
considered the primary analysis. The PP population will consist of all randomized patients who 
receive at least one dose of study drug and do not have protocol deviations that could 
significantly affect the interpretation of the results for the primary endpoints. Patients’ 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 28 of 135 
inclusion/exclusion from the PP population will be determined and documented prior to the 
database lock and unblinding. 
Baseline is defined as the last value prior to start of dosing with study medication (typically the 
Day 1 pre-dose value). For BVAS and VDI, baseline will be taken from the Screening visit. 
Safety Analysis 
Safety endpoints, other than glucocorticoid-induced toxicity, include: 
1. Patient incidence of treatment-emergent serious adverse events, adverse events, and 
withdrawals due to adverse events; 
2. Change from baseline and shifts from baseline in all safety laboratory parameters; 
3. Change from baseline in vital signs, and 
4. Incidence of clinically significant ECG changes from baseline. 
All patients who are randomized and received at least one dose of study medication will be 
included in the safety population.  
All clinical safety and tolerability data will be listed by treatment group and by patient, and will 
be summarized by treatment group. 
All reported adverse events will be coded using MedDRA and listed by System Organ Class, 
Preferred Term, and verbatim term. 
Treatment-emergent adverse events will be listed and will be summarized by treatment group 
by System Organ Class and Preferred Term, by relatedness and by maximum severity. 
Treatment-emergent serious adverse events and adverse events leading to withdrawal will be 
summarized by treatment group. 
Individual vital signs and change from baseline in vital signs will be listed by treatment group, 
patient, and study visit, and summarized by treatment group. 
Laboratory data (actual values and change from baseline) will be listed by treatment group, 
patient, and study visit. Abnormal laboratory values will be flagged. Laboratory data will also 
be summarized by treatment group and study visit. Shift tables will be generated for shifts in 
laboratory parameters by study visit. 
Abnormal ECG findings will be listed by treatment group and study visit, and clinical 
significance of abnormalities indicated. 
Sample Size Assumptions 
The proportion of patients in the control group achieving clinical remission at Week 26 is 
estimated to be ~60%, a blended proportion of 64% and 53% observed in the rituximab and 
cyclophosphamide/azathioprine groups, respectively, in the largest prior registration study in 
AAV (Stone et al, 2010). 
A non-inferiority margin of -20 percentage points has been derived for the difference between 
CCX168 and control groups, and a one-sided alpha level of 0.025. This non-inferiority margin 
is based on a thorough review and meta-analysis of all previous clinical trials conducted in 
patients with AAV, as well as precedent (Stone et al, 2010). 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0  
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 29 of 135 
A sample size of 150 patients per group (300 in total) is estimated to provide more than 90% 
power for the non-inferiority test. This sample size provides 90% power to detect approximately 
18% superiority in the proportion of patients achieving clinical remission at Week 26 if the 
control group remission rate is 60%. 
The proportion of patients in the control group with sustained remission at Week 52 is 
estimated to be ~45%, a blended proportion observed in a prior study comparing rituximab and 
cyclophosphamide/azathioprine in AAV (Specks et al, 2013). 
A sample size of 150 patients per group (300 in total) is estimated to provide 85% power to 
detect approximately 18% superiority if the control group sustained remission rate at Week 52 
is 45%. 
Pharmacokinetic and pharmacodynamic marker analysis 
Individual plasma concentrations of CCX168 and significant metabolites at all study visits 
where these are measured will be listed, plotted, and summarized descriptively and graphically. 
Population PK analysis will be conducted based on the CCX168 and metabolite plasma 
concentration measurements. 
For data collected in adolescents, PK parameters such as Cmax, Tmax, and AUC0-6hr will be 
calculated on Day 1 for CCX168 and significant metabolites. 
Plasma and urinary PD markers will be summarized and may be analyzed using methods 
analogous to the efficacy parameters. 
The relationship between PK parameters and renal function based on eGFR will be evaluated. 
The data may also be used to evaluate the PK/PD relationship of CCX168 treatment. To this 
end, the change and/or percent change from baseline in eGFR, UACR, urinary MCP-
1:creatinine ratio, or other biomarkers may be used as PD markers. 


CCX168 (avacopan) 
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 30 of 135 
Figure 1: 
Study Schema 
 


CCX168 (avacopan) 
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 31 of 135 
TIME AND EVENTS TABLE: Please refer to bottom of this table for table footnotes. 
 
SCR1 
Treatment Period 
ET 
F/U 
Study  
Day 
-14 
to -1 
12 
8 
15 
22 
29 
43 
50 
57 
71 
92 
99 
106 
113 
141 
162 
183 
204 
225 
246 
274 
295 
316 
337 
365 
 
421 
Study  
Week3 
 
 
1 
2 
3 
4 
6 
7 
8 
10 
13 
14 
15 
16 
20 
23 
26 
29 
32 
35 
39 
42 
45 
48 
52 
 
60 
Visit to  
study center 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Phone call to 
patients as  
reminder to 
change 
prednisone/ 
placebo dose 
 
 
 
 
 
 
X 
 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phone call to 
patients in 
CYC strata as 
reminder 
to start  
azathioprine 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Informed  
Consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics
Medical 
History, Prior 
Medications 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical 
Examination4 
X 
X5 
X 
X 
 
X 
 
 
 
X 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
 
 
X 
X 
X 
Vital Signs6 
X 
X5 
X 
X 
X 
X 
 
X 
 
X 
X 
 
 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
X 
12-lead ECG 
X 
 
 
X 
 
 
 
X 
 
 
X 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
X 
X 
Chest  
Radiography7 
(X) 
 
 
 
 
(X) 
 
 
 
(X
) 
 
 
 
(X) 
 
 
(X) 
 
 
 
(X) 
 
 
 
(X) 
(X) 
(X) 
Tuberculosis 
Screening8 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV, HBV, 
HCV 
Screening  
(if not done  
within 6 
weeks) 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANA,               
anti-GBM 
antibodies, C3, 
C4, IgG, IgM,  
and IgA9 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


CCX168 (avacopan) 
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 32 of 135 
 
SCR1 
Treatment Period 
ET 
F/U 
Study  
Day 
-14 
to -1 
12 
8 
15 
22 
29 
43 
50 
57 
71 
92 
99 
106 
113 
141 
162 
183 
204 
225 
246 
274 
295 
316 
337 
365 
 
421 
Study  
Week3 
 
 
1 
2 
3 
4 
6 
7 
8 
10 
13 
14 
15 
16 
20 
23 
26 
29 
32 
35 
39 
42 
45 
48 
52 
 
60 
Serum 
Chemistry, 
Hematology 
X 
X5 
X 
X 
X 
X 
 
X 
 
X 
X 
 
 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
X 
ALT, AST, 
Bilirubin, 
Alkaline 
Phosphatase 
Hematology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
 
 
HbA1c, LDL 
cholesterol 
 
X5 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
X 
 
Serum  
pregnancy test  
in women of 
childbearing 
potential 
X 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
X 
 
 
 
X 
 
 
 
X 
X 
X 
Urine  
pregnancy test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
 
ANCA 
Measurement10 
X 
X5 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
X 
X 
PK Plasma 
Sample 
Collection 
 
X5,11 
X 
X 
 
X 
 
X 
 
 
X 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
Record date 
and time of 
last dose of 
CCX168/ 
placebo prior 
to PK blood 
sample 
collection 
 
 
X 
X 
 
X 
 
X 
 
 
X 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
Blood Sample 
Collection for 
PD markers  
and cells 
 
X5 
X 
X 
 
X 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
X 
WBC count 
(local lab)12 
 
X5 
 
X 
 
X 
 
X 
 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine sample 
for 
Urinalysis13 
X 
X5 
X 
X 
X 
X 
 
X 
 
X 
X 
 
 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
X 


CCX168 (avacopan) 
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 33 of 135 
 
SCR1 
Treatment Period 
ET 
F/U 
Study  
Day 
-14 
to -1 
12 
8 
15 
22 
29 
43 
50 
57 
71 
92 
99 
106 
113 
141 
162 
183 
204 
225 
246 
274 
295 
316 
337 
365 
 
421 
Study  
Week3 
 
 
1 
2 
3 
4 
6 
7 
8 
10 
13 
14 
15 
16 
20 
23 
26 
29 
32 
35 
39 
42 
45 
48 
52 
 
60 
Urine samples 
for albumin, 
MCP-1 and 
creatinine  
Assays 
 
X5 
X 
X 
 
X 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
X 
Urine sample 
for PD 
markers 
 
X5 
X 
X 
 
X 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
X 
Renal Biopsy14 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
BVAS 
X 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
X 
 
 
 
X 
 
 
 
X 
X 
X 
Record relapse 
events15 
 
 
 
 
 
 
 
X 
 
X 
X 
 
 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
X 
VDI 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
X 
X 
SF-36 v2 and  
EQ-5D-5L 
 
X5 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
X 
 
 
 
X 
 
 
 
X 
X 
X 
Glucocorticoid 
Toxicity Index 
 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
X 
 
Saliva sample 
collection 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stratification 
and       
randomization 
 
X5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCX168 or 
Placebo 
Dispensing16 
 
X5 
 
 
 
X 
 
X 
 
X 
X 
 
 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
 
 
 
Inspection of 
CCX168 or 
Placebo  
bottles to 
ensure patient 
compliance 
 
 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCX168 or 
Placebo 
Accountability 
 
 
 
 
 
X 
 
X 
 
X 
X 
 
 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
 
Prednisone or 
Placebo  
Dispensing 
 
X5 
X 
X 
X 
X 
 
X 
 
X 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prednisone or 
Placebo 
Accountability 
 
 
X 
X 
X 
X 
 
X 
 
X 
X 
 
 
X 
X 
 
 
 
 
 
 
 
 
 
 
X 
 


CCX168 (avacopan) 
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 34 of 135 
 
SCR1 
Treatment Period 
ET 
F/U 
Study  
Day 
-14 
to -1 
12 
8 
15 
22 
29 
43 
50 
57 
71 
92 
99 
106 
113 
141 
162 
183 
204 
225 
246 
274 
295 
316 
337 
365 
 
421 
Study  
Week3 
 
 
1 
2 
3 
4 
6 
7 
8 
10 
13 
14 
15 
16 
20 
23 
26 
29 
32 
35 
39 
42 
45 
48 
52 
 
60 
Cyclo-
phosphamide  
IV dose17 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cyclo-
phosphamide  
oral dosing18 
 
X→ 
→ → 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Azathioprine 
dosing19 
 
 
 
 
 
 
 
 
 
 
 
 
X→ 
→ 
→ 
 
→ 
 
→ 
 
→ 
 
→ 
 
→ 
 
→X 
Rituximab IV 
dose20 
 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concomitant 
Medications 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
If receiving 
non-study 
supplied 
glucocorticoid
s on Day 1, 
instruct 
patients 
regarding 
tapering21 
 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adverse 
Event 
Assessment 
 
X 
X 
X 
X 
X 
 
X 
 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
ET = Early Termination; F/U = Follow-up; SCR = Screening. 
1 Screening must occur expeditiously (not to exceed 14 days) in order not to delay start of treatment; screening labs may be done at the local laboratory to expedite eligibility 
assessment; results from a renal biopsy, if performed within 4 weeks prior to Day 1 will be collected on the Histology Form provided. Laboratory and urinalysis results from 
the local laboratories obtained within 72 hours of screening are acceptable in order to avoid unnecessary blood draws. 
2 A patient could be kept overnight in the hospital on Day 1, if necessary based on the patient’s condition. This hospital stay could be extended if deemed clinically necessary and 
would not be considered a serious adverse event, unless other SAE criteria are met. 
3 Visits for Weeks 1, 2, 3, and 4 may occur within a ± 2-day window. Visits for the rest of the study may occur within a ± 3-day window of the scheduled visit. 
4 Physical examination will include body weight measurement; Height will only be measured at Screening, except in adolescents (12-17 years old), in whom height will be 
measured as part of all physical examinations. 
5 These procedures must be done BEFORE taking the first dose of study medication. 
6 Assessment of heart rate, body temperature, and blood pressure (after at least 3 minutes of rest) 
7 Chest radiography (X rays or CT scan) done only if needed for TB screening or if in the clinical opinion of the Investigator there is pulmonary disease involvement that needs to 
be assessed for safety, BVAS, VDI, or GTI. 
8 Screening for TB could be done by one of the following: Interferon γ release assay (IGRA), tuberculin purified protein derivative (PPD) skin test, or chest radiography (done 
within 6 weeks prior to Screening or done during Screening).  
9 These tests do not need to be performed if results are available from tests done within the past 12 months prior to the Screening visit. 


CCX168 (avacopan) 
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 35 of 135 
10 At screening, tests for anti-proteinase-3 (PR3) and anti-myeloperoxidase (MPO) will be performed for study eligibility, if no historical data are available; for the rest of the 
study visits, ELISA tests for anti- PR3 and anti-MPO antibodies will be performed at the central laboratory. 
11 Only for patients who are 12 to 17 years old, blood samples will be taken at Hours 0 (pre-dose), 0.5, 1, 2, 3, 4, and 6 after the first dose of CCX168/placebo and plasma 
samples will be frozen and sent for expeditious measurements of CCX168 and metabolite plasma concentrations.  
12 For patients receiving cyclophosphamide, a blood sample must be taken early during the visit for WBC count at the local laboratory; the WBC count is necessary for 
cyclophosphamide dose decisions on these days. For patients receiving azathioprine, local WBC count will be done at the Week 13 visit. 
13 A clean catch, midstream urine sample will be collected. During screening, the local laboratory may perform a urinalysis for hematuria and proteinuria for eligibility 
assessment. For the rest of the visits, a urine sample will be sent to the central laboratory for urinalysis including protein, blood, and nitrites; if positive for blood, protein, or 
nitrites, a microscopic RBC count will be done. 
14 Renal biopsies are optional. In patients with renal involvement of AAV, renal histology results from biopsies performed within 4 weeks prior to Screening should be recorded 
on the provided standard Histology Form; follow-up biopsies should be performed within a 14-day window before or after the Week 52 visit, if a patient consents. 
15 Relapse assessment; relapse is defined as return of at least one major item, or three or more minor items, or one or two minor items in the BVAS recorded at two consecutive 
visits, after disease remission has been achieved previously (BVAS = 0). 
16 One bottle of CCX168/placebo will be dispensed at the Day 1 and Week 4, 7, 10, and 13 visits, and two bottles will be dispensed at the Week 16, 20, 26, 32, 39, and 45 visits. 
17 Applicable only to the IV cyclophosphamide stratum. Cyclophosphamide doses given from Day 1 through Week 13 must be given according to directions provided in the 
protocol. The date, and start and end time of the cyclophosphamide infusion will be recorded. 
18 Applicable only to the oral cyclophosphamide stratum.  Cyclophosphamide must be taken daily from Day 1 through the day before Week 15 according to the protocol.  
19 Azathioprine must be taken daily from Week 15 (for those who received IV or oral cyclophosphamide) through the end of the study, but not for those patients receiving 
rituximab. Mycophenolate will be given instead of azathioprine to patients for whom azathioprine is not suitable. 
20 Applicable only to the rituximab stratum. A rituximab dose of 375 mg/m2 IV must be given on Day 1 and Weeks 1, 2, and 3. 
21 If the patient has received glucocorticoids during the screening period, the glucocorticoid dose must be reduced to a dose not higher than 20 mg prednisone equivalent on Day 
1, and the patient must be instructed on tapering the dose to zero within a period of 4 weeks after the Day 1 visit. 
 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 36 of 135 
LIST OF ABBREVIATIONS AND ACRONYMS 
AAV 
anti-neutrophil cytoplasmic antibody associated vasculitis 
AE 
adverse event 
ALBIA 
Addressable Laser Bead ImmunoAssay 
ALT 
alanine aminotransferase 
ANA 
anti-nuclear antibodies 
ANC 
absolute neutrophil count 
ANCA 
anti-neutrophil cytoplasmic antibody 
API 
active pharmaceutical ingredient 
AST 
aspartate aminotransferase 
BID 
twice daily 
BLQ 
below limit of quantification 
BSA 
body surface area 
BUN 
blood urea nitrogen 
BVAS 
Birmingham Vasculitis Activity Score 
C3 
complement 3 
C4 
complement 4 
C3a 
complement 3a 
C4a 
complement 4a 
C5a 
complement 5a 
C5aR 
complement 5a receptor 
C5b-9 
complement 5b-9 (also called membrane attack complex) 
CA 
competent authority 
CBC 
complete blood cell 
Cmax 
maximum (plasma) concentration 
CPK 
creatinine phosphokinase 
CRA 
Clinical Research Associate (also known as the Study Monitor) 
CRF 
case report form 
CRO 
contract research organization 
CSR 
clinical study report 
CYC 
cyclophosphamide 
DMC 
Data Monitoring Committee 
EC 
ethics committee 
ECG 
electrocardiogram 
eGFR 
estimated glomerular filtration rate 
EQ-5D-5L 
EuroQOL-5D-5L 
ELISA 
enzyme linked immunosorbent assay 
FDA 
Food and Drug Administration 
g 
gram 
GBM 
glomerular basement membrane 
GCP 
good clinical practice 
GPA 
granulomatosis with polyangiitis (Wegener’s) 
GTI 
Glucocorticoid Toxicity Index 
HEENT 
head, eyes, ears, nose, throat 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 37 of 135 
HIV 
human immunodeficiency virus 
hpf 
high power field 
HRQOL 
health-related quality-of-life 
IC50 
concentration to inhibit 50% 
ICH 
International Council for Harmonisation 
IGRA 
interferon γ release assay 
INN 
International Nonproprietary Name 
IRB 
Institutional Review Board 
IRT 
interactive response technology 
ITT 
Intent-to-Treat 
IVIg 
intravenous immunoglobulin 
kg 
kilogram 
KIM-1 
kidney injury molecule-1 
LDH 
lactate dehydrogenase 
MAC 
membrane attack complex 
MCP-1 
monocyte chemoattractant protein-1 
MDRD 
Modification of Diet in Renal Disease 
MedDRA 
Medical Dictionary for Drug Regulatory Affairs 
mg 
milligram 
mL 
milliliter 
MPA 
microscopic polyangiitis 
MPO 
myeloperoxidase 
N 
number 
NGAL 
neutrophil gelatinase-associated lipocalin 
NIM 
non-inferiority margin 
NOAEL 
No observed adverse effect level 
PD 
pharmacodynamic(s) 
PK 
pharmacokinetic(s) 
PP 
Per Protocol 
PPD 
purified protein derivative 
PR3 
proteinase 3 
RBC 
red blood cell 
RTX 
rituximab 
SAE 
serious adverse event 
SAR 
serious adverse reaction 
SF-36 v2 
Short Form-36 version 2 
SOP 
standard operating procedure 
SUSAR 
suspected unexpected serious adverse reaction 
TCC 
terminal complement complex 
Tmax 
time of maximum (plasma) concentration 
TPMT 
thiopurine S-methyltransferase 
UACR 
urinary albumin:creatinine ratio 
USAN 
United States Adopted Name 
VDI 
vasculitis damage index 
WBC 
white blood cell 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 38 of 135 
1. 
INTRODUCTION 
1.1. 
Background Information 
The activation of the complement pathway generates biologically active fragments of 
complement proteins, e.g. C3a, C4a and C5a anaphylatoxins, and the C5b-9 membrane attack 
complex (MAC) or terminal complement complex (TCC), all of which mediate inflammatory 
responses by inducing leukocyte chemotaxis, activating macrophages, neutrophils, platelets, 
mast cells and endothelial cells and by increasing vascular permeability, cytolysis, and tissue 
injury. 
C5a is one of the most potent pro-inflammatory mediators of the complement system, being at 
least 100 times more potent than C3a. This 12 to 14.5 kD polypeptide, along with a C5b 
fragment, is produced by enzymatic cleavage of a C5 precursor during activation of any of the 3 
complement pathways. C5a induces expression of adhesion molecules and chemotactic 
migration of neutrophils, eosinophils, basophils, and monocytes. It also mediates inflammatory 
reactions by causing smooth muscle contraction, increasing vascular permeability, inducing 
basophil and mast cell degranulation, and inducing release of lysosomal proteases and oxidative 
free radicals. The anaphylactic and chemotactic effects of C5a are mediated through its 
interaction with the C5aR, a G protein-coupled receptor expressed on human neutrophils, 
monocytes, basophils, eosinophils, renal glomerular tissues, and lung smooth muscle and 
endothelial cells. 
CCX168 (INN/USAN avacopan as of August 2016) is an orally administered, small molecule, 
selective complement 5a receptor (C5aR) antagonist. 
As measured in vitro, CCX168 functionally inhibits C5a-mediated chemotaxis, displaces [125I]-
C5a from human C5aR, and inhibits C5a-mediated increase in cytoplasmic calcium levels with a 
potency (IC50) of 0.2 to 0.9 nM. 
CCX168 was evaluated for its ability to inhibit the C5a-mediated chemotaxis of neutrophils in 
freshly isolated human whole blood. CCX168 produced 50% inhibition (IC50) of C5a-mediation 
neutrophil migration in this assay at a concentration of 1.7 nM; 90% inhibition (A10 value) 
occurred at a CCX168 concentration of 15.4 nM. CCX168 also inhibits C5aR in cynomolgus 
monkeys and hamsters with potencies similar to that observed with human whole blood. 
However, CCX168 possesses moderate potency for rabbit C5aR (IC50 ~ 1.4 µM) and lacks 
affinity for mouse, rat, or dog C5aR (IC50 >10 µM). 
The efficacy of CCX168 was assessed using genetically-modified mice where the mouse C5aR 
coding region was substituted for the human C5aR coding region. In these studies, intravenous 
injection of mouse anti-myeloperoxidase (anti-MPO) IgG into the human C5aR knock-in mice 
caused glomerulonephritis in a manner mimicking ANCA disease in humans. At daily oral doses 
of 30 mg/kg CCX168, a marked inhibition of anti-MPO induced glomerulonephritis was 
documented histologically, as assessed by the number of necrotic and crescent-containing 
glomeruli. These results were consistent with reduced protein, leukocytes, and red blood cells in 
the urine, and reduced serum blood urea nitrogen and creatinine in mice receiving CCX168 
(Xiao et al, 2014). 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 39 of 135 
CCX168 has been evaluated in a series of safety pharmacology and toxicology studies. Results 
from these studies support chronic oral dosing of 30 mg CCX168 twice daily to humans. Refer to 
the Investigator’s Brochure for details of these studies. 
A randomized, double-blind, placebo-controlled Phase 1 study in 48 healthy volunteers was 
performed (CL001_168). This is a study in which subjects received either CCX168 or placebo 
(3:1 ratio) as a single oral dose in Period 1 and as multiple once daily or twice daily oral doses in 
Period 2. Single doses of 1, 3, 10, 30, and 100 mg CCX168 were studied. In Period 2, CCX168 
doses of 1, 3, and 10 mg once daily for 7 days, and 30 and 50 mg twice daily for 7 days, were 
studied. 
CCX168 appeared to be well tolerated by study subjects. No serious adverse events or 
withdrawals due to adverse events were observed. 
A randomized, double-blind, placebo-controlled Phase 2 clinical trial in 67 patients with anti-
neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) was performed 
(CL002_168). In this clinical trial, eligible patients were randomized to one of three treatment 
groups: 
1. Placebo twice daily orally plus cyclophosphamide/azathioprine or rituximab plus full dose 
prednisone (60 mg), 
2. 30 mg CCX168 twice daily orally plus cyclophosphamide/azathioprine or rituximab plus 
one-third dose prednisone (20 mg), or 
3. 30 mg CCX168 twice daily orally plus cyclophosphamide/azathioprine or rituximab plus no 
oral prednisone.  
The treatment period was 12 weeks, with a 12-week follow-up period. 
The aim of the trial was to determine if CCX168 could provide an effective treatment for AAV 
while also allowing for the reduction or elimination of glucocorticoids without compromising 
safety or efficacy. The primary efficacy objective was to evaluate the efficacy of CCX168 based 
on the Birmingham Vasculitis Activity Score (BVAS). 
Results showed that CCX168 plus cyclophosphamide/azathioprine or rituximab was at least as 
effective as high dose glucocorticoids plus cyclophosphamide/azathioprine or rituximab in 
treatment of patients with AAV. The BVAS response rate, defined as the proportion of patients 
with a BVAS percent change from baseline of at least 50%, with no worsening in any body 
system, at Week 12 was numerically higher and statistically non-inferior in patients receiving 
CCX168 compared to control. CCX168 treatment was effective across all specified subgroups, 
including patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis 
(MPA), and patients with proteinase-3 (PR3) or MPO ANCA disease. Remission (defined as 
BVAS of 0) was similar across treatment groups at Week 12; however, patients receiving 
CCX168 appeared to achieve remission faster than patients in the control group since more 
patients receiving CCX168 were in remission at Week 4 and stayed in remission through Week 
12. The CCX168 groups showed a more rapid improvement in albuminuria compared to control, 
and eGFR and hematuria improved similarly across treatment groups, indicating that prednisone 
was not needed if patients were taking CCX168. Urinary monocyte chemoattractant protein-1 
(MCP-1) excretion, a marker of renal inflammation, decreased more in patients receiving 
CCX168 compared to control. Health-related quality of life measurements, based on the 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 40 of 135 
EuroQOL-5D-5L (EQ-5D-5L) and Short Form-36 version 2 (SF-36 v2) instruments, generally 
showed improvement in the CCX168 groups compared to control. Based on these results, 
chronic glucocorticoid use was successfully replaced with CCX168 and the efficacy profile was 
similar or better in patients receiving CCX168 compared to the high dose glucocorticoids SOC 
control group. 
A second Phase 2 study in patients with AAV (CL003_168) was also conducted. In this study, 
two oral doses of CCX168, 10 mg and 30 mg twice daily, were tested on top of full-dose 
glucocorticoid plus either cyclophosphamide or rituximab standard of care. Results from this 
study showed that CCX168 appeared safe when given to standard of care treatment, and that the 
30 mg CCX168 dose was appropriate for further study. Refer to the Investigator’s Brochure for 
more details. 
An open-label Phase 1 clinical trial in 6 healthy volunteers was conducted to evaluate mass 
balance and the metabolic disposition of CCX168 (CL004_168). Results showed that >86% of 
the dose was recovered, with hepatic metabolism and fecal excretion being the major route of 
elimination. Urinary excretion was a minor route of elimination. CCX168 was well tolerated in 
this study. 
An open-label Phase 2 clinical trial in 7 patients with IgA nephropathy has been conducted 
(CL005_168). Proteinuria was decreased with CCX168 treatment in 6 of 7 patients. An open-
label Phase 2 clinical trial was conducted in 6 patients with atypical hemolytic uremic syndrome 
(CL006_168). Preliminary results showed that serum collected from patients dosed with 
CCX168 has a substantial reduction in thrombogenic potential compared to control serum. 
An open-label Phase 1 clinical trial in 16 healthy volunteers (CL007_168) has been conducted to 
evaluate the food effect and potential effect of CCX168 on ECG parameters. Results showed that 
a high-fat, high-calorie meal increased the Tmax by ~4 hours, and the plasma AUC by ~2-fold. It 
is therefore recommended to take CCX168 with meals. Results also showed that CCX168 does 
not adversely affect the ECG parameters including the QTcF interval. 
An open-label Phase 1 clinical trial in 32 healthy volunteers (CL008_168) to evaluate the drug-
drug interaction potential of CCX168 has been completed. Results showed that co-administration 
of CCX168 with a potent cytochrome P450 3A4 (CYP3A4) inhibitor, itraconazole, increases that 
CCX168 plasma levels ~2-fold (i.e., a moderate effect), and co-administration of CCX168 with a 
potent CYP3A4 inducer, rifampicin, decreases the CCX168 plasma levels ~90% (i.e., a strong 
effect). Therefore, it is recommended that CCX168 not be co-administered with potent CYP3A4 
inducers since this may decrease the CCX168 plasma exposure substantially. 
For more detail regarding the pharmacology and toxicology, and in-depth descriptions of clinical 
studies conducted with CCX168, please refer to the Investigator’s Brochure. 
This clinical trial will be conducted in compliance with the protocol, good clinical practice 
(GCP), and applicable regulatory requirements. 
The clinical trial will be conducted in patients with active newly-diagnosed or relapsing AAV, 
who need cyclophosphamide/azathioprine or rituximab treatment. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 41 of 135 
1.2. 
Rationale for the Study 
AAV standard therapy includes cyclophosphamide (IV or oral), and glucocorticoids. Severe 
disease warrants plasma exchange. Results from clinical trials with rituximab (Jones et al, 2010 
and Stone et al, 2010) indicated that rituximab could be used instead of cyclophosphamide 
followed by azathioprine, but that the incidence of adverse events and the mortality remain high 
with rituximab. Glucocorticoid use contributes significantly to these high morbidity and 
mortality rates (Robson et al, 2015; Little et al, 2010). Therefore, the medical need for alternate 
therapies remains high and it is important to find ways to reduce or eliminate chronic high dose 
glucocorticoid use in the treatment of patients with AAV. 
Based on encouraging results from a Phase 2 clinical trial in 67 patients with AAV 
(CL002_168), as well as preclinical studies in a human C5aR knock-in transgenic mouse model 
of AAV (Xiao et al, 2014), CCX168 has the potential to be a glucocorticoid-sparing therapy for 
this disease, with potential safety and tolerability advantages. CCX168 also showed efficacy that 
was at least as good as the standard of care regimen that included high dose glucocorticoid 
treatment. 
Hence, the clinical hypothesis of the current clinical trial is to test whether CCX168, as a 
glucocorticoid replacement therapy, in combination with cyclophosphamide followed by 
azathioprine, or in combination with rituximab is safe and effective in inducing and maintaining 
remission when compared to prednisone in combination with cyclophosphamide followed by 
azathioprine, or in combination with rituximab in patients with active AAV. 
2. 
OBJECTIVES 
2.1. 
Primary Objective 
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain 
remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, 
or in combination with rituximab. Disease remission is defined as achieving a Birmingham 
Vasculitis Activity Score (BVAS) of 0 and not taking glucocorticoids for treatment of AAV 
within 4 weeks prior to Week 26. Sustained remission is defined as remission at Week 26 
without relapse to Week 52 (BVAS of 0 and not taking glucocorticoids for treatment of AAV for 
4 weeks prior to Week 52). 
2.2. 
Secondary Objectives 
The secondary objectives of this study include: 
1. Evaluation of the glucocorticoid-induced toxicity in the CCX168 plus rituximab or 
cyclophosphamide/azathioprine group, compared to prednisone plus rituximab or 
cyclophosphamide/azathioprine, based on the Glucocorticoid Toxicity Index (GTI; 
Miloslavsky et al, 2016); 
2. Evaluation of rapidity of response in the CCX168 plus rituximab or 
cyclophosphamide/azathioprine group, compared to prednisone plus rituximab or 
cyclophosphamide/azathioprine, based on remission (BVAS of 0) at Week 4; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 42 of 135 
3. Evaluation of the safety of CCX168 plus rituximab or cyclophosphamide/azathioprine, 
compared to prednisone plus rituximab or cyclophosphamide/azathioprine based on the 
incidence of adverse events and changes in vital signs, physical examinations, clinical 
laboratory tests, and electrocardiograms (ECGs) in these patients; 
4. Assessment of health-related quality-of-life changes based on the Medical Outcomes Survey 
Short Form-36 version 2 (SF-36 v2) and EuroQOL-5D-5L (EQ-5D-5L) with CCX168 plus 
rituximab or cyclophosphamide/azathioprine, compared to prednisone plus rituximab or 
cyclophosphamide/azathioprine; 
5. Assessment of changes in parameters of renal disease including estimated glomerular 
filtration rate (eGFR), albuminuria, and urinary excretion of monocyte chemoattractant 
protein-1 (MCP-1) in patients with active renal disease at baseline with CCX168 plus 
rituximab or cyclophosphamide/azathioprine, compared to prednisone plus rituximab or 
cyclophosphamide/azathioprine; 
6. Assessment of changes in cumulative organ damage based on the Vasculitis Damage Index 
(VDI) with CCX168 plus rituximab or cyclophosphamide/azathioprine, compared to 
prednisone plus rituximab or cyclophosphamide/azathioprine; 
7. Assessment of changes in markers of pharmacodynamics in plasma and urine with CCX168 
plus rituximab or cyclophosphamide/azathioprine, compared to prednisone plus rituximab or 
cyclophosphamide/azathioprine; 
8. Evaluation of the pharmacokinetic profile of CCX168 in patients with AAV. 
3. 
STUDY DESIGN 
Standard therapy for patients with AAV, including granulomatosis with polyangiitis (GPA) and 
microscopic polyangiitis (MPA), includes cyclophosphamide followed by azathioprine or 
rituximab, plus a tapering schedule of oral glucocorticoids. Severe disease may warrant the 
addition of IV glucocorticoids and/or plasma exchange. Glucocorticoid use in these patients is 
associated with an increased risk of serious adverse events such as infections. 
Based on compelling results both from preclinical studies in a mouse model of AAV and Phase 2 
clinical trial results, CCX168 has the potential to be an effective therapy for this disease that will 
also allow for glucocorticoid sparing or elimination. Hence, the clinical hypothesis of the trial is 
to test whether CCX168 is effective in inducing and then sustaining remission in patients with 
AAV who are also treated with either cyclophosphamide/azathioprine or rituximab. 
This hypothesis will be tested in a randomized, double-blind, double-dummy, active-controlled, 
Phase 3 clinical trial in approximately 300 patients with newly diagnosed or relapsing AAV. 
3.1. 
Stratification 
To obtain balance across treatment groups, eligible patients will be stratified, prior to 
randomization, based on the following factors: 
1. One of the following treatment regimens: 
a. IV rituximab 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 43 of 135 
b. IV cyclophosphamide followed by oral azathioprine 
c. Oral cyclophosphamide followed by oral azathioprine 
2. Positive test for proteinase-3 (PR3) vs. myeloperoxidase (MPO) ANCA at diagnosis  
3. Newly-diagnosed vs. relapsing disease 
3.2. 
Randomization 
Patients will be randomized with an interactive response technology (IRT) system and a 
minimization algorithm, using the stratification factors, in a 1:1 ratio to one of two treatment 
groups: 
Group A: Placebo CCX168 plus cyclophosphamide/azathioprine or rituximab plus a full starting 
dose of prednisone; 
Group B: CCX168 plus cyclophosphamide/azathioprine or rituximab plus placebo prednisone. 
3.3. 
Study Treatments 
Treatments for each group are shown in Table 1. The selection of IV cyclophosphamide, oral 
cyclophosphamide, or IV rituximab is at the discretion of the Investigator. 
The treatment period is 52 weeks (364 days), followed by an 8-week (56 days) follow-up period.  
Study drug and other medication for vasculitis will be taken as described in Section 5.3. 
For study centers where enrollment of adolescents (12 to 17 years old) is approved, CCX168 or 
placebo dosing will initially be given based on body weight at screening and the dose will be 
adjusted based on CCX168 plasma levels on Day 1 as shown in Table 2. 
Table 1: 
CCX168/Placebo, Prednisone/Placebo, and Cyclophosphamide/Azathioprine 
or Rituximab Treatments for the Two Study Groups 
Group 
CCX168 
Active 
CCX168-
Matching 
Placebo 
Prednisone Active 
Prednisone-
Matching 
Placebo 
Cyclophosphamide 
(CYC)/azathioprine or 
Rituximab (RTX) 
A 
None 
3 Placebo 
capsules 
orally twice 
daily 
60 mg starting dose (or 
45 mg for patients <55 
kg) with standard 
tapering schedule; 
Adolescents who weigh 
≤37 kg will start at a 
prednisone dose of 30 
mg per day (see Section 
12.6). 
None 
CYC: 15 mg/kg IV up to 1.2 g 
maximum every 2 to 3 weeks 
for 13 weeks, followed by 
azathioprine 1 mg/kg/day 
starting at Week 15, with 
titration up to 2 mg/kg/day  
or  
CYC 2 mg/kg/day orally for 
14 weeks, followed by 
azathioprine 1 mg/kg/day 
starting at Week 15, with 
titration up to 2 mg/kg/day 
or 
RTX: 375 mg/m2 IV weekly x 
4 infusions. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 44 of 135 
Group 
CCX168 
Active 
CCX168-
Matching 
Placebo 
Prednisone Active 
Prednisone-
Matching 
Placebo 
Cyclophosphamide 
(CYC)/azathioprine or 
Rituximab (RTX) 
B 
3 x 10 mg 
CCX168 
capsules 
orally 
twice daily 
None 
None 
Placebo 
capsules 
CYC: 15 mg/kg IV up to 1.2 g 
maximum every 2 to 3 weeks 
for 13 weeks, followed by 
azathioprine 1 mg/kg/day 
starting at Week 15, with 
titration up to 2 mg/kg/day 
or  
CYC 2 mg/kg/day orally for 
14 weeks, followed by 
azathioprine 1 mg/kg/day 
starting at Week 15, with 
titration up to 2 mg/kg/day 
or 
RTX: 375 mg/m2 IV weekly x 
4 infusions. 
Table 2: 
CCX168/Placebo Starting Dose and Dose Adjustments Based on CCX168 
Plasma Exposure in Adolescents 
Body weight 
Initial CCX168/placebo 
dose 
CCX168 Plasma AUC0-6 
(ng•hr/mL) on Day 1 
CCX168 Dose 
Adjustment 
< 40 kg (88 lb) 
10 mg (1 capsule) twice 
daily 
≥351  
None 
 
 
<351  
Increase dose to 20 mg (2 
capsules) twice daily 
40-55 kg (88-121 lb) 
20 mg (2 capsules) twice 
daily 
351 to 699 
None 
 
 
<351 
Increase dose to 30 mg (3 
capsules) twice daily 
 
 
>699 
Decrease dose to 10 mg 
(1 capsule) twice daily 
>55 kg (121 lb) 
30 mg (3 capsules) twice 
daily 
≤699 
None 
 
 
>699 
Decrease dose to 20 mg 
(2 capsules) twice daily 
Only in 12 to 17 year old patients, blood samples will be taken pre-dosing and at Hours 0.5, 1, 2, 
3, 4, and 6 after the first CCX168 dose on Day 1 and plasma samples will be sent for expeditious 
measurement of CCX168 and CCX168-M1 in these patients. Dose adjustments will be made 
based on AUC0-6 as shown in Table 2. 
These AUC0-6 thresholds are based on the mean CCX168 plasma exposure (525 ng•hr/mL) and 
one standard deviation (174 ng•hr/mL) above or below the mean in adult patients from Phase 2 
study CL002_168 in AAV. In order to maintain the blind, some adolescent patients on placebo 
will also be instructed to modify the number of placebo capsules taken. This will be done by a 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 45 of 135 
designated person who is unblinded to the plasma CCX168 levels, and not by otherwise blinded 
study team members. 
3.4. 
Study Visits and Procedures 
All patients will visit the study center during the screening period, and, if eligible, on Day 1 and 
Weeks 1, 2, 3, 4, 7, 10, 13, 16, 20, 23, 26, 29, 32, 35, 39, 42, 45, 48, 52, and 60. 
CCX168/placebo will be taken orally in the morning, preferably with food, and in the evening, 
preferably with food. 
The screening period will be kept as short as possible in order not to delay initiation of treatment. 
The screening period must not exceed 14 days. Screening procedures will include written 
informed consent, collecting demographic data, medical history, medication history, physical 
examination and vital signs, serum chemistry tests, hematology tests, serum pregnancy test (in 
women of childbearing potential: have experienced menarche and who is not permanently sterile 
or postmenopausal; postmenopausal is defined as 12 consecutive months with no menses without 
an alternative medical cause), urinalysis (including hematuria and albuminuria), 12-lead ECG, a 
test to exclude tuberculosis (interferon γ release assay [IGRA], tuberculin purified protein 
derivative [PPD] skin test, or chest radiography [X rays or CT scan]) if not done within 6 weeks 
prior to screening, viral screening (if not done within 6 weeks prior to screening), serology (anti-
nuclear antibodies [ANA], anti-glomerular basement membrane [GBM] antibodies, IgG, IgM, 
and IgA) and complement (C3 and C4) measurements (if not done within the previous 12 
months), eGFR based on serum creatinine (Modification of Diet in Renal Disease [MDRD] 
equation for adults, and modified Schwartz equation for adolescents), ANCA measurement (anti-
PR3 and anti-MPO) if not done previously), BVAS and VDI assessments. The BVAS version 3 
will be used in this study (Mukhtyar et al, 2009; Suppiah et al, 2011).  
To expedite the screening process, blood and urine tests may be done at the local laboratories for 
only the Screening visit. Laboratory results from the local laboratories obtained within 72 hours 
of screening are acceptable in order to avoid unnecessary blood draws. Results from histology of 
renal biopsies (if performed within 4 weeks prior to Screening) will be recorded on standard 
histology forms. 
Eligible patients must be ANCA-positive (having tested positive for antibodies to PR3 or MPO 
by ELISA or ALBIA, either at the time of enrollment or in the past), and must have at least one 
“major” item, or at least 3 minor items, or at least the two renal items of proteinuria and 
hematuria in the BVAS (see Section 12.3.2 for major, minor, and renal items). Care must be 
taken to ensure that the renal items are due to vasculitis activity and not other factors such as 
menses or cyclophosphamide-related cystitis. If a patient has “other” items, not specified in the 
BVAS, these need to be discussed with the Medical Monitor before enrollment. 
Eligible patients will visit the study center on Day 1, after an overnight fast of at least 9 hours, 
for physical examination and vital signs, serum chemistry tests (including HbA1c and LDL 
cholesterol), hematology tests, serum pregnancy test (in women of childbearing potential), 
urinalysis (including hematuria, urinary albumin:creatinine ratio [UACR], and MCP-1:creatinine 
ratio assessment), eGFR, ANCA measurement (anti-PR3 and anti-MPO), SF-36 v2 and EQ-5D-
5L assessment, Glucocorticoid Toxicity Index (GTI) baseline assessment (see Section 12.5 for 
details), baseline pharmacokinetic (PK) and pharmacodynamic (PD) blood sample collection, 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 46 of 135 
stratification and randomization. Medication will be administered (IV) and dispensed (for oral 
medications). The patients will take the first dose of CCX168 or placebo, and prednisone or 
placebo while at the study center. A patient could be kept overnight in the hospital on Day 1, if 
necessary, based on the patient’s clinical condition. This hospital stay may be extended, if the 
patient’s condition requires it, and this hospital stay would not be considered a serious adverse 
event, unless other SAE criteria are met. 
Twice daily dosing of CCX168 or placebo will continue for 364 days. At post-Day 1 study visits, 
study medication will be administered according to the protocol schedule, and blood and urine 
samples will be collected for safety and efficacy and PK/PD measurements. BVAS assessments 
will be made at Screening and Weeks 4, 10, 16, 26, 39, 52, and 60. VDI assessments will be 
made at Screening and Weeks 26, 52, and 60. SF-36 v2 and EQ-5D-5L will be completed on 
Day 1 and Weeks 4, 10, 16, 26, 39, 52, and 60. GTI assessments will be performed on Day 1 and 
at Weeks 13 and 26. If a patient consents, renal biopsy for histology will be performed at Week 
52 or at the time of treatment discontinuation. Physical examinations, vital sign assessments, and 
ECG measurements will be performed throughout the study. Concomitant medication and 
adverse event assessments will be made at every study visit.  
Patients will be discharged from the study when all the Study Week 60 visit procedures have 
been completed. Each patient's condition will be evaluated by the Investigator at the end of the 
clinical trial (Week 60) and appropriate standard of care medical treatment will be provided to all 
patients as needed. 
To the extent possible, any adverse events that are deemed study drug-related and are ongoing at 
discharge will be followed to resolution or until a determination is made that the unresolved 
event is stable. 
4. 
STUDY POPULATION 
4.1. 
Size of the Population 
The aim is to enroll approximately 300 patients in this clinical trial. Patients who drop out of the 
study prematurely will not be replaced. 
4.2. 
Inclusion Criteria 
Patients must meet all of the following inclusion criteria in order to enter the study: 
1. Clinical diagnosis of granulomatosis with polyangiitis (GPA;Wegener's) or microscopic 
polyangiitis (MPA), consistent with Chapel-Hill Consensus Conference definitions (Jennette 
et al, 2013); 
2. Aged at least 18 years, with newly-diagnosed or relapsed AAV where treatment with 
cyclophosphamide or rituximab is needed; where approved, adolescents (12-17 years old) 
may be enrolled; female patients of childbearing potential may participate if adequate 
contraception is used during the study, and for at least 6 months after the last 
cyclophosphamide dose (if receiving cyclophosphamide) and at least 12 months after the last 
rituximab dose (if receiving rituximab); male patients with partners of childbearing potential 
may participate in the study if they had a vasectomy at least 6 months prior to randomization 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 47 of 135 
or if adequate contraception is used during the study, and for at least 6 months after the last 
cyclophosphamide dose (if receiving cyclophosphamide) and at least 12 months after the last 
rituximab dose (if receiving rituximab); Adequate contraception is defined as resulting in a 
failure rate of less than 1% per year (combined estrogen and progestogen [oral, intravaginal, 
or transdermal], or progestogen-only hormonal contraception [oral, injectable, or 
implantable], intra-uterine device, intra-uterine hormone releasing system, bilateral tubal 
occlusion, vasectomized partner, or true [absolute] sexual abstinence, i.e., in line with the 
preferred and usual lifestyle of the patient); for patients who will be receiving mycophenolate 
instead of azathioprine, a second form of birth control must be used if the first form of birth 
control is hormonal contraception, such as progestogen-only hormonal contraception, 
because mycophenolate reduces blood levels of the hormones in the oral contraceptive pill 
and could theoretically reduce its effectiveness; sperm donation for at least 6 months after the 
last cyclophosphamide dose (if receiving cyclophosphamide), and at least 12 months after the 
last rituximab dose (if receiving rituximab), must not be performed. 
3. Positive test for anti-PR3 or anti-MPO (current or historic) antibodies; 
4. At least one major item, or at least 3 minor items, or at least the 2 renal items of proteinuria 
and hematuria in the BVAS (see Section 12.3); care must be taken to ensure that the renal 
items are due to vasculitis activity, and not other factors such as menses or 
cyclophosphamide-related cystitis; if a patient has “other” items, not specified in the BVAS, 
these need to be discussed with the Medical Monitor before enrollment. 
5. Estimated glomerular filtration rate ≥15 mL/minute/1.73 m2 (using the MDRD method for 
adults, and modified Schwartz equation for adolescents; see Section 7.1.3) at screening; 
6. Willing and able to give written Informed Consent and to comply with the requirements of 
the study protocol; written Informed Consent should be obtained from the legal guardian in 
accordance with regional laws or regulations for patients 12 to 17 years of age, and 
7. Judged by the Investigator to be fit for the study, based on medical history, physical 
examination (including electrocardiogram [ECG]), and clinical laboratory assessments. 
Patients with clinical laboratory values that are outside of normal limits (other than those 
specified in the Exclusion Criteria) and/or with other abnormal clinical findings that are 
judged by the Investigator not to compromise patient participation in the study, may be 
entered into the study. 
4.3. 
Exclusion Criteria 
1. Pregnant or breast-feeding; 
2. Alveolar hemorrhage requiring invasive pulmonary ventilation support anticipated to last 
beyond the screening period of the study; 
3. Any other known multi-system autoimmune disease including eosinophilic granulomatosis 
with polyangiitis (Churg-Strauss), systemic lupus erythematosus, IgA vasculitis (Henoch-
Schönlein), rheumatoid vasculitis, Sjögren's syndrome, anti-glomerular basement membrane 
disease, or cryoglobulinemic vasculitis; 
4. Required dialysis or plasma exchange within 12 weeks prior to screening; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 48 of 135 
5. Have had a kidney transplant; 
6. Received cyclophosphamide within 12 weeks prior to screening; if on azathioprine, 
mycophenolate, or methotrexate at the time of screening, these drugs must be withdrawn 
prior to receiving the cyclophosphamide or rituximab dose on Day 1;  
7. Received intravenous glucocorticoids, >3000 mg methylprednisolone equivalent, within 4 
weeks prior to screening; 
8. Have been taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone-
equivalent for more than 6 weeks continuously prior to the screening visit; 
9. Received rituximab or other B-cell antibody within 52 weeks of screening or 26 weeks 
provided B cell reconstitution has occurred (i.e., CD19 count > 0.01x109/L); received anti-
TNF treatment, abatacept, alemtuzumab, IVIg, belimumab, tocilizumab, or eculizumab 
within 12 weeks prior to screening; immunosuppressive drugs not listed here must be 
discussed with the Medical Monitor; 
10. Currently taking a strong inducer of the cytochrome P450 3A4 (CYP3A4) enzyme, such as 
carbamazepine, phenobarbital, phenytoin, rifampin, or St. John’s wort; 
11. Any of the following within 12 weeks prior to screening: symptomatic congestive heart 
failure requiring prescription medication, unstable angina (unless successfully treated with 
stent or bypass surgery), clinically significant cardiac arrhythmia, myocardial infarction or 
stroke; 
12. History or presence of any form of cancer within the 5 years prior to screening, with the 
exception of excised basal cell or squamous cell carcinoma of the skin, or carcinoma in situ 
such as cervical or breast carcinoma in situ that has been excised or resected completely and 
is without evidence of local recurrence or metastasis; 
13. Evidence of tuberculosis based on interferon γ release assay (IGRA), tuberculin purified 
protein derivative (PPD) skin test, or chest radiography (X rays or CT scan) done at 
screening or within 6 weeks prior to screening;  
14. HBV, HCV, or HIV viral screening test showing evidence of active or chronic viral infection 
done at screening or within 6 weeks prior to screening; 
15. Received a live vaccine within 4 weeks prior to screening; 
16. WBC count less than 3500/μL, or neutrophil count less than 1500/μL, or lymphocyte count 
less than 500/µL before start of dosing; 
17. Evidence of hepatic disease: AST, ALT, alkaline phosphatase, or bilirubin > 3 times the 
upper limit of normal before start of dosing; 
18. Clinically significant abnormal ECG during screening, e.g., QTcF greater than 450 msec; 
19. Known hypersensitivity to CCX168 or inactive ingredients of the CCX168 capsules 
(
, cyclophosphamide or its metabolites 
(for patients scheduled to receive cyclophosphamide), or known Type I hypersensitivity or 
anaphylactic reactions to murine proteins, Chinese Hamster Ovary cell proteins, or to any 
component of rituximab (for patients scheduled to receive rituximab), or any 
contraindications or hypersensitivity to the use of azathioprine, cyclophosphamide, 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 49 of 135 
mycophenolate, or prednisone, or excipients, where applicable, as per the local prescribing 
information; for patients who will receive azathioprine, concomitant use with allopurinol is 
contraindicated; 
20. For patients scheduled to receive cyclophosphamide treatment, urinary outflow obstruction, 
active infection (especially varicella zoster infection), or platelet count < 50,000/L before 
start of dosing; 
21. Participated in any clinical study of an investigational product within 30 days prior to 
screening or within 5 half-lives after taking the last dose;  
22. Participated previously in a CCX168 study; and 
23. History or presence of any medical condition or disease which, in the opinion of the 
Investigator, may place the patient at unacceptable risk for study participation. 
4.4. 
Removal of Patients from Therapy of Assessment 
Investigators must clearly distinguish between study drug treatment discontinuation and study 
withdrawal. Patients who discontinue study drug treatment or who initiate medication changes 
(including those prohibited by the protocol) will not be automatically withdrawn from the study, 
but all efforts must be made to continue to follow the patients for all regularly scheduled visits.  
Investigators must take appropriate measures to make sure that patients are motivated to comply 
with all requirements of the protocol in order to minimize the amount of missing data. Patients 
who discontinue study treatment early or initiate medication changes (including those prohibited 
by the protocol) should continue to be followed for all regularly scheduled visits for safety and 
efficacy assessments. Investigators and their staff must take measures to actively maintain 
contact with their patients in the study, such as telephone calls, texts, or emails between visits, 
and offers for transportation support to visit the study site. 
Patients may be withdrawn from the study for only one of the following two reasons: 
1. Patient withdrawal of consent to contribute additional outcome information; 
2. Loss to follow-up. 
Patients may discontinue study drug treatment for any of the following reasons: 
1. Patient withdrawal of consent; 
2. The Investigator may discontinue study drug treatment if, in his/her clinical judgment, it is in 
the best interest of the patient; 
3. The Sponsor may request discontinuation of study drug treatment for safety reasons. 
If a patient develops a Grade 3 or higher adverse event considered possibly related to study 
medication (CCX168/placebo), the study medication needs to be suspended, and may only be re-
started if the event has resolved and the Investigator considers it appropriate to do so. 
If a patient develops Grade 3 or  greater increased hepatic transaminases (>5 times the upper 
limit of normal), or if a patient develops Grade 2 or greater increased transaminases (>3 times 
the upper limit of normal) with elevation of bilirubin to >2 times the upper limit of normal, 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 50 of 135 
dosing with study drug (CCX168/placebo) must be paused in this patient, and evaluation for 
possible drug-induced liver injury must be undertaken. 
Study medication (CCX168 or placebo) must be permanently discontinued if any of the 
following markers of hepatic injury and/or impaired liver synthetic activity are observed, and 
cannot be attributed to a reversible etiology unrelated to study medication (e.g. cholelithiasis): 
• 
ALT or AST >8xULN 
• 
ALT or AST >5xULN for more than 2 weeks 
• 
ALT or AST >3xULN and (Total Bilirubin >2xULN or INR >1.5) 
• 
ALT or AST >3xULN with the appearance of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%) 
If drug induced hepatic toxicity is ruled out following complete evaluation and if all labs have 
returned to normal, then resumption of study drug may be considered only after discussion with 
and the agreement of the Medical Monitor. If study drug is resumed, hepatic transaminases and 
bilirubin are to be monitored closely. 
If a patient develops Grade 3 or greater leukopenia (WBC count < 2 x 109/L) or neutropenia (< 1 
x 109/L), or grade 4 lymphopenia (< 0.2 x 109/L), then study drug must be paused in this patient. 
In addition, if a patient develops Grade 2 leukopenia (WBC count <3 x 109/L, but 2 x 109), the 
patient must be followed closely for infection and for further significant reduction (reduction by 
an additional 0.5 x 109/L, or to < 2 x 109/L) in WBC count; if either occurs, then study drug must 
be paused in this patient. Study drug may be resumed only if the abnormal value returns to 
normal and the Investigator deems resumption to be appropriate.  
If a patient develops grade 3 or worse CPK increase (>5 times the upper limit of normal), dosing 
with study drug must be paused in this patient. Study drug may be resumed only if the CPK 
returns to normal levels. 
In the event of early withdrawal from the study, the tests and evaluations listed for the Early 
Termination visit in Section 6.27 will be performed, whenever possible. Data collected at this 
visit will be designated as an “Early Termination” visit in the EDC. The Sponsor should be 
notified of all study drug treatment and study withdrawals in a timely manner. 
Extra glucocorticoid treatment, i.e., that was not provided as study medication must be avoided 
as much as possible during the study. However, patients who experience a relapse of their AAV 
during the study may be treated with IV glucocorticoids (typically 0.5 to 1 g methylprednisolone 
per day for 3 days) and/or oral glucocorticoids, tapered according to the patient's condition. A 
relapse is defined as worsening of disease, after having previously achieved remission (BVAS = 
0), that involves: 
• one or more major item in the BVAS, or  
• three or more minor items in the BVAS, or 
• one or two minor items in the BVAS recorded at two consecutive study visits.  
These patients may continue study drug treatment and should continue in the study. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 51 of 135 
Patients who experience worsening of disease that involves a major item in the BVAS may be 
treated with IV glucocorticoids (typically 0.5 to 1 g methylprednisolone per day for 3 days) 
and/or oral glucocorticoids, tapered according to the patient's condition. Worsening not involving 
a major item in the BVAS may be treated with a short burst (i.e., not more than 2 weeks) of oral 
glucocorticoids, at a maximum dose of 20 mg prednisone equivalent. Patients experiencing 
worsening of disease may continue study drug treatment and should continue in the study. 
Patients who have one or more major items in the BVAS before study entry, and who do not 
show an improvement or stabilization of these items within the first 4 weeks of the study, may 
receive additional IV or oral glucocorticoids, tapered according to the patient’s condition. 
Patients who relapse may require additional immunosuppressive therapy. If the Investigator 
considers giving other medications, such as additional rituximab or cyclophosphamide treatment, 
these should be discussed with the Medical Monitor. These patients may continue study drug 
treatment and should continue in the study. 
Refer to Section 12.6.2 for more detail on use of non-study supplied glucocorticoids prior to the 
screening period, during the screening period, and during the treatment period. 
5. 
STUDY MEDICATION/TREATMENT 
5.1. 
Product Characteristics 
CCX168 will be administered orally as hard gelatin capsules containing 10 mg CCX168. The 
capsules are manufactured under current good manufacturing practice. All doses of study 
medication will be administered orally. The CCX168 capsules will be supplied to the study 
centers in plastic bottles containing 180 capsules. This is sufficient for 30 days of dosing at 30 
mg CCX168 twice daily. 
CCX168-matching placebo will be administered orally as matching hard gelatin capsules 
containing no CCX168. The capsules are manufactured under current good manufacturing 
practice. All doses of study medication will be administered orally. The placebo capsules will be 
supplied to the study centers in plastic bottles containing 180 capsules. This is sufficient for 30 
days of twice daily dosing. 
Prednisone will be administered orally as hard gelatin capsules containing either 20 mg or 5 mg 
prednisone. The capsules are manufactured under current good manufacturing practice. All doses 
of prednisone will be administered orally. The prednisone capsules will be supplied to the study 
centers in plastic bottles containing 30 capsules of either 20 mg or 5 mg prednisone. The dose of 
prednisone will be tapered according to a standard schedule (see Section 12.6). 
Prednisone-matching placebo will be administered orally as hard gelatin capsules containing 
placebo tablets. The capsules are manufactured under current good manufacturing practice. All 
doses of prednisone-matching placebo will be administered orally. The prednisone-matching 
placebo capsules will be supplied to the study centers in plastic bottles containing 30 capsules, 
matching either 20 mg or 5 mg prednisone capsules. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 52 of 135 
5.2. 
Randomization and Method of Treatment Assignment 
Eligible patients will be enrolled, stratified based on three stratification factors (i.e., IV 
rituximab, IV cyclophosphamide, or oral cyclophosphamide use, anti-PR3 or anti-MPO AAV, 
and newly-diagnosed or relapsing disease), and then randomized to one of the two treatment 
groups in a ratio of 1:1, control:CCX168. Randomization will be performed centrally via an 
interactive response technology (IRT) system and minimization algorithm, using the 
stratification factors. In order to protect the blinding, the randomization schedule will not be 
accessible to study personnel who have contact with study centers or who are involved in data 
management and analysis. 
5.3. 
Doses and Regimens 
Treatments for each group are shown in Table 2. 
Adult patients will receive 30 mg CCX168 or matching placebo twice daily. For patients who are 
12 to 17 years old, initial CCX168 or placebo doses will be selected based on body weight, and 
further refined based on CCX168 plasma exposure according to Table 2. 
The treatment period is 52 weeks (364 days), followed by an 8-week (56 days) follow-up period. 
Study drug and other medication for vasculitis will be taken as follows by study patients: 
Group A (control group): 
• Three CCX168-matching placebo capsules in the morning, preferably with food, and 3 in 
the evening, preferably with food, approximately 12 hours after the morning dose, daily 
for 52 weeks (364 days). 
• Prednisone 60 mg orally per day if the patient's body weight is ≥55 kg, or 45 mg per day 
if the patient's body weight is <55 kg, starting on Day 1 with tapering according to the 
protocol-specified schedule. Adolescents who weigh ≤37 kg will start at a prednisone 
dose of 30 mg per day (see Section 12.6). 
• If a patient is in the IV cyclophosphamide stratum, cyclophosphamide 15 mg/kg IV up to 
1.2 g maximum will be given on Day 1 and also at the Week 2, 4, 7, 10, and 13 study 
visits. The cyclophosphamide dose will be adjusted based on the patient’s age, eGFR, and 
WBC count according to protocol-specified criteria (see Section 12.7). Starting at Week 
15, all patients will receive oral azathioprine at a starting dose of 1 mg/kg/day, with 
titration up to a target dose of 2 mg/kg/day at 2 weeks (see Section 12.7 . If azathioprine 
is not tolerated, mycophenolate mofetil at a target dose of 2 g/day may be given. If 
mycophenolate mofetil is not tolerated or not available, enteric coated mycophenolate 
sodium may be given at a target dose of 1440 mg/day. 
• If a patient is in the oral cyclophosphamide stratum, cyclophosphamide 2 mg/kg/day 
(maximum 200 mg/day) will be given orally starting on Day 1 and continuing up to the 
day before Week 15. The cyclophosphamide dose will be adjusted based on the patient’s 
age, eGFR, and WBC count according to protocol-specified criteria (see Section 12.7). 
Starting at Week 15, all patients will receive oral azathioprine at a starting dose of 1 
mg/kg/day, with titration up to a target dose of 2 mg/kg/day at 2 weeks (see 
Section 12.7). If azathioprine is not tolerated, mycophenolate mofetil at a target dose of 2 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 53 of 135 
g/day may be given. If mycophenolate mofetil is not tolerated or not available, enteric 
coated mycophenolate sodium may be given at a target dose of 1440 mg/day. 
• If in the rituximab stratum, rituximab IV will be given on Day 1, and then Weeks 1, 2, 
and 3 at a dose of 375 mg/m2 at each visit for a total of 4 weekly infusions (see 
Section 12.8). 
Group B (CCX168): 
• Three 10 mg CCX168 capsules in the morning, preferably with food, and 3 in the 
evening, preferably with food, approximately 12 hours after the morning dose, daily for 
52 weeks (364 days). 
• Prednisone-matching placebo capsules equivalent to 60 mg orally per day if the patient's 
body weight is ≥55 kg, or 45 mg per day if the patient's body weight is <55 kg, starting 
on Day 1 with tapering according to a protocol-specified schedule. Adolescents who 
weigh ≤37 kg will start at a prednisone-matching placebo dose of 30 mg per day (see 
Section 12.6). 
• If a patient is in the IV cyclophosphamide stratum, cyclophosphamide 15 mg/kg IV up to 
1.2 g maximum will be given on Day 1 and also at the Week 2, 4, 7, 10, and 13 study 
visits. The cyclophosphamide dose will be adjusted based on the patient’s age, eGFR, and 
WBC count according to protocol-specified criteria (see Section 12.7). Starting at Week 
15, all patients will receive oral azathioprine at a starting dose of 1 mg/kg/day, with 
titration up to a target dose of 2 mg/kg/day at 2 weeks (see Section 12.7). If azathioprine 
is not tolerated, mycophenolate mofetil at a target dose of 2 g/day may be given. If 
mycophenolate mofetil is not tolerated or not available, enteric coated mycophenolate 
sodium may be given at a target dose of 1440 mg/day. 
• If a patient is in the oral cyclophosphamide stratum, cyclophosphamide 2 mg/kg/day 
(maximum 200 mg/day) will be given orally starting on Day 1 and continuing up to the 
day before Week 15. The cyclophosphamide dose will be adjusted based on the patient’s 
age, eGFR, and WBC count according to protocol-specified criteria (see Section 12.7). 
Starting at Week 15, all patients will receive oral azathioprine at a starting dose of 1 
mg/kg/day, with titration up to a target dose of 2 mg/kg/day at 2 weeks (see 
Section 12.7). If azathioprine is not tolerated, mycophenolate mofetil at a target dose of 2 
g/day may be given. If mycophenolate mofetil is not tolerated or not available, enteric 
coated mycophenolate sodium may be given at a target dose of 1440 mg/day. 
• If in the rituximab stratum, rituximab IV will be given on Day 1, and then Weeks 1, 2, 
and 3 at a dose of 375 mg/m2 at each visit for a total of 4 weekly infusions (see 
Section 12.8). 
The dose regimens selected for oral prednisone, IV cyclophosphamide, oral cyclophosphamide, 
IV rituximab, oral azathioprine, and oral mycophenolate are in line with current standard clinical 
practice. 
The study will be double-blind, double-dummy, i.e., placebo capsules will be identical in 
appearance to the CCX168 capsules, and prednisone capsules will also have matching placebo 
capsules. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 54 of 135 
Patients in Group A will receive one bottle of CCX168-matching placebo capsules on Day 1 and 
Weeks 4, 7, 10, and 13, and two bottles at the Week 16, 20, 26, 32, 39, and 45 visits. Patients 
will be asked to take 3 capsules every morning, preferably with food, and 3 capsules every 
evening, preferably with food, as instructed. Patients will be asked to bring all bottles, whether 
empty or not, to the study center at each study visit. Capsules will be taken with water. Patients 
in Group A will also take prednisone capsules as indicated in Section 12.6.  
Patients in Group B will receive one bottle of CCX168 capsules on Day 1 and Weeks 4, 7, 10, 
and 13, and two bottles at the Week 16, 20, 26, 32, 39, and 45 visits. Patients will be asked to 
take 3 capsules every morning, preferably with food, and 3 capsules every evening, preferably 
with food, as instructed. Patients will be asked to bring all bottles, whether empty or not, to the 
study center at each study visit. Capsules will be taken with water. Patients in Group B will also 
take prednisone-matching placebo capsules as indicated in Section 12.6. 
Prednisone will be given as tablets, over-encapsulated with hard gelatin capsules in order to 
maintain the blind. Two dose strengths of prednisone will be provided, 20 mg and 5 mg. 
Prednisone-matching placebo will be given as matching hard gelatin capsules with inert contents. 
Each patient will receive one or more bottles containing prednisone or placebo prednisone on 
Study Day 1, and Week 1, 2, 3, 4, 7, 10, 13, and 16 visits. Each bottle will contain either 20 mg 
or 5 mg prednisone capsules, or matching placebo capsules. Patients will be provided with 
detailed instructions regarding the number of capsules to take each day from each bottle (see 
Section 12.6 for more detail). The dose of prednisone in Group A will be tapered over the course 
of the study (see Section 12.6 for the tapering schedule). 
Please refer to Section 12.6.2 for non-study supplied glucocorticoid use. 
5.4. 
Rationale for Dose Selection 
Single doses of 1 mg up to 100 mg CCX168 were studied in a Phase 1 study (CL001_168) in 48 
healthy volunteers, and once daily doses of 1, 3, and 10 mg CCX168 and twice daily doses of 30 
mg and 50 mg for up to 7 days were studied in the multiple dose period of the study. Doses from 
3 mg up to 100 mg twice daily for 7 days were tested in 16 healthy volunteers in Phase 1 study 
CL007_168, and 30 mg single doses and 30 mg twice daily doses for 17 days in Phase 1 study 
CL008_168. All these CCX168 doses were found to be safe in these studies. 
A dose of 30 mg CCX168 twice daily given for 12 weeks was studied in clinical trial 
CL002_168 in patients with AAV. This dose regimen was shown to be effective and safe in 
study CL002_168. Doses of 10 mg and 30 mg CCX168 twice daily given for 12 weeks were 
studied in clinical trial CL003_168 in patients with AAV and found to be safe. 
A dose of 30 mg CCX168 twice daily has been selected for this Phase 3 study in patients with 
AAV, which is lower than the maximum dose of 100 mg twice daily tested in study CL007_168. 
A dose regimen of 30 mg CCX168 twice daily provides trough (Cmin) plasma CCX168 
concentrations that provide at least 95% C5aR blockade on blood neutrophils continuously 
throughout the day. This level of C5aR coverage is deemed appropriate to achieve optimal 
pharmacology based on blockade of C5a-induced CD11b upregulation and C5a-induced 
migration of neutrophils in in vitro assays conducted in whole blood samples obtained from 
subjects in Phase 1 clinical trial CL001_168. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 55 of 135 
Based on the favorable safety profile observed in the long-term toxicology studies (26 weeks in 
rats and 44 weeks in cynomolgus monkeys), and on the safety and tolerability results from the 
clinical trials conducted to date, the risk for serious or unanticipated untoward events associated 
with CCX168 occurring in this clinical trial is considered low. 
5.5. 
Drug Supply 
5.5.1. 
Packaging and Labeling 
CCX168 capsules containing 10 mg CCX168 and identical appearing placebo capsules will be 
packaged in high density polyethylene (HDPE) bottles with child-resistant screw caps and 
provided to the study sites for dispensing. Each bottle will contain 180 capsules. 
Prednisone capsules containing either 20 mg or 5 mg prednisone, and identical appearing 
placebo capsules will be packaged in HDPE bottles with child-resistant screw caps and provided 
to the study sites. Each bottle will contain 30 capsules. 
Cyclophosphamide (oral or IV), azathioprine, mycophenolate (if needed), and rituximab will be 
prescribed and provided by the study centers. 
5.5.2. 
Storage 
CCX168 and CCX168-matching placebo capsules, as well as prednisone and prednisone-
matching placebo capsules will be stored according to label instructions. Access should be 
restricted to pharmacy staff or to the designated responsible member of the Investigator’s staff, 
and to the study monitor. The Investigator agrees that neither s/he nor any of the study staff will 
supply study medication to any persons other than those enrolled in the study. 
5.6. 
Blinding 
This study is double-blind, double-dummy. Blinding of the study will be achieved by the 
following measures: 
1. The study drug bottles and capsule appearance for CCX168 and its matching placebo, as well 
as prednisone and its matching placebo, will be identical; 
2. Limited access to the randomization code; Sponsor personnel, study site personnel, study 
patients, personnel responsible for study monitoring, and biostatisticians and data managers 
involved in data analysis of the study will remain blinded to treatment assignment for the 
duration of the study; 
3. While laboratory personnel conducting the PK assays will not be blinded to treatment 
assignment, unblinded CCX168 plasma concentration results will not be shared with the 
study site personnel or study staff who have direct contact with study sites during the study; 
4. Efficacy data that could potentially be unblinding, i.e., urinary MCP-1:creatinine ratio, 
UACR, HbA1c, LDL cholesterol, and WBC and neutrophil count data within the normal 
range will not be made available to study site personnel, study patients, personnel responsible 
for study monitoring, and biostatisticians and data managers during the study unless for 
safety monitoring. Investigators will be provided with safety laboratory data reports, flagging 
abnormally high and low values to make informed decisions regarding patient care. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 56 of 135 
Treatment assignments for individual patients will remain blinded to the study team, 
investigators, and patients until after the study database has been cleaned and locked. Designated 
study staff will be provided with instructions regarding how to unblind an individual patient 
treatment assignment. An individual patient treatment assignment may be unblinded only in the 
case of an adverse event that requires knowledge of the study medication received by the patient 
in order to provide appropriate treatment or management of the adverse event. The study monitor 
and Sponsor should be notified as soon as possible in the event that unblinding of an individual 
patient’s treatment assignment occurs prior to study completion. 
An external data monitoring committee (DMC) will be constituted prior to start of the study (see 
Section 7.6). The DMC members will review data periodically over the course of the study in an 
unblinded manner. The DMC will provide recommendations to the Sponsor regarding further 
conduct of the study. The DMC will operate according to a charter developed prior to study 
initiation. 
5.7. 
Drug Accountability 
The study pharmacist and Investigator must maintain accurate records of dates and quantities of 
product(s) received, to whom dispensed (patient-by-patient accounting), and accounts of any 
product accidentally or deliberately destroyed. The Investigator must retain all unused and/or 
expired study supplies until the study monitor has confirmed the accountability data. 
5.8. 
Treatment Compliance 
The CCX168 and CCX168-matching placebo capsules, and prednisone and prednisone-matching 
placebo capsules, will be self-administered by participating study patients. The morning dose of 
study drug on Day 1 will be taken in the presence of study site personnel. Patients will be 
provided with dosing instructions at the start of the study, and will be encouraged by study site 
personnel to take the study medication according to the instructions for the duration of the study. 
Patients will be instructed to bring the assigned bottles of study medication to the site staff at 
each study visit, whether empty or not. The study drug dispensed will be checked, and a capsule 
count will be done from Week 4 through Week 52 of any remaining CCX168 or placebo 
capsules and from Week 1 through 20 of prednisone or matching placebo capsules. This 
information will be recorded and entered into the electronic data capture (EDC) system. 
CCX168 plasma concentration measurements over the course of the study may also be used to 
assess patient compliance. Any events of non-compliance to the protocol will be documented in 
the study records. 
5.9. 
Concomitant Medications and Restrictions 
Use of any drug other than protocol-specified CCX168 or CCX168-matching placebo, oral 
prednisone or prednisone-matching placebo supplied as part of the study medication, IV or oral 
cyclophosphamide or rituximab, azathioprine, medication to treat relapses, worsening of disease, 
or non-responders, or prophylactic medicine as described below is prohibited over the course of 
the study. This includes use of mycophenolate (except if used instead of azathioprine), 
methotrexate, anti-TNF treatment, abatacept, alemtuzumab, IVIg, belimumab, tocilizumab, 
eculizumab, or other experimental or immunosuppressive drugs. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 57 of 135 
Drugs that are strong inducers of CYP3A4 enzyme, such as carbamazepine, phenobarbital, 
phenytoin, rifampin, or St. John’s wort are prohibited during the study, because these drugs may 
substantially reduce the plasma concentrations of CCX168 and reduce its effectiveness. 
Substances that are strong inhibitors of CYP3A4, such as boceprevir, clarithromycin, conivaptan, 
indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, 
posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, and voriconazole, and grapefruit 
juice should be avoided during the study, because these may modestly increase (~2-fold) the 
plasma concentrations of CCX168. However, these are not absolutely contra-indicated. In case it 
is inevitable to use these concomitantly with CCX168, patients should be monitored carefully for 
any untoward side effects. 
Patients need to receive appropriate prophylactic therapy during the course of the study. This 
includes prophylaxis against Pneumocystis jirovecii (formerly carinii) infections 
(sulfamethoxazole 400 mg-trimethoprim 80 mg daily or sulfamethoxazole 800 mg-trimethoprim 
160 mg every second day; atovaquone 1500 mg/day orally (once daily or divided twice daily, 
with food), aerosolized pentamidine 300 mg every 4 weeks, or oral dapsone 100 mg/day may be 
given in case sulfamethoxazole-trimethoprim is contra-indicated), osteoporosis, nausea, and 
therapy for gastroprotection. 
Please refer to Section 12.6.2 for more detailed guidance regarding allowed non-study supplied 
glucocorticoid use. 
All concomitant medications taken during the course of the study must be recorded meticulously 
on the concomitant medication pages of the CRF. 
Patients will be receiving various concomitant therapies in this trial, e.g., rituximab, IV or oral 
cyclophosphamide, and azathioprine or mycophenolate. There are precautions listed in the 
prescribing information for each of these drugs. The local prescribing information for each 
concomitant drug must be consulted prior to its use, so that these precautions can be taken into 
consideration. Adverse events observed with these drugs are summarized in Section 12.10 for 
prednisone, Section 12.9 for cyclophosphamide, Section 12.11 for rituximab, Section 12.12 for 
azathioprine, and Section 12.13 for mycophenolate mofetil. 
6. 
STUDY PROCEDURES 
6.1. 
Screening and Enrollment 
Informed Consent must be obtained prior to performance of any study-specific tests or 
evaluations. It is important to complete the screening procedures in the shortest time possible to 
allow patients to start treatment. Within a period not to exceed 14 days prior to randomization, 
patients will undergo the following evaluations to determine their eligibility for study 
participation: 
• Recording of demographic data and medical history in the EDC; 
• Recording of all prior medications for AAV for the 12-month period prior to screening in 
the EDC; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 58 of 135 
• Recording of all other prior medications for the 6-month period prior to screening in the 
EDC; 
• Recording of all other concomitant medications on the screening day(s) in the EDC; 
• In order to expedite the screening process, blood may be collected for testing at the local 
laboratory for the following: 
− Urinalysis, serum chemistry and hematology tests (results from tests done within 72 
hours prior to screening may be used for eligibility assessment); 
− Serum pregnancy test (in women of childbearing potential: have experienced 
menarche and who is not permanently sterile or postmenopausal; postmenopausal is 
defined as 12 consecutive months with no menses without an alternative medical 
cause); 
− An estimated glomerular filtration rate will be calculated based on the following 
Modification of Diet in Renal Disease (MDRD) study equation for adults, and 
modified Schwartz equation (Schwartz et al, 2009) for adolescents: 
MDRD: eGFR (mL/min/1.73 m2) = 175 x (serum creatinine in mg/dL)-1.154 x 
(Age)-0.203 x (0.742 if female) x (1.212 if African-American/Black). 
Modified Schwartz: eGFR = (0.413 x Height [in cm]) / Serum creatinine (in 
mg/dL) 
− ANCA measurement (anti-PR3 and anti-MPO antibody levels) if not done previously; 
− Virology assessments as detailed in Section 7.2.2, unless done within 6 weeks prior to 
screening; 
− Serology and complement assessments as detailed in Section 7.2.2. These tests do not 
need to be performed if results are available from tests done within the past 12 
months prior to the Screening visit. Results from the prior tests must be recorded in 
the EDC. 
• Results from tests that have been performed prior to screening may be used to determine 
study eligibility if these tests were performed as part of the practice of medicine and were 
done whether or not study entry was contemplated, such as for diagnosis or treatment of 
the patient’s condition. Results from the prior tests must be recorded in the EDC. 
• BVAS assessment (see Section 12.3); to be eligible for enrollment, a patient must have: 
− At least one “major” item (see bold italicized items in Section 12.3.2) in BVAS, or 
− At least three minor items in BVAS, or 
− At least the two renal items of proteinuria and hematuria due to vasculitis (and not 
other factors such as menses or cyclophosphamide-related cystitis), i.e.: 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 59 of 135 
o Proteinuria >1+ on urinalysis or >0.2 g/g creatinine, and 
o Hematuria (“moderate” on urinalysis or ≥10 RBC per high power field, usually 
accompanied by RBC casts). 
If a patient has “other” items, not specified in the BVAS, these need to be discussed with the 
Medical Monitor before enrollment. 
• VDI assessment (see Section 12.4); 
• A clean catch, midstream urine sample will be collected and may be sent to the local 
laboratory, instead of the central laboratory, to expedite screening in order to perform 
urinalysis for hematuria, RBC casts, and proteinuria; 
• A physical examination will be performed; body weight, height, and body mass index 
will be determined; 
• Vital signs (temperature, blood pressure, heart rate) will be measured after at least 3 
minutes of rest; 
• A 12-lead ECG, after at least 3 minutes of rest, will be recorded and assessed for any 
clinically significant abnormality; 
• At least one of the following tests to exclude tuberculosis: interferon γ release assay 
(IGRA), tuberculin purified protein derivative (PPD) skin test, or chest radiography (X 
rays or CT scan); tests performed within 6 weeks prior to screening are allowed to assess 
eligibility; chest radiography may also be needed for BVAS and VDI assessment; 
• If a renal biopsy has been performed within 4 weeks prior to screening, or during 
screening, the standard Histology Form will be completed and data entered into EDC; a 
copy of the biopsy results will be kept in the study records. 
• Please refer to Section 12.6.2.2 for allowable glucocorticoid use during the screening 
period. 
• After all screening procedures have been completed, and the patient satisfies all 
eligibility criteria, the study schedule will be discussed with the patient and the schedule 
will be provided to the patient to ensure compliance with the study visits. 
• The patient will be reminded to come to the clinic after an overnight fast of at least 9 
hours prior to the Day 1 study visit for the LDL cholesterol measurement. 
6.2. 
Study Day 1 
If eligible for the study, the patient will visit the study center on Day 1, after an overnight fast of 
at least 9 hours for the LDL cholesterol measurement. The following procedures will be 
performed before taking the first dose of CCX168 or placebo: 
• Stratification and randomization in the IVRS; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 60 of 135 
• A physical examination including body weight; height will also be measured in 12-17 
year old patients; 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, hematology, serum pregnancy test (in women of childbearing potential), 
ANCA (anti-PR3 and anti-MPO ELISA) measurement, HbA1c, LDL cholesterol, PK and 
PD baseline measurements; 
• A blood sample will also be taken for an expedited WBC count at the local laboratory in 
order to determine the appropriate cyclophosphamide dose for patients who are in the 
cyclophosphamide strata (see Section 12.7); 
• Patients will be asked to complete the SF-36 v2 and EQ-5D-5L; 
• Items will be collected to support calculation of the Glucocorticoid Toxicity Index (GTI; 
see Section 12.5); 
• Any pre-treatment adverse events (from time of the screening visit) will be recorded; 
• A clean catch, midstream urine sample will be collected, aliquoted, and sent to the central 
laboratory for urinalysis (including blood, protein, and nitrites; if positive for blood, 
protein, or nitrites, a microscopic assessment for RBC casts and RBC count will be 
performed), albumin, MCP-1, and creatinine measurement (for UACR and MCP-
1:creatinine), and urinary PD markers related to inflammation and the complement 
system; 
• A saliva sample will be collected for genetic marker assessments in patients who have 
provided consent. 
The patient will be stratified and randomized, and the following procedures will be performed: 
• Study medication (1 bottle of CCX168 or CCX168-matching placebo, and 1 bottle of 20 
mg prednisone and/or prednisone-matching placebo if ≥55 kg, and 1 bottle of 20 mg 
prednisone and/or prednisone-matching placebo plus 1 bottle of 5 mg prednisone and/or 
prednisone-matching placebo if <55 kg) will be provided to the patient with dosing 
instructions (see Section 12.6); 
• The patient will be asked to take the first doses of study medication while at the study 
center; 
• The time of the dosing of CCX168 or CCX168-matching placebo, as well as the time of 
dosing of prednisone or prednisone-matching placebo, will be recorded; 
• If the patient is 12 to 17 years old, blood samples will be taken at Hour 0.5, 1, 2, 3, 4, and 
6 after the first dose of CCX168 and plasma samples will be frozen and sent for 
expeditious measurement of CCX168 and metabolite plasma concentrations; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 61 of 135 
• Cyclophosphamide IV or oral dose will be given after receipt of the local WBC count 
(see Section 12.7) to patients in the cyclophosphamide strata; The start and end times of 
the infusion and the dose time of the oral dose will be recorded; 
• Rituximab will be given to patients in the rituximab stratum (see Section 12.8); A dose of 
375 mg/m2 will be given IV; The start and end times of the infusion will be recorded; 
• Any changes in concomitant medication use will be recorded; 
• If the patient is on non-study supplied glucocorticoids, the dose on Day 1 may not exceed 
20 mg prednisone-equivalent, and the patient will be provided with instructions regarding 
tapering to a dose of zero within a period of 4 weeks from Day 1; if glucocorticoids 
cannot be tapered to a dose of zero due to adrenal insufficiency the adverse event of 
adrenal insufficiency and treatment administered must be recorded, along with the 
evidence supporting the diagnosis; 
• Any post-dosing adverse events will be recorded; 
• A patient could be kept overnight in the hospital on Day 1, and longer, if necessary. This 
hospital stay would not be considered a serious adverse event, unless other SAE criteria 
are met; 
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 1 study visit; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study; 
− Take the CCX168 or matching placebo, prednisone or matching placebo, as well as 
oral cyclophosphamide, if applicable, as instructed, and 
− Continue taking all their other concomitant medications as usual. 
6.3. 
Study Week 1 (Day 8) 
The Study Week 1 visit must occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12 to17 
year-old patients; 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, hematology, PK, and PD measurements; 
• The date and time of the last dose of CCX168/placebo prior to collection of the PK 
sample will be recorded; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 62 of 135 
• If the patient has not yet taken the morning dose of CCX168/placebo for this day, the 
patient will be asked to take the dose; 
• A clean catch, midstream urine sample will be collected and aliquoted for urinalysis, 
UACR, urinary MCP-1:creatinine ratio, and PD assessment, and sent to the central 
laboratory. 
• The bottle of study medication will be checked to make sure the patient is taking the 
study medication as instructed; 
• Drug accountability will be performed on the study-supplied prednisone bottles; 
• One bottle of 20 mg prednisone or matching placebo and one bottle of 5 mg prednisone 
or matching placebo will be dispensed with appropriate dosing instructions (see 
Section 12.6); 
• If on oral cyclophosphamide, the patient will be questioned to confirm compliance; any 
change in cyclophosphamide dose, based on WBC count and eGFR, will be recorded; 
• Rituximab will be given to patients in the rituximab stratum (see Section 12.8); A dose of 
375 mg/m2 will be given IV; The start and end times of the infusion will be recorded; 
• Any changes in concomitant medication use will be recorded; 
• If the patient is on non-study supplied glucocorticoids, the tapering schedule will be 
discussed with the patient to ensure that tapering to a dose of zero occurs within a period 
of 4 weeks from Day 1; if glucocorticoids cannot be tapered to a dose of zero due to 
adrenal insufficiency the adverse event of adrenal insufficiency and treatment 
administered must be recorded, along with the evidence supporting the diagnosis. 
•  Any adverse events will be recorded; 
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 2 study visit; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study; 
− Take the CCX168 or matching placebo, prednisone or matching placebo, as well as 
oral cyclophosphamide, if applicable, as instructed, and  
− Continue taking all their other concomitant medications as usual. 
6.4. 
Study Week 2 (Day 15) 
The Study Week 2 visit must occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 63 of 135 
• A physical examination including body weight; height will also be measured in 12-17 
year old patients; 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• A 12-lead ECG, after at least 3 minutes of rest, will be recorded and assessed for any 
clinically significant abnormality; 
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, hematology, PK, and PD measurements; 
• The date and time of the last dose of CCX168/placebo prior to collection of the PK 
sample will be recorded; 
• If the patient has not yet taken the morning dose of CCX168/placebo for this day, the 
patient will be asked to take the dose; 
• A blood sample will also be taken for an expedited WBC count at the local laboratory in 
order to determine the appropriate cyclophosphamide dose (see Section 12.7) for patients 
who are in the cyclophosphamide strata; 
• A clean catch, midstream urine sample will be collected and aliquoted for urinalysis, 
UACR, urinary MCP-1:creatinine ratio, and PD assessment, and sent to the central 
laboratory. 
• The bottle of study medication will be checked to make sure the patient is taking the 
study medication as instructed; 
• Drug accountability will be performed on the study-supplied prednisone bottles; 
• One bottle of 20 mg prednisone or matching placebo and one bottle of 5 mg prednisone 
or matching placebo will be dispensed with appropriate dosing instructions (see 
Section 12.6); 
• Cyclophosphamide IV dose will be given after receipt of the local WBC count (see 
Section 12.7) to patients in the IV cyclophosphamide stratum; The start and end times of 
the infusion will be recorded; 
• If on oral cyclophosphamide, the patient will be questioned to confirm compliance; any 
change in cyclophosphamide dose, based on WBC count and eGFR, will be recorded; 
• Rituximab will be given to patients in the rituximab stratum (see Section 12.8); A dose of 
375 mg/m2 will be given; The start and end times of the infusion will be recorded; 
• Any changes in concomitant medication use will be recorded; 
• If the patient is on non-study supplied glucocorticoids, the tapering schedule will be 
discussed with the patient to ensure that tapering to a dose of zero occurs within a period 
of 4 weeks from Day 1; if glucocorticoids cannot be tapered to a dose of zero due to 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 64 of 135 
adrenal insufficiency the adverse event of adrenal insufficiency and treatment 
administered must be recorded, along with the evidence supporting the diagnosis 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 3 study visit; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study; 
− Take the CCX168 or matching placebo, prednisone or matching placebo, as well as 
oral cyclophosphamide, if applicable, as instructed, and 
− Continue taking all their other concomitant medications as usual. 
6.5. 
Study Week 3 (Day 22) 
The Study Week 3 visit must occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, and hematology measurements; 
• If the patient has not yet taken the morning dose of CCX168/placebo for this day, the 
patient will be asked to take the dose; 
• A clean catch, midstream urine sample will be collected for urinalysis at the central 
laboratory; 
• The bottle of study medication will be checked to make sure the patient is taking the 
study medication as instructed; 
• Drug accountability will be performed on the study-supplied prednisone bottles; 
• The bottle of 20 mg prednisone or matching placebo dispensed at the Week 2 visit will be 
re-dispensed and one new bottle of 5 mg prednisone or matching placebo will be 
dispensed with appropriate dosing instructions (see Section 12.6); 
• If on oral cyclophosphamide, the patient will be questioned to confirm compliance; any 
change in cyclophosphamide dose, based on WBC count and eGFR, will be recorded; 
• Rituximab will be given to patients in the rituximab stratum (see Section 12.8); A dose of 
375 mg/m2 will be given; The start and end times of the infusion will be recorded; 
• Any changes in concomitant medication use will be recorded; 
• If the patient is on non-study supplied glucocorticoids, the tapering schedule will be 
discussed with the patient to ensure that tapering to a dose of zero occurs within a period 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 65 of 135 
of 4 weeks from Day 1; if glucocorticoids cannot be tapered to a dose of zero due to 
adrenal insufficiency the adverse event of adrenal insufficiency and treatment 
administered must be recorded, along with the evidence supporting the diagnosis 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 4 study visit; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study; 
− Take the CCX168 or matching placebo, prednisone or matching placebo, as well as 
oral cyclophosphamide, if applicable, as instructed, and 
− Continue taking all their other concomitant medications as usual. 
6.6. 
Study Week 4 (Day 29) 
The Study Week 4 visit must occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12to17 
years old patients; 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• Chest radiograms will be acquired if necessary for BVAS; 
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, hematology, serum pregnancy test (in women of childbearing potential), PK, 
and PD measurements; 
• The date and time of the last dose of CCX168/placebo prior to collection of the PK 
sample will be recorded; 
• If the patient has not yet taken the morning dose of CCX168/placebo for this day, the 
patient will be asked to take the dose; 
• A blood sample will also be taken for an expedited WBC count at the local laboratory in 
order to determine the appropriate cyclophosphamide dose (see Section 12.7) for patients 
who are in the cyclophosphamide strata; 
• A clean catch, midstream urine sample will be collected and aliquoted for urinalysis, 
UACR, urinary MCP-1:creatinine ratio, and PD assessment, and sent to the central 
laboratory; 
• BVAS assessment (see Section 12.3); For this assessment, the disease activity status 
within 7 days prior to the Week 4 visit will be scored; 
• Patients will be asked to complete the SF-36 v2 and EQ-5D-5L; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 66 of 135 
• Drug accountability will be performed on the returned CCX168/placebo bottle; 
• A new bottle of CCX168/placebo will be dispensed; 
• Drug accountability will be performed on the study-supplied prednisone bottles; 
• One bottle of 20 mg prednisone or matching placebo will be dispensed and the bottle of 5 
mg prednisone or matching placebo provided at the Week 3 visit will be re-dispensed 
with appropriate dosing instructions (see Section 12.6); 
• Cyclophosphamide IV dose will be given after receipt of the local WBC count (see 
Section 12.7) to patients in the IV cyclophosphamide stratum; The start and end times of 
the infusion will be recorded; 
• If on oral cyclophosphamide, the patient will be questioned to confirm compliance; any 
change in cyclophosphamide dose, based on WBC count and eGFR, will be recorded; 
• Any changes in concomitant medication use will be recorded; 
• If the patient was on non-study supplied glucocorticoids, confirm that the patient has 
stopped this glucocorticoid use; if glucocorticoids cannot be tapered to a dose of zero due 
to adrenal insufficiency the adverse event of adrenal insufficiency and treatment 
administered must be recorded, along with the evidence supporting the diagnosis   
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient will be reminded to: 
− Change the prednisone or matching placebo dose, starting on Day 43; 
− Come to the study center for the Week 7 study visit; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 or matching placebo, prednisone or matching placebo, as well as 
oral cyclophosphamide, if applicable, as instructed, and  
− Continue taking all their other concomitant medications as usual. 
6.7. 
Study Week 6 (Day 43) 
The study site personnel will contact the patients prior to this time point to remind them of the 
prednisone/placebo dose change from one 20 mg/placebo capsule and one 5 mg/placebo capsule 
per day to only one 20 mg/placebo capsule per day, starting on Day 43. 
6.8. 
Study Week 7 (Day 50) 
The Study Week 7 visit must occur within ± 3 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 67 of 135 
• A 12-lead ECG, after at least 3 minutes of rest, will be recorded and assessed for any 
clinically significant abnormality; 
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, hematology, and PK measurements; 
• The date and time of the last dose of CCX168/placebo prior to collection of the PK 
sample will be recorded; 
• If the patient has not yet taken the morning dose of CCX168/placebo for this day, the 
patient will be asked to take the dose; 
• A blood sample will also be taken for an expedited WBC count at the local laboratory in 
order to determine the appropriate cyclophosphamide dose (see Section 12.7) for patients 
who are in the cyclophosphamide strata; 
• A clean catch, midstream urine sample will be collected for urinalysis at the central 
laboratory; 
• Drug accountability will be performed on the returned CCX168/placebo bottle; 
• A new bottle of CCX168/placebo will be dispensed; 
• Drug accountability will be performed on the study-supplied prednisone bottles; 
• Three bottles of 5 mg prednisone or matching placebo will be dispensed with appropriate 
dosing instructions (see Section 12.6); 
• Cyclophosphamide IV dose will be given after receipt of the local WBC count (see 
Section 12.7) to patients in the IV cyclophosphamide stratum; The start and end times of 
the infusion will be recorded; 
• If on oral cyclophosphamide, the patient will be questioned to confirm compliance; any 
change in cyclophosphamide dose, based on WBC count and eGFR, will be recorded; 
• Any changes in concomitant medication use will be recorded; 
• Record any AAV relapse events in patients who have previously achieved remission 
(BVAS = 0); relapse is defined as return of at least one major item, or three or more 
minor items, or one or two minor items recorded at two consecutive visits in the BVAS; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient will be reminded to: 
− Change the prednisone or matching placebo dose, starting on Day 57; 
− Come to the study center for the Week 10 study visit; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 68 of 135 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 or matching placebo, prednisone or matching placebo, as well as 
oral cyclophosphamide, if applicable, as instructed, and  
− Continue taking all their other concomitant medications as usual. 
6.9. 
Study Week 8 (Day 57) 
The study site personnel will contact the patients prior to this time point to remind them of the 
prednisone/placebo dose change from four 5 mg/placebo capsules per day to three 5 mg/placebo 
capsules per day, starting on Day 57. 
6.10. 
Study Week 10 (Day 71) 
The Study Week 10 visit must occur within ± 3 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12-17 
year old patients; 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• Chest radiograms will be acquired if necessary for BVAS;  
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, hematology, and serum pregnancy test (in women of childbearing potential); 
• If the patient has not yet taken the morning dose of CCX168/placebo for this day, the 
patient will be asked to take the dose; 
• A blood sample will also be taken for an expedited WBC count at the local laboratory in 
order to determine the appropriate cyclophosphamide dose (see Section 12.7) for patients 
who are in the cyclophosphamide strata; 
• A clean catch, midstream urine sample will be collected for urinalysis at the central 
laboratory; 
• BVAS assessment (see Section 12.3); 
• Patients will be asked to complete the SF-36 v2 and EQ-5D-5L; 
• Drug accountability will be performed on the returned CCX168/placebo bottle; 
• A new bottle of CCX168/placebo will be dispensed; 
• Drug accountability will be performed on the study-supplied prednisone bottles; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 69 of 135 
• Two bottles of 5 mg prednisone or matching placebo will be dispensed with appropriate 
dosing instructions (see Section 12.6); 
• Cyclophosphamide IV dose will be given after receipt of the local WBC count (see 
Section 12.7) to patients in the IV cyclophosphamide stratum; The start and end times of 
the infusion will be recorded; 
• If on oral cyclophosphamide, the patient will be questioned to confirm compliance; any 
change in cyclophosphamide dose, based on WBC count and eGFR, will be recorded; 
• Any changes in concomitant medication use will be recorded; 
• Record any AAV relapse events in patients who have previously achieved remission;  
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 13 study visit; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 or matching placebo, prednisone or matching placebo, as well as 
oral cyclophosphamide, if applicable, as instructed, and  
− Continue taking all their other concomitant medications as usual. 
− The patient will be reminded to come to the clinical after an overnight fast of at least 
9 hours prior to the visit for the LDL cholesterol measurement. 
6.11. 
Study Week 13 (Day 92) 
The patient must be fasting for at least 9 hours prior to this visit for the LDL cholesterol 
measurement. The Study Week 13 visit must occur within ± 3 days of the scheduled date. During 
this visit, the following study procedures will be performed: 
• A physical examination including body weight and BMI calculation; height will also be 
measured in 12-17 year old patients; 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• A 12-lead ECG, after at least 3 minutes of rest, will be recorded and assessed for any 
clinically significant abnormality; 
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, hematology, ANCA (anti-PR3 and anti-MPO ELISA) measurement, HbA1c, 
LDL cholesterol, PK, and PD measurements; 
• The date and time of the last dose of CCX168/placebo prior to collection of the PK 
sample will be recorded; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 70 of 135 
• Items will be collected to support calculation of the GTI (see Section 12.5); 
• If the patient has not yet taken the morning dose of CCX168/placebo for this day, the 
patient will be asked to take the dose; 
• A blood sample will also be taken for an expedited WBC count at the local laboratory in 
order to determine the appropriate cyclophosphamide dose (see Section 12.7) for patients 
who are in the IV cyclophosphamide stratum; 
• A clean catch, midstream urine sample will be collected and aliquoted for urinalysis, 
UACR, urinary MCP-1:creatinine ratio, and PD assessment, and sent to the central 
laboratory; 
• Drug accountability will be performed on the returned CCX168/placebo bottle; 
• A new bottle of CCX168/placebo will be dispensed; 
• Drug accountability will be performed on the study-supplied prednisone bottles; 
• Two bottles of 5 mg prednisone or matching placebo will be dispensed with appropriate 
dosing instructions (see Section 12.6); 
• Cyclophosphamide IV dose will be given after receipt of the local WBC count (see 
Section 12.7) to patients in the IV cyclophosphamide stratum; The start and end times of 
the infusion will be recorded; 
• If the patient is in the IV cyclophosphamide stratum, the patient will be instructed to start 
taking oral azathioprine on the 14th day after the Week 13 visit at a starting dose of 1 
mg/kg/day (see Section 12.7.2);  
• If the patient is in the oral cyclophosphamide stratum, the patient will be instructed to 
continue taking oral cyclophosphamide for an additional 13 days after the Week 13 visit. 
Then, on the 14th day after the Week 13 visit, the patient will be instructed to stop taking 
oral cyclophosphamide and start taking azathioprine orally at a starting dose of 1 
mg/kg/day (see Section 12.7.2); 
• Any changes in concomitant medication use will be recorded; 
• Record any AAV relapse events in patients who have previously achieved remission;  
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient will be reminded to: 
− Change the prednisone or matching placebo dose, starting on Day 99; 
− Come to the study center for the Week 16 study visit; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study;  


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 71 of 135 
− Take the CCX168 or matching placebo, as well as prednisone or matching placebo as 
instructed, and  
− Continue taking all their other concomitant medications as usual. 
6.12. 
Study Week 14 (Day 99) 
The study site personnel will contact the patients prior to this time point to remind them of the 
prednisone/placebo dose change from two 5 mg/placebo capsules per day to one 5 mg/placebo 
capsule per day, starting on Day 99. 
6.13. 
Study Week 15 (Day 106) 
For patients who are in the oral or IV cyclophosphamide strata, the study site personnel will 
contact the patients prior to this time point to remind them to start taking azathioprine at a 
starting dose of 1 mg/kg/day, or if azathioprine is not suitable, to start taking mycophenolate 
mofetil at a starting dose of 500 mg twice daily (1 g/day). If mycophenolate mofetil is not 
tolerated or not available, enteric coated mycophenolate sodium may be given at a starting dose 
of 720 mg/day. 
6.14. 
Study Week 16 (Day 113) 
The Study Week 16 visit must occur within ± 3 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12-17 
year old patients; 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• Chest radiograms will be acquired if necessary for BVAS;  
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, hematology, and serum pregnancy test (in women of childbearing potential); 
• If the patient has not yet taken the morning dose of CCX168/placebo for this day, the 
patient will be asked to take the dose; 
• A clean catch, midstream urine sample will be collected for urinalysis at the central 
laboratory; 
• BVAS assessment (see Section 12.3); 
• Patients will be asked to complete the SF-36 v2 and EQ-5D-5L; 
• Drug accountability will be performed on the returned CCX168/placebo bottle; 
• Two new bottles of CCX168/placebo will be dispensed; 
• Drug accountability will be performed on the study-supplied prednisone bottles; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 72 of 135 
• Two bottles of 5 mg prednisone or matching placebo will be dispensed with appropriate 
dosing instructions (see Section 12.6); 
• As indicated in Section 6.11, patients in the IV and oral cyclophosphamide strata will 
start taking oral azathioprine at Week 15 (see Section 12.7 for dosing instructions); The 
dose of azathioprine will be titrated up to a dose of 2 mg/kg/day; 
• Any changes in concomitant medication use will be recorded; 
• Record any AAV relapse events in patients who have previously achieved remission;  
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 20 study visit; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 or matching placebo, as well as prednisone or matching placebo as 
instructed, and  
− Continue taking all their other concomitant medications as usual. 
6.15. 
Study Week 20 (Day 141) 
The Study Week 20 visit must occur within ± 3 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry and hematology; 
• If the patient has not yet taken the morning dose of CCX168/placebo for this day, the 
patient will be asked to take the dose; 
• A clean catch, midstream urine sample will be collected for urinalysis at the central 
laboratory and a local urine pregnancy test; 
• Drug accountability will be performed on the returned CCX168/placebo bottle; 
• Two new bottles of CCX168/placebo will be dispensed; 
• Drug accountability will be performed on the study-supplied prednisone bottles; 
• For the cyclophosphamide strata, compliance with azathioprine dosing will be checked; 
• Any changes in concomitant medication use will be recorded; 
• Record any AAV relapse events in patients who have previously achieved remission;  


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 73 of 135 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week  23 study visit; 
− Store the study medication in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 or matching placebo, as well as azathioprine, if applicable, as 
instructed, and  
− Continue taking all their other concomitant medications as usual. 
− The patient will be reminded to come to the clinical after an overnight fast of at least 
9 hours prior to the visit for the LDL cholesterol measurement. 
6.16. 
Study Week 23 (Day 162) 
The Study Week 23 visit must occur within ± 7 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• Blood samples will be collected for shipment to the central laboratory for hematology, 
and for liver function measurements (AST, ALT, Bilirubin and Alkaline Phosphatase) 
• Any changes in concomitant medication use will be recorded; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 26 study visit; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study; 
− Take the CCX168 or matching placebo, as well as prednisone or matching placebo as 
instructed; and 
− Continue taking all their other concomitant medications as usual. 
6.17. 
Study Week 26 (Day 183) 
The patient must be fasting for at least 9 hours prior to this visit for the LDL cholesterol 
measurement. The Study Week 26 visit must occur within ± 3 days of the scheduled date. During 
this visit, the following study procedures will be performed: 
• A physical examination including body weight and BMI calculation; height will also be 
measured in 12-17 year old patients; 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• A 12-lead ECG, after at least 3 minutes of rest, will be recorded and assessed for any 
clinically significant abnormality; 
• Chest radiograms will be acquired if necessary for BVAS;  


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 74 of 135 
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, hematology, serum pregnancy test (in women of childbearing potential), 
ANCA (anti-PR3 and anti-MPO ELISA) measurement, HbA1c, LDL cholesterol, PK, 
and PD measurements; 
• The date and time of the last dose of CCX168/placebo prior to collection of the PK 
sample will be recorded; 
• If the patient has not yet taken the morning dose of CCX168/placebo for this day, the 
patient will be asked to take the dose; 
• A clean catch, midstream urine sample will be collected and aliquoted for urinalysis, 
UACR, urinary MCP-1:creatinine ratio, and PD assessment, and sent to the central 
laboratory; 
• BVAS assessment (see Section 12.3); 
• VDI assessment (see Section 12.4); 
• Patients will be asked to complete the SF-36 v2 and EQ-5D-5L; 
• Items will be collected to support calculation of the GTI (see Section 12.5); 
• Drug accountability will be performed on the returned CCX168/placebo bottles; 
• Two new bottles of CCX168/placebo will be dispensed; 
• For the cyclophosphamide strata, compliance with azathioprine dosing will be checked; 
• Any changes in concomitant medication use will be recorded; 
• Record any AAV relapse events in patients who have previously achieved remission;  
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week  29 study visit; 
− Store the study medication in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 or matching placebo as well as azathioprine, if applicable, as 
instructed, and  
− Continue taking all their other concomitant medications as usual 
6.18. 
Study Week 29 (Day 204) 
The Study Week 29 visit must occur within ± 7 days of the scheduled date. During this visit, the 
following study procedures will be performed: 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 75 of 135 
•  Blood samples will be collected for shipment to the central laboratory for hematology, 
and for liver function measurements (AST, ALT, Bilirubin and Alkaline Phosphatase) 
• Any changes in concomitant medication use will be recorded; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 32 study visit; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study; 
− Take the CCX168 or matching placebo, as well as prednisone or matching placebo as 
instructed; and  
− Continue taking all their other concomitant medications as usual. 
6.19. 
Study Week 32 (Day 225) 
The Study Week 32 visit must occur within ± 3 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry and hematology; 
• If the patient has not yet taken the morning dose of CCX168/placebo for this day, the 
patient will be asked to take the dose; 
• A clean catch, midstream urine sample will be collected for urinalysis at the central 
laboratory and a local urine pregnancy test; 
• Drug accountability will be performed on the returned CCX168/placebo bottle; 
• Two new bottles of CCX168/placebo will be dispensed; 
• For the cyclophosphamide strata, compliance with azathioprine dosing will be checked; 
• Any changes in concomitant medication use will be recorded; 
• Record any AAV relapse events in patients who have previously achieved remission;  
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week  35 study visit; 
− Store the study medication in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 or matching placebo as well as azathioprine, if applicable, as 
instructed, and  
− Continue taking all their other concomitant medications as usual. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 76 of 135 
6.20. 
Study Week 35 (Day 246) 
The Study Week 35 visit must occur within ± 7 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• Blood samples will be collected for shipment to the central laboratory for hematology, 
and for liver function measurements (AST, ALT, Bilirubin and Alkaline Phosphatase) 
• Any changes in concomitant medication use will be recorded; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 39 study visit; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study; 
− Take the CCX168 or matching placebo, as well as prednisone or matching placebo as 
instructed; and 
− Continue taking all their other concomitant medications as usual. 
6.21. 
Study Week 39 (Day 274) 
The Study Week 39 visit must occur within ± 3 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12-17 
year old patients; 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• A 12-lead ECG, after at least 3 minutes of rest, will be recorded and assessed for any 
clinically significant abnormality;  
• Chest radiograms will be acquired if necessary for BVAS;  
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry and hematology, serum pregnancy test (in women of childbearing potential), 
ANCA (anti-PR3 and anti-MPO ELISA) measurement, PK and PD measurements; 
• The date and time of the last dose of CCX168/placebo prior to collection of the PK 
sample will be recorded; 
• If the patient has not yet taken the morning dose of CCX168/placebo for this day, the 
patient will be asked to take the dose; 
• A clean catch, midstream urine sample will be collected and aliquoted for urinalysis, 
UACR, urinary MCP-1:creatinine ratio, and PD assessment, and sent to the central 
laboratory; 
• BVAS assessment (see Section 12.3); 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 77 of 135 
• Patients will be asked to complete the SF-36 v2 and EQ-5D-5L; 
• Drug accountability will be performed on the returned CCX168/placebo bottles; 
• Two new bottles of CCX168/placebo will be dispensed; 
• For the cyclophosphamide strata, compliance with azathioprine dosing will be checked; 
• Any changes in concomitant medication use will be recorded; 
• Record any AAV relapse events in patients who have previously achieved remission;  
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week  42 study visit; 
− Store the study medication in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 or matching placebo as well as azathioprine, if applicable, as 
instructed, and  
− Continue taking all their other concomitant medications as usual. 
6.22. 
Study Week 42 (Day 295) 
The Study Week 42 visit must occur within ± 7 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• Blood samples will be collected for shipment to the central laboratory for hematology, 
and for liver function measurements (AST, ALT, Bilirubin and Alkaline Phosphatase) 
• Any changes in concomitant medication use will be recorded; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 45 study visit; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study; 
− Take the CCX168 or matching placebo, as well as prednisone or matching placebo as 
instructed; and 
− Continue taking all their other concomitant medications as usual. 
6.23. 
Study Week 45 (Day 316) 
The Study Week 45 visit must occur within ± 3 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 78 of 135 
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry and hematology; 
• If the patient has not yet taken the morning dose of CCX168/placebo for this day, the 
patient will be asked to take the dose; 
• A clean catch, midstream urine sample will be collected for urinalysis at the central 
laboratory and a local urine pregnancy test; 
• Drug accountability will be performed on the returned CCX168/placebo bottles; 
• Two new bottles of CCX168/placebo will be dispensed; 
• For the cyclophosphamide strata, compliance with azathioprine dosing will be checked; 
• Any changes in concomitant medication use will be recorded; 
• Record any AAV relapse events in patients who have previously achieved remission;  
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 48 study visit; 
− Store the study medication in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 or matching placebo as well as azathioprine, if applicable, as 
instructed, and  
− Continue taking all their other concomitant medications as usual. 
6.24. 
Study Week 48 (Day 337) 
The Study Week 48 visit must occur within ± 7 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• Blood samples will be collected for shipment to the central laboratory for hematology, 
and for liver function measurements (AST, ALT, Bilirubin and Alkaline Phosphatase) 
• Any changes in concomitant medication use will be recorded; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 52 study visit; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study; 
− Take the CCX168 or matching placebo, as well as prednisone or matching placebo as 
instructed; and 
− Continue taking all their other concomitant medications as usual. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 79 of 135 
6.25. 
Study Week 52 (Day 365) 
The Study Week 52 visit must occur within ± 3 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12-17 
year old patients; 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• A 12-lead ECG, after at least 3 minutes of rest, will be recorded and assessed for any 
clinically significant abnormality;  
• Chest radiograms will be acquired if necessary for BVAS;  
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, hematology, serum pregnancy test (in women of childbearing potential), 
ANCA (anti-PR3 and anti-MPO ELISA) measurement, PK, and PD measurements; 
• The date and time of the last dose of CCX168/placebo prior to collection of the PK 
sample will be recorded; 
• A clean catch, midstream urine sample will be collected and aliquoted for urinalysis, 
UACR, urinary MCP-1:creatinine ratio, and PD assessment, and sent to the central 
laboratory; 
• If a patient consents, a renal biopsy will be obtained to assess histologic changes; the 
standard Histology Form will be completed; the biopsy needs to be performed within a 
14-day window prior to or after the Week 52 visit; 
• BVAS assessment (see Section 12.3); 
• VDI assessment (see Section 12.4); 
• Patients will be asked to complete the SF-36 v2 and EQ-5D-5L; 
• Drug accountability will be performed on the returned CCX168/placebo bottles; 
• For the cyclophosphamide strata, compliance with azathioprine dosing will be checked; 
• Any changes in concomitant medication use will be recorded; 
• Record any AAV relapse events in patients who have previously achieved remission;  
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 60 study visit;  
− Take the azathioprine, if applicable, as instructed, and  
− Continue taking all their other concomitant medications as usual. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 80 of 135 
6.26. 
Study Week 60 (Day 421) 
The Study Week 60 visit must occur within ± 3 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12-17 
year old patients; 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• A 12-lead ECG, after at least 3 minutes of rest, will be recorded and assessed for any 
clinically significant abnormality;  
• Chest radiograms will be acquired if necessary for BVAS;  
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, hematology, serum pregnancy test (in women of childbearing potential), 
ANCA (anti-PR3 and anti-MPO ELISA) measurement, and PD measurements; 
• A clean catch, midstream urine sample will be collected and aliquoted for urinalysis, 
UACR, urinary MCP-1:creatinine ratio, and PD assessment, and sent to the central 
laboratory; 
• BVAS assessment (see Section 12.3); 
• VDI assessment (see Section 12.4); 
• Patients will be asked to complete the SF-36 v2 and EQ-5D-5L; 
• For the cyclophosphamide strata, compliance with azathioprine dosing will be checked; 
• Any changes in concomitant medication use will be recorded; 
• Record any AAV relapse events in patients who have previously achieved remission;  
• Any adverse events will be recorded; 
• After all study procedures have been completed, the patient will be discharged from the 
study. The patient’s condition will be evaluated by the Investigator at the end of the 
clinical trial (Week 60) and appropriate standard of care medical treatment will be 
provided to all patients as needed. 
6.27. 
Early Termination Visit 
If a patient will be withdrawn early from the study, the following termination procedures must be 
completed whenever possible: 
• A physical examination including body weight; height will also be measured in 12-17 
year old patients; 
• Vital signs (temperature, blood pressure, heart rate) after at least 3 minutes of rest; 
• A 12-lead ECG, after at least 3 minutes of rest, will be recorded and assessed for any 
clinically significant abnormality;  
• Chest radiograms will be acquired if necessary for BVAS;  


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 81 of 135 
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, hematology, serum pregnancy test (in women of childbearing potential), and 
ANCA (anti-PR3 and anti-MPO ELISA) measurement; 
• A clean catch, midstream urine sample will be collected and aliquoted for urinalysis, 
UACR, and urinary MCP-1:creatinine ratio and sent to the central laboratory; 
• BVAS assessment (see Section 12.3); 
• VDI assessment (see Section 12.4) if early termination occurs prior to Study Week 60; 
• If the early withdrawal occurs within the first 26 weeks of the study, items will be 
collected to support calculation of the GTI, including HbA1c and LDL cholesterol tests 
(see Section 12.5); 
• Patients will be asked to complete the SF-36 v2 and EQ-5D-5L if early termination 
occurs prior to Week 60; 
• Drug accountability will be performed on the returned CCX168/placebo and 
prednisone/placebo bottles; 
• Any changes in concomitant medication use will be recorded; 
• Record any AAV relapse events or progression/worsening of disease activity in patients 
who were in remission or had stable disease at the previous visit; and 
• Any adverse events will be recorded. If an adverse event remains unresolved at the 
conclusion of the study, a clinical assessment will be made by the Investigator and the 
Sponsor’s Medical Monitor to determine whether continued follow-up of the adverse 
event is warranted. 
7. 
STUDY ASSESSMENTS 
7.1. 
Efficacy Assessments 
7.1.1. 
BVAS 
The BVAS form will be completed according to the schedule provided in the Time and Events 
Table. In Section 12.3, instructions for completion, and the BVAS organ systems and items 
within each system are provided. The “major” BVAS items are listed in bold italics. Data need to 
be recorded in the EDC system. Calculation of the BVAS score does not need to be performed 
by the investigators, but will be performed in the EDC system. BVAS data recorded by 
investigators will be adjudicated, according to an adjudication charter, before data finalization 
and unblinding. The adjudicated data will be used in the final analysis. 
7.1.2. 
Urinary Measurements 
A clean catch midstream urine sample needs to be collected according to instructions provided 
separately. The screening urine sample may be sent to the local laboratory, instead of the central 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 82 of 135 
laboratory, for proteinuria assessment, as well as a microscopic examination for RBC casts and 
RBC count to determine patient eligibility. 
Starting on Day 1, the urine samples will be sent to the central laboratory for analysis. The 
following analyses will be performed according to the Time and Events Table: 
• Urinalysis including blood, protein, and nitrites; if positive for blood, protein, or nitrites, 
a microscopic assessment for RBC casts and RBC count will be performed;  
• Quantitative albumin and creatinine measurements to calculate the urinary 
albumin:creatinine ratio (UACR); 
• Quantitative MCP-1 measurements to calculate the MCP-1:creatinine ratio;  
• Other urinary markers related to inflammation and the complement system may also be 
performed. 
Microscopic review is triggered if a urinary dipstick test is positive for blood, nitrite, or protein. 
When microscopy is performed, hematuria will be categorized as follows:  None, Occasional 
(Occ), 1 - 2, 3 - 5, 6 - 9, 10 - 15, 16 - 29, 30 - 49, 50 - 75, and >75 RBCs per high power field.  
Proteinuria will be assessed by measuring the albumin and creatinine concentrations and 
calculating the UACR. Results will be expressed as mg albumin/g creatinine.  
Urine MCP-1 will be measured by specific ELISA assay. Urine MCP-1 levels will be 
standardized to urine creatinine and expressed as pg MCP-1/mg creatinine.  
Other inflammation and complement markers will be measured using validated assay 
methodology. 
7.1.3. 
Estimated Glomerular Filtration Rate 
Estimated glomerular filtration rate (eGFR) will be calculated from serum creatinine 
measurements at all applicable study visits using the following MDRD equation for adults, and 
modified Schwartz equation (Schwartz et al, 2009) for adolescents: 
MDRD: eGFR (mL/min/1.73 m2) = 175 x (serum creatinine in mg/dL)-1.154 x (Age)-0.203 x 
(0.742 if female) x (1.212 if African-American/Black) 
Modified Schwartz: eGFR = (0.413 x Height [in cm]) / Serum creatinine (in mg/dL) 
7.1.4. 
Health-Related Quality of Life Assessments 
The SF-36 v2 and EQ-5D-5L will be completed by study patients at visits specified in the Time 
and Events Table to measure changes from baseline in health-related quality of life. Proven 
translations will be used for non-English speaking patients, whenever possible. An administrator 
will facilitate completion of the questionnaires by the patients, but will not complete the forms 
for the patients. The administrator will establish a rapport with the patient, emphasize the 
importance of completing the form, and serve to answer questions and address concerns. The 
questionnaires should be completed by patients before seeing the Investigator at the visit.  


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 83 of 135 
7.1.5. 
Vasculitis Damage Index (VDI) 
The VDI form will be completed at the visits specified in the Time and Events Table. In 
Section 12.4, instructions for completion, the organ systems with individual damage items, and 
the scoring of the VDI are provided. Data need to be recorded in the EDC. Investigators do not 
need to calculate the VDI. This will be done within the EDC system. VDI data will be 
adjudicated before finalization and unblinding according to an adjudication charter. The 
adjudicated data will be used in the final analysis. 
7.1.6. 
Disease Relapse 
A relapse is defined as worsening of disease, after having previously achieved remission at week 
26 (BVAS = 0 and having received no glucocorticoids for treatment of vasculitis for 4 weeks), 
that involves: 
• one or more major item in the BVAS, or  
• three or more minor items in the BVAS, or 
• one or two minor items in the BVAS recorded at two consecutive study visits. 
Major items are indicated in bold italics in Section 12.3.2. Patients who experience a relapse 
during the study may be treated with glucocorticoids at a dose and regimen according to the 
patient’s condition. Refer to Section 12.6.2.3 for detailed guidance. These patients should 
continue to be followed in the study if at all possible. In patients experiencing a relapse, the 
study-supplied prednisone/matching placebo may be temporarily halted during the IV and/or oral 
course of glucocorticoids, and if the patient’s condition stabilizes, the study-supplied 
prednisone/matching placebo may be restarted according to the original study visit schedule. The 
CCX168/matching placebo may also continue during the treatment for the relapse, or restarted 
when interrupted, at the discretion of the PI. 
7.1.7. 
Renal Histology 
Kidney biopsies are optional procedures for this study. A standard Histology Form will be 
provided to investigators to document histologic findings in a standard manner for all patients 
from whom renal biopsies are taken. This will be completed for available baseline and Week 52 
renal biopsies. Data will be entered into the EDC. If a sufficient number of biopsies have been 
performed, changes from baseline in typical histologic findings, e.g., percentage of glomeruli 
with crescents or necrosis will be summarized by treatment group. Efficacy outcomes in patients, 
based on baseline histologic findings, may be assessed, if appropriate. 
7.2. 
Safety Assessments 
7.2.1. 
Physical Examinations, Vital Signs, and ECGs 
A complete physical examination (including evaluation of general appearance/mental status, 
HEENT [head, eyes, ears, nose, throat], and the following body systems: dermatologic, 
cardiovascular, respiratory, gastrointestinal, musculoskeletal and neurologic) for safety, BVAS, 
GTI, and VDI assessments will be performed at visits indicated in the Time and Events Table.  


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 84 of 135 
Physical examinations must be sufficiently comprehensive to include ALL components of the 
BVAS, VDI, and GTI (see Section 12.3, Section 12.4, and Section 12.5). Findings must be 
recorded in the source documents.  
Any new or worsening findings upon physical examination need to be recorded as adverse 
events, and also be captured in the BVAS, VDI, and GTI, as appropriate. 
Body weight will be measured as part of the physical examinations. Height needs to be recorded 
at screening only, except for adolescents (12-17 years old) in whom height will also be included 
as part of all physical examinations. BMI will be calculated from the body weight and height 
measurements. 
Vital signs will be measured during screening and on each scheduled study day as indicated in 
the Time and Events Table. Blood pressure, pulse rate, and body temperature will be measured.  
All vital signs assessments will be performed after the patient has rested for at least three 
minutes. 
Twelve-lead ECGs, after resting for at least 3 minutes, will be acquired according to the schedule 
in the Time and Events Table. All ECGs will be assessed for any clinically significant 
abnormalities. All abnormalities will be recorded in the EDC system. 
7.2.2. 
Clinical Safety Laboratory Assessments 
The following tests will be performed at the visits identified in the Time and Events Table. 
• Hematology:  hemoglobin, hematocrit, RBC count, WBC count with differential, platelet 
count, mean cell hemoglobin, mean cell hemoglobin concentration, mean corpuscular 
volume; 
• Local laboratory WBC counts will be performed prior to administration of 
cyclophosphamide or azathioprine for potential dose adjustments; 
• Serum Chemistry:  liver panel (bilirubin, lactate dehydrogenase [LDH], AST, ALT), 
renal panel (BUN, creatinine), creatine phosphokinase (CPK), albumin, sodium, 
potassium, magnesium, bicarbonate, chloride, calcium, inorganic phosphorus, glucose, 
total protein, alkaline phosphatase, total cholesterol, uric acid, serum amylase, and serum 
lipase; at a subset of visits only AST, ALT, bilirubin and alkaline phosphatase will be 
assessed. Visits should be scheduled so that laboratory tests are measured at a frequency 
not to exceed 1 month between assessments. 
• Hemoglobin A1c and LDL cholesterol; 
• Urinalysis:  At the central laboratory, nitrite, blood, and protein, will be tested. If 
positive, microscopy will be performed;  
• Virology (measured only at screening and may be measured at the local laboratory): 
hepatitis B surface antigen, hepatitis C antibodies, HIV 1 and 2 antibodies; virology tests 
done within 6 weeks prior to screening are acceptable for eligibility assessment; 
• Serology and Complement (measured only at screening and may be measured at the local 
laboratory): anti-nuclear and anti-GBM antibody levels, C3, C4, IgG, IgM, and IgA. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 85 of 135 
These tests do not need to be performed if results are available from tests done within the 
past 12 months prior to the screening visit. Results from these prior tests must be 
recorded in the EDC system. 
• TB screen: Only one of the following is needed: interferon γ release assay (IGRA), 
tuberculin purified protein derivative (PPD) skin test, or chest radiograms (X rays or CT 
scan); chest radiography done within 6 weeks prior to screening is allowed for eligibility 
assessment. Chest radiography at subsequent visits will only be performed if deemed 
clinically necessary by the Investigator for BVAS, VDI, or GTI assessment, or to assess 
safety. 
7.2.3. 
Anti-Neutrophil Cytoplasmic Antibody (ANCA) Assessments 
Tests for anti-PR3 and anti-MPO will be performed according to the Time and Events Table. If 
necessary to determine eligibility, anti-PR3 and anti-MPO tests during screening may be 
performed at the local laboratory if more time-efficient. ELISA or ALBIA (Addressable Laser 
Bead ImmunoAssay) assays at local laboratories will be allowed for eligibility assessment. 
Starting on Day 1, ELISA assays will be performed by a central laboratory. 
7.2.4. 
Adverse Events 
An adverse event (AE) is defined as any untoward medical occurrence associated with the use of 
a drug in humans, whether or not considered drug related. An adverse event could therefore be 
any unfavorable and/or unintended sign (including abnormal laboratory findings), symptom, or 
disease temporally associated with the use of the drug, whether or not considered related to the 
drug. This definition includes intercurrent illnesses or injuries, and exacerbation of pre-existing 
conditions. 
An unexpected adverse event is an adverse event that is not identified in nature, severity, or 
frequency in the current Investigator’s Brochure, or that is of greater severity than expected 
based on the information in the Reference Safety Information listing within the Investigator’s 
Brochure. 
All adverse events occurring in patients who have been randomized to treatment will be recorded 
in the EDC system and will be reported in accordance with regulatory requirements. Adverse 
events reported prior to commencement of administration of study medication will be considered 
pre-treatment events. 
All adverse events will be monitored until resolution or, if the adverse event is determined to be 
chronic, until a cause is identified. If an adverse event remains unresolved at the conclusion of 
the study, a clinical assessment will be made by the Investigator and the Sponsor’s Medical 
Monitor to determine whether continued follow-up of the adverse event is warranted. 
7.2.4.1. 
Adverse Event Severity Assessment 
The severity of each adverse event will be determined by the investigator using the following 
scale: 
• Mild (Grade 1):  no limitation of usual activities 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 86 of 135 
• Moderate (Grade 2):  some limitation of usual activities 
• Severe (Grade 3):  inability to carry out usual activities 
• Life-threatening (Grade 4):  an immediate risk of death 
• Death (Grade 5) 
7.2.4.2. 
Causality Assessment 
The relationship of CCX168/placebo to an adverse event will be determined by the Investigator 
and Sponsor based on the following definitions: 
• Probably Not Related:  the adverse event was more likely explained by causes other than 
CCX168/placebo.  
• Possibly Related:  there is evidence for a reasonable possibility that CCX168/placebo 
administration caused the adverse event. 
The relationship of glucocorticoid use, cyclophosphamide, rituximab, and azathioprine or 
mycophenolate use to an adverse event will also be determined by the Investigator and Sponsor 
based on the following definitions: 
• Probably Not Related:  the adverse event was more likely explained by causes other than 
glucocorticoid, cyclophosphamide, rituximab, azathioprine, or mycophenolate use.  
• Possibly Related:  there is evidence for a reasonable possibility that the glucocorticoid, 
cyclophosphamide, rituximab, azathioprine, or mycophenolate administration caused the 
adverse event. 
7.2.4.3. 
Serious Adverse Events 
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose: 
• Results in death; 
• Is life-threatening (i.e., the patient was, in the opinion of the Investigator, at immediate 
risk of death from the event as it occurred); 
• Requires or prolongs hospitalization; 
• Results in persistent or significant disability or incapacity; 
• Is a congenital anomaly or birth defect; 
• Is an important and significant medical event that, based on appropriate medical 
judgment, may jeopardize the patient and/or may require medical or surgical intervention 
to prevent one of the other outcomes defining serious. 
Elective surgery already known during screening to occur in the course of the study, and elective 
hospitalizations for convenience of the patient which are clearly unrelated to any medical 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 87 of 135 
condition, and agreed upon between the Investigator and the patient prior to randomization, will 
not have to be reported as SAEs. Hospital stays on the evening of Day 1 (or beyond) will also not 
be considered an SAE, unless other SAE criteria are met. 
7.2.4.4. 
Infections 
Any adverse events of infections are of particular importance in this study, since infections are 
one of the more common adverse events associated with current therapies for AAV. For 
medically important infections, the organism(s) involved in the infection needs to be determined 
whenever possible. As a selective C5aR antagonist, CCX168 does not appear to affect formation 
of the C5b-9 membrane attack complex, a defense mechanism against infection by encapsulated 
bacteria such as Neisseria meningitidis. Nevertheless, any such events need to be clearly 
documented in the EDC and all local and national vaccination recommendations should be 
followed. 
Glucocorticoids are often associated with fungal and Herpes infections. These need to be 
meticulously documented in the EDC. 
7.2.4.5. 
SARs and SUSARs 
A serious adverse reaction (SAR) is defined as an SAE for which there is at least a reasonable 
possibility that the study drug (CCX168/placebo) caused the event. 
A suspected unexpected serious adverse reaction (SUSAR) is defined as an SAE for which there 
is at least a reasonable possibility that the study drug (CCX168/placebo) caused the event, and 
the SAE is ‘unexpected’, i.e., not described in terms of nature, severity, or frequency in the 
Reference Safety Information within the current Investigator’s Brochure. 
‘Reasonable possibility’ means that there is evidence to suggest a causal relationship between the 
study drug and the adverse event. Within the reporting requirements, the following examples 
illustrate the types of evidence that would suggest a causal relationship: 
• A single occurrence of an event that is uncommon and known to be strongly associated 
with drug exposure (e.g., angioedema, hepatic injury, Stevens-Johnson Syndrome); 
• One or more occurrences of an event that is not commonly associated with drug 
exposure, but is otherwise uncommon in the population exposed to the drug (e.g., tendon 
rupture); 
• An aggregate analysis of specific events observed in a clinical trial (such as known 
consequences of the underlying disease or condition under investigation or other events 
that commonly occur in the study population independent of drug therapy) that indicates 
those events occur more frequently in the drug treatment group than in a concurrent or 
historical control group. 
Patients with AAV are often elderly and have many co-morbidities. Therefore, single 
occurrences of SAEs that are considered more likely related to the underlying disease or 
concomitant medications would typically not be considered reasonably related to CCX168. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 88 of 135 
The therapies used to treat patients with AAV, i.e., cyclophosphamide, rituximab, 
glucocorticoids, azathioprine, and mycophenolate are often associated with adverse events. A list 
of reported adverse events observed with cyclophosphamide use is provided in Section 12.9, 
with glucocorticoid use in Section 12.10, with rituximab use in Section 12.11, with azathioprine 
use in Section 12.12, and with mycophenolate mofetil use in Section 12.13. In assessing potential 
causality of adverse events to CCX168/placebo, the known association between 
cyclophosphamide, glucocorticoids, rituximab, azathioprine, and mycophenolate to these adverse 
events will be taken into account. 
Events related to the underlying disease, such as relapses or worsening of disease, will not be 
considered as SUSARs, unless there is a reasonable possibility that CCX168 use was associated 
with these events. 
7.2.4.6. 
Laboratory Abnormalities 
Safety laboratory tests are performed frequently over the course of the study. Laboratory reports 
with abnormal findings will be reviewed by the Investigator and the Medical Monitor. The 
Investigator may be advised to take appropriate steps, such as increasing the frequency of 
monitoring, or potentially discontinuing study medication, in case the abnormalities persist. 
If a patient develops Grade 3 or greater increased hepatic transaminases (> 5 times the upper 
limit of normal), or if a patient develops Grade 2 or greater increased transaminases (> 3 times 
the upper limit of normal) with elevation of bilirubin to > 2 times the upper limit of normal, 
dosing with study drug (CCX168/placebo) must be paused in this patient, and evaluation for 
possible drug-induced liver injury must be undertaken. 
Study medication (CCX168 or placebo) must be permanently discontinued if any of the 
following markers of hepatic injury and/or impaired liver synthetic function are observed, and 
cannot be attributed to a reversible etiology unrelated to study medication (e.g. cholelithiasis): 
• 
ALT or AST >8xULN 
• 
ALT or AST >5xULN for more than 2 weeks 
• 
ALT or AST >3xULN and (Total Bilirubin >2xULN or INR >1.5) 
• 
ALT or AST >3xULN with the appearance of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%) 
If drug induced hepatic toxicity is ruled out following complete evaluation and if all laboratory 
values have returned to normal, then resumption of study drug may be considered only after 
discussion with and the agreement of the Medical Monitor. If study drug is resumed, hepatic 
transaminases and bilirubin are to be monitored closely. 
If a patient develops Grade 3 or greater leukopenia (WBC count < 2 x 109/L) or neutropenia (< 1 
x 109/L), or grade 4 (< 0.2 x 109/L), then study drug must be paused in this patient. In addition, if 
a patient develops Grade 2 leukopenia (WBC count <3 x 109/L, but 2 x 109), the patient must be 
followed closely for infection and for further significant reduction (reduction by an additional 0.5 
x 109/L, or to < 2 x 109/L) in WBC; if either occurs, then study drug must be paused in this 
patient. Study drug may be resumed only if the abnormal value returns to normal and the 
Investigator deems resumption to be appropriate. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 89 of 135 
If a patient develops grade 3 or worse CPK increase (>5 times the upper limit of normal), dosing 
with study drug must be paused in this subject. Study drug may be resumed only if the CPK 
returns to normal levels. 
7.2.4.7. 
Pregnancies 
Any pregnancies that occur in female patients or partners of male study patients must be reported 
to the Safety team within 24 hours of awareness as indicated in Section 7.2.5. All pregnancies 
must be followed up until conclusion and the outcome of the pregnancy reported within 24 hours 
of awareness to the Safety team as indicated in Section 7.2.5. 
7.2.5. 
Serious Adverse Event Reporting 
Any SAE occurring from screening through the end of the follow-up period, whether or not 
considered study related, will be reported immediately (within 24 hours) to the Safety team. 
Reporting is done by completing the SAE form in the EDC system. If it is not possible to access 
the EDC system, the Investigator will send an email to the appropriate regional clinical safety 
mailbox (see information below) or call their regional SAE hotline and fax the completed SAE 
report form within 24 hours of awareness. 
Contact details are as follows: 
 
Any medication or other therapeutic measures used to treat the event, in addition to the outcome 
of the adverse event, will be recorded in the EDC system.  
Follow-Up Reports 
The investigator must continue to follow the patient until the SAE has subsided or until the 
condition becomes chronic in nature, stabilizes (in the case of persistent impairment), or the 
patient dies. 
Within 24 hours of receipt of follow-up information, the investigator must update the SAE form 
electronically in the EDC system for the study and submit any supporting documentation (e.g., 
patient discharge summary or autopsy reports) to 
 via fax or e-mail. If it 
is not possible to access the EDC system, refer to the procedures outlined above for initial 
reporting of SAEs. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 90 of 135 
The Sponsor or its representatives will report all SUSARs to national health authorities and 
ethics committees in an expedited manner in accordance with Clinical Trial Directive, Articles 
16 and 17, ICH Guideline E2A and ENTR CT3 on the reporting of all SUSARs. 
7.3. 
Pharmacokinetic Assessments 
Concentrations of CCX168 (and metabolites) will be determined in plasma according to the 
schedule in the Time and Events Table. The samples on Day 1 will be collected prior to the first 
dose of CCX168/placebo on that day. Only for patients 12 to 17 years of age, samples will also 
be taken at Hours 0.5, 1, 2, 3, 4, and 6 following the first dose of CCX168/placebo on Day 1. 
The blood samples collected on the other study days do not need to be collected prior to the 
CCX168/placebo dose on those days. However, the date and time of the last dose of 
CCX168/placebo prior to the sample collections must be recorded in the EDC system. 
Population PK analysis will be performed based on the CCX168 and metabolite plasma 
concentrations. 
Total plasma concentrations of CCX168 (and metabolites) will be determined using validated 
analytical methods. These plasma samples may also be used to measure cytokines, complement 
fragments, or other markers associated with AAV. 
7.4. 
Pharmacodynamic Assessments 
Blood samples will be collected according to the schedule in the Time and Events Table for PD 
marker measurements in plasma, including, for example, cystatin C, complement fragments, and 
inflammatory cytokine and chemokine levels. Blood samples collected may be used for 
lymphocyte subset counts including B cells, T cells, and natural killer cells, and for DNA and 
other biomarker assessments by RNA analysis. The complete blood cell (CBC) count results 
from the hematology samples will also be included in the PD assessments. The PK plasma 
samples may be used for these PD marker measurements.  
Urine samples will also be collected according to the schedule in the Time and Events Table for 
biomarker assessments including, for example, renal injury and inflammation markers (e.g., 
kidney injury molecule-1 [KIM-1] and neutrophil gelatinase-associated lipocalin [NGAL]), 
soluble CD163, complement fragments, inflammatory chemokine and cytokine levels.  
A saliva sample will be collected on Day 1 from patients who have provided Informed Consent 
for assessment of genetic markers of AAV as well as the complement pathway. Potential 
markers include HLA DPB1*0401, SERPINA1, PRTN3, and HLA-DQ. C5aR polymorphisms 
may also be investigated. 
7.5. 
Study Completion and Withdrawal 
The Week 60 visit will be the last Study Day for all patients. Procedures for this day will be 
completed per the Time and Events Table. Each patient’s condition will be evaluated by the 
Investigator at the end of the clinical trial and appropriate standard of care medical treatment will 
be prescribed for to all patients as needed. For early withdrawals from the study, the procedures 
for the Early Termination visit will be performed, when possible (see Section 6.27). 
The clinical trial will be terminated early if there is a safety concern that cannot be addressed by 
a modification of the protocol. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 91 of 135 
7.6. 
Data Monitoring Committee 
In addition to continuous safety monitoring by the Medical Monitor and clinical staff, an external 
Data Monitoring Committee (DMC) will monitor the safety of patients over the course of the 
study. The DMC will consist of external physicians and a biostatistician. A DMC charter will be 
developed before start of the study and the DMC will function according to the charter. 
It is anticipated that the DMC will have regular meetings, once every 3 to 6 months, depending 
on study enrollment rate. Ad hoc meetings may be scheduled if unanticipated safety events 
occur. After review of data at each meeting, the DMC will make recommendations about further 
conduct of the study. 
8. 
STATISTICS 
Details of the statistical analysis will be provided in a separate statistical analysis plan (SAP), 
which will be written, finalized, and approved prior to unblinding of the study. Additional details 
will be provided in the SAP; in all cases the SAP will take precedence over the analyses 
described in the protocol. (as described below). 
The SAP will supersede the statistical analysis methods described in this clinical protocol. Any 
deviation from the protocol will be documented and described in the final report. If changes to 
principal features stated in the protocol are required, these will be documented in a protocol 
amendment. The final SAP will take into account any amendment to the protocol. Data analysis 
and writing of a clinical study report (CSR) for all study data will be performed by the 
designated CRO in accordance with its standard operating procedures (SOPs). Analysis of PK 
and PD data, and writing of PK and PD reports will be performed by designated PK and PD 
teams in accordance with their SOPs. 
8.1. 
Patient Populations 
8.1.1. 
Intent-to-Treat Population 
For the purposes of data analysis, the ITT Population will include all patients who have provided 
written informed consent and are randomized in the study and who received at least one dose of 
blinded study drug. 
8.1.2. 
Per Protocol Population 
The Per Protocol (PP) population will consist of all randomized patients who receive at least one 
dose of study drug and do not have protocol deviations that could significantly affect the 
interpretation of the results for the primary endpoints. Patients’ inclusion/exclusion from the PP 
population will be determined and documented prior to the database lock and unblinding. 
8.1.3. 
Safety Population 
The safety population will include all patients who are randomized and have received at least one 
dose of study drug. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 92 of 135 
8.2. 
Efficacy Endpoints 
8.2.1. 
Primary Endpoints 
The primary efficacy endpoints are: 
1. The proportion of patients achieving disease remission at Week 26, defined as a BVAS of 0 
and not taking glucocorticoids for treatment of AAV within 4 weeks prior to Week 26. 
2. The proportion of patients achieving sustained disease remission, defined as remission at 
Week 26 without relapse to Week 52 (BVAS of 0 and not taking glucocorticoids for 
treatment of AAV within 4 weeks prior to Week 52). 
8.2.2. 
Secondary Endpoints 
Secondary efficacy endpoints include: 
1. Glucocorticoid-induced toxicity as measured by change from baseline over the first 26 weeks 
in the glucocorticoid toxicity index; 
2. Early remission, defined as BVAS of 0 at Week 4; 
3. Change from baseline over 52 weeks in health-related quality-of-life as measured by the 
domains and component scores of the SF-36 v2 and EQ-5D-5L VAS and index; 
4. Proportion of patients and time to experiencing a relapse after previously achieving remission 
at Week 26 in the study; relapse is defined as occurrence of at least one major item in the 
BVAS, or three or more minor items in the BVAS, or one or two minor items in the BVAS 
recorded at two consecutive visits, after having achieved remission at Week 26 (BVAS = 0 
and no glucocorticoids for treatment of AAV within 4 weeks) in the study; 
5. In patients with renal disease at baseline (based in the BVAS renal component), the change in 
eGFR from baseline over 52 weeks; 
6. In patients with renal disease at baseline (based in the BVAS renal component), the percent 
change in UACR from baseline over 52 weeks;  
7. In patients with renal disease at baseline (based in the BVAS renal component), the percent 
change in urinary MCP-1:creatinine ratio from baseline over 52 weeks;  
8. Change in the VDI from baseline over 52 weeks. 
8.3. 
Safety Endpoints 
Safety endpoints, other than glucocorticoid-induced toxicity listed under the efficacy endpoints, 
include: 
1. Patient incidence of treatment-emergent serious adverse events, adverse events, and 
withdrawals due to adverse events; 
2. Change from baseline and shifts from baseline in all safety laboratory parameters; 
3. Change from baseline in vital signs, and 
4. Incidence of clinically significant ECG changes from baseline. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 93 of 135 
8.4. 
Pharmacokinetic Endpoints 
CCX168 (and metabolite) plasma concentration results will be used to calculate trough plasma 
concentrations (Cmin) over the course of the clinical trial. If sufficient data are available, 
population PK analyses may also be performed to determine PK parameters for CCX168 and 
significant metabolites. 
The Cmax, Tmax, and AUC0-6 will be determined for patients 12 to 17 years old based on CCX168 
and metabolite plasma concentration data on Day 1. 
8.5. 
Pharmacodynamic Endpoints 
The following PD endpoints may be assessed: 
1. Change and percent change from baseline in plasma biomarkers such as cystatin C, 
complement fragments, inflammatory chemokine and cytokine levels. The cystatin C levels 
may be used in calculating eGFR changes from baseline using the following equation: 
eGFRcys (mL/min/1.73 m2) = 127.7 x (cystatin C in mg/L)−1.17 x (Age)−0.13 x (0.91 if female) 
x (1.06 if African-American/Black) 
2. Change and percent change from baseline in urine biomarkers such as renal injury and 
inflammation markers (e.g., KIM-1 and NGAL), soluble CD163, complement fragments, 
inflammatory chemokine and cytokine levels; 
3. Change from baseline in CBC count (especially WBCs, neutrophils, and lymphocytes) and 
lymphocyte subset counts including B cells, T cells, and natural killer cells; 
4. Change from baseline in blood cell gene expressions such as neutrophil functional status 
markers. 
The effect of polymorphism in genetic markers such as HLA DPB1*0401, SERPINA1, PRTN3, 
and HLA-DQ, as well as C5aR polymorphism may also be investigated. 
8.6. 
Statistical Analysis Methodology 
A statistical analysis plan with specific details of all the planned analyses and sensitivity analyses 
will be generated and approved before unblinding the data for analysis. 
All statistical testing will be two-sided, with the type I error rate at α=0.05.  
The efficacy analyses for the efficacy endpoints will be performed in the ITT and PP 
populations, with the ITT analysis being the primary analysis. 
The analysis of the efficacy endpoints will be conducted when all patients have completed at 
least the Week 52 study visit. Individual patient group assignment will remain blinded to 
investigators and patients until after the analysis of the data in order to maintain study integrity. 
Baseline is defined as the last value prior to start of dosing with study medication (typically the 
Day 1 pre-dose value). For BVAS and VDI, baseline will be from the Screening visit. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 94 of 135 
8.6.1. 
Patient Disposition 
The number of patients who were screened, who screen failed (by reason), who were 
randomized, who completed Week 26, Week 52, and Week 60 of the study, who withdrew early 
from the study, along with the reasons for withdrawal, will be presented by treatment group.  
8.6.2. 
Demographics and Baseline Characteristics 
All patient baseline characteristics and demographic data, i.e., age, gender, race, ethnicity, 
weight, height, body mass index, anti-PR3 and anti-MPO status, GPA vs. MPA, newly-
diagnosed vs. relapsing disease, IV cyclophosphamide vs. oral cyclophosphamide vs. IV 
rituximab use, vasculitis disease duration (from time of diagnosis), BVAS, VDI, GTI, SF-36 v2, 
EQ-5D-5L, eGFR, hematuria status, UACR, urinary MCP-1:creatinine ratio, will be listed and 
summarized by treatment group. 
Glomerular histopathology (if biopsy was taken), physical examination abnormalities, and 
medical history will be listed and, where applicable, summarized by treatment group. 
8.6.3. 
Prior and Concomitant Medications 
All prior (within 12 months of screening for AAV medications, and within 6 months of screening 
for all other medications) and concomitant medications (including vasculitis medication) will be 
listed and summarized by Anatomic Therapeutic Chemistry (ATC) classification. All patients 
who received prior IV or oral glucocorticoids, concomitant IV or oral non-study supplied 
glucocorticoids, as well as other non-study supplied treatments for AAV during the study will be 
listed and summarized by treatment group. 
8.6.4. 
Study Drug Exposure and Compliance 
Patient drug exposure will be calculated based on the study drug dispensing and return records, 
as well as CCX168 plasma concentrations over the course of the study. The CCX168/placebo 
and prednisone/placebo compliance will be calculated comparing the study drug dispensed and 
the study drug returned. The study drug exposure (duration, total dose, and average daily dose) 
and compliance will be summarized and/or listed. 
8.6.5. 
Efficacy Analyses 
Summary statistics will be calculated for each of the efficacy endpoints. For categorical 
endpoints, numbers and percentages will be calculated. For continuous variables, numbers, 
means, medians, ranges, standard deviations, and standard error of means will be calculated. 
Geometric means will be calculated for UACR and urinary MCP-1:creatinine, and other data that 
are not normally distributed. 
Results will be presented by treatment group. Results will be presented by stratum for each of the 
three stratification factors, IV rituximab vs. IV cyclophosphamide vs. oral cyclophosphamide 
use, anti-PR3 vs. anti-MPO positive ANCA, and newly-diagnosed vs. relapsing patients, as well 
as GPA vs. MPA. Results will be presented for patients with renal AAV and those without renal 
AAV at baseline, as well as those who received IV glucocorticoids upfront compared to those 
who did not. Data will also be presented by geographic distribution, sex, age group (including a 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 95 of 135 
separate analysis in 12-17 year old patients), race, and ethnicity for at least the primary 
endpoints. 
The overall efficacy hypothesis in this study is that CCX168 treatment will be effective in 
treatment of patients with AAV based on inducing and then sustaining remission without 
requiring chronic oral prednisone treatment.  
The primary efficacy endpoints are: 
1. The proportion of patients in disease remission at Week 26, defined as BVAS score of 0 and 
not taking glucocorticoids for treatment of AAV within 4 weeks prior to Week 26, and  
2. The proportion of patients achieving sustained remission, defined as remission at Week 26 
without relapse to Week 52 (BVAS of 0 and not taking glucocorticoids for treatment of AAV 
within 4 weeks prior to Week 52). 
The proportion of patients achieving disease remission at Week 26 will be calculated as the 
number of patients with a BVAS of 0 during the 4-week period preceding the Week 26 visit, and 
having not received any glucocorticoid treatment during the 4-week period preceding and 
including the Week 26 visit, divided by the total number of patients randomized to the particular 
treatment group and who received at least 1 dose of blinded study drug. 
The proportion of patients achieving sustained disease remission at Week 52 will be calculated 
as the number of patients who achieved remission at Week 26 (with a BVAS of 0 during the 4-
week period preceding the Week 26 visit, and having not received any glucocorticoid treatment 
during the 4-week period preceding and including the Week 26 visit) AND who have also 
achieved remission at Week 52 (with a BVAS of 0 during the 4-week period preceding the Week 
52 visit, and having not received any glucocorticoid treatment for AAV during the 4-week period 
preceding and including the Week 52 visit), divided by the total number of patients randomized 
to the particular treatment group and who received at least 1 dose of blinded study drug.  
The following hypotheses will be tested for the first primary efficacy endpoint: 
• The non-inferiority null hypothesis (H10) is that the CCX168 group is inferior to the 
control group when comparing the remission rate based on BVAS at Week 26.   
• The non-inferiority alternative hypothesis (H11) is that the CCX168 group is not inferior 
to the control group when comparing the remission rate at Week 26. 
• The superiority null hypothesis (H20) is that the CCX168 group is not different from the 
control group when comparing the remission rate at Week 26. 
• The superiority alternative hypothesis (H21) is that the CCX168 group is superior to the 
control group when comparing the remission rate at Week 26. 
The following hypotheses will be tested for the second primary efficacy endpoint:  
• The non-inferiority null hypothesis (H30) is that the CCX168 group is inferior to the 
control group when comparing the sustained remission rate based on remission at Week 
26 without relapse to Week 52. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 96 of 135 
• The non-inferiority alternative hypothesis (H31) is that the CCX168 group is not inferior 
to the control group when comparing the sustained remission rate based on remission at 
Week 26 without relapse to Week 52. 
• The superiority null hypothesis (H40) is that the CCX168 group is not different from the 
control group when comparing the sustained remission rate based on remission at Week 
26 without relapse to Week 52. 
• The superiority alternative hypothesis (H41) is that the CCX168 group is superior to the 
control group when comparing the sustained remission rate at Week 26 without relapse to 
Week 52. 
The two primary endpoints will be tested sequentially using a gatekeeping procedure to preserve 
the Type I error rate at 0.05. The sequence of testing will be as follows: 
1. Test for non-inferiority (H10) of the CCX168 group compared to the control group regarding 
remission at Week 26; if the p-value for non-inferiority is < 0.05, proceed to step 2; 
2. Test for non-inferiority (H30) of the CCX168 group compared to the control group regarding 
sustained remission at Week 52; if the p-value for non-inferiority is < 0.05, proceed to step 3; 
3. Test for superiority (H40) of the CCX168 group compared to the control group regarding 
sustained remission at Week 52; if the p-value for superiority is < 0.05, proceed to step 4; 
4. Test for superiority (H20) of the CCX168 group compared to the control group regarding 
remission at Week 26. 
For the non-inferiority test of the first primary efficacy endpoint, if the lower bound of the 95% 
confidence interval is greater than -0.20 (i.e., P < 0.05 for the non-inferiority test) and the control 
group disease remission rate is at least 40% at Week 26, the CCX168 group will be considered 
not inferior to the control group. For the superiority test, if the lower bound of the 95% 
confidence interval is greater than 0.0 (i.e., P < 0.05 for the superiority test), the CCX168 group 
will be considered superior to the control group in achieving the disease remission at Week 26.  
The disease remission rate at Week 26 in the control group is based on a meta-analysis of 20 
published studies in patients treated with rituximab plus glucocorticoids or cyclophosphamide 
plus glucocorticoids. The lower bound of the 95% confidence interval for the remission rate was 
approximately 60%. The non-inferiority margin of -0.20 was selected to demonstrate that the 
CCX168 group retains at least 50% of the control group benefit. 
For the second primary endpoint, the proportion of patients in disease remission at Week 26 
without relapse to Week 52, and the two-sided 95% confidence interval for the difference in 
proportion (CCX168 minus control) will be estimated for the comparison between the CCX168 
group and the control group. For the non-inferiority test of the second primary endpoint, if the 
lower bound of the 95% confidence interval is greater than -0.20 (i.e., P < 0.05 for the non-
inferiority test), the CCX168 group will be considered not inferior to the control group. For the 
superiority test, if the lower bound of the 95% confidence interval is greater than 0.0 (i.e., P < 
0.05 for the superiority test), the CCX168 group will be considered superior to the control group 
in achieving the disease remission at Week 26 without relapse to Week 52. 
Patients who relapse after Week 26 and before Week 52 will be considered treatment failures for 
the sustained remission analysis at Week 52. A relapse is defined as worsening of disease that 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 97 of 135 
involves at least one major item, or three or more minor items, or one or two minor items 
recorded at two consecutive visits in the BVAS, after having previously achieved remission at 
Week 26 (BVAS = 0 and not receiving glucocorticoids for treatment of AAV within 4 weeks)  
The confidence intervals for the difference in proportions will be calculated using the Newcombe 
hybrid-score method for the common difference from the stratified contingency tables. 
The secondary endpoints will be tested in parallel and nominal p-values will be provided. 
The proportion of patients with early remission (Week 4) and the proportion of patients with 
relapse events will be analyzed using the same method as for the primary endpoints.  
If there are a sufficient number of relapse events, time from achieving remission at Week 26  to 
relapse will be analyzed by Kaplan Meier methodology and log rank testing of the differences 
between treatment groups.  
Continuous variables will be analyzed using a mixed effects model for repeated measures 
(MMRM) with treatment group, visit, treatment-by-visit interaction, and randomization strata 
(IV rituximab, IV or oral cyclophosphamide, anti-PR3 or anti-MPO ANCA, and newly-
diagnosed AAV or relapsed AAV) as factors, and baseline as covariate. Patients will be 
considered as repeated measure units over visits. Point estimates and corresponding 95% 
confidence intervals will be estimated for the difference across 52 weeks using simple contrast 
from the model. Continuous variables include change and/or percent change from baseline in 
GTI, eGFR, UACR, urinary MCP-1:creatinine ratio, SF-36 v2 (component scores and domains) 
and EQ-5D-5L VAS and index, VDI, and pharmacodynamic markers. Data that are not normally 
distributed, e.g., UACR will be log-transformed before analysis. In the MMRM model, missing 
data will not be imputed. This analysis is unbiased under the missing at random (MAR) 
assumption. A Toeplitz covariance matrix will be used to model the within-patient variance-
covariance deviation. A sensitivity analysis will be carried out using analysis of covariance 
(ANCOVA) with missing data imputed by last observation carried forward (LOCF). 
The Week 60 follow-up data will be summarized with no formal statistical testing. 
8.6.6. 
Handling of Missing Data 
Missing remission data at Week 26 and Week 52 will be imputed as remission not achieved for 
the primary endpoints. Time to relapse will be censored at the time when the first data point is 
missing. Missing data in the continuous variables will not be imputed for the MMRM analysis. 
As a sensitivity analysis, missing data in the continuous variables will be imputed with LOCF 
and analyzed using analysis of covariance (ANCOVA). Other sensitivity analysis may be added 
in the statistical analysis plan (SAP) to further explore the robustness of the treatment effect. 
8.6.7. 
Covariates and Subgroups 
The analysis of the efficacy endpoints may be adjusted by the following variables in the form of 
covariate analysis, stratified analysis, and/or subgroup analysis: 
• Randomization stratification variables 
− IV rituximab, IV cyclophosphamide, or oral cyclophosphamide 
− Anti-PR3 or anti-MPO ANCA 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 98 of 135 
− Newly diagnosed AAV or relapsed AAV 
• Sex 
• BMI 
• Age at diagnosis of AAV 
• Age at study entry; a subgroup analysis will be performed in 12-17 year old patients, if 
feasible. 
• Duration of AAV 
• Patient’s age, race, and ethnicity (if plausible) 
• GPA vs. MPA 
• Renal disease or not 
• Baseline BVAS 
• Baseline VDI 
• Baseline GTI 
• Baseline eGFR 
• Baseline hematuria 
• Baseline UACR 
• Baseline urinary MCP-1:creatinine ratio 
• Geographic distribution (North America vs. Europe and Rest of World) 
8.6.8. 
Safety Analyses 
Analysis of change from baseline in the glucocorticoid toxicity index is discussed in 
Section 8.6.5. In addition to the GTI, the proportion of patients who had any of the items in the 
“Specific List” will be summarized by specific item, treatment group, and study visit.  
All clinical safety and tolerability data will be listed by treatment group and by patient, and will 
be summarized by treatment group.  
All reported adverse events will be coded using MedDRA and listed by System Organ Class, 
preferred term, and verbatim term.  
Treatment-emergent adverse events will be listed and summarized by System Organ Class, by 
relatedness and by maximum severity, and by treatment group.  
Serious adverse events and adverse events leading to withdrawal will be summarized by 
treatment group. This will include serious infections. 
Individual vital signs and change from baseline in vital signs will be listed by treatment group, 
patient, and study visit, and summarized by treatment group.  
Laboratory data (actual values and change from baseline) will be listed by treatment group, 
patient, and study visit. Abnormal laboratory values will be flagged. Laboratory data will also be 
summarized by treatment group and study visit. Shift tables will be generated for shifts in 
laboratory parameters by study visit.  


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 99 of 135 
Abnormal ECG findings will be listed by treatment group and study visit, and clinical 
significance of abnormalities indicated. 
8.6.9. 
Pharmacokinetic and Pharmacodynamic Marker Analysis 
Individual plasma concentrations of CCX168 and significant metabolites will be listed, plotted, 
and summarized descriptively and graphically. PK parameters such as Cmax, Tmax, and AUC0-6hr 
will be calculated in adolescents for CCX168 based on plasma concentrations for samples 
collected on Day 1. Plasma levels of significant metabolites may also be determined and PK 
parameters calculated. Population PK modeling may be performed to calculate PK parameters.  
Plasma and urinary PD markers will be summarized and may be analyzed using methods 
analogous to the efficacy parameters. 
The relationship between PK parameters and renal function based on eGFR will also be 
evaluated. The data may also be used to evaluate the PK/PD relationship of CCX168 treatment. 
To this end, the change and/or percent change from baseline in eGFR, VDI, UACR, urinary 
MCP-1:creatinine ratio, or other biomarkers may be used as PD markers. 
8.7. 
Sample Size Justification 
The proportion of patients in the control group achieving clinical remission at Week 26 is 
estimated to be ~60%, a blended proportion of 64% and 53% observed in the rituximab and 
cyclophosphamide/azathioprine groups, respectively, in the largest prior registration study in 
AAV (Stone et al, 2010).  
A non-inferiority margin of -20 percentage points has been derived for the difference between 
CCX168 and control groups, and a one-sided alpha level of 0.025. This non-inferiority margin is 
based on a thorough review and meta-analysis of all previous clinical trials conducted in patients 
with AAV, as well as precedent (Stone et al, 2010). 
A sample size of 150 patients per group (300 in total) is estimated to provide more than 90% 
power for the non-inferiority test. This sample size provides 90% power to detect approximately 
18% superiority in the proportion of patients achieving clinical remission at Week 26 if the 
control group remission rate is 60%. 
The proportion of patients in the control group with sustained remission at Week 52 is estimated 
to be ~45%, a blended proportion observed in a prior study comparing rituximab and 
cyclophosphamide/azathioprine in AAV (Specks et al, 2013).  
A sample size of 150 patients per group (300 in total) is estimated to provide 85% power to 
detect approximately 18% superiority if the control group sustained remission rate at Week 52 is 
45%. 
8.8. 
Interim Analysis 
Safety data from the study will be summarized for review by the DMC at various points over the 
course of the study (see Section 7.6). The DMC charter will include details of these reviews.  
No Type I error adjustment will be made based on the DMC review of the data, since these 
reviews will focus on safety assessment. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 100 of 135 
8.9. 
Protocol Deviations 
Significant protocol deviations will be listed and summarized by category. The effect of 
significant protocol deviations on the safety and efficacy outcomes will be assessed by 
conducting sensitivity analyses excluding patients and/or study visits with significant protocol 
deviations. This will be determined and documented before unblinding the study. 
The Sponsor will assess any protocol deviation and decide whether any of these should be 
reported to Competent Authorities as a serious breach of GCP and the protocol. Protocol waivers 
are not acceptable. 
9. 
STUDY COMPLETION AND TERMINATION 
9.1. 
Study Completion 
A patient has completed the study when s/he has completed the study procedures per protocol. 
9.2. 
Study Termination 
The end of study is defined as the last study visit of the last clinical trial patient. 
10. 
REGULATORY AND ADMINISTRATIVE REQUIREMENTS 
10.1. 
Investigator Responsibilities 
Prior to trial initiation, the Investigator will provide the Sponsor with a fully executed and signed 
FDA Form 1572, a Financial Disclosure Form, and a curriculum vitae. Financial Disclosure 
Forms also will be completed for all Sub-Investigators listed on the Form 1572 who will be 
involved directly in the treatment or evaluation of research patients in this trial. 
The study will be conducted in accordance with the Declaration of Helsinki (amended by the 
59th World Medical Association General Assembly, October 2008) and Good Clinical Practice 
(GCP) according to International Conference on Harmonisation (ICH) guidelines. Specifically, 
the study is based on adequately performed laboratory and animal experimentation; the study 
will be conducted under a protocol reviewed by a properly constituted IRB/EC; the study will be 
conducted by scientifically and medically qualified persons; the benefits of the study are in 
proportion to the risks; the rights and welfare of the patients will be respected; and each patient 
or his/her legal guardian will give his/her written Informed Consent before any protocol-specific 
tests or evaluations are performed. 
10.2. 
Institutional Review Board or Ethics Committee 
Prior to initiating the study, the Investigator will obtain written confirmation from the IRB/EC 
that the IRB/EC was properly constituted and met the definition of all United States Code of 
Federal Regulations Title 21, Section 312.3(b) and Part 56, and/or the applicable local, regional 
or national Regulatory requirements. A copy of the confirmation will be provided to the Sponsor.  
The Principal Investigator will provide the IRB/EC with all appropriate materials, including the 
protocol and Informed Consent documents. The trial will not be initiated until IRB/EC approval 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 101 of 135 
of the protocol, the Informed Consent document, and all recruiting materials are obtained in 
writing by the Investigator and copies are received by the Sponsor. Appropriate reports on the 
progress of the study will be made to the IRB/EC and the Sponsor by the Principal Investigator 
in accordance with applicable governmental regulations and in agreement with the policy 
established by the Sponsor. 
10.3. 
Informed Consent 
A properly executed, written, and appropriately explained Informed Consent Form, in 
compliance with the Declaration of Helsinki, ICH GCP, and US Code of Federal Regulations for 
Protection of Human Patients (21 CFR 50.25[a,b], CFR 50.27, and CFR Part 46, Subpart A), will 
be signed by each patient or his/her legal guardian prior to entering the trial. Either the 
Investigator or the Investigator’s designee will obtain the consent of the study patient. The 
patient will be provided as much time as necessary to review the document, to inquire about 
details of the trial, and to decide whether or not to participate in the study. The Informed Consent 
will be signed and dated by the study patient and by the person who conducted the Informed 
Consent discussion. The Investigator will provide a copy of the signed Informed Consent Form 
to each patient and will maintain a copy in the patient’s record file. 
10.4. 
Protocol Modifications 
Only the Sponsor may modify the protocol. The only exception is when the Investigator 
considers that a patient’s safety would be compromised without immediate action. In this 
circumstance, immediate approval of the chairperson of the IRB/EC must be sought, and the 
Investigator should inform the Sponsor’s Medical Monitor and the full IRB/EC within five 
working days after the emergency occurred. All other amendments that have an impact on 
patient risk or the study objectives, and/or that require revision of the Informed Consent Form, 
must receive approval from the IRB/EC prior to their implementation, except when the changes 
involve only logistical or administrative aspects of the trial. The IRB/EC must be notified of 
changes that are made to study contact personnel, but IRB/EC review or approval of these 
changes is not required. If protocol amendments are substantial and are likely to have an impact 
on the safety of the trial patients or to change the interpretation of the scientific documents in 
support of the conduct of the trial, or if they are otherwise significant, the sponsor shall notify the 
FDA and other competent authorities concerned of the reasons for, and content of, these 
amendments according to the European Directive “Detailed guidance on the request to the 
competent authorities for authorization of a clinical trial on a medical products for human use, 
the notification of substantial amendments and the declaration of the end of trial (CT-1)(2010/C 
82/01)” and other regulatory guidance. In case of a substantial amendment to the protocol, 
approval will be sought from Competent Authorities before implementation. 
10.5. 
Regulatory Documentation 
All regulatory documentation including regulatory submissions, 1572 forms, and correspondence 
regarding this study will be kept by the Sponsor. The CRO that will conduct the study on behalf 
of the Sponsor will maintain all study documentation according to their SOPs. Clinical trial 
related documents will be archived for the longest of:  
1. 10 years according to national Swedish and EU regulations (LVFS 2003:3), or  


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 102 of 135 
2. For 2 years following the date a full marketing application is approved, or  
3. For 2 years after the FDA is notified that the IND is discontinued if there is no marketing 
application. 
10.6. 
Patient Identification Register 
The Investigator agrees to complete a patient identification register, which will be used for the 
purpose of long term follow-up, if needed. This form will be treated as confidential, and will be 
filed by the Investigator in a secure locked place. Otherwise, all reports and communications 
relating to the study will identify participants by initials and/or assigned number only. 
10.7. 
Record Retention 
The Investigator must retain all study records required by the Sponsor and by the applicable 
regulations in a secure and safe facility. The Investigator must consult a Sponsor CRA before 
disposal of any study records, and must notify the Sponsor of any change in the location, 
disposition, or custody of the study files. Clinical trial related documents will be archived for the 
longest of:  
1. 10 years according to national Swedish and EU regulations (LVFS 2003:3), or  
2. For 2 years following the date a full marketing application is approved, or  
3. For 2 years after the FDA is notified that the IND is discontinued if there is no marketing 
application. 
10.8. 
Case Report Form Completion 
Electronic Case Report Forms (CRFs) will be generated for each patient. The electronic data 
capture (EDC) system will comply with CFR 21 Part 11. 
It is the policy of the Sponsor that study data must be verifiable to the source data, which 
necessitates access to all original recordings, laboratory reports, and patients’ records. The 
Investigator must therefore agree to allow access to patients’ records, and source data must be 
made available for all study data. The patients (or their legal representatives) must also allow 
access to the patients’ medical records, and they will be informed of this requirement and will 
indicate their agreement when giving Informed Consent. Upon completion of the study, 
electronic copies of the CRFs will be provided to the investigators and should be included as part 
of his/her study files and retained as per FDA or local regulations. 
10.9. 
Monitoring 
At intervals during the study, as well as after the completion of patient enrollment at the study 
center, the study center will be monitored by a CRA for compliance, which will include ensuring 
that accurate and complete data are promptly recorded in EDC, and reviewing source 
documentation and drug accountability records. The study will be conducted according to the 
principles of GCP as accepted in the United States and according to CPMP/ICH/135/95. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 103 of 135 
10.10. 
On-site Visits and Audits 
The Sponsor’s representatives will visit the study center prior to initiation of the study to review 
with the center personnel information regarding the investigational agent, protocol requirements, 
monitoring requirements, and reporting of serious adverse events. 
In certain circumstances, a secondary audit may be conducted by members of a Quality 
Assurance group designated by the Sponsor. The Investigator will be informed if this is to take 
place and advised as to the nature of the audit. Representatives of the Food and Drug 
Administration (FDA) and/or representatives of other regulatory authorities may also conduct an 
audit of the study. If informed of such an audit, the Investigator should notify the Sponsor 
immediately. 
10.11. 
Use of Information and Publication 
It is understood by the Investigator that the information generated in this study will be used by 
the Sponsor in connection with the development of the product and therefore may be disclosed to 
government agencies in various countries. To allow for the use of information derived from the 
study, it is understood that the Investigator is obliged to provide the Sponsor with complete test 
results, all study data, and access to all study records. 
The Sponsor recognizes the importance of communicating study data and will disclose or publish 
the results in a suitable form regardless of outcome. The Sponsor will post the clinical trial 
information on appropriate registries, e.g., clinicaltrials.gov prior to enrollment of the first 
patients, and publish the results of this study in scientific journals, at seminars or conferences, 
and/or in other manner(s) it so chooses. Results from this study shall not be made available to 
any third party by the investigating team without the express permission of the Sponsor. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 104 of 135 
11. 
REFERENCES 
Exley AR, et al. 1997 Development and initial validation of the VDI. Arthritis Rheum 40:371-
380. 
Jennette JC, et al. 2013 Revised International Chapel Hill Consensus Conference Nomenclature 
of Vasculitides. Arthritis Rheum 65:1–11. 
Johnson TN, et al. Prediction of the clearance of eleven drugs and associated variability in 
neonates, infants and children. Clin Pharmacokinet 2006; 45:931–956. 
Jones JH, et al. 2010 Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. 
N Engl J Med 363:211-220. 
Little M, et al. 2010 Early mortality in systemic vasculitis: relative contribution of adverse events 
and active vasculitis. Ann Rheum Dis 69:1036−1043.  
Miloslavsky EM, et al. 2016 Development of a Glucocorticoid Toxicity Index (GTI) using 
multicriteria decision analysis. Ann Rheum Dis 2016;0:1–4. doi:10.1136/annrheumdis-2016-
210002. 
Momper JD, et al. Adolescent Dosing and Labeling Since the Food and Drug Administration 
Amendments Act of 2007. JAMA Pediatr 2013;167:926–932. 
Mukhtyar C, et al. 2009 Modification and validation of the Birmingham Vasculitis Activity 
Score (version 3) Ann Rheum Dis 68:1827–1832. 
Robson J, et al. 2015 Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm 
antibody-associated vasculitides: long-term data from the European Vasculitis Study Group 
trials. Rheumatol 54:471-481. 
Schwartz GJ, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 
2009;20:629–637. 
Specks U, et al. 2013 Efficacy of remission-induction regimens for ANCA-associated vasculitis. 
N Engl J Med 369:417-427.  
Stone JH, et al. 2010 Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N 
Engl J Med 363:221-232. 
Suppiah R, et al. 2011 A cross-sectional study of the Birmingham Vasculitis Activity Score 
version 3 in systemic vasculitis. Rheumatol 50:899-905. 
Xiao H, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc 
Nephrol 2014;25:225–231. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 105 of 135 
12. 
APPENDICES 
12.1. 
Statement of Obligations of Sponsor, Monitor, and Clinical 
Investigator 
Sponsor and Monitor 
If the Sponsor is not familiar with the Study Site, the Sponsor or its designated representative, 
will: 
A. Conduct a pre-study visit to: 
1. Establish the acceptability of the facility, the recruitment potential and the standard of patient 
care at this site, and record this in a written report. 
2. Discuss the proposed clinical trial with the Investigator, review the CRF requirements, and 
supply the Investigator’s Brochure and the draft protocol for review and approval. 
3. Discuss with the Investigator FDA and other regulatory requirements with respect to 
Informed Consent, competent authority (CA) and ethics committee (EC) approval of the trial, 
the protocol, protocol amendments, and Informed Consent changes. 
B. Conduct periodic site visits to: 
1. Assure adherence to the protocol. 
2. Review CRFs and medical records for accuracy and completeness of information. 
3. Examine pharmacy records for documentation of quantity and date of receipt of 
investigational supplies, dispensation and accountability data for administration to each 
patient, loss of materials, contamination, and unused supplies. 
4. Record and report observations on the progress of the trial and continued acceptability of the 
facilities in a Site Visit Report. 
5. Review Investigator files for required documents, e.g., protocols, protocol amendments, CA 
and EC approvals (protocols, amendments, Informed Consent, etc.), EC charter and 
membership, and communications between the EC and the Investigator.  
Clinical Investigator 
A. EC 
The Investigator must assure the monitor that the EC: 
1. Meets FDA regulations as defined in 21 CFR Part 56 and other applicable ICH and GCP 
requirements. 
2. Has authority delegated by the parent institution and found in EC by-laws, operation 
guidelines, or charter to approve or disapprove clinical trials and protocols, including 
Informed Consent Forms and other documents (protocol amendments, information to be 
supplied to patients concerning Informed Consent, etc.). 
3. Complies with proper personnel makeup of an EC and maintains an active up-to-date roster 
of all EC members participating in the meetings. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 106 of 135 
4. Convenes meetings using acceptable rules of order for making decisions, recording such 
decisions, and implementing them. 
5. Files contain (a) documentation of its decisions such as are found in EC minutes and 
correspondence, (b) written guidelines or by-laws governing EC functions, (c) protocols, (d) 
protocol information to be supplied to the patient, (e) correspondence between the EC and 
the Investigator (Informed Consent Form changes, protocol amendments, etc.). 
B. Informed Consent of Human Patients. 
The Principal Investigator must assure the monitor that the Informed Consent Form: 
1. Meets FDA regulations as defined in 21 CFR Part 50 Informed Consent, and other applicable 
ICH and GCP requirements. 
2. Has been approved by the EC, including, when required, information to be given to the 
patient regarding the trial in which s/he is enrolled. 
a. The Informed Consent Form includes the Basic Elements and any Additional Elements 
necessary. 
b. The patient and a study center representative sign the Informed Consent Form and the 
patient is given a copy. 
C. Storage and Dispensing of Study Supplies. 
The Investigator (or pharmacist or pharmacy technician) must demonstrate to the monitor that: 
1. Adequate and accurate written records show receipt and disposition of all study supplies, 
including dates, serial or lot numbers, quantities received, and each quantity dispensed, 
administered, or used, with identification of each patient. 
2. Purpose and reasons are given in written records for study material disposal, e.g., the amount 
contaminated, broken, or lost, and the quantity returned to the Sponsor. 
D. Case Report Forms. 
The Investigator must assure the monitor that: 
1. Case report forms, when complete, accurately reflect the medical records on each patient. 
2. Case report forms and medical records will be accessible to the monitor or FDA and other 
Regulatory inspectors during site visits. 
E. Files and Records. 
The Investigator must assure the quality, integrity, and content of his or her files that will be 
inspected by the monitor and regulatory inspectors.  The files must contain, at a minimum: 
1. Correspondence between the EC and the Investigator. 
2. The following documents: 
a. EC-approved protocols. 
b. EC-approved protocol amendments. 
c. EC-approved Informed Consent Form and information supplied to the patient. 
d. EC charter, membership, and qualifications. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 107 of 135 
3. Clinical supplies: 
a. Record of receipt, date and quantity, and batch or lot number. 
b. Disposition dates and quantity administered to each patient. 
c. Inventory records. 
Clinical trial related documents will be archived for the longest of:  
1. 10 years according to national Swedish and EU regulations (LVFS 2003:3), or  
2. For 2 years following the date a full marketing application is approved, or  
3. For 2 years after the FDA is notified that the IND is discontinued if there is no marketing 
application. 
12.2. 
Informed Consent Form  
In seeking Informed Consent, the following information shall be provided to each patient: 
1. A statement that the study involves research, an explanation of the purposes of the research 
and the expected duration of the patient's participation, a description of the procedures to be 
followed, and identification of any procedures which are experimental. 
2. A description of any reasonably foreseeable risks or discomforts to the patient. 
3. A description of any benefits to the patient or to others that may reasonably be expected from 
the research. 
4. A disclosure of appropriate alternative procedures or courses of treatment, if any, that might 
be advantageous to the patient. 
5. A statement describing the extent, if any, to which confidentiality of records identifying the 
patient will be maintained and that notes the possibility that the Food and Drug 
Administration or other regulatory agency may inspect the records. 
6. For research involving more than minimal risk, an explanation as to whether any 
compensation and as to whether any medical treatments are available if injury occurs and, if 
so, what they consist of, or where further information may be obtained. 
7. An explanation of who to contact for answers to pertinent questions about the research and 
research patients' rights, and who to contact in the event of a research related injury to the 
patient. 
8. A statement that participation is voluntary, that refusal to participate will involve no penalty 
or loss of benefits to which the patient is otherwise entitled, and that the patient may 
discontinue participation at any time without penalty or loss of benefits to which the patient 
is otherwise entitled. 
ADDITIONAL ELEMENTS OF INFORMED CONSENT 
1. A statement that the particular treatment or procedure may involve risks to the patient (or to 
the embryo or fetus if the patient is or may become pregnant) which are currently 
unforeseeable. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 108 of 135 
2. Anticipated circumstances under which the patient’s participation may be terminated by the 
Investigator without regard to the patient’s consent. 
3. Any additional costs to the patient that may result from participation in the research. 
4. The consequences of a patient’s decision to withdraw from the research and procedures for 
orderly termination of participation by the patient. 
5. A statement that significant new findings developed during the course of the research which 
may relate to the patient’s willingness to continue participation will be provided to the 
patient. 
6. The approximate number of patients involved in the study. 
12.3. 
Birmingham Vasculitis Activity Score (BVAS) Version 3 
12.3.1. 
Instructions 
The BVAS was previously validated (Mukhtyar et al, 2009; Suppiah et al, 2011). 
The following instructions need to be followed to complete the BVAS according to the Time and 
Events Table. 
1. Record BVAS items and enter the data into the EDC for this study; 
2. Record only symptoms/signs ascribed to the presence of active AAV (GPA or MPA) on this 
form; 
3. Check “none” for category only if there are no disease activity for the category; 
4. “Major” items are indicated in bold italics; 
5. For the Week 4 BVAS assessment, record the disease activity present within the 7 days prior 
to the visit. For all the other study visits, record the disease activity present within the 28 
days prior to the visit. 
12.3.2. 
AAV Organ Systems and Activity Items in BVAS 
There are 9 organ systems, plus an “Other” category in the BVAS. Major items are indicated in 
bold italics. For study eligibility, a patient must have at least one major item, at least 3 minor 
items, or at least the two renal items of hematuria and proteinuria. If a patient has “other” items, 
not specified in the BVAS, these need to be discussed with the Medical Monitor before 
enrollment. 
1. General 
• Myalgia 
• Arthralgia / arthritis 
• Fever ≥38 °C 
• Weight loss ≥2 kg 
2. Cutaneous 
• Infarct 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 109 of 135 
• Purpura 
• Ulcer 
• Gangrene 
• Other skin vasculitis 
3. Mucous membranes / eyes    
• Mouth ulcers 
• Genital ulcers 
• Adnexal inflammation 
• Significant proptosis 
• Scleritis / Episcleritis 
• Conjunctivitis / Blepharitis / Keratitis 
• Blurred vision 
• Sudden visual loss 
• Uveitis 
• Retinal changes (vasculitis / thrombosis / exudate / haemorrhage)  
4. ENT 
• Bloody nasal discharge / crusts / ulcers / granulomata 
• Paranasal sinus involvement 
• Subglottic stenosis 
• Conductive hearing loss 
• Sensorineural hearing loss 
5. Chest 
• Wheeze 
• Nodules or cavities 
• Pleural effusion / pleurisy 
• Infiltrate 
• Endobronchial involvement 
• Massive haemoptysis / alveolar haemorrhage 
• Respiratory failure 
6. Cardiovascular 
• Loss of pulses 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 110 of 135 
• Valvular heart disease 
• Pericarditis 
• Ischaemic cardiac pain 
• Cardiomyopathy 
• Congestive cardiac failure 
7. Abdominal 
• Peritonitis 
• Bloody diarrhoea 
• Ischaemic abdominal pain 
8. Renal 
• Hypertension 
• Proteinuria >1+ or >0.2 g/g creatinine 
• Haematuria ≥10 RBCs/hpf  
• Serum creatinine 125-249 μmol/L 
• Serum creatinine 250-499 μmol/L 
• Serum creatinine ≥500 μmol/L  
• Rise in serum creatinine >30% or fall in creatinine clearance >25% 
9. Nervous system 
• Headache 
• Meningitis  
• Seizures (not hypertensive) 
• Cerebrovascular accident 
• Organic confusion 
• Spinal cord lesion 
• Cranial nerve palsy 
• Sensory peripheral neuropathy  
• Mononeuritis multiplex 
10. Other 
• RBC casts and/or glomerulonephritis 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 111 of 135 
12.3.3. 
Scoring of BVAS 
The Investigators will not be required to calculate the BVAS. This will be done 
programmatically in the EDC according to Mukhtyar et al, 2009. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 112 of 135 
12.4. 
Vasculitis Damage Index 
12.4.1. 
Instructions 
The Vasculitis Damage Index (VDI) was developed by Exley et al, 1997 and is for recording 
organ damage that has occurred in patients since the onset of vasculitis. 
Damage is defined as the presence of non-healing scars and does not give any indication of 
current disease activity. Damage items in the VDI are often the direct result of previous disease 
activity (captured in the BVAS). Damage is defined as having been present or currently present 
for at least 3 months. It is therefore possible for abnormalities to have occurred in the past, not be 
currently present, but to still count as damage. 
Patients often have co-morbidity before they develop vasculitis, which must not be scored. 
Record features of active disease using the BVAS, not the VDI. 
New patients should usually have a VDI score of zero, unless: 
a. They have had vasculitis for more than three months of onset of disease, and 
b. The damage has developed or become worse since the onset of vasculitis. 
The VDI item list can only deteriorate or be stable over time (damage is defined as irreversible in 
this scoring system). For each item in turn, record all features which have occurred since the 
onset of vasculitis, regardless of the cause. For specific events, such as GI surgery, damage can 
be scored as positive if the procedure was undertaken at least three months prior to the 
assessment (and also must have occurred after the onset of the disease). The same time frame is 
applied to all the damage items. If the patient is seen for the first time, and their vasculitis onset 
date is within three months of the assessment, then by definition, the patient cannot be recorded 
as having any damage. However, any features which are observed can be recorded as ascribable 
to damage after the arbitrary time of three months has elapsed. 
12.4.2. 
AAV Organ Systems in VDI 
There are 11 organ systems in the VDI: 
1. Musculoskeletal 
a. Significant muscle atrophy or weakness 
b. Deforming / erosive arthritis 
c. Osteoporosis / vertebral collapse 
d. Avascular necrosis 
e. Osteomyelitis 
2. Skin/Mucous Membranes 
a. Alopecia 
b. Cutaneous ulcers 
c. Mouth ulcers 
3. Ocular 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 113 of 135 
a. Cataract 
b. Retinal change 
c. Optic atrophy 
d. Visual impairment / diplopia 
e. Blindness in one eye 
f. Blindness in a second eye 
g. Orbital wall destruction 
4. Ear, Nose & Throat 
a. Hearing loss 
b. Nasal blockage / chronic discharge/crusting 
c. Nasal bridge collapse / septal perforation 
d. Chronic sinusitis / radiological damage 
e. Subglottic stenosis (no surgery) 
f. Subglottic stenosis (with surgery) 
5. Pulmonary 
a. Pulmonary hypertension 
b. Pulmonary fibrosis 
c. Pulmonary infarction 
d. Pleural fibrosis 
e. Chronic asthma 
f. Chronic breathlessness 
g. Impaired lung function 
6. Cardiovascular 
a. Angina angioplasty 
b. Myocardial infarction 
c. Subsequent myocardial infarction 
d. Cardiomyopathy 
e. Valvular disease 
f. Pericarditis ≥3 months or pericardectomy 
g. Diastolic BP ≥95 or requiring antihypertensives 
7. Peripheral Vascular Disease 
a. Absent pulses in one limb 
b. Second episode of absent pulses in one limb 
c. Major vessel stenosis 
d. Claudication >3 months 
e. Minor tissue loss 
f. Major tissue loss 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 114 of 135 
g. Subsequent major tissue loss 
h. Complicated venous thrombosis 
8. Gastrointestinal 
a. Gut infarction / resection 
b. Mesenteric insufficiency / pancreatitis 
c. Chronic peritonitis 
d. Esophageal stricture / surgery 
9. Renal 
a. Estimated / measured GFR ≤50 
b. Proteinuria ≥0.5 g/24 hours 
c. End stage renal disease 
10. Neuropsychiatric 
a. Cognitive impairment 
b. Major psychosis 
c. Seizures 
d. Cerebrovascular accident 
e. 2nd Cerebrovascular accident 
f. Cranial nerve lesion 
g. Peripheral neuropathy 
h. Transverse myelitis 
11. Other 
a. Gonadal failure 
b. Marrow failure 
c. Diabetes 
d. Chemical cystitis 
e. Malignancy 
f. Etc. 
12.4.3. 
Scoring of VDI 
The number of positive items is added for the total VDI score. Any previously scored items on 
the VDI must be carried forward to subsequent visits. The VDI score cannot decrease over time. 
The investigators will not need to calculate the VDI. This will be done in the EDC. 
12.5. 
Glucocorticoid Toxicity Index (GTI) 
The GTI was developed to quantify toxicity associated with glucocorticoid use (Miloslavsky et 
al, 2016). The Index consists of the components in Table 3. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 115 of 135 
Table 3: 
The Glucocorticoid Toxicity Index 
Composite GTI 1 
 
Item Weight 
Specific List 2 
BMI 
Improvement in BMI 
-8 
Major increase in BMI (>8 units and 
above 24.9 kg/m2) 
No change in BMI 
0 
 
Moderate increase in BMI 
21 
 
Major increase in BMI 
36 
 
Glucose tolerance 
Improvement in glucose tolerance 
-8 
Diabetic retinopathy 
No change in glucose tolerance 
0 
Diabetic nephropathy 
Worsening of glucose intolerance 
32 
Diabetic neuropathy 
Worsening of glucose intolerance 
despite treatment 
44 
 
Blood pressure 
Improvement in blood pressure 
-10 
Hypertensive emergency (or 
posterior reversible encephalopathy 
syndrome) 
No change in blood pressure 
0 
Posterior reversible encephalopathy 
syndrome 
Worsening hypertension 
19 
 
Worsening hypertension despite 
treatment 
44 
 
Lipids 
Improvement in lipids 
-9 
 
No change in lipids 
0 
 
Worsening hyperlipidaemia 
10 
 
Worsening hyperlipidaemia 
despite treatment 
30 
 
Bone density 3 
Improvement in bone density 
-1 
Major decrease in bone density 
No change in bone density 
0 
Insufficiency fracture 
Decrease in bone density 
29 
 
Steroid myopathy 
No steroid myopathy 
0 
Severe steroid myopathy or tendon 
rupture 
Mild steroid myopathy 
9 
 
Moderate steroid myopathy or 
greater 
63 
 
Skin toxicity 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 116 of 135 
Composite GTI 1 
 
Item Weight 
Specific List 2 
No skin toxicity 
0 
Severe skin toxicity 
Mild skin toxicity 
8 
 
Moderate skin toxicity or greater 
26 
 
Neuropsychiatric toxicity 
No neuropsychiatric symptoms 
0 
Psychosis (hallucinations, delusions, 
or disorganized thought processes, 
occurring in the absence of mania, 
delirium, or depression) 
Mild neuropsychiatric symptoms 
11 
Glucocorticoid-induced violence 
towards self or others 
Moderate neuropsychiatric 
symptoms or greater 
74 
Other severe neuropsychiatric 
symptoms 
Infection 
No significant infection 
0 
Grade IV infection 
Oral/vaginal candidiasis or 
uncomplicated zoster 
19 
Grade V infection (death from 
infection) 
Grade III infection or greater 
93 
 
Endocrine  
 
Symptomatic adrenal insufficiency 
Gastrointestinal 
 
Perforation (occurring in the absence 
of regular nonsteroidal anti-
inflammatory drug use) 
 
 
Peptic ulcer disease confirmed by 
endoscopy (excluding H. pylori) 
Musculoskeletal 
 
Avascular necrosis 
 
 
Tendon rupture 
Ocular 
 
Central serous retinopathy 
 
 
New onset or worsened elevation of 
intraocular pressure requiring 
treatment or change in treatment. 
 
 
Posterior subcapsular cataract (or 
history of the same) 
Total 
-35 to 410 
 
1 See Section 12.5.1 for definitions of each item in the GTI. 
2 See Section 12.5.2 for definitions of each specific list item. 
3 Since the last assessment of the GTI will be performed at Week 26, and bone density assessments are typically 
performed annually, the osteoporosis component will not be included in the GTI for this study, according to the 
authors’ recommendation. 
12.5.1. 
Definitions of Items Comprising the GTI 
Definitions for each of the items in the first column in Table 3 are provided below. 
Body Mass Index (BMI) (compared to baseline) 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 117 of 135 
a. Improvement in the direction of the normal range by more than 2 BMI units (normal 
range = 18.5-24.9 kg/m2); 
b. No significant change (BMI remains within ± 2 BMI units compared with baseline) OR 
BMI remains within the normal range; 
c. Moderate increase in BMI (increase by more than 2 but less than 5 BMI units, to above 
the upper limit of normal BMI [24.9 kg/m2]); 
d. Major increase in BMI (increase by at least 5 but less than 8 BMI units above normal 
BMI [24.9 kg/m2]). 
Glucose Tolerance (compared to baseline) 
a. Improvement in glucose tolerance: 
− HbA1c declined >10% from baseline without medication increase OR 
− Decrease in diabetic medication without an increase in HbA1c of >10% or HbA1c < 
5.7%. 
b. No significant change in glucose tolerance: 
− HbA1c within 10% of baseline or HbA1c <5.7% AND no change in medication, OR 
− HbA1c increased to >10% of baseline with a decrease in medication, OR 
− HbA1c decreased by >10% of baseline with an increase in medication. 
c. Worsening of glucose tolerance or medication status: 
− HbA1c >5.7% and increased to >10% of baseline without a change in medication, OR 
− Increase in diabetic medication with <10% increase in HbA1c. 
d. Worsening of glucose tolerance despite increased treatment: 
− HbA1c >5.7% AND increased to >10% of baseline AND an increase in diabetic 
medication. 
Blood Pressure (BP) (compared to baseline) 
a. Improvement in BP: 
− Decrease in BP of >10% of baseline without medication increase, unless baseline 
systolic BP ≤120 and diastolic BP ≤85, OR 
− Decrease in medication without an increase in BP of >10%, unless baseline systolic 
BP ≤120 and diastolic BP ≤85. 
b. No significant change in BP: 
− BP within 10% of baseline or systolic BP ≤120 and diastolic BP ≤85 AND no change 
in medication, OR 
− Increase in either systolic or diastolic BP >10% with a decrease in medication, OR 
− Improvement in systolic or diastolic BP of >10% with an increase in medication. 
c. Worsening of hypertension: 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 118 of 135 
− Increase in BP of >10% such that the systolic BP exceeds 120 mmHg or the diastolic 
BP exceeds 85 mmHg without a change in medication, OR 
− An increase in anti-hypertensive medication accompanied by stability or no 
significant change in both the systolic and diastolic BP. 
d. Worsening of hypertension despite treatment: 
− Increase in BP of >10% such that the systolic BP exceeds 120 mmHg or the diastolic 
BP exceeds 85 mmHg AND an increase in medication. 
Lipid metabolism (low-density lipoprotein [LDL] compared to baseline) 
a. Improvement in lipids: 
− Decrease in LDL concentration >10% of baseline toward the target range without 
medication increase, OR 
− Decrease in medication without an increase in LDL of >10% or LDL remains within 
target range. 
b. No significant change in LDL: 
− LDL within 10% of baseline or within the target range for patient AND no change in 
medication, OR 
− Increase in LDL >10% with a decrease in medication, OR 
− Improvement in LDL of >10% with an increase in medication. 
c. Worsening of LDL or medication status: 
− Increase in LDL of >10% to above target range without a change in medication, OR 
− Increase in medication with <10% change in LDL. 
d. Worsening of LDL despite treatment: 
− Increase in LDL of >10% AND an increase in medication. 
Glucocorticoid-induced myopathy 
Glucocorticoid-induced myopathy is defined as mild symmetrical weakness of the proximal 
muscles and/or neck flexors associated with steroid therapy, and NOT due to any other apparent 
cause. Muscle enzymes are typically within normal limits. 
a. No steroid myopathy; 
b. Mild steroid myopathy (Grade 4 weakness WITHOUT functional limitation); “Grade 4 
weakness” is defined as weaker than normal, but greater than antigravity strength 
against resistance; 
c. Moderate steroid myopathy (weakness WITH functional limitation, enough to interfere 
with normal daily activities). 
Note that a person may have muscle weakness consistent with glucocorticoid-induced myopathy 
that is detectable on physical examination but might not be aware of it or have any corresponding 
functional limitation - this would be classified as mild. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 119 of 135 
Severe glucocorticoid-induced myopathy (defined as weakness of Grade 3 or less, which means 
no more than antigravity strength and unable to overcome any resistance or any degree weaker) 
is included in the Specific List (see Table 3). People who are severely weak may have difficulty 
rising from a chair without assistance or other major functional limitations but the formal 
categorization for severe should be based on the degree of weakness on strength testing. 
Skin 
Manifestations to be considered: 
• Acneiform rash 
• Easy Bruising 
• Hirsutism 
• Atrophy/striae 
• Erosions/tears/ulcerations 
Severity is graded as shown in Table 4.  
Table 4: 
Severity of Glucocorticoid Toxicity in the Skin 
Manifestation 
Mild 
Moderate 
Severe 
Acneiform rash 
Papules and/or pustules 
covering ≤30% body 
surface area (BSA), which 
may or may not be 
associated with symptoms 
of pruritus or tenderness; 
OR associated with 
psychosocial impact; OR 
limiting instrumental 
activities of daily living 
(ADL). 
Papules and/or pustules 
covering >30% BSA, 
which may or may not be 
associated with symptoms 
of pruritus or tenderness; 
OR limiting self-care 
ADL; OR associated with 
local superinfection with 
oral antibiotics indicated. 
Papules and/or pustules 
covering any % BSA, 
which may or may not be 
associated with symptoms 
of pruritus or tenderness 
and are associated with 
extensive superinfection 
with IV antibiotics 
indicated; OR life- 
threatening consequences. 
Easy Bruising 
Localized or in a 
dependent area. 
Generalized 
 
Hirsutism; In women, 
increase in length, 
thickness or density of hair 
in a male distribution 
Hirsutism that the patient 
is able to camouflage by 
periodic shaving, 
bleaching, or removal of 
hair. 
Hirsutism that requires 
daily shaving or consistent 
destructive means of hair 
removal to camouflage; 
OR associated with 
psychosocial impact. 
 
Atrophy/striae 
Covering <10% BSA; OR 
associated with 
telangiectasias or changes 
in skin color. 
Covering 10 - 30% BSA; 
OR associated with striae 
or adnexal structure loss. 
Covering >30% BSA; OR 
associated with ulceration. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 120 of 135 
Manifestation 
Mild 
Moderate 
Severe 
Erosions/tears/ulcerations 
Combined area of ulcers 
<1 cm; OR nonblanchable 
erythema of intact skin 
associated with warmth or 
erythema. 
Combined area of ulcers 1 
to 2 cm; OR partial 
thickness skin loss 
involving skin or 
subcutaneous fat. 
Combined area of ulcers 
>2 cm; OR full-thickness 
skin loss involving 
damage to or necrosis of 
subcutaneous tissue that 
may extend down to 
fascia. 
Neuropsychiatric Toxicity 
Manifestations to be considered: 
• Insomnia 
• Mania 
• Cognitive Impairment 
• Depression 
Severity is graded as shown in Table 5. 
Table 5: 
Severity of Neuropsychiatric Glucocorticoid Toxicity 
Manifestation 
Mild 
Moderate 
Severe 
Insomnia; Dissatisfaction 
with sleep quality and 
difficulty initiating or 
maintaining sleep or early 
morning awakening 
Not associated with 
functional impairment. 
Associated with functional 
impairment. 
 
Mania 
Slightly or occasionally 
elevated or irritable mood 
and 0-1 mild or occasional 
additional symptoms of 
inflated self-esteem, 
decreased need for sleep, 
increased talkativeness, 
feeling that thoughts are 
faster than usual, 
distractibility, increased 
activity or agitation, and 
impulsive actions. 
Frequent or moderately 
elevated or irritable mood 
and 2-3 mild additional 
symptoms of inflated self-
esteem, decreased need for 
sleep, increased 
talkativeness, feeling that 
thoughts are faster than 
usual, distractibility, 
increased activity or 
agitation, and impulsive 
actions. 
Severe or constantly 
elevated or irritable mood 
and 4 or more additional 
symptoms of inflated self-
esteem, decreased need for 
sleep, increased 
talkativeness, feeling that 
thoughts are faster than 
usual, distractibility, 
increased activity or 
agitation, and impulsive 
actions. 
Cognitive impairment 
Minor cognitive 
complaints, no objective 
findings on mental status 
examination (i.e., not 
apparent to the examiner) 
that were not present 
before initiating steroids. 
New moderate cognitive 
deficits that were not 
present before initiating 
steroids. 
Frank delirium 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 121 of 135 
Manifestation 
Mild 
Moderate 
Severe 
Depression 
Feeling slightly down or 
depressed and 0-2 mild or 
occasional addition 
symptoms of loss of 
interest, low energy, guilt, 
poor concentration, 
insomnia, restlessness, or 
change in appetite. 
Frequent or moderate 
feelings of being down or 
depression and/or 3-4 
symptoms of loss of 
interest, low energy, guilt, 
poor concentration, 
insomnia, restlessness, or 
change in appetite. 
Severe constant feeling of 
being down or depression 
and/or 5 or more 
symptoms of loss of 
interest, low energy, guilt, 
poor concentration, 
insomnia, restlessness, or 
change in appetite and/or 
suicidal thoughts. 
Infection 
a. No significant infection = No specific infections or serious infections, Grade 3 or 
greater 
b. Specific Infections <Grade 3 – Oral or vaginal candidiasis or zoster infections without 
post-herpetic neuralgia or eye involvement 
c. Grade 3 or complicated herpes zoster 
• Grade 3 – Intravenous antibiotic, antifungal, or antiviral intervention or hospitalization 
indicated, OR radiologic or operative intervention indicated, OR herpes zoster 
complicated by post-herpetic neuralgia or eye involvement. 
• Grade 4 or 5 - Life-threatening consequences; urgent intervention indicated, OR death 
from infection (included in the Specific List; see Table 3). 
12.5.2. 
Definitions of Specific List Items 
Definitions of each of the Specific List Items in the third column in Table 3 are provided below: 
Hypertensive emergency: The blood pressure has reached levels that are damaging organs. 
Hypertensive emergencies generally occur at blood pressure levels exceeding 180 mmHg 
systolic OR 120 mmHg diastolic, but can occur at even lower levels in patients whose blood 
pressure have not been elevated before. Complications can include: stroke, loss of consciousness, 
memory loss, myocardial infarction, hypertensive retinopathy or nephropathy, aortic dissection, 
angina, pulmonary edema. 
Posterior reversible leukoencephalopathy syndrome (PRES): A clinical radiological entity. 
Clinical features may include headaches, altered mental status, seizures, and visual loss, 
depending on the affected neuroanatomy. Characteristic Magnetic Resonance Imaging (MRI) 
findings include vasogenic edema involving the white matter that predominantly affects the 
posterior occipital and parietal lobes of the brain, although other brain regions may also be 
affected. Confirmation by MRI is required as is exclusion of other potential causes (including 
hypertensive emergency). 
Severe glucocorticoid myopathy: Grade 3 or worse myopathic weakness or respiratory 
myopathic weakness attributable to glucocorticoid myopathy. 
Central serous retinopathy: a fluid detachment of macula layers from their supporting tissue. 
Requires formal ophthalmology examination, typically accompanied by optical coherence 
tomography and/or fluorescein angiography for diagnostic confirmation. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 122 of 135 
Grade 4 infection: Life-threatening consequences (e.g., septic shock, hypotension, acidosis, 
necrosis). 
Diabetic nephropathy: Macroalbuminuria; i.e., a urinary albumin excretion >300 mg in a 24-hour 
collection or a urinary protein: creatinine ratio >300mg/g. 
Diabetic neuropathy: Any of four types of peripheral neuropathy occurring in the setting of 
diabetes mellitus, namely: 1) a distal sensory polyneuropathy; 2) autonomic neuropathy 
(hypoglycemia unawareness, bladder or bowel problems, erectile dysfunction, and other 
autonomic nervous system issues); 3) diabetic amyotrophy (muscle infarction); or 4) 
mononeuritis (e.g., foot drop attributed to diabetic neuropathy). 
12.6. 
Prednisone Dose Schedule 
12.6.1. 
Study-Supplied Prednisone 
Patients who are randomized to the control group will receive prednisone according to a 
standardized tapering schedule over the course of the study. Patients who are randomized to the 
CCX168 group will receive prednisone-matching placebo capsules, with the type and number of 
capsules matching the type and number of capsules taken by the control group patients over the 
course of the study.  
Patients with a body weight of ≥55 kg, who are randomized to the control group, will start at an 
oral prednisone dose of 60 mg per day and will taper the dose down to zero over 20 weeks (140 
days). Adult patients with a body weight less than 55 kg will start at an oral prednisone dose of 
45 mg per day and will taper the dose down to zero over 20 weeks. Adolescents with a body 
weight >37 kg will start at an oral prednisone dose of 45 mg per day and will taper the dose 
down to zero over 20 weeks, and adolescents with a body weight ≤37 kg will start at an oral 
prednisone dose of 30 mg per day and will taper the dose down to zero over 20 weeks.  
The tapering schedule for patients in the control group is provided in Table 6. 
Table 6: 
Prednisone/Matching Placebo Schedule for the Control Group 
Study Day 
CCX168 Group 
Control Group 
 
Daily Prednisone Dose 
 
All 
Adults 
Adolescents 
 
 
≥55 kg 
<55 kg 
>37 kg 
≤37 kg 
Day 1 to 7 
0 
60 mg 
45 mg 
45 mg 
30 mg 
Day 8 to 14 
0 
45 mg 
45 mg 
45 mg 
30 mg 
Day 15 to 21 
0 
30 mg 
30 mg 
30 mg 
30 mg 
Day 22 to 42 
0 
25 mg 
25 mg 
25 mg 
25 mg 
Day 43 to 56 
0 
20 mg 
20 mg 
20 mg 
20 mg 
Day 57 to 70 
0 
15 mg 
15 mg 
15 mg 
15 mg 
Day 71 to 98 
0 
10 mg 
10 mg 
10 mg 
10 mg 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 123 of 135 
Day 99 to 
140 
0 
5 mg 
5 mg 
5 mg 
5 mg 
≥ Day 141 
0 
0 
0 
0 
0 
Patients will receive prednisone bottles containing either 20 mg prednisone/matching capsules or 
5 mg prednisone/matching capsules or both, depending on the study visit, and will take 
prednisone/matching placebo capsules each day as shown in Table 7. 
 
Table 7: 
Prednisone/Matching Placebo Dosing by Study Day 
Study Day 
Prednisone 
dose 
Dosing instructions for 20 mg/ 
matching placebo bottle 
Dosing instructions for 5 mg/ 
matching placebo bottle 
Day 1 to 7 (for adults 
≥55 kg) 
60 mg 
Take 3 capsules per day 
NA 
Day 1 to 7 (for adults 
<55 kg and 
adolescents >37 kg) 
45 mg 
Take 2 capsules per day 
Take 1 capsule per day 
Day 1 to 7 (for 
adolescents ≤37 kg) 
30 mg 
Take 1 capsule per day 
Take 2 capsules per day 
Day 8 to 14 (for all 
adults and adolescents 
>37 kg) 
45 mg 
Take 2 capsules per day 
Take 1 capsule per day 
Day 8 to 14 (for 
adolescents ≤37 kg) 
30 mg 
Take 1 capsule per day 
Take 2 capsules per day 
Day 15 to 21 (all) 
30 mg 
Take 1 capsule per day 
Take 2 capsules per day 
Day 22 to 42 (all) 
25 mg 
Take 1 capsule per day 
Take 1 capsule per day 
Day 43 to 49 (all) 
20 mg 
Take 1 capsule per day 
Not applicable 
Day 50 to 56 (all) 
20 mg 
Not applicable 
Take 4 capsules per day 
Day 57 to 70 (all) 
15 mg 
Not applicable 
Take 3 capsules per day 
Day 71 to 98 (all) 
10 mg 
Not applicable 
Take 2 capsules per day 
Day 99 to 140 (all) 
5 mg 
Not applicable 
Take 1 capsule per day 
≥ Day 141 (all) 
0 
Not applicable 
Not applicable 
Note that all patients will take prednisone or matching placebo capsules in order to maintain the 
study blinding. The appropriate number of 20 mg prednisone/matching placebo capsule bottles, 
and 5 mg prednisone/matching placebo capsule bottles will be dispensed to patients at each study 
visit, with detailed dosing instructions. 
12.6.2. 
Non-Study Supplied Glucocorticoid Use 
Extra glucocorticoids, i.e., that which is not supplied as study drug, must be avoided as much as 
possible during the study. The following sections provide guidance for non-study supplied 
glucocorticoid use. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 124 of 135 
12.6.2.1. Prior to the Screening Period 
Patients with severe AAV will be allowed to have received IV glucocorticoids at a cumulative 
dose up to 3 g methylprednisolone equivalent in the 4-week period prior to screening. 
Patients will also be allowed to have received oral glucocorticoids at any dose in the 6-week 
period prior to screening.  
Patients will not be eligible for screening if they have received continuous treatment with 
moderate or high dose glucocorticoids continuously for more than 6 weeks; moderate to high 
dose is defined as greater than 10 mg prednisone-equivalent per day. 
12.6.2.2. During the Screening Period 
During the screening period of the study (which is not to exceed 14 days), IV glucocorticoids 
will be allowed for patients with severe AAV, as long as the cumulative dose for the 4-week 
period prior to screening plus the IV dose(s) given during the screening period does not exceed 3 
g methylprednisolone equivalent. 
During the screening period of the study (which is not to exceed 14 days), oral glucocorticoids 
will be allowed for patients with severe AAV. If a patient receives oral glucocorticoids during 
the screening period, the dose needs to be tapered to a dose that does not exceed 20 mg 
prednisone equivalent on Day 1 of the study.  
12.6.2.3. During the Treatment Period 
If a patient is still taking a dose of ≤20 mg non-study supplied oral prednisone on Day 1 of the 
study, this dose of non-study supplied oral glucocorticoids must be tapered to zero over a 4-week 
period after Day 1. If glucocorticoids cannot be tapered to a dose of zero due to adrenal 
insufficiency, the adverse event of adrenal insufficiency and treatment administered must be 
recorded, along the evidence supporting the diagnosis. Replacement glucocorticoids for adrenal 
insufficiency should not exceed 10 mg prednisone equivalent per day; taper should be re-
initiated as soon as possible, and condition should be monitored consistent with Investigator 
judgment and local standards. The adverse event of adrenal insufficiency, and treatment for the 
event, must be recorded and updated as treatment is tapered.    
Patients who experience a relapse of their AAV during the study may be treated with IV 
glucocorticoids (typically 0.5 to 1 g methylprednisolone per day for 3 days) and/or oral 
glucocorticoids, tapered according to the patient's condition. A relapse is defined as worsening of 
disease, after having previously achieved remission (BVAS = 0) at Week 26, that involves: 
• one or more major item in the BVAS, or  
• three or more minor items in the BVAS, or 
• one or two minor items in the BVAS recorded at two consecutive study visits.  
These patients may continue study drug treatment and should continue in the study. 
Patients who experience worsening of disease during the study that involves a major item in the 
BVAS may be treated with IV glucocorticoids (typically 0.5 to 1 g methylprednisolone per day 
for 3 days) and/or oral glucocorticoids, tapered according to the patient's condition. Worsening 
not involving a major item in the BVAS may be treated with a short burst (i.e., not more than 2 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 125 of 135 
weeks) of oral glucocorticoids, at a maximum dose of 20 mg prednisone equivalent. Patients 
experiencing worsening of disease may continue study drug treatment and should continue in the 
study.  
Patients experiencing a relapse or worsening of disease may continue study drug treatment and 
should continue in the study. In patients experiencing a relapse, the study-supplied 
prednisone/matching placebo will be temporarily halted during the IV and/or oral course of 
glucocorticoids, and if the patient’s condition stabilizes, the study-supplied prednisone/matching 
placebo may be restarted according to the original study visit schedule. The CCX168/matching 
placebo may also continue during and following the treatment for the relapse, at the discretion of 
the investigator. 
Patients who have one or more major items in the BVAS before study entry, and who do not 
show an improvement or stabilization of these major items within the first 4 weeks of the study, 
may receive additional IV or oral glucocorticoids, tapered according to the patient’s condition. If 
the Investigator considers giving other medications, such as additional rituximab or 
cyclophosphamide treatment, these should be discussed with the Medical Monitor. These 
patients may continue study drug treatment and should continue in the study.  
In patients with early resistant disease, the study-supplied prednisone/matching placebo will be 
temporarily halted during the IV and/or oral course of glucocorticoids, and if the patient’s 
condition improves, the study-supplied prednisone/matching placebo may be resumed according 
to the original visit schedule. The CCX168/matching placebo may also continue during the 
treatment for early resistance, at the discretion of the investigator. 
12.7. 
Cyclophosphamide and Azathioprine Dosing 
12.7.1. 
Cyclophosphamide Dosing 
• For patients in the cyclophosphamide strata, cyclophosphamide doses must be given 
according to directions provided below. 
• A dose of 15 mg/kg cyclophosphamide will be given IV to all patients in the IV 
cyclophosphamide stratum, unless a lower dose is required per instructions below. The 
maximum permitted IV dose is 1.2 g. 
• A dose of 2 mg/kg/day cyclophosphamide will be given orally to all patients in the oral 
cyclophosphamide stratum, unless a lower dose is required per instructions below. The 
maximum daily oral dose permitted is 200 mg. Cyclophosphamide doses will be rounded 
down to the nearest 25 mg (or 50 mg, if 25 mg dose units are not available). 
• Mesna and antiemetic treatment need to be given according to local practice.  
• IV cyclophosphamide needs to be administered over a one-hour period. The start and end 
time of the IV infusion needs to be recorded.  
• The cyclophosphamide dose will be determined by four factors: patient age, eGFR, WBC 
at the study visit, and WBC nadir in between dose pulses (where applicable). The dose 
for oral and IV cyclophosphamide, based on age and eGFR, is provided in Table 8. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 126 of 135 
Table 8: 
Dose (mg/kg) for Oral or IV Cyclophosphamide Based on Age and eGFR  
Age (years) 
Oral Cyclophosphamide Dose 
(mg/kg/day) 
IV Cyclophosphamide Dose (mg/kg) 
 
eGFR (mL/min/1.73 m2) 
eGFR (mL/min/1.73 m2) 
 
>30 
≤30 
>30 
≤30 
<60 
2 
1.5 
15 
12.5 
60-70 
1.5 
1.25 
12.5 
10 
>70 
1.25 
1 
10 
7.5 
For those receiving IV cyclophosphamide, the dose should be reduced further based on the WBC 
count as follows: 
• WBC count assessed just prior to the IV dose:  
− If ≥ 3.5 x 109/L, dosing according to Table 8 will be given; 
− If < 3.5 x 109/L, the dose will be postponed until the WBC count is ≥ 3.5 x 109/L and 
then the dose from Table 8 will be reduced by another 25%; 
• WBC count nadir in between IV cyclophosphamide doses:  
− If > 3 x 109/L, dosing according to Table 8 will be given; 
− If 2 to 3 x 109/L, the dose from Table 8 will be reduced by 20%; 
− If 1 to 1.9 x 109/L, the dose from Table 8 will be reduced by 40%;  
− If < 1 x 109/L, the next dose will be withheld and further dosing will only be given if 
the WBC is > 3 x 109/L. 
For those receiving oral cyclophosphamide, the dose should be reduced further based on the 
WBC count as follows: 
• If WBC count is < 3.5 x 109/L, withhold dosing. When WBC count returns to ≥3.5 x 
109/L for two consecutive tests, or ≥ 5 x 109/L on a single test, restart oral 
cyclophosphamide at 25 mg less than dose from Table 8. Monitor WBC count weekly 
after this episode. If only 50 mg dose units are available, restart oral cyclophosphamide at 
50 mg less than dose from Table 8.  
• If WBC count is < 1 x 109/L, or < 3.5 x 109/L for more than 2 weeks, withhold dosing. 
When WBC count returns to ≥ 3.5 x 109/L for two consecutive tests or ≥ 5 x 109/L on a 
single test, restart oral cyclophosphamide at 50 mg less than dose from Table 8. Monitor 
WBC count weekly after this episode. Consider giving granulocyte colony stimulating 
factor (G-CSF), fungal prophylaxis, or other precautions. 
• If WBC count decreases markedly without overt leukopenia, e.g., WBC count < 6 x 109/L 
and at least 2 x 109/L lower than before, weekly WBC count monitoring should be done 
and the oral cyclophosphamide dose from Table 8 reduced by 25 mg (or 50 mg if 25 mg 
dose units are not available) if the WBC count continues to decrease. 
The last IV cyclophosphamide dose will be given at the Week 13 visit. The last oral 
cyclophosphamide dose will be given the day prior to Week 15. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 127 of 135 
12.7.2. 
Azathioprine and Mycophenolate Dosing 
• Oral azathioprine will be started at Week 15 for those patients in the IV and oral 
cyclophosphamide strata and continue through the end of the study. 
• The azathioprine dose will be started at 1 mg/kg/day for the first week, and increased to  
a target dose of 2 mg/kg/day by 2 weeks.  
• Doses will be rounded down to the nearest 25 mg increment, e.g., a patient weighing 
60 kg will have a target dose of 100 mg azathioprine per day.  
• Testing for thiopurine S-methyltransferase polymorphism and dose adjustment should be 
implemented according to the local institution policy.  
• Azathioprine will not be initiated if the WBC count is < 2 x 109/L. In this case, treatment 
initiation will be delayed until the WBC has increased to above 3 x 109/L.  
• In case azathioprine is not tolerated due to gastrointestinal intolerance/bleeding, 
hematologic abnormalities, hepatotoxicity, or other major side effects, mycophenolate 
mofetil (target dose of 2 g/day) may be used instead. In this case, the starting dose is 
500 mg twice daily for the first week, and increased to 1000 mg twice daily in the second 
week according to patient tolerance. If mycophenolate mofetil is not tolerated or not 
available, enteric coated mycophenolate sodium may be given at a target dose of 1440 
mg/day. The starting dose is 720 mg/day. 
12.8. 
Rituximab Dosing 
• The following dosing regimen of rituximab will be given: 
− 375 mg/m2 given as an IV infusion on Study Day 1, and Weeks 1, 2, and 3. 
• It is recommended to pre-medicate before each infusion with acetaminophen and an anti-
histamine. For the first rituximab infusion, 100 mg methylprednisolone, or equivalent is 
given. Glucocorticoid pre-medication for the second, third, and fourth rituximab 
infusions is allowed. 
• For the first IV infusion, it is recommended to initiate the infusion at a rate of 50 mg/hr. 
In the absence of infusion toxicity, it is recommended to increase the infusion rate by 
50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr. 
• For subsequent infusions, it is recommended to initiate the infusion at a rate of 100 
mg/hr. In the absence of infusion toxicity, it is recommended to increase the rate by 
100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr. 
• The start and end times of the IV rituximab infusions need to be recorded. 
12.9. 
Adverse Events Reported with Cyclophosphamide 
Carcinogenesis 
Increased risk of cancer; most frequently, these have been urinary bladder, myeloproliferative, or 
lymphoproliferative malignancies. 
Cardiac System 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 128 of 135 
Congestive heart failure, hemorrhagic myocarditis, hemopericardium, myocardial necrosis, 
pericarditis 
Digestive System 
Nausea, vomiting, anorexia, abdominal discomfort, abdominal pain, diarrhea, hemorrhagic 
colitis, oral mucosal ulceration, jaundice 
Hematopoietic System 
Leukopenia, neutropenia, fever in neutropenic patients, thrombocytopenia, anemia  
Infections 
Viral, bacterial, fungal, protozoan, or helminthic infections 
Reproductive System 
Cyclophosphamide interferes with oogenesis and spermatogenesis. It may cause sterility in both 
sexes. Men treated with cyclophosphamide may develop oligospermia, azoospermia, impaired 
sexual potency or libido, and testicular atrophy  
Respiratory System 
Interstitial pneumonitis, interstitial pulmonary fibrosis 
Skin and Its Structures 
Alopecia, skin rash, skin pigmentation, nail disorders, Stevens-Johnson syndrome, toxic 
epidermal necrolysis 
Urinary System 
Cystitis, urinary bladder fibrosis, hemorrhagic ureteritis, renal tubular necrosis 
Other 
Anaphylactic reactions; death associated with anaphylactic reactions, SIADH (syndrome of 
inappropriate ADH secretion), malaise, asthenia 
12.10. 
Adverse Events Reported with Glucocorticoid Use 
Allergic Reactions 
Anaphylactoid or hypersensitivity reactions, anaphylaxis, angioedema 
Cardiovascular System  
Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, 
congestive heart failure, ECG changes caused by potassium deficiency, edema, fat embolism, 
hypertension or aggravation of hypertension, myocardial rupture following recent myocardial 
infarction, necrotizing angiitis, pulmonary edema, syncope, tachycardia, thromboembolism, 
thrombophlebitis, vasculitis 
Dermatologic  
Acne, acneiform eruptions, allergic dermatitis, alopecia, angioedema, angioneurotic edema, 
atrophy and thinning of skin, dry scaly skin, ecchymoses and petechiae (bruising), erythema, 
facial edema, hirsutism, impaired wound healing, increased sweating, Karposi’s sarcoma, lupus 
erythematosus-like lesions, perineal irritation, purpura, rash, striae, subcutaneous fat atrophy, 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 129 of 135 
suppression of reactions to skin tests, striae, telangiectasis, thin fragile skin, thinning scalp hair, 
urticaria 
Endocrine  
Adrenal insufficiency-typically caused by high potency glucocorticoids with long duration of 
action (associated symptoms include; arthralgias, buffalo hump, dizziness, life-threatening 
hypotension, nausea, severe tiredness or weakness), amenorrhea, postmenopausal bleeding or 
other menstrual irregularities, decreased carbohydrate and glucose tolerance, development of 
cushingoid state, diabetes mellitus (new onset or manifestations of latent), glycosuria, 
hyperglycemia, hypertrichosis, hyperthyroidism, hypothyroidism, increased requirements for 
insulin or oral hypoglycemic agents in diabetics, lipids abnormal, moon face, negative nitrogen 
balance caused by protein catabolism, secondary adrenocortical and pituitary unresponsiveness 
(particularly in times of stress, as in trauma, surgery or illness) 
Fluid and Electrolyte Disturbances  
Congestive heart failure in susceptible patients, fluid retention, hypokalemia, hypokalemic 
alkalosis, metabolic alkalosis, hypotension or shock-like reaction, potassium loss, sodium 
retention with resulting edema. 
Gastrointestinal  
Abdominal distention, abdominal pain, anorexia which may result in weight loss, constipation, 
diarrhea, elevation in serum liver enzyme levels (usually reversible upon discontinuation), 
gastric irritation, hepatomegaly, increased appetite and weight gain, nausea, oropharyngeal 
candidiasis, pancreatitis, peptic ulcer with possible perforation and hemorrhage, perforation of 
the small and large intestine (particularly in patients with inflammatory bowel disease), 
ulcerative esophagitis, vomiting 
Hematologic  
Anemia, neutropenia (including febrile neutropenia) 
Metabolic  
Negative nitrogen balance due to protein catabolism 
Musculoskeletal  
Arthralgias, aseptic necrosis of femoral and humeral heads, increase risk of fracture, loss of 
muscle mass, muscle weakness, myalgias, osteopenia, osteoporosis, pathologic fracture of long 
bones, steroid myopathy, tendon rupture (particularly of the Achilles tendon), vertebral 
compression fractures 
Neurological/Psychiatric  
Amnesia, anxiety, benign intracranial hypertension, convulsions, delirium, dementia 
(characterized by deficits in memory retention, attention, concentration, mental speed and 
efficiency, and occupational performance), depression, dizziness, EEG abnormalities, emotional 
instability and irritability, euphoria, hallucinations, headache, impaired cognition, incidence of 
severe psychiatric symptoms, increased intracranial pressure with papilledema (pseudotumor 
cerebri) usually following discontinuation of treatment, increased motor activity, insomnia, 
ischemic neuropathy, long-term memory loss, mania, mood swings, neuritis, neuropathy, 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 130 of 135 
paresthesia, personality changes, psychiatric disorders including steroid psychoses or 
aggravation of pre-existing psychiatric conditions, restlessness, schizophrenia, verbal memory 
loss, vertigo, withdrawn behavior 
Ophthalmic  
Blurred vision, cataracts (including posterior subcapsular cataracts), central serous 
chorioretinopathy, establishment of secondary bacterial, fungal and viral infections, 
exophthalmos, glaucoma, increased intraocular pressure, optic nerve damage, papilledema 
Other  
Abnormal fat deposits, aggravation/masking of infections, decreased resistance to infection, 
hiccups, immunosuppresion, increased or decreased motility and number of spermatozoa, 
malaise, insomnia, moon face, pyrexia 
12.11. 
Adverse Events Reported with Rituximab Use 
The following adverse events were reported at an incidence of ≥ 10% in patients receiving 
rituximab in patients with GPA or MPA: nausea, diarrhea, headache, muscle spasms, anemia, 
peripheral edema, insomnia, arthralgia, cough, fatigue, increased ALT, hypertension, epistaxis, 
dyspnea, leukopenia, and rash. Infusion reactions included cytokine release syndrome, flushing, 
throat irritation, and tremor. Progressive multifocal leukoencephalopathy resulting in death has 
been reported. Hepatitis B reactivation with fulminant hepatitis, sometimes fatal, has been 
reported. Other infections including upper respiratory tract infections, urinary tract infections, 
and herpes zoster have been reported. Cardiac arrhythmias and angina can occur and can be life-
threatening. Bowel obstruction and perforation have been observed. Hypogammaglobulinemia 
was also reported.  
12.12. 
Adverse Events Reported with Azathioprine Use 
Azathioprine use has been associated with an increased risk of certain types of cancers including 
skin cancer and lymphoma. Azathioprine may also cause serious (rarely fatal) blood disorders 
(decreased bone marrow function leading to anemia, low WBC and platelet count). Its use is also 
associated with increased risk of infection. Gastrointestinal side effects, including nausea and 
vomiting, diarrhea, fever, malaise, myalgias, pancreatitis, hepatotoxicity, and other side effects 
including hypersensitivity reactions, hepatic veno-occlusive disease, skin rashes, alopecia, fever, 
arthralgias, steatorrhea, negative nitrogen balance, reversible pneumonitis, and Sweet’s 
syndrome (acute febrile neutrophilic dermatosis) have been reported. 
12.13. 
Adverse Events Reported with Mycophenolate Mofetil Use 
Immunosuppression leading to increased risk for infection, allergic reactions, increased risk of 
developing lymphomas and other malignancies, particularly skin malignancies, progressive 
multifocal encephalopathy, neutropenia, pure red cell aplasia, gastrointestinal bleeding and 
perforations, diarrhea, leukopenia, sepsis, vomiting, and pulmonary edema have been reported. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 131 of 135 
12.14. 
Benefit-Risk Assessment 
12.14.1. 
Nonclinical Evaluation 
Single-dose and repeat-dose toxicology, safety pharmacology, and genotoxicity studies have 
been conducted with CCX168. General toxicity studies of up to 26-week duration in rats and 44-
week duration in cynomolgus monkeys have been conducted at CCX168 doses up to 200 and 45 
mg/kg/day, respectively, significantly higher than the highest human daily dose of 30 mg b.i.d. 
being tested in patients with AAV and other indications. 
Based on in vivo safety pharmacology studies, which included neuropharmacology, pulmonary, 
and renal safety studies in rats, and a cardiovascular safety study in conscious telemetered 
cynomolgus monkeys, there was no evidence of toxicity of CCX168. No evidence of 
electrocardiographic alterations was seen in the monkey 4-week, 20-week, or 44-week studies or 
in in vitro cardiovascular safety studies (IC50 values for hERG inhibition was determined to be 
>2.3 µM for CCX168 and >3.0 µM for its metabolite CCX168-M1, the limit of solubility for 
both compounds). A safety margin for CCX168 and metabolite CCX168-M1 of at least 3,500-
fold relative to expected steady state human unbound maximum plasma is projected. 
Protein binding, red blood cell partitioning, hepatocyte metabolism, cytochrome P450 inhibition 
and induction, Caco-2 permeability and genotoxicity studies, including in vitro bacterial 
mutagenicity (Ames test) and in vitro mammalian cell mutagenicity (mouse lymphoma) studies, 
in vivo bone marrow rat micronucleus and in silico mutagenicity evaluation of starting materials, 
intermediates and chemical impurities utilized and formed during the synthesis of CCX168) were 
also conducted and did not identify any safety concerns or significant potential for drug-drug 
interactions. In an acute toxicity study, single doses of CCX168 up to 100 mg/kg in rats 
produced no remarkable effects. No effects on IgG and IgM antibody production in rats or 
monkeys were noted following immunization with keyhole limpet hemocyanin (KLH) antigen. 
Immunophenotypic analyses performed in the 44-week monkey study did not reveal any 
CCX168-related effects. No phototoxicity potential was observed for CCX168 in the in vitro 3T3 
assay.   
CCX168 was well tolerated in studies up to 26 and 44 weeks in rats and cynomolgus monkeys, 
respectively, up to the highest doses tested (200 mg/kg/day in rats and 45 mg/kg/day in 
cynomolgus monkeys). There were no significant toxicological findings of concern in these 
chronic studies or the preceding sub-chronic studies. Metabolite CCX168-M1 (which has been 
identified in humans) was present in samples collected in the rat 13- and 26-week and the 
monkey 20- and 44-week studies at relatively high levels indicating that this metabolite has been 
qualified. 
No CCX168-related effects were observed upon pregnancy or embryo-fetal development in 
studies at doses up to 1000 mg/kg and 200 mg/kg in hamsters and rabbits, respectively. No 
evidence of histopathological alterations to the male or female reproductive system was seen in 
rats or monkeys in toxicity studies.  
In summary, no safety findings in toxicology studies in rats, cynomolgus monkeys, rabbits and 
hamsters have been observed that would preclude dosing to humans at the 30 mg b.i.d. dose in 
this clinical trial. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 132 of 135 
12.14.2. 
Clinical Evaluation 
Four Phase 1 clinical trials have been conducted with CCX168 in 102 healthy volunteers. 
CCX168 doses up to 100 mg twice daily for up to 7 days have been tested in these studies. 
CCX168 generally has been well tolerated by subjects in these trials. No serious adverse events 
have been observed in the Phase 1 trials.  
The most frequently reported adverse events in subjects receiving CCX168 in Phase 1 clinical 
studies were headache (14.6% vs. 14.3% for placebo), diarrhea (6.7% vs. 7.1% for placebo), 
dizziness (4.5% vs. 0% for placebo), upper respiratory tract infection (4.5% vs. 0% for placebo), 
nausea (3.4% vs. 0% for placebo), oropharyngeal pain (3.4% vs. 7.1% for placebo), and WBC 
count decreased (3.4% vs. 0% for placebo). All other adverse events occurred at an incidence 
less than 3%. 
Two Phase 2 clinical trials (CL002_168 and CL003_168) have been conducted in 109 patients 
with AAV; 73 of these were randomized to receive CCX168 in these trials. A total of 60 patients 
received 30 mg CCX168 twice daily and 13 patients received 10 mg CCX168 twice daily for 12 
weeks. 
No deaths were observed in the Phase 2 AAV studies. As anticipated, since all patients received 
rituximab or cyclophosphamide, and most also received glucocorticoids, serious infections were 
the most common serious adverse event. The incidence of serious infections was similar in 
patients receiving CCX168 compared to the control group. Vasculitis or renal vasculitis 
(worsening) was also reported at a similar incidence in the two groups. 
The most commonly reported treatment-emergent adverse events in patients with AAV receiving 
CCX168 in studies CL002_168 and CL003_168 combined were hypertension (17.8% vs. 16.7% 
in the control group), nausea (17.8% vs. 19.4% in the control group), vomiting (13.7% vs. 0.0% 
in the control group), headache (11.0% vs. 11.1% in the control group), nasopharyngitis (11.0% 
vs. 8.3% in the control group), peripheral edema (9.6% vs. 11.1% in the control group), 
arthralgia (8.2% vs. 2.8% in the control group), and diarrhea (8.2% vs. 2.8% in the control 
group). Grade 3 lymphopenia has been observed in more patients receiving CCX168 plus 
cyclophosphamide or rituximab compared to cyclophosphamide or rituximab alone. This 
lymphopenia occurred within the first 2 weeks of treatment, and was not progressive with 
continued treatment. 
CCX168 did not show evidence of pro-arrhythmic potential in an intensive ECG study 
(CL007_168).  
Caution should be exercised when CCX168 is given with potent CYP3A4 inhibitors such as 
itraconazole, since the CCX168 plasma exposure may increase. 
CCX168 has shown evidence of efficacy in Phase 2 study CL002_168 based on BVAS, quality 
of life measurements, renal response, urinary albuminuria, and urinary MCP-1:creatinine results. 
This efficacy was demonstrated across a number of relevant immunological and clinical 
subgroups, i.e., patients with MPO ANCA-positive disease vs. PR3 ANCA-positive disease, 
newly diagnosed vs. relapsing patients, patients on cyclophosphamide vs. those on rituximab. 
CCX168 was able to safely replace the oral prednisone use, with the same or greater efficacy 
based on results from this study. 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 133 of 135 
It is of note that CCX168 as a selective C5aR blocker does not appear to affect the formation of 
C5b and the membrane attack complex (MAC) or terminal complement complex (TCC) which is 
needed to protect against Neisseria infections. Nevertheless, all local and national vaccination 
protocols should be followed and investigators should be vigilant in reporting all infections 
occurring during clinical trials and should attempt to identify the organisms involved in all 
infections. 
Based on DMC review of unblinded safety data in the present study, the Investigator Brochure 
has been updated to state that general gastrointestinal adverse events (e.g. nausea, diarrhea) 
observed in Phase 2 studies have also been observed in the ongoing Phase 3 study at 
approximately the same frequency and severity. The Investigator Brochure has also been updated 
to state that adverse events of urticaria with angioedema, and adverse events of hepatic 
transaminase elevation with or without elevation of bilirubin have been observed in the ongoing 
Phase 3 study; suspension of study drug was associated with improvement of the observed 
events. The frequency of monitoring hepatic transaminases, alkaline phosphatase and bilirubin 
has been increased to monthly.   
Based on DMC review of unblinded safety data from all completed and ongoing studies of 
CCX168, the frequency of monitoring of hematology has been increased to monthly and rules 
for pausing administration of blinded study drug have been modified.
 In all reported cases, subjects were 
receiving multiple immunosuppressants (e.g. cyclophosphamide, rituximab, mycophenolate 
mofetil, others) in addition to study medication. Therefore a causal relationship with study 
medication is not clear. 
12.14.3. 
Pediatric Testing 
There is currently no approved therapy for ANCA-associated vasculitis in juveniles.  
CCX168 appears to be generally well tolerated and safe in adults with ANCA-associated 
vasculitis who have been included in clinical trials. There are no data currently available on the 
efficacy and safety of CCX168 in patients younger than 18 years of age. However, CCX168 has 
been well tolerated at supra-therapeutic doses in young animals (rats and cynomolgus monkeys) 
in long term toxicology studies, and at doses up to 100 mg twice daily in adults. Therefore, it is 
reasonable to postulate that CCX168 may be well tolerated in younger patients.  
The current therapies that are used to treat ANCA-associated vasculitis in children have 
significant safety concerns. Glucocorticoids increase the risk of infection, new onset diabetes and 
hypertension, acne and Cushingoid changes, psychiatric disorders, glaucoma, cataracts, and 
peptic ulceration. It may negatively impact growth, immunity, and adrenal function. 
Cyclophosphamide use leads to a high incidence of infertility and increases the risk of 
developing cancer in later years. Rituximab use is associated with increased risk of infection, 
progressive multifocal leukoencephalopathy, and hypogammaglobulinemia with chronic use. 
Other immunosuppressive drugs also increase the risk of infection.  
CCX168 is a highly selective inhibitor of the terminal effector of the complement cascade, C5a, 
by blocking the binding of C5a to its receptor, C5aR. It does not appear to block other parts of 
the complement pathway, e.g., formation of the terminal complement complex, C5b-9, C3a, C3b, 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 134 of 135 
or other parts of the immune system. It is not known at this time whether the efficacy and safety 
profile of CCX168 would be different in children compared to adults. However, it is anticipated 
that the mechanism of action of CCX168 would also apply to ANCA-associated vasculitis in 
children. There is also no evidence from the animal toxicology studies in young growing animals 
that CCX168 affects growth and organ maturation. 
CCX168 is orally administered, which makes it more suitable for use in children compared to 
drugs such as rituximab that need to be given intravenously.  
CCX168 has shown evidence of efficacy in adults in Phase 2 studies in adults with AAV 
(CL002_168 and CL003_168) based on the Birmingham Vasculitis Activity Score (BVAS), 
quality of life, and other markers such as albuminuria. 
The PK profile of CCX168 in children is not known. However, since CCX168 is cleared from 
the body primarily through hepatic metabolism mediated by CYP3A4, which is known to mature 
in children well before the age of 12 (Johnson et al, 2006), it can be scientifically justified to 
adjust the CCX168 dose for 12-17 year old patients based on body weight. This methodology is 
proposed in this clinical trial. In a recent study of 126 unique products with pediatric studies by 
FDA scientists (Momper et al, 2013), allometric scaling using body weight was found to predict 
adolescent drug clearance well, with an overall mean absolute percentage error of 17.0%. By 
taking this approach, a 40 kg adolescent would need a 2/3 dose relative to a 70 kg adult to 
produce similar drug exposure. In this study (CL010_168), a conservative approach is followed 
with an adolescent <40 kg, with a starting dose that is 1/3 of the adult dose (i.e., 10 mg instead of 
30 mg CCX168 b.i.d.), and the dose is further adjusted based on the Day 1 CCX168 plasma 
concentrations. Linear pharmacokinetics is assumed for this approach based on the approximate 
dose linearity in AUC observed between 10 mg and 30 mg in adult AAV patients in Study 
CL003_168 (153 ± 86.7 and 525 ± 276 ng•hr/mL for 10 mg and 30 mg CCX168, respectively).  
The level of discomfort and the risk threshold for adolescents participation in this study have 
been carefully considered, and measures taken to monitor patients closely during the study: 
• Based on all available data, there is no evidence of a negative effect of CCX168 on 
growth and maturation of all relevant organ systems.  
• All patients will be monitored closely over the course of the study by the study center 
personnel, study monitors, as well as an external data monitoring committee for any 
untoward effects.  
• The protocol provides clear guidance regarding management of patients with severe 
AAV, those experiencing disease relapses, as well as those who have early resistant 
disease during the trial (see Section 12.6.2.3).  
• The protocol provides stopping rules for significant laboratory abnormalities, such as 
hepatic enzyme elevations, WBC, neutrophil, and lymphocyte count decreases, and CPK 
increases (Section 7.1.6 and Section 7.2.4.6).  
• Patients will be seen frequently over the course of the study, with a particularly high 
frequency in the first 4 weeks of treatment.  
• Adolescents will be kept for at least 6 hours at the clinic, and in severe cases, overnight. 
During this time, plasma samples will be taken to measure the levels of CCX168, and to 
adjust the dose of CCX168 if the plasma levels are too high or low (Section 3.3). 


CCX168 (avacopan)  
 
Protocol CL010_168 
 
 
Amendment 4.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 135 of 135 
In summary, the potential benefits of testing CCX168 in adolescent patients with AAV in this 
study, i.e., no currently approved medications for AAV in juveniles, complement biology 
involvement in AAV, potential safety and efficacy advantages compared to other non-approved 
therapies such as glucocorticoids, orally administered selective inhibition of C5aR, outweigh the 
potential risk, i.e., lack of data with CCX168 in adolescents. 
Summary Benefit-Risk Statement 
Based on the nonclinical and clinical study results, the potential benefits of testing CCX168 in 
subjects with AAV outweigh the potential risks. 
Subjects participating in clinical trials must be closely monitored for any adverse events, and 
laboratory, physical examination, vital signs, or ECG abnormalities. Hepatic enzyme levels, CPK 
levels, WBC, neutrophil, and lymphocyte counts must be monitored over the course of the 
studies.  
As with all investigational compounds, the potential exists for unanticipated serious or life-
threatening toxicities or adverse events not predicted by the animal toxicology or clinical studies 
conducted to date. Investigators should exercise vigilance in the monitoring of subjects involved 
in this clinical trial with CCX168. 
For additional details, please refer to the current version of the Investigator’s Brochure. 

SAP_001.pdf: 
Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 1 
Version Date:  28 October 2019 
 
STATISTICAL ANALYSIS PLAN 
 
A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the 
Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil 
Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with 
Rituximab or Cyclophosphamide/Azathioprine 
 
 
Investigational Product: Complement 5a Receptor Antagonist CCX168 (INN/USAN avacopan) 
Protocol Number: CL010_168 
 
 
Sponsor: 
ChemoCentryx, Inc. 
Mountain View, CA 94043 
 
 
Version Number: 2.0 
Date: 28 Oct 2019 
 
 
Original Protocol: 28 November 2016 
Amendment 1.0: 21 June 2017 
Amendment 2.0: 15 June 2018 
Amendment 3.0: 06 December 2018 
Amendment 4.0: 18 January 2019 
 
 
 
 
 
 
CONFIDENTIAL 
The information contained herein is the property of the Sponsor and may not be reproduced, published, or disclosed 
to others without the written authorization from the Sponsor. 




SIGNATURE PAGE 
Pt·otocoI Title: A Randomized, Doub.le-Blind. ActivewControlled, Phase 3 Study to Evaluate the 
Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti~Neutrophil Cyt()pl.asmic 
Antibody {ANC A)~Associated Vasculit1s Treated Concomitantly with Rhuximab or 
Cyclophosphamide/ Azathioprine 
Proto<·ol Number: CL010_168 
We, the undersigned, have reviev:ed and approve this Statisti(~ai Analysis Plan. 
Signature 
Project Statisticmn 
Therapeutic Lead Statistician 
Study Din.~ctor 
C_hemoCentryx, me. 
Date 
--··········-·······-----
. 
____ M_ 6 L-X Wl IC/ 
Medical Monitor 
Statistical Analysis Plan 
Version Number: 2.0 
Page2 
Protocol Number: CL010.J68 
Version Date: 28 Ocrober 2019 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 3 
Version Date:  28 October 2019 
 
VERSION HISTORY 
Version  
Date 
Description 
1.0 
15May2019 
Original Version 
2.0 
28Oct2019 
Updates to the following Sections: 
Section 3.1.1 – To clarify glucocorticoid use for purposes of 
assessing the primary endpoints is specific to treatment for 
AAV. 
Section 4.1.4 – Change the threshold for significant lack of 
compliance of study medication administration 
(CCX168/placebo) to <75% 
Section 6.4 – To specific additional summaries of Medical 
History by background therapy with rituximab or 
cyclophosphamide will also be produced 
Section 6.5.1 – To specify the addition of the time period 
‘End of Treatment to Week 60’ for the summaries of non 
study-supplied glucocorticoid use 
Sections 7.1, 7.2, 7.3 – Clarify the stratification factor 
values as collected in the eCRFs will be used for all 
stratified efficacy analyses, subgroup analyses and 
summaries of baseline characteristics 
Section 7.3.1.1 –  MMRM Analysis is incorrectly specified 
in the example SAS code and should mimic the analysis 
specified in 7.3.3.1 with exception of removing baseline 
from the model.   
Section 7.3.3.1 – To specify alternate matrix structure if 
convergence is not achieved with Toeplitz matrix structure 
and updates to example SAS code. 
Sections 7.3.1.1, 7.3.1.2, 7.3.1.3 –  To remove references to 
‘change from baseline’ for GTI AIS and CWS analyses 
since calculation of these outcome measures inherently 
incorporate ‘change from baseline’  
Section 7.3.4.2 – To change the exploratory analysis for 
time to relapse from the first time point when BVAS of 0 
was achieved will be based on the Adjudicators’ assessment 
of BVAS=0 and relapse and not the Investigators’ 
assessment, 
Section 7.3.4.2 – To specify Relapse during the 52 week 
treatment period 
Section 7.3.5.1 – Add reference to section 7.3.3.1 for 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 4 
Version Date:  28 October 2019 
MMRM analysis 
Section 8.2 – To further define the number of days in the 
randomized treatment period 
Section 8.4 – Additional laboratory parameters were added 
to the CTCAE summaries 
Section 10 – Specify occurrence of relapse, as assessed by 
the Adjudication Committee, was performed separately for 
the 52 week treatment period and during the follow-up 
period from week 52 to week 60 
Appendix 15.1.4 – Added this section to describe reference 
data for EQ-5D-5L Crosswalk value for countries where 
reference data is not available 
Appendices 15.3, 15.4 and 15.5 – Added to pre-specify 
preferred terms for Adverse events potentially associated 
with liver injury, WBC count decrease and glucocorticoid 
related toxicity. 
 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 5 
Version Date:  28 October 2019 
 
TABLE OF CONTENTS 
1 
Introduction ........................................................................................................................... 11 
2 
Study Overview ..................................................................................................................... 11 
2.1 Study Objectives ............................................................................................................ 11 
2.1.1 Primary Objective ................................................................................................. 11 
2.1.2 Secondary Objectives ........................................................................................... 11 
2.2 Study Design .................................................................................................................. 12 
2.2.1 Overview .............................................................................................................. 12 
2.2.2 Randomization and Blinding ................................................................................ 12 
2.2.3 Up to 14-Day Screening Period ............................................................................ 14 
2.2.4 52-Week Double-blind Treatment Period ............................................................ 14 
2.2.5 8-Week Follow-up Period at Study End ............................................................... 15 
3 
Study Endpoints ..................................................................................................................... 15 
3.1 Efficacy Endpoints ......................................................................................................... 15 
3.1.1 Primary Efficacy Endpoints ................................................................................. 15 
3.1.2 Secondary Efficacy Endpoints ............................................................................. 16 
3.1.3 Efficacy Assessment ............................................................................................. 16 
3.2 Safety Endpoints ............................................................................................................ 17 
3.2.1 Adverse Events ..................................................................................................... 17 
3.2.2 Safety Laboratory Evaluations ............................................................................. 18 
3.2.3 Vital Signs ............................................................................................................ 18 
3.2.4 Other Safety Assessments .................................................................................... 18 
3.3 Pharmacokinetic Assessments........................................................................................ 19 
3.4 Pharmacodynamic Assessments ..................................................................................... 19 
4 
Statistical Methodology ......................................................................................................... 20 
4.1 Analysis Populations ...................................................................................................... 20 
4.1.1 Randomized Population ....................................................................................... 20 
4.1.2 Intent-to-Treat Population .................................................................................... 20 
4.1.3 Safety Population ................................................................................................. 20 
4.1.4 Per Protocol Population ........................................................................................ 20 
4.1.5 Subjects with Renal Disease at Baseline .............................................................. 21 
5 
General Considerations for Data Analysis ............................................................................ 22 
5.1 General Statistical Considerations ................................................................................. 22 
5.2 Study Day/Study Week .................................................................................................. 22 
5.3 Baseline Definition ......................................................................................................... 23 
5.4 Assessment Window ...................................................................................................... 23 
5.5 Handling of Missing Data .............................................................................................. 24 
5.6 Other Data Handling Approaches .................................................................................. 24 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 6 
Version Date:  28 October 2019 
6 
Analysis of Disposition and Subject Characteristics ............................................................. 24 
6.1 Disposition and Analysis Populations ............................................................................ 24 
6.2 Protocol Deviations ........................................................................................................ 24 
6.3 Demographics and Baseline Characteristics .................................................................. 25 
6.4 Medical History .............................................................................................................. 25 
6.5 Concomitant Medications .............................................................................................. 25 
6.5.1 Glucocorticoid Use ............................................................................................... 25 
6.5.2 Other Non-Study Supplied Treatments for AAV ................................................. 27 
7 
Analysis of Efficacy .............................................................................................................. 27 
7.1 Covariates and Subgroups .............................................................................................. 27 
7.2 Primary Efficacy Analysis ............................................................................................. 28 
7.2.1 Primary Analysis .................................................................................................. 33 
7.2.2 Sensitivity Analyses ............................................................................................. 33 
7.2.3 Subgroup Analyses ............................................................................................... 35 
7.2.4 Per-Protocol Analyses .......................................................................................... 36 
7.3 Secondary Efficacy Analyses ......................................................................................... 36 
7.3.1 Glucocorticoid Toxicity Index ............................................................................. 36 
7.3.2 Early Disease Remission ...................................................................................... 39 
7.3.3 SF-36 v2 and EQ-5D-5L VAS and Index - Change from Baseline ..................... 39 
7.3.4 Relapses up to Week 52 ....................................................................................... 40 
7.3.5 eGFR (in Subjects with Renal Disease at Baseline) - Change from Baseline...... 41 
7.3.6 UACR (in Subjects with Renal Disease at Baseline) – Percent Change from 
Baseline .......................................................................................................................... 42 
7.3.7 MCP-1:creatinine ratio (in Subjects with Renal Disease at Baseline) – Percent 
Change from Baseline .................................................................................................... 42 
7.3.8 VDI - Change from Baseline to Week 52 ............................................................ 42 
7.4 8-week Follow-Up Period Data...................................................................................... 43 
8 
Analysis of Safety .................................................................................................................. 44 
8.1 Population....................................................................................................................... 44 
8.2 Extent of Exposure ......................................................................................................... 44 
8.3 Adverse Events ............................................................................................................... 44 
8.4 Safety Laboratory Parameters ........................................................................................ 46 
8.5 Vital Signs ...................................................................................................................... 47 
8.6 ECG Parameters ............................................................................................................. 47 
8.7 Physical Examinations ................................................................................................... 47 
8.8 Other Safety Parameters ................................................................................................. 47 
8.9 Pharmacokinetic and Pharmacodynamic Marker Analysis ............................................ 47 
9 
Data Monitoring Committee .................................................................................................. 47 
10 Adjudication of Endpoints ..................................................................................................... 48 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 7 
Version Date:  28 October 2019 
11 Interim Analysis .................................................................................................................... 48 
12 Sample Size and Power Considerations ................................................................................ 48 
13 Changes from protocol–specified statistical analyses ........................................................... 49 
14 References ............................................................................................................................. 49 
15 Appendices ............................................................................................................................ 50 
15.1 Data Derivation Details .................................................................................................. 50 
15.1.1 BVAS ................................................................................................................... 50 
15.1.2 VDI ....................................................................................................................... 53 
15.1.3 Glucocorticoid Toxicity Index (GTI) ................................................................... 55 
15.1.4 EQ-5D-5L ............................................................................................................. 59 
15.2 Imputation for Missing/Partially Missing Adverse Event and Concomitant Medication 
Dates ...................................................................................................................................... 60 
15.2.1 Incomplete Adverse Event Start Date: ................................................................. 60 
15.2.2 Incomplete AE Stop Date: .................................................................................... 60 
15.2.1 Incomplete Start/Stop Dates for Prior/Concomitant Medications/Procedures ..... 61 
15.3 Preferred Terms of Adverse Events Potentially Associated with Liver Injury .............. 61 
15.4 Preferred Terms of Adverse Events Indicating WBC Count Decrease ......................... 62 
15.5 Preferred Terms of Adverse Events Potentially Associated with Glucocorticoid-Related 
Toxicity .................................................................................................................................. 62 
 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 8 
Version Date:  28 October 2019 
 
LIST OF ABBREVIATIONS 
AAV 
ANCA-associated vasculitis 
AC 
Adjudication Committee 
AE 
adverse event 
AIS 
Aggregate Improvement Score 
ALBIA 
Addressable Laser Bead ImmunoAssay 
ALT 
alanine aminotransferase 
ANCA 
anti-neutrophil cytoplasmic antibody 
AR(1) 
Autoregressive(1) 
AST 
aspartate aminotransferase 
ATC 
Anatomic Therapeutic Chemistry 
BP 
blood pressure 
BMI 
body mass index 
BUN 
blood urea nitrogen 
BVAS 
Birmingham Vasculitis Activity Score 
CPK 
creatine phosphokinase  
CSR 
Clinical Study Report 
CTCAE 
Common Terminology Criteria for Adverse Events 
CWS 
Cumulative Worsening Score 
DMC  
Data Monitoring Committee 
EDC  
Electronic Data Capture system 
ECG  
electrocardiogram 
EQ-5D-5L 
EuroQOL-5D-5L 
eCRF 
electronic case report form 
eGFR  
estimated glomerular filtration rate 
ELISA 
enzyme linked immunosorbent assay 
EULAR 
European League Against Rheumatism 
GPA 
granulomatosis with polyangiitis (Wegener’s) 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 9 
Version Date:  28 October 2019 
GTI 
Glucocorticoid Toxicity Index 
HEENT 
head, eyes, ears, nose, throat 
IRT 
interactive response technology 
ITT 
Intent-to-Treat 
IV 
intravenous(ly) 
LDH 
lactate dehydrogenase 
LDL 
low-density lipoprotein 
mg 
milligram 
MAR 
missing at random 
MedDRA 
Medical Dictionary for Regulatory Activities 
MCP-1 
monocyte chemoattractant protein-1 
MDRD 
Modification of Diet in Renal Disease 
MedDRA 
Medical Dictionary for Regulatory Activities 
MMRM 
mixed effects model for repeated measures 
MPA 
microscopic polyangiitis 
MPO 
myeloperoxidase 
MRI 
Magnetic Resonance Imaging 
PD 
pharmacodynamic(s) 
PK 
pharmacokinetic(s) 
PP 
Per Protocol 
PR3 
proteinase-3 
PRES 
posterior reversible leukoencephalopathy syndrome 
SAP 
statistical analysis plan 
SAE 
serious adverse event 
SD 
standard deviation 
SEM 
standard error of the mean 
SF-36 v2 
Short Form-36 version 2 
TB 
tuberculosis 
TEAE 
treatment emergent adverse event 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 10 
Version Date:  28 October 2019 
TESAE 
treatment emergent serious adverse events 
UACR 
urinary albumin:creatinine ratio 
VAS 
visual analogue scale 
VDI 
Vasculitis Damage Index 
WHO 
World Health Organization  


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 11 
Version Date:  28 October 2019 
 
1 
INTRODUCTION 
The purpose of this document is to provide a description of the statistical methods and 
procedures to be implemented for the analysis of data from ChemoCentryx, Inc. Protocol 
CL010_168. This document is based on protocol amendment 4.0 (18JAN2019) and CRF version 
7.7 (09OCT2019). If circumstances arise during the study such that more appropriate analytic 
procedures become available, the statistical analysis plan (SAP) may be revised. The statistical 
definitions and analytical methods described in this SAP supersede that in the protocol. Any 
revisions to the primary endpoint analyses and significant revisions to the secondary endpoint 
analyses will be made prior to the database freeze for the data in the double-blind treatment 
period through Week 52. Reasons for such revisions will be described in the final Clinical Study 
Report (CSR). 
2 
STUDY OVERVIEW 
2.1 
Study Objectives 
2.1.1 Primary Objective 
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain 
remission in subjects with active anti-neutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, 
or in combination with rituximab. Disease remission is defined as achieving a Birmingham 
Vasculitis Activity Score (BVAS) of zero (0) and not taking glucocorticoids for treatment of 
AAV within 4 weeks prior to Week 26. Sustained remission is defined as remission at Week 26 
without relapse to Week 52 (BVAS of 0 and not taking glucocorticoids for treatment of AAV 
within 4 weeks prior to Week 52). A relapse between Week 26 and 52 would disqualify a subject 
from having a sustained remission. 
2.1.2 Secondary Objectives 
1. Evaluation of the glucocorticoid-induced toxicity in the CCX168 plus rituximab or 
cyclophosphamide/azathioprine group, compared to prednisone plus rituximab or 
cyclophosphamide/azathioprine, based on the Glucocorticoid Toxicity Index (GTI); 
2. Evaluation of rapidity of response in the CCX168 plus rituximab or 
cyclophosphamide/azathioprine group, compared to prednisone plus rituximab or 
cyclophosphamide/azathioprine, based on remission (BVAS of 0) at Week 4. (BVAS 
remission at Week 4 is defined as BVAS = 0, regardless of receipt of glucocorticoids); 
3. Evaluation of the safety of CCX168 plus rituximab or cyclophosphamide/azathioprine, 
compared to prednisone plus rituximab or cyclophosphamide/azathioprine based on the 
incidence of serious and non-serious adverse events, adverse events of interest, and changes 
in vital signs, clinical laboratory tests, and electrocardiograms (ECGs) in these subjects; 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 12 
Version Date:  28 October 2019 
4. Assessment of health-related quality-of-life changes based on the Medical Outcomes Survey 
Short Form-36 version 2 (SF-36 v2) and EuroQOL-5D-5L (EQ-5D-5L) with CCX168 plus 
rituximab or cyclophosphamide/azathioprine, compared to prednisone plus rituximab or 
cyclophosphamide/azathioprine; 
5. Assessment of changes in parameters of renal disease including estimated glomerular 
filtration rate (eGFR), albuminuria, and urinary excretion of monocyte chemoattractant 
protein-1 (MCP-1) in subjects with active renal disease at baseline with CCX168 plus 
rituximab or cyclophosphamide/azathioprine, compared to prednisone plus rituximab or 
cyclophosphamide/azathioprine; 
6. Assessment of changes in cumulative organ damage based on the Vasculitis Damage Index 
(VDI) with CCX168 plus rituximab or cyclophosphamide/azathioprine, compared to 
prednisone plus rituximab or cyclophosphamide/azathioprine;  
7. Assessment of changes in markers of pharmacodynamics in plasma and urine with CCX168 
plus rituximab or cyclophosphamide/azathioprine, compared to prednisone plus rituximab or 
cyclophosphamide/azathioprine; 
8. Evaluation of the pharmacokinetic profile of CCX168 in subjects with AAV. 
2.2 
Study Design 
2.2.1 Overview 
This is a Phase 3, randomized, double-blind, double-dummy, active-controlled, multicenter 
international clinical trial. Approximately 300 subjects with AAV who fulfill all the eligibility 
criteria will be enrolled into the study from study sites in North America, Europe, Australia, New 
Zealand, and Japan. 
All subjects have scheduled visits during the screening period, on Day 1 and at Weeks 1, 2, 3, 4, 
7, 10, 13, 16, 20, 23, 26, 29, 32, 35, 39, 42, 45, 48, 52 (last treatment visit with blinded study 
drug), and 60 (follow up). The study schema is provided below. For additional details regarding 
the study design, please refer to the protocol.  
2.2.2 Randomization and Blinding 
Subjects will be randomized in a 1:1 ratio to the following study treatments: 
Group A: CCX168-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a 
full starting dose of prednisone (Placebo + Standard of Care) or  
Group B: CCX168 plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching 
placebo (Avacopan + Standard of Care).   
The treatment period is 52 weeks (364 days), followed by an 8-week (56 days) follow-up.  
Randomization will be stratified by the following factors: 
 One of the following treatment regimens: 
a. IV rituximab 
b. IV cyclophosphamide followed by oral azathioprine 
c. Oral cyclophosphamide followed by oral azathioprine 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 13 
Version Date:  28 October 2019 
 Positive test for proteinase-3 (PR3) vs. myeloperoxidase (MPO) ANCA at diagnosis 
 Newly-diagnosed vs. relapsing disease (AAV) 
 
 
 
STUDY SCHEMA  
 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 14 
Version Date:  28 October 2019 
Randomization will be performed centrally via an interactive response technology (IRT) system 
and minimization algorithm, using the stratification factors. In order to protect the blinding, the 
randomization schedule will not be accessible to study personnel who have contact with study 
centers or who are involved in data management and analysis prior to database freeze. 
2.2.3 Up to 14-Day Screening Period 
The screening period will be kept as short as possible in order not to delay initiation of treatment 
and must not exceed 14 days. Screening evaluations will be performed to determine subject 
eligibility for study. Eligible subects must be ANCA-positive (having tested positive for 
antibodies to PR3 or MPO by ELISA or ALBIA, either at the time of enrollment or in the past), 
and must have at least one “major” item, or at least 3 minor items, or at least the two renal items 
of proteinuria and hematuria in the BVAS. Care must be taken to ensure that the renal items are 
due to vasculitis activity and not other factors such as menses or cyclophosphamide-related 
cystitis. If a subject has “other” items, not specified in the BVAS, these need to be discussed 
with the Medical Monitor before enrollment. 
After all screening procedures have been completed, and the subject satisfies all eligibility 
criteria, the study schedule will be discussed with the subject and the schedule will be provided 
to the subject to ensure compliance with the study visits. 
2.2.4 52-Week Double-blind Treatment Period 
Eligible subjects will visit the study center on Day 1, after an overnight fast of at least 9 hours, 
for physical examination and vital signs, serum chemistry tests (including HbA1c and LDL 
cholesterol), hematology tests, serum pregnancy test (in women of childbearing potential), 
urinalysis (including hematuria, urinary albumin:creatinine ratio [UACR], and MCP-1:creatinine 
ratio assessment), eGFR, ANCA measurement (anti-PR3 and anti-MPO ELISA), SF-36 v2 and 
EQ-5D-5L assessment, Glucocorticoid Toxicity Index (GTI) baseline assessment, baseline 
pharmacokinetic (PK) and pharmacodynamic (PD) blood sample collection, saliva sample 
collection, stratification and randomization. Medication will be administered (IV) and dispensed 
(for oral medications). The subjects will take the first dose of CCX168 or placebo, and 
prednisone or placebo while at the study center. The selection of IV cyclophosphamide, oral 
cyclophosphamide, or IV rituximab is at the discretion of the Investigator. For study centers 
where enrollment of adolescents (12 to 17 years old) is approved, CCX168 or placebo dosing 
will initially be given based on body weight at screening and the dose will be adjusted based on 
CCX168 plasma levels on Day 1 (refer to the Section 3.3 of the protocol for more details). 
Twice daily dosing of CCX168 or placebo will continue for 364 days. At post-Day 1 study visits, 
study medication will be administered according to the protocol schedule, and blood and urine 
samples will be collected for safety and efficacy and PK/PD measurements. BVAS assessments 
will be made at Screening and Weeks 4, 10, 16, 26, 39, 52, and 60. VDI assessments will be 
made at Screening and Weeks 26, 52, and 60. SF-36 v2 and EQ-5D-5L will be completed on 
Day 1 and Weeks 4, 10, 16, 26, 39, 52, and 60. GTI assessments will be done on Day 1 and at 
Weeks 13 and 26. Renal biopsy for histology at Week 52 is optional. Physical examinations, 
vital sign assessments, and ECG measurements will be performed throughout the study. 
Concomitant medication and adverse event assessments will be made at every study visit. 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 15 
Version Date:  28 October 2019 
2.2.5 8-Week Follow-up Period at Study End 
After completion of the 52-week double-blind treatment period, subjects will be followed up for 
an additional 8 weeks during which the blinding will be maintained. Subjects will be discharged 
from the study when all the Study Week 60 visit procedures have been completed. Each subject's 
condition will be evaluated by the Investigator at the end of the clinical trial (Week 60) and 
appropriate standard of care medical treatment will be provided to all subjects as needed.   
3 
STUDY ENDPOINTS  
3.1 
Efficacy Endpoints 
3.1.1 Primary Efficacy Endpoints 
1. The proportion of subjects achieving disease remission at Week 26. 
Disease remission at Week 26 is defined as: 
 Achieving a BVAS of 0 as determined by the Adjudication Committee (AC) AND 
 No administration of glucocorticoids for the treatment of AAV within 4 weeks prior 
to Week 26 AND  
 No BVAS>0 during the 4 weeks prior to Week 26 (if collected for an unscheduled 
assessment).  
2. The proportion of subjects achieving sustained disease remission at Week 52. 
Sustained remission at Week 52  is defined as:  
 Disease remission at Week 26 defined as a BVAS score of 0 as determined by the AC 
 No disease relapse between Week 26 and Week 52 as determined by the AC AND 
 Disease remission at Week 52 defined as a BVAS of 0 as determined by the AC and 
no administration of glucocorticoids for treatment of AAV within 4 weeks prior to 
Week 52.  
The proportion of subjects achieving sustained disease remission at Week 52 will be based on 
assessment by the blinded AC that disease remission has been achieved at Week 26, that disease 
remission has been achieved at Week 52, and that no relapse has occurred between Week 26 and 
Week 52. Relapse is defined in section 3.1.2. 
Glucocorticoid use for purposes of assessing the primary endpoints are based on absence of 
glucocorticoid use, both study supplied and non-study supplied, for treatment of AAV for the 4 
weeks prior to the BVAS assessment at Week 26 and Week 52. Note that subjects are permitted 
to receive low doses of oral glucocorticoids (no more than 10 mg per day) for treatment of 
adrenal insufficiency or glucocorticoid treatment for other conditions, e.g., allergic reaction, and 
will be classified as responders for purposes of assessment of the primary endpoints if all other 
requirements for response are met.  


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 16 
Version Date:  28 October 2019 
3.1.2 Secondary Efficacy Endpoints 
Secondary efficacy endpoints include: 
1. Glucocorticoid-induced toxicity as measured at specified timepoints over the first 26 weeks 
in the glucocorticoid toxicity index (GTI). GTI assessments are performed on Day 1 and at 
Weeks 13 and 26. Both the Cumulative Worsening Score (CWS) and the Aggregate 
Improvement Score (AIS) will be analyzed (see section 7.3.1). 
2. Early remission defined as a BVAS of 0 at Week 4, regardless of whether the subjects 
received glucocorticoids during this period of time. Early remission at Week 4 will be based 
on assessment by the blinded AC that disease remission has been achieved at Week 4 based 
on BVAS=0 at Week 4. 
3. Change from baseline over 52 weeks in health-related quality-of-life as measured by the 
domains and component scores of the SF-36 v2 and EQ-5D-5L visual analogue scale (VAS) 
and index. SF-36 v2 and EQ-5D-5L are completed on Day 1 and Weeks 4, 10, 16, 26, 39, 
and 52. 
4. Proportion of subjects and time to experiencing a relapse after achieving remission at Week 
26, as assessed by the blinded AC.  
Relapse is assessed by the AC and is defined as active disease, after previously achieving 
remission at Week 26 in the study, that involves (1) one or more major items in the BVAS, 
(2) three or more minor items in the BVAS, or (3) one or two minor items in the BVAS 
recorded at two consecutive study visits. See Section 3.1.1 for a description of determination 
of disease remission at Week 26. 
5. In subjects with renal disease at baseline (based on the BVAS renal component; see section 
4.1.5), the change in absolute eGFR from baseline over 52 weeks including the following 
timepoints: Weeks 1, 2, 3, 4, 7, 10, 13, 16, 20, 26, 32, 39, 45, and 52.  
6. In subjects with renal disease at baseline (based in the BVAS renal component, including 
albuminuria; see section 4.1.5), the percent change in UACR from baseline over 52 weeks 
including the following timepoints: Weeks 1, 2, 4, 13, 26, 39, and 52. 
7. In subjects with renal disease at baseline (based in the BVAS renal component; see section 
4.1.5), the percent change in urinary MCP-1:creatinine ratio from baseline over 52 weeks 
including the following timepoints: Weeks 1, 2, 4, 13, 26, 39, and 52. 
8. Change in Vasculitis Damage Index (VDI) from baseline over 52 weeks including the 
following timepoints: Weeks 26 and 52. 
3.1.3 Efficacy Assessment 
The BVAS version 3 will be used in this study and has been previously validated (Mukhtyar et 
al, 2009; Suppiah et al, 2011). BVAS provides a measure of current disease activity.  
The Vasculitis Damage Index (VDI) was developed by Exley et al, 1997 and is for recording 
organ damage that has occurred in subjects since the onset of vasculitis. The VDI provides a 
measure of cumulative organ damage since the onset of the disease.  


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 17 
Version Date:  28 October 2019 
The GTI was developed to quantify toxicity associated with glucocorticoid use (Miloslavsky et 
al, 2016). The GTI version 2.0 will be used to quantify changes in glucocorticoid toxicity. Please 
refer to section 7.3.1 and Appendix, Section 15.1.3 for more detail. 
Calculation of eGFR will be based on serum creatinine (Modification of Diet in Renal Disease 
[MDRD] equation for adults, and modified Schwartz equation for adolescents). 
MDRD: eGFR (mL/min/1.73 m2) = 175 x (serum creatinine in mg/dL)-1.154 x (Age)-0.203 x 
(0.742 if female) x (1.212 if African-American/Black) 
Modified Schwartz: eGFR = (0.413 x Height [in cm]) / Serum creatinine (in mg/dL) 
Japan unique formula for eGFR in Japanese adults is defined by Protocol Addendum Japan-
specific as follows:  
eGFR (mL/min/1.73 m2) = 194 x (serum creatinine in mg/dL)-1.094 x (Age)-0.287 x (0.739 if 
female) 
BVAS and VDI data are assessed and documented  by the study investigators. The  assessments 
performed by the study investigators will then be adjudicated by an Adjudication Committee 
(AC) comprised of experts in the field of vasculitis. The members of the AC are blinded to 
individual subject treatment assignment and their actions are governed by an adjudication 
charter. The adjudication charter specifies adjudications of the BVAS assessments over the 
course of the study, as well as whether BVAS=0 has been achieved at Week 4, remission has 
been achieved at Week 26, and sustained remission has been achieved at Week 52. The AC also 
adjudicates all potential relapses. The adjudicated data will be used in the primary analyses. 
3.2 
Safety Endpoints 
3.2.1 Adverse Events 
Safety endpoints include subject incidence of treatment-emergent serious adverse events, adverse 
events, and withdrawals due to adverse events. 
An adverse event will be considered treatment-emergent (TEAE) if the start date of the event is 
on or after the date of administration of the first dose of study medication. All reported adverse 
events will be classified by system organ class and preferred term using the Medical Dictionary 
for Regulatory Activities (MedDRA) (version 19.1). 
The relationship of CCX168/placebo as well as the relationship of glucocorticoid use, 
cyclophosphamide, rituximab, and azathioprine or mycophenolate use to an adverse event will be 
determined by the Investigator. The sponsor will perform a safety analysis based on an aggregate 
analysis across the safety database as well as the assessment of individual cases of interest.  
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose 
results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or 
significant disability or incapacity, is a congenital anomaly or birth defect, or is an important and 
significant medical event that, based on appropriate medical judgment, may jeopardize the 
subject and/or may require medical or surgical intervention to prevent one of the other outcomes 
defining serious. 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 18 
Version Date:  28 October 2019 
In addition, certain safety endpoints of special interest including laboratory parameters and 
TEAEs will be presented by treatment group (see Section 8.3). 
3.2.2 Safety Laboratory Evaluations 
Safety endpoints include change from baseline and shifts from baseline in all safety laboratory 
parameters, including blood chemistry, hematology, and urinalysis. Visits to be listed and 
summarized include Day 1, and Weeks 1, 2, 3, 4, 7, 10, 13, 16, 20, 23, 26, 29, 32, 35, 39, 42, 45, 
48, 52, and 60 (Follow-up). 
Clinical safety laboratory assessments include the following: 
 Hematology: hemoglobin, hematocrit, RBC count, WBC count with differential, platelet 
count, mean cell hemoglobin, mean cell hemoglobin concentration, mean corpuscular 
volume 
 Serum Chemistry: liver panel (bilirubin, lactate dehydrogenase [LDH], aspartate 
aminotransferase [AST], alanine aminotransferase [ALT]), renal panel (blood urea 
nitrogen [BUN], creatinine), creatine phosphokinase (CPK), albumin, sodium, potassium, 
magnesium, bicarbonate, chloride, calcium, inorganic phosphorus, glucose, total protein, 
alkaline phosphatase, total cholesterol, uric acid, serum amylase, and serum lipase 
 Hemoglobin A1c and LDL cholesterol (for use in the GTI) 
 Urinalysis: At the central laboratory, nitrite, blood, and protein, will be tested. If positive, 
microscopy will be performed. 
Laboratory assessments measured at the local laboratory include WBC counts prior to 
administration of cyclophosphamide or azathioprine for potential dose adjustments. Virology, 
serology, and complement are measured only at screening and may be measured at the local 
laboratory). Tuberculosis (TB) screen results will also be listed. 
3.2.3 Vital Signs 
Individual vital sign values including temperature, blood pressure and heart rate, and change 
from baseline will be calculated. Visits to be listed and summarized include Day 1, and Weeks 1, 
2, 3, 4, 7, 10, 13, 16, 20, 26, 32, 39, 45, 52, and Week 60 (Follow-up). 
3.2.4 Other Safety Assessments 
3.2.4.1 ECG 
ECG Interpretation (normal/abnormal), clinical significance (yes/no) and description of 
abnormality will be listed. Visits to be listed include Screening and Weeks 2, 7, 13, 26, 39, 52, 
and 60 (Follow-up). 
3.2.4.2 Physical Exam 
A complete physical examination (including evaluation of general appearance/mental status, 
HEENT [head, eyes, ears, nose, throat], and the following body systems: dermatologic, 
cardiovascular, respiratory, gastrointestinal, musculoskeletal and neurologic) for safety, BVAS, 
GTI, and VDI assessments will be performed at Screening, Day 1, Weeks 1, 2, 4, 10, 13, 16, 26, 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 19 
Version Date:  28 October 2019 
39, 52, and 60 (Follow-up). Physical examinations are to be sufficiently comprehensive to 
include ALL components of the BVAS, VDI, and GTI. Any new or worsening findings upon 
physical examination are to be recorded as adverse events, and also captured in the BVAS, VDI, 
and GTI, as appropriate. Body weight is to be measured as part of the physical examinations. 
Height is to be recorded at screening only, except for adolescents (12-17 years old) in whom 
height is also to be included as part of all physical examinations. BMI will be calculated from the 
body weight and height measurements. Abnormalities in physical examination, body weight, 
height, and vital signs will be listed. 
3.3 
Pharmacokinetic Assessments 
Concentrations of CCX168 (and metabolites) will be determined in plasma from samples 
obtained on Day 1, and Weeks 1, 2, 4, 7, 13, 26, 39, and 52. The samples on Day 1 will be 
collected prior to the first dose of CCX168/placebo on that day. Only for subjects 12 to 17 years 
of age, samples will also be taken at hours 0.5, 1, 2, 3, 4, and 6 following the first dose of 
CCX168/placebo on Day 1. The blood samples collected on the other study days do not need to 
be collected prior to the CCX168/placebo dose on those days. However, the date and time of the 
last dose of CCX168/placebo prior to the sample collections must be recorded in the EDC 
system. Population PK analysis will be performed based on the CCX168 and metabolite plasma 
concentrations. 
Total plasma concentrations of CCX168 (and metabolites) will be determined using validated 
analytical methods. These plasma samples may also be used to measure cytokines, complement 
fragments, or other markers associated with AAV. 
CCX168 (and metabolite) plasma concentration results will be used to calculate trough plasma 
concentrations (Cmin) over the course of the clinical trial. If sufficient data are available, 
population PK analyses may also be performed to determine PK parameters for CCX168 and 
significant metabolites.  
The Cmax, Tmax, and AUC0-6 will be determined for subjects 12 to 17 years old based on CCX168 
and metabolite plasma concentration data on Day 1. 
3.4 
Pharmacodynamic Assessments 
The following PD endpoints may be assessed if the PD analytes are measured: 
1. Change and percent change from baseline in plasma biomarkers including, but not limited to, 
cystatin C, complement fragments, inflammatory chemokine and cytokine levels. The 
cystatin C levels may be used in calculating eGFR changes from baseline using the following 
equation: 
eGFRcys (mL/min/1.73 m2) = 127.7 x (cystatin C in mg/L)−1.17 x (Age)−0.13 x (0.91 if female) 
x (1.06 if African-American/Black) 
2. Change and percent change from baseline in urine biomarkers including, but not limited too, 
renal injury and inflammation markers (e.g., KIM-1 and NGAL), soluble CD163, 
complement fragments, inflammatory chemokine and cytokine levels; 
3. Change from baseline in CBC count (especially WBCs, neutrophils, and lymphocytes) and 
lymphocyte subset counts including B cells, T cells, and natural killer cells; 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 20 
Version Date:  28 October 2019 
4. Change from baseline in blood cell gene expressions such as neutrophil functional status 
markers. 
The effect of polymorphism in genetic markers such as HLA DPB1*0401, SERPINA1, PRTN3, 
and HLA-DQ, as well as C5aR polymorphism may also be investigated. 
4 
STATISTICAL METHODOLOGY 
4.1 
Analysis Populations 
4.1.1 Randomized Population 
The Randomized Population will include all subjects who have provided written informed 
consent and are randomized in the study. 
4.1.2 Intent-to-Treat Population 
The Intent-to-Treat (ITT) Population will include all subjects who are randomized and have 
received at least one dose of study drug. 
4.1.3 Safety Population 
The Safety Population will include all subjects who are randomized and have received at least 
one dose of study drug; the Safety Population is identical to the ITT population. 
4.1.4 Per Protocol Population 
The Per Protocol (PP) Population will include all of the subjects in the ITT population who were 
compliant with taking CCX168/placebo and who did not have major protocol deviations that 
might significantly affect the interpretation of the study results. 
The following aspects will be relevant for consideration of subjects to be excluded from the PP 
analysis or imputed as non-responders for the PP analysis: 
 Subjects with significant protocol deviations regarding inclusion and exclusion criteria 
that may impact evaluation of the primary endpoints (see section 6.2).  
 Subjects with significant lack of compliance of study medication administration 
(CCX168/placebo) defined as: 
 For the Week 26 primary endpoint: All subjects who were <75% compliant with 
taking CCX168/placebo from Day 1 through Week 26 based on study medication 
accountability records; 
 For the Week 52 primary endpoint: All subjects who were <75% compliant with 
taking CCX168/placebo from Day 1 through Week 52 based on study medication 
accountability records. 
 Subjects administered non-allowed medications defined as: 
 For the Week 26 primary endpoint: All subjects who had received rituximab or 
cyclophosphamide, or a clinically significant dose of mycophenolate (except if used 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 21 
Version Date:  28 October 2019 
instead of azathioprine per protocol), methotrexate, anti-TNF treatment, abatacept, 
alemtuzumab, belimumab, tocilizumab, eculizumab, or other experimental or 
immunosuppressive drugs other than protocol-specified use between Day 1 and Week 
26;  
 For the Week 52 primary endpoint: In addition to those for the Week 26 primary 
endpoint, all subjects who had rituximab or cyclophosphamide, or a clinically 
significant dose of mycophenolate (except if used instead of azathioprine per 
protocol), methotrexate, anti-TNF treatment, abatacept, alemtuzumab, belimumab, 
tocilizumab, eculizumab, or other experimental or immunosuppressive drugs between 
Week 26 and 52 that was not associated with a relapse event. 
 Subjects with missing BVAS data: 
 For the Week 26 primary endpoint: All subjects with missing Week 26 BVAS data 
due to BVAS not being assessed or early withdrawal from the study; 
 For the Week 52 primary endpoint: All subjects with missing Week 26 or Week 52 
BVAS data due to BVAS not being assessed or early withdrawal from the study. 
Subjects who had minor deviations in per protocol use of rituximab or cyclophosphamide, e.g., 
IV infusion rates, dose withholding due to infections (which is recommended in the prescribing 
information for these drugs), rituximab dosing without glucocorticoid pre-medication, or dosing 
not on the exact day of the protocol-specified schedule will be considered for inclusion in the PP 
population. However, subjects with rituximab or cyclophosphamide use at times not specified 
per protocol will be taken into account for the PP population, e.g., dosing of rituximab or 
cyclophosphamide during the last 26 weeks of the treatment period. 
Subjects who need to be taken into account for the PP population will be identified and 
documented prior to the database freeze and prior to unblinding of the database for the analysis 
of the primary endpoints. 
For the analysis of the primary efficacy endpoints in the PP population, subjects with important 
deviations regarding inclusion criteria, e.g., no clear evidence of anti-PR3 or anti-MPO AAV at 
study entry, and subjects with missing Week 26 data will be excluded as a whole from the PP 
population. For lack of compliance and for non-allowed medications, non-responder imputation 
will be applied, i.e., not achieving remission at Week 26 and/or not achieving sustained 
remission at Week 52. Exploratory sensitivity analyses may be performed using other 
methodologies, e.g., total exclusion of subjects with major deviations from the study population. 
Subjects who have received glucocorticoids at doses higher than those provided in the protocol 
guidance will be assessed through sensitivity analyses in the ITT population (see section 7.2.2). 
4.1.5 Subjects with Renal Disease at Baseline 
Since renal disease is one of the most important manifestations of AAV, most endpoints will be 
analyzed in the subgroup of subjects with renal disease at baseline. This is defined as subjects 
who have at least one of the renal components of the BVAS at the Screening visit: 
 Hypertension 
 Proteinuria >1+ or >0.2 g/g creatinine 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 22 
Version Date:  28 October 2019 
 Hematuria ≥10 RBCs/hpf 
 Elevated serum creatinine (125 μmol/L) 
 Rise in serum creatinine >30% or fall in creatinine clearance >25% from previous 
assessment. 
Whether a subject has renal disease will be based on the Investigators’ assessment of BVAS at 
the Screening visit of this study. 
For the endpoint of change from baseline in UACR, subjects must also have albuminuria at 
baseline, defined as UACR of at least 10 mg/g creatinine.  
Subgroup analyses will also be performed in those subjects with no renal disease at baseline. 
5 
GENERAL CONSIDERATIONS FOR DATA ANALYSIS 
5.1 
General Statistical Considerations 
The analysis of the efficacy endpoints will be conducted when all randomized subjects have 
completed at least the Week 52 study visit (section 8.6 of the protocol). The database will be 
frozen when all data through Week 52 have been cleaned and verified. The Week 52 analysis is 
the primary analysis of the study. The data collected in the 8-week follow-up period (between the 
end of the treatment period at Study Week 52 and the end of the follow-up period at Study Week 
60) will be described in the follow-up analysis. A final database lock will take place after all the 
follow-up data have been cleaned and verified. The follow-up analysis will not affect the primary 
efficacy analysis which is based on the Week 52 BVAS assessments. All study results will be 
included in a single Clinical Study Report.    
Data will be summarized descriptively by treatment group. For continuous variables, numbers, 
means, medians, ranges, standard deviations, and standard error of means will be calculated. 
Geometric means will be calculated for UACR and urinary MCP-1:creatinine ratio, and other 
data that are not normally distributed. Frequency counts and percentages will be presented for 
categorical variables. Listings of raw and derived data will be included as part of an appendix to 
the Clinical Study Report (CSR). 
In analysis tables and listings, the two treatment groups will be referred to as 
 ‘Prednisone + Standard of Care’,  referenced in the protocol as Group A: CCX168-
matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting 
dose of prednisone 
 ‘Avacopan + Standard of Care’, referenced in the protocol as Group B: CCX168 plus 
cyclophosphamide/azathioprine or rituximab plus prednisone-matched placebo 
5.2 
Study Day/Study Week 
Study day or analysis day will be calculated from the date of first dose of study drug. The day of 
the first dose of study drug will be Day 1, and the day immediately before will be Day -1. There 
will be no Day 0. Study week will be calculated in 7 day intervals from study Day 1. 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 23 
Version Date:  28 October 2019 
The 4-week glucocorticoid free periods prior to Week 26 and Week 52 will be calculated from 
the actual dates of the Week 26 and Week 52 visits. This is important for measurement of BVAS 
remission endpoints.  
5.3 
Baseline Definition 
Baseline is defined as the last value prior to start of dosing with study medication (typically the 
Day 1 pre-dose value). For ANCA positivity, BVAS, and VDI, baseline will be taken from the 
Screening visit. However, if the ANCA levels were not measured at the Screening visit but 
instead at the Day 1 visit, these Day 1 measurements may be used to assess ANCA status, if 
measured prior to administration of any study medication. In addition, if the BVAS and VDI 
were not completed at the Screening visit, but at the Day 1 visit and prior to administration of 
any study medication, these may be used in the data analyses. 
5.4 
Assessment Window 
Scheduled visits will be assigned to analysis visits as recorded in the electronic data capture 
(EDC) system. If a scheduled visit is not available, unscheduled and early termination visits will 
be assigned to analysis visits using analysis visit windows based on the actual date the 
assessment took place. The start day of the analysis window will be calculated as the midpoint 
between the scheduled assessment and previously scheduled assessment for that parameter. The 
end day of the analysis window will be calculated as the midpoint between the scheduled 
assessment and the next scheduled assessment for that parameter. Where multiple measurements 
for a particular parameter appear within an analysis window, the scheduled visit will be used. If 
no scheduled visit appears in the analysis window, the result closest to the target day will be 
used. If equidistant and both are unscheduled and/or early termination visits, the later result will 
be used for the summary measure. 
Though all measures may not be used in data summaries (e.g., two lab measures within the same 
analysis visit window), all measurements appear in the datasets and listings. For subjects where 
the event date is missing, the study day and analysis window will also be missing. See Table 1 
below for an example of analysis windows. 
Table 1. Analysis Window Example for SF-36 
Analysis Window 
Start Day 
End Day 
Target Day 
   Baseline 
 
1 
1 
   Day 1 
1 
1 
1 
   Week 4 
2 
42 
29 
   Week 10 
43 
92 
71 
   Week 16 
93 
148 
113 
   Week 26 
149 
228 
183 
   Week 39 
229 
319 
274 
   Week 52 
320 
420 
365 
   Week 60  (Follow-up) 
421 
Last Day in double 
blind follow-up 
NA 
Note: Baseline is defined as the last value prior to start of dosing with study medication (typically the Day 1 pre-
dose value). For BVAS and VDI, baseline will be taken from the Screening visit. 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 24 
Version Date:  28 October 2019 
5.5 
Handling of Missing Data 
Dates will be printed in ISO 8601 date format (YYYY-MM-DD). If only year and month are 
available, date will be displayed as YYYY-MM. If only year, then just YYYY. Dates that are 
missing because they are not applicable for the subjects are output as “NA”, unless otherwise 
specified. 
For the primary endpoints, missing data at Week 26 and Week 52 will be imputed as not 
achieving remission (Week 26) or sustained remission (Week 52), respectively, for the ITT 
population analyses. No imputation will be performed for other time points. 
No imputation will be performed for missing safety endpoints, including safety laboratory 
values, vital signs, electrocardiograms, etc. 
Adverse events and prior/concomitant medications/procedures with incomplete start or stop dates 
will be imputed according to the rules stated in Section 15.2. 
5.6 
Other Data Handling Approaches 
For continuous variables, the estimated mean and median for a set of values will be printed out to 
one more decimal place than the individual units of measurement, and the standard deviation will 
be printed out to 1 additional place.  P-values will be given with 4 decimals (i.e., 0.xxxx). When 
a p-value is less than 0.0001, ‘<0.0001’ will be printed.  
All fractional numeric values will be printed with a zero to the left of the decimal point (e.g., 
0.12, 0.3 etc.). Percentage values will be printed with 1 digit to the right of the decimal point 
(e.g., 52.3%, 8.9% etc.). 
6 
ANALYSIS OF DISPOSITION AND SUBJECT CHARACTERISTICS 
6.1 
Disposition and Analysis Populations 
The number of subjects who were screened, who screen failed (by reason), who were 
randomized, who completed Week 26, Week 52, completed the study (Week 60), who withdrew 
early from the study, along with the reasons for withdrawal, and who prematurely discontinued 
blinded study drug, along with the reasons for discontinuation, will be presented by treatment 
group. These data will also be presented in a flow diagram in the CSR. 
6.2 
Protocol Deviations 
Significant protocol deviations, i.e., those pertaining to GCP violations and those that may affect 
the efficacy evaluation, will be captured in the Study Management System as CSR Reportable 
deviations. These significant deviations will be listed and summarized by category. These 
deviations will be reviewed prior to database freeze to determine the potential impact on the 
interpretation of the efficacy outcomes. The effect of major protocol deviations will be assessed 
by conducting per-protocol analyses (see section 4.1.4). This will be determined and documented 
prior to unblinding the study for the Week 52 primary analysis. Any protocol deviations 
identified during the follow-up period will be included in the CSR.  


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 25 
Version Date:  28 October 2019 
6.3 
Demographics and Baseline Characteristics 
All subject baseline characteristics and demographic data, i.e., age, gender, race, ethnicity, 
weight, height, body mass index, anti-PR3 and anti-MPO antibody status, AAV type: 
granulomatosis with polyangiitis (GPA) vs. microscopic polyangiitis (MPA), newly diagnosed 
vs. relapsing disease, IV cyclophosphamide vs. oral cyclophosphamide vs. IV rituximab use, age 
at diagnosis of AAV, vasculitis disease duration (from time of diagnosis), renal disease at 
baseline, BVAS, VDI, SF-36 v2, EQ-5D-5L, eGFR, hematuria status, UACR, urinary 
MCP-1:creatinine ratio, geographic region (North America vs. Europe, New Zealand and 
Australia vs. Japan) will be listed and summarized by treatment group. 
Glomerular histopathology (if biopsy was taken) will be collected in a standardized histology 
CRF. Baseline and any follow-up data will be listed and summarized by treatment group. If 
sufficient data are available, the relationship between various categories of baseline renal disease 
based on histology and BVAS outcome will be examined. 
6.4 
Medical History 
Medical history terms will be coded using MedDRA (version 19.1) and will be listed and 
summarized by system organ class, preferred term and treatment group with counts and 
percentages. Disease burden at baseline, e.g., cardiovascular disease, pulmonary disease, and 
renal disease, will be compared between treatment groups, and the potential relationship between 
imbalances and adverse event profiles will be evaluated. Additional summaries by background 
therapy with rituximab or cyclophosphamide will also be produced. 
6.5 
Concomitant Medications 
All prior and concomitant medications (including vasculitis medication) will be listed and 
summarized by Anatomic Therapeutic Chemistry (ATC) classification. The numbers and 
percentages of subjects taking prior and concomitant medications will be summarized by 
treatment group, ATC class, and preferred term for the randomized population. Concomitant 
medications will be coded using the World Health Organization (WHO) Drug Dictionary (Sep 
2016E B2). 
Prior medications are defined as any medication taken prior to the first dose of study medication.  
Concomitant medications are defined as any medication taken on or after the first dose of study 
medication. A medication can be classified as both prior and concomitant if it started during the 
screening period and continued into the treatment period. 
6.5.1 Glucocorticoid Use 
6.5.1.1 Study Supplied Glucocorticoid Use  
Subjects who are randomized to the control group are to receive oral prednisone according to a 
standardized tapering schedule over the course of the study (see section 12.6.1 of the study 
protocol).  
The duration of dosing, overall percent compliance, and total dose of study supplied prednisone 
will be listed for each subject. The exposure as measured by study period, duration of exposure, 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 26 
Version Date:  28 October 2019 
total dose, average daily dose, and overall percent compliance will be summarized by treatment 
group. 
6.5.1.2 Non-Study Supplied Glucocorticoid Use 
Extra glucocorticoids, i.e., those that are not supplied as study drug, were to be avoided as much 
as possible during the study. The protocol outlines scenarios for which non-study supplied 
glucocorticoid use was permitted, including treatment for subjects with severe AAV during the 
screening period, adrenal insufficiency or persistence, and worsening or relapse of AAV during 
the treatment period. Glucocorticoid use as pre-medication for rituximab infusion (typically 100 
mg methylprednisolone, or equivalent) was allowed during the study, and is classified as non-
study supplied. If a subject received glucocorticoids during the Screening period, the dose 
needed to be tapered to not more than 20 mg prednisone equivalent by Day 1 of the study. 
Furthermore, the glucocorticoid dose needed to be tapered to zero by Week 4 of the study. 
Non-study supplied glucocorticoids will be listed by study period, type of glucocorticoid, route 
of delivery (IV or oral), dose, unit, and frequency of administration, total prednisone-equivalent 
dose, start and end dates, and indication for administration. Glucocorticoid use will be presented 
as milligram (mg) prednisone equivalent (see Table 2 for conversion factors). 
Table 2. Glucocorticoid Conversion Factors to Prednisone-Equivalent Dose  
Preferred Term 
Conversion 
Prednisolone 
1 mg prednisolone = 1 mg prednisone 
Methylprednisolone 
Methylprednisolone Sodium Succinate 
1 mg methylprednisolone = 1.25 mg prednisone 
Hydrocortisone 
Hydrocortisone Sodium Succinate 
Hydrocortisone Sodium Phosphate 
4 mg hydrocortisone = 1 mg prednisone 
Cortisone 
5 mg Cortisone = 1 mg prednisone 
Betamethasone 
Betamethasone Sodium Phosphate 
0.75 mg Betamethasone = 5.6 mg prednisone 
For each subject, the non-study supplied glucocorticoid use will be listed for each of the 
following periods: Screening (Days -14 to -1), Days 1 through 29, Days 30 through 183, Four 
Weeks Prior to the Week 26 Endpoint, Days 184 – End of Treatment (Day 365 visit or time of 
dropout), Four Weeks Prior to the Week 52 Endpoint, Days 1 through 183, Days 1 through End 
of Treatment, and End of Treatment through Week 60.  
Total non-study supplied glucocorticoid use will be summarized by treatment group for the 
following study periods: Screening (Days -14 to -1), Days 1 through 29, Days 30 through 183, 
Four Weeks Prior to the Week 26 Endpoint, Days 184 – End of Treatment, Four Weeks Prior to 
the Week 52 Endpoint, Days 1 through 183, Days 1 through End of Treatment, and End of 
Treatment to Week 60. 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 27 
Version Date:  28 October 2019 
6.5.1.3 Total Glucocorticoid Use  
Total glucocorticoid use includes both study supplied and non-study supplied glucocorticoids, 
including rituximab pre-medication glucocorticoid use.  
Total glucocorticoid use will be listed by study subject, by study day, by study supplied vs. non-
study supplied glucocorticoid use (by route). To facilitate review, by subject graphs may be 
generated showing the cumulative amount of glucocorticoid use (separated by study-supplied 
and non-study supplied glucocorticoids) over the course of the study. These graphs will be 
presented by Week 26 BVAS remitters vs. non-remitters and Week 52 sustained remitters vs. 
non-remitters. 
The number and percentage of subjects who used prior glucocorticoids and glucocorticoids 
during the study will be summarized. Total glucocorticoid use will be summarized by treatment 
group for the following study periods: Screening (Days -14 to -1), Days 1 through 29, Days 30 
through 183, Four Weeks Prior to the Week 26 Endpoint, Days 184 – End of Treatment, Four 
Weeks Prior to the Week 52 Endpoint, Days 1 through 183, Days 1 through End of Treatment, 
and End of Treatment to Week 60 (only for Non-Study supplied). 
6.5.2 Other Non-Study Supplied Treatments for AAV 
Non-study specified or supplied treatments for AAV (other than glucocorticoids) will be listed 
and summarized by treatment group. These treatments include non-protocol allowed rituximab, 
cyclophosphamide, mycophenolate (except if used instead of azathioprine per protocol), 
methotrexate, anti-TNF treatment, abatacept, alemtuzumab, IVIg, belimumab, tocilizumab, 
eculizumab, or other experimental or immunosuppressive drugs. 
7 
ANALYSIS OF EFFICACY 
The overall efficacy hypothesis in this study is that CCX168 treatment will be effective in 
treatment of subjects with AAV based on inducing remission, and then sustaining remission 
without requiring chronic oral prednisone treatment at the levels currently used in Standard of 
Care treatment regimens.  
7.1 
Covariates and Subgroups 
The analysis of the efficacy endpoints may be adjusted by the following variables in the form of 
covariate analysis and/or subgroup analysis: 
Stratification factors [1]: 
 Subjects receiving IV rituximab background therapy 
 Subjects receiving IV or oral cyclophosphamide therapy [2] 
 Subjects with PR3 ANCA positivity 
 Subjects with MPO ANCA positivity 
 Subjects with newly diagnosed AAV 
 Subjects with relapsed AAV 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 28 
Version Date:  28 October 2019 
[1] The stratification factor values as collected in the electronic case report forms (eCRFs) will 
be used for all stratified efficacy analyses, subgroup analyses and summaries of baseline 
characteristics. 
 [2] IV and oral cyclophosphamide use will be combined due to the low number of subjects in 
the oral cyclophosphamide group. 
Subgroups and Covariates 
 Subjects with renal disease at baseline (based on BVAS renal component) 
 Subjects without active renal disease at baseline 
 Subjects with Granulomatosis with Polyangititis (Wegener’s) 
 Subjects with Microscopic Polyangitis 
 Subjects in North America 
 Subjects in Europe and Rest of World except Japan 
 Subjects in Europe 
 Subjects in Japan 
 Sex (Male, Female) 
 BMI (<30, 30 kg/m2) at baseline 
 Age at diagnosis of AAV (50, >50 years old) 
 Duration of AAV (<1 year, 1 year) at baseline 
 Subject’s age at baseline (12-17, 18-50, 51-64, 65-74, 75 years old), race (Asian, 
Black/African American, White/Caucasian, Other), and ethnicity (Hispanic, Non-
hispanic, Unknown/Not reported) 
 Baseline BVAS (<15, 15) 
 Baseline VDI (0, >0) 
 Baseline eGFR (<30, 30-59, >59 mL/min/1.73 m2) 
 Baseline hematuria (<10 RBCs/hpf, 10 RBCs/hpf) 
 Baseline UACR (<10 mg/g, 10-300 mg/g, >300 mg/g creatinine) 
 Baseline urinary MCP-1:creatinine ratio (<median of all subjects in study, median of all 
subjects in study) 
7.2 
Primary Efficacy Analysis  
The primary efficacy endpoints are: 
1. The proportion of subjects in disease remission at Week 26. The proportion of subjects 
achieving disease remission at Week 26 is defined as a BVAS score of 0 and not taking 
glucocorticoids for treatment of AAV within 4 weeks prior to Week 26. Achievement of this 
endpoint will be based on assessment by the blinded AC that disease remission has been 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 29 
Version Date:  28 October 2019 
achieved at Week 26. The AC will assess remission based on BVAS=0 at Week 26, and 
having not received any glucocorticoids for treatment of AAV during the 4-week period 
preceding and including the Week 26 visit. 
The number of subjects adjudicated as having achieved remission at Week 26 will be divided 
by the total number of subjects in the respective treatment group in the ITT or PP population. 
 Subjects who discontinue the study prior to Week 26 will be assessed as not in remission 
for assessment of the endpoint for the ITT and PP analyses.  
 Subjects who permanently discontinue treatment with blinded study drug prior to Week 
26 for any reason, but who remain in the study will be assessed as remission or no 
remission based on adjudication for the ITT analysis. They will be assessed as not in 
remission for the Per Protocol Analysis if their compliance with taking study medication 
(CCX168/placebo) was <75% during the first 26 weeks of the study (see Section 4.1.4). 
 Subjects with missing data at Week 26 will be assessed as no remission for the ITT but 
these subjects will be excluded from the PP analyses. 
2. The proportion of subjects achieving sustained remission. The proportion of subjects 
achieving sustained disease remission at Week 52 is defined as remission at Week 26 without 
relapse to Week 52 (BVAS of 0 and not taking glucocorticoids for treatment of AAV within 
4 weeks prior to Week 52). Achievement of this endpoint will be based on assessment by the 
blinded AC that disease remission has been achieved at Week 26, that disease remission has 
been achieved at Week 52, and that no relapse has occurred between Weeks 26 and Week 52. 
The proportion will be calculated as the number of subjects who achieved sustained 
remission divided by the total number of subjects in the respective treatment group in the ITT 
or PP population.  
 Subjects who discontinue the study prior to Week 52 will be assessed as not in sustained 
remission for assessment of this endpoint for the ITT and PP analyses.  
 Subjects who permanently discontinue treatment with blinded study drug prior to Week 
52 for any reason, but who remain in the study, will be assessed as having achieved 
sustained remission or not having achieved sustained remission based on adjudication for 
the ITT analysis. They will be assessed as not achieving sustained remission for the Per 
Protocol Analysis if their compliance with taking study medication (CCX168/placebo) 
was <75%  during the 52-week treatment period (see Section 4.1.4). 
 Subjects with missing data at Week 52 will be assessed as no sustained remission for the 
ITT but these subjects will be excluded from the PP analyses. 
Statistical Hypothesis Testing and Procedure 
For the two primary efficacy endpoints, the proportion of subjects achieving disease remission at 
Week 26 and sustained disease remission at Week 52, and the two-sided 95% confidence 
intervals for the difference in proportions (CCX168 minus control) will be estimated for the 
comparison between the CCX168 group and the control group. For both the non-inferiority and 
superiority tests, the 1-sided p-values will be presented. They will be compared to the 1-sided 
type-I error of 0.025 for statistical significance. 
Confidence intervals for the stratified analysis will be calculated as follows: 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 30 
Version Date:  28 October 2019 
Summary score estimate of the common difference in remission rates (Agresti 2013, p. 231) by 
using inverse-variance stratum weights and Miettinen-Nurminen (score) confidence limits for the 
common difference in remission rates will be provided for the stratified contingency tables  at 
Weeks 26 and 52. Summary score test will be used for both non-inferiority and superiority test of 
the stratified analysis at Weeks 26 and 52. The stratification factors will come from the 
stratification values collected in the eCRFs. For unstratified analysis, the Wald confidence limits 
for the difference in remission rates at Weeks 26 and 52 will be calculated. The Wald test will be 
used for both non-inferiority and  superiority test of the difference in remission rates at Weeks 26 
and 52. 
The Clopper–Pearson exact interval will be provided for single proportion data. 
The following hypotheses will be tested for the first primary efficacy endpoint: 
 The non-inferiority null hypothesis (H10) is that the CCX168 group is inferior to the 
control group when comparing the remission rate based on BVAS at Week 26.   
 The non-inferiority alternative hypothesis (H11) is that the CCX168 group is not inferior 
to the control group when comparing the remission rate at Week 26. 
 The superiority null hypothesis (H20) is that the CCX168 group is not different from the 
control group when comparing the remission rate at Week 26. 
 The superiority alternative hypothesis (H21) is that the CCX168 group is superior to the 
control group when comparing the remission rate at Week 26. 
The following hypotheses will be tested for the second primary efficacy endpoint:  
 The non-inferiority null hypothesis (H30) is that the CCX168 group is inferior to the 
control group when comparing the sustained remission rate based on remission at Week 
26 without relapse to Week 52.   
 The non-inferiority alternative hypothesis (H31) is that the CCX168 group is not inferior 
to the control group when comparing the sustained remission rate based on remission at 
Week 26 without relapse to Week 52. 
 The superiority null hypothesis (H40) is that the CCX168 group is not different from the 
control group when comparing the sustained remission rate based on remission at Week 
26 without relapse to Week 52. 
 The superiority alternative hypothesis (H41) is that the CCX168 group is superior to the 
control group when comparing the sustained remission rate at Week 26 without relapse to 
Week 52. 
The two primary endpoints will be tested sequentially using a gatekeeping procedure to preserve 
the overall Type I error rate at 5% level. The sequence of testing will be as follows: 
1. Test for non-inferiority (H10) of the CCX168 group compared to the control group regarding 
remission at Week 26; if the p-value for non-inferiority for the 1-sided test is < 0.025, 
proceed to step 2; 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 31 
Version Date:  28 October 2019 
2. Test for non-inferiority (H30) of the CCX168 group compared to the control group regarding 
sustained remission at Week 52; if the p-value for non-inferiority for the 1-sided test is < 
0.025, proceed to step 3; 
3. Test for superiority (H40) of the CCX168 group compared to the control group regarding 
sustained remission at Week 52; if the p-value for superiority for the 1-sided test is < 0.025, 
proceed to step 4; 
4. Test for superiority (H20) of the CCX168 group compared to the control group regarding 
remission at Week 26. 
For the non-inferiority test of the first primary efficacy endpoint, if the lower bound of the 2-
sided 95% confidence interval is greater than -0.20 (the non-inferiority margin) and the control 
group disease remission rate is at least 40% at Week 26 (if the observed rate of CCX168 is lower 
than that of the control group), the CCX168 group will be considered not inferior to the control 
group. For the superiority test, if the lower bound of the 2-sided 95% confidence interval is 
greater than 0.0, the CCX168 group will be considered superior to the control group in achieving 
the disease remission at Week 26.  
In deriving the non-inferiority margin, the historical disease remission rate at Week 26 in the 
control group is based on a meta-analysis of 20 published studies in subjects treated with 
rituximab plus glucocorticoids or cyclophosphamide plus glucocorticoids. The lower bound of 
the 95% confidence interval for the remission rate was approximately 60%. The non-inferiority 
margin of -0.20 was selected to demonstrate that the CCX168 group retains at least 50% of the 
control group benefit. 
For the second primary endpoint, the proportion of subjects in sustained remission at Week 52 
(disease remission at Week 26 without relapse to Week 52, as adjudicated by the AC) and the 
two-sided 95% confidence interval for the difference in proportion (CCX168 minus control) will 
be estimated for the comparison between the CCX168 group and the control group. For the non-
inferiority test of the second primary endpoint, if the lower bound of the 95% confidence interval 
is greater than -0.20 and the control group disease remission rate is at least 40% at Week 26 (if 
the observed rate of CCX168 is lower than that of the control group), the CCX168 group will be 
considered not inferior to the control group. For the superiority test, if the lower bound of the 
95% confidence interval is greater than 0.0, the CCX168 group will be considered superior to the 
control group in achieving the disease remission at Week 26 and sustained to Week 52. 
A successful study will be declared if (at minimum) non-inferiority is achieved for the CCX168 
group vs. the control group for remission at Week 26. 
**********************************************************************************   
Note:  TRTN = randomized treatment group 
              1 = Placebo + Standard of Care, 2 = Avacopan + Standard of Care 
       RESP = Value of response variable (Y/N) 
       TRTREG = Standard of Care Treatment Regimen  
  *IV rituximab 
  *Cyclophosphamide followed by oral azathioprine [1] 
       ANCAPOS = ANCA Positivity:  PR3 vs MPO 
       AAVSTAT = AAV Status:  Newly diagnosed vs. relapsing disease 
 
[1] IV and Oral Cyclophosphamide use will be combined due to the low number of 
subjects in the Oral Cyclophosphamide group 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 32 
Version Date:  28 October 2019 
**********************************************************************************   
The SAS code used to generate estimates and difference in proportions and 1-sided p-value for 
superiority will be similar to the following: 
Stratified 
 
proc freq data=efficacy; 
 
 
tables TRTREG*ANCAPOS*AAVSTAT*TRTN*RESP / 
               COMMONRISKDIFF(test=SCORE)  alpha=0.05; *Summary Score CI and p-values; 
 
run; 
Non-Stratified 
 
ods listing close; 
 
proc freq data=efficacy; 
 
 
tables TRTN*RESP / riskdiff(EQUAL) alpha=0.05; 
 
 
ods output RiskDiffCol1=equalci;  *Estimate and CI for difference; 
 
 
ods output PdiffTest=equaltest;   *1-sided p-values for Superiority; 
 
run; 
 
ods listing; 
 
 
The SAS code used to generate non-inferiority will be similar to the following: 
Stratified 
The common risk difference estimates and standard errors from the Stratified Analysis specified 
above will be used to calculate the non-inferiority p-value from the Z test. 
 
Z=(Common Risk Difference estimates – (margin))/standard error 
 
The non-inferiority test p-value will be 1-sided from the Z test above: Pr > Z.  The margin is -
 20%.  
 
Non-Stratified 
 
ods listing close; 
 
proc freq data=efficacy; 
 
 
tables TRTN*RESP/ riskdiff(noninf margin=0.2 norisks) alpha=0.025; 
    ods output PdiffNoninf=noninf; *p-values for non-inferiority; 
     run; 
     ods listing; 
 
Subjects who relapse after Week 26 and before Week 52 will be adjudicated as treatment failures 
for the sustained remission analysis at Week 52, per the Adjudication Charter. A relapse is 
defined as worsening of disease that involves at least one major item, or three or more minor 
items, or one or two minor items recorded at two consecutive visits in the BVAS, after having 
previously achieved remission (BVAS = 0) at Week 26 in the study. In all cases the decision of 
the Adjudication Committee supersedes other data.  


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 33 
Version Date:  28 October 2019 
7.2.1 Primary Analysis 
The primary analysis will be based on the stratified analyses comparing the remission rates 
described above for the two primary efficacy endpoints for the ITT population. The stratification 
factors include the following: 
1. Standard of Care Treatment Regimen: 
a. Rituximab 
b. Cyclophosphamide use (IV and oral cyclophosphamide use will be combined due to the 
low number of subjects in the oral cyclophosphamide group) 
2. ANCA Positivity 
a. anti-proteinase 3 (PR3) 
b. anti-myeloperoxidase (MPO)   
3. AAV Status 
a. Newly diagnosed 
b. Relapsing disease   
The primary analyses are adjusted for the potential confounding effects from the stratification 
variables that were collected in the eCRFs. The overall adjusted results will be presented. The 
same hypothesis tests described for the primary analysis will be applied to the sensitivity 
analyses.  
7.2.2 Sensitivity Analyses 
7.2.2.1 Unstratified Analyses 
Sensitivity analyses will be based on the unstratified analysis comparing the remission rates 
described above for the two primary efficacy endpoints for the ITT population. The same 
hypothesis tests described for the primary analysis will be applied to the sensitivity analyses. 
7.2.2.2 Sensitivity Analyses for High Non-Study Supplied Glucocorticoid Use 
Sensitivity analyses (stratified) will also be performed to assess the impact of non-study-supplied 
glucocorticoid use on the secondary 4-week efficacy endpoint (BVAS = 0 at Week 4), and the 
primary 26-week and 52-week efficacy endpoints for the ITT populations. Analyses will be 
based on adjudicated BVAS and relapse data: 
1. For the BVAS = 0 at Week 4 endpoint:  
a. Subjects who used more than 900 mg prednisone equivalent within the first 4 weeks of 
the study will be considered not to have achieved the BVAS = 0 endpoint at Week 4 
(BVAS=0 would be ‘No’ for these subjects and denominator would be the ITT 
population); 
b. Subjects who used more than 900 mg prednisone equivalent within the first 4 weeks of 
the study will be excluded from the analysis (denominator would be the ITT population 
minus subjects excluded from the analysis).  


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 34 
Version Date:  28 October 2019 
The rationale for selection of a 900-mg threshold is as follows: Pre-medication with 
glucocorticoids for IV rituximab use to avoid hypersensitivity reactions is common. The 
glucocorticoid dose typically used for this purpose is 100 mg methylprednisolone IV (i.e., 
125 mg prednisone equivalent) for each of 4 IV rituximab doses given within the first 4 
weeks of the study. This is the prednisone equivalent of 500 mg, i.e., 125 mg x 4. The 
protocol also allows (section 12.6.2.3) for tapering of oral glucocorticoids from 20 mg on 
Day 1 to zero by the end of 4 weeks. The equates to up to 400 mg prednisone equivalent dose 
over the first 4 weeks (see subject 101-003, for example). Therefore, the total prednisone 
equivalent dose over the first 4 weeks could be up to 900 mg, i.e., 500 mg for rituximab pre-
medication plus 400 mg for oral glucocorticoid tapering over the first 4 weeks.    
2. For the BVAS remission at Week 26 endpoint:  
a. Subjects who used more than 1460 mg prednisone equivalent within the first 26 weeks 
of the study will be considered not to have achieved the BVAS remission at Week 26 
endpoint (Remission would be ‘No’ for these subjects and denominator would be the 
ITT population); 
b. Subjects who used more than 1460 mg prednisone equivalent within the first 26 weeks 
of the study will be excluded from the analysis (denominator would be the ITT 
population minus subjects excluded from the analysis).  
The rationale for selection of a 1460-mg threshold is as follows: As discussed in (1) above, 
up to 900 mg prednisone equivalent could be used within the first 4 weeks of the study. The 
protocol also allows for short bursts of low dose glucocorticoids to treat non-major 
manifestations of AAV (doses up to 20 mg for up to 14 days). Two such short bursts equate 
to 560 mg prednisone equivalent, i.e., 20 mg x 14 days x 2 bursts. Therefore, the total 
prednisone equivalent dose over the first 26 weeks could be up to 1460 mg in subjects who 
do not have major manifestations of AAV over the first 26 weeks of the study, i.e., 900 mg 
over the first 4 weeks plus 560 mg for two short bursts of glucocorticoids. 
3. For the BVAS sustained remission at Week 52 endpoint:  
a. Subjects who used more than 560 mg prednisone equivalent from Week 26 through 
Week 52 will be considered not to have achieved the BVAS sustained remission at 
Week 52 endpoint (Sustained Remission would be ‘No’ for these subjects and 
denominator would be the ITT population); 
b. Subjects who used more than 560 mg prednisone equivalent from Week 26 through 
Week 52 will be excluded from the analysis (denominator would be the ITT population 
minus subjects excluded from the analysis).  
The rationale for selection of a 560-mg threshold is as follows: As mentioned in (2) above, 
the protocol allows for short bursts of low dose glucocorticoids to treat non-major 
manifestations of AAV (doses up to 20 mg for not more than 14 days). Two such short bursts 
equate to 560 mg prednisone equivalent, i.e., 20 mg x 14 days x 2 bursts. 
Exploratory sensitivity analyses may be performed to evaluate alternative glucocorticoid 
thresholds for each of the Week 4, Week 26, and Week 52 endpoints. 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 35 
Version Date:  28 October 2019 
7.2.2.3 Alternative Endpoints 
The following preplanned analyses based on BVAS=0 will be done: 
1. Proportion of subjects achieving BVAS=0 at Week 26, independent of non-study supplied 
glucocorticoid use, will be compared across treatment groups in the ITT population. 
2. The proportion of subjects achieving BVAS=0 at Week 26 and Week 52, independent of 
non-study supplied glucocorticoid use, and with no relapse between Week 26 and 52 will be 
compared across treatment groups in the ITT population. 
Analyses for the alternative endpoints will be based on adjudicated BVAS data. 
7.2.2.4 Adjudicated vs Non-Adjudicated Results 
The primary endpoint analyses will be based on the adjudicated BVAS remission at Week 26, 
and adjudicated BVAS sustained remission at Week 52 results. The secondary endpoint of 
BVAS = 0 at Week 4 will also be based on adjudicated Week 4 BVAS results. 
Sensitivity analyses will be conducted on the Investigator-assessed BVAS data (non-adjudicated 
results) for the two primary endpoints, BVAS remission at Week 26 and BVAS sustained 
remission at Week 52, as well as the BVAS = 0 at Week 4 secondary endpoint. 
7.2.2.5 Analysis Excluding Japan 
When the clinical trial was launched, Japan was not included. Japan was added later to the trial 
and therefore Japanese subjects were enrolled towards the end of the enrollment period. In order 
to evaluate the efficacy of the regions included at study initiation, a sensitivity analysis will be 
conducted for the two primary endpoints, BVAS remission at Week 26 and BVAS sustained 
remission at Week 52, as well as the BVAS = 0 at Week 4 secondary endpoint, excluding 
subjects enrolled in Japan. 
7.2.3 Subgroup Analyses 
For both primary efficacy endpoints, the proportion of subjects achieving adjudicated disease 
remission at Week 26 and proportion of subjects achieving adjudicated sustained remission at 
Week 52 will be presented by the following subgroups for the ITT population. No p-values will 
be provided, since the sample size will be small in several subgroups. 
 Subjects receiving IV Rituximab background therapy 
 Subjects receiving IV or Oral Cyclophosphamide therapy 
 Subjects with PR3 ANCA positivity 
 Subjects with MPO ANCA positivity 
 Subjects with newly diagnosed AAV 
 Subjects with relapsed AAV 
 Subjects with renal disease at baseline (based on BVAS renal component) 
 Subjects without active renal disease at baseline 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 36 
Version Date:  28 October 2019 
 Subjects with Granulomatosis with Polyangititis (Wegener's) 
 Subjects with Microscopic Polyangitis 
 Subjects in North America 
 Subjects in Europe and Rest of World except Japan 
 Subjects in Europe 
 Subjects in Japan 
 Sex (Male, Female) 
 BMI (<30, 30 kg/m2) 
 Age at diagnosis of AAV (50, >50 years old) 
 Duration of AAV (<1 year, 1 year) 
 Subject's age (12-17, 18-50, 51-64, 65-74, 75 years old), race (Asian, Black/African 
American, White/Caucasian, Other), and ethnicity (Hispanic, Non-hispanic, 
Unknown/Not reported) 
 Baseline BVAS (<15, 15) 
 Baseline VDI (0, >0) 
 Baseline eGFR (<30, 30-59, >59 mL/min/1.73 m2) 
 Baseline hematuria (<10 RBCs/hpf, 10 RBCs/hpf) 
 Baseline UACR (<10 mg/g, 10-300 mg/g, >300 mg/g creatinine) 
 Baseline urinary MCP-1:creatinine ratio (<median of all subjects in study, median of all 
subjects in study) 
7.2.4 Per-Protocol Analyses 
The same analyses as described for the Primary Analysis will also be conducted for the Per-
Protocol population. 
7.3 
Secondary Efficacy Analyses 
The secondary endpoints will be tested in parallel and nominal p-values will be provided.    
7.3.1 Glucocorticoid Toxicity Index 
7.3.1.1 Primary Analysis 
Glucocorticoid toxicity will be analyzed by the Glucocorticoid Toxicity Index (GTI) version 2.0 
(Ehlers et al, 2019a, Ehlers et al, 2019b), an instrument upgrade from the original GTI version 
1.0 (Miloslawsky et al, 2017). The GTI 2.0 instrument uses two GTI scores: the Cumulative 
Worsening Score (CWS) and the Aggregate Improvement Score (AIS). These scores are referred 
to respectively as:  
 The GTI-CWS 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 37 
Version Date:  28 October 2019 
 The GTI-AIS       
The two scores are outlined briefly below.        
The Cumulative Worsening Score  
The GTI-CWS serves as a lasting record of any glucocorticoid toxicity that occurs over the 
course of a trial. The GTI-CWS assesses cumulative glucocorticoid toxicity, regardless of 
whether the toxicity has lasting effects or is transient. New toxicities that occur are added, but 
toxicities that resolve on follow-up are not removed. The GTI-CWS can only increase or remain 
the same over time. Thus, if an investigational agent is effective at decreasing glucocorticoid 
toxicity over time, the GTI-CWS will be lower in the investigational treatment arm.  
The Aggregate Improvement Score  
In contrast to the CWS, with the GTI-AIS, toxicities are removed if improvement occurs.  
Toxicities can also be added in the GTI-AIS if a new toxicity event occurs or if worsening in a 
specific item of toxicity compared to baseline occurs. The rationale for the GTI-AIS is that in a 
clinical trial in a disease in which patients are anticipated to have some glucocorticoid toxicity at 
baseline, the GTI-AIS is important in establishing that the new therapy is effective at 
diminishing any baseline glucocorticoid toxicity over time.   
If an item of toxicity that is present at baseline or occurs during the trial resolves over the course 
of follow-up, then that improvement is reflected in a negative GTI-AIS for that item during that 
interval. If an investigational agent is effective at decreasing glucocorticoid toxicity over time, 
the GTI-AIS will decrease over the course of the trial in the investigational treatment arm. 
The GTI domains and weights of individual items are shown in Section 15.1.3. 
The primary analysis of total GTI-CWS and GTI-AIS at Week 13 and 26 will be performed in 
the ITT population using a mixed effects model for repeated measures (MMRM). Separate 
models for GTI-CWS and GTI-AIS will incorporate treatment group, visit, treatment-by-visit 
interaction and stratification factors as covariates. The stratification factors will come from the 
stratification values collected in the eCRFs. Subjects will be considered as repeated measure 
units over visits. Linear contrast from the model will be used to test the treatment difference at 
week 13 and 26 separately. Test p-values, point estimates and corresponding 95% confidence 
intervals of treatment difference will be provided at Week 13 and Week 26 separately for GTI-
CWS and GTI-AIS. 
In the MMRM model, missing data will not be imputed. This analysis is unbiased under the 
missing at random (MAR) assumption. A Toeplitz covariance matrix will be used to model the 
within-subject variance-covariance structure for the model errors.  If the model does not 
converge using the Toeplitz covariance matrix, AR(1) covariance matrix will be used.  If 
convergence is still not met, then compound symmetry (CS) will be used. 
The code used to generate the MMRM analysis will be similar to the following: 
**********************************************************************************   
Note:  TRTN = randomized treatment group (numeric) 
                1 = Placebo + Standard of Care, 2 = Avacopan + Standard of Care 
       TRTREG = Standard of Care Treatment Regimen  
  *IV rituximab 
  *Cyclophosphamide followed by oral azathioprine [1] 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 38 
Version Date:  28 October 2019 
       ANCAPOS = ANCA Positivity:  PR3 vs MPO 
       AAVSTAT = AAV Status:  Newly diagnosed vs.relapsing disease 
       VISITN = Visit Number       RESP = Value of continuous response variable 
 [1] IV and Oral Cyclophosphamide use will be combined due to the low number of 
subjects in the Oral Cyclophosphamide group 
**********************************************************************************   
 
    proc mixed data=MMRMDATA; 
      class SUBJECT TRTN VISITN TRTREG ANCAPOS AATSTAT; 
      model RESP = TRTN VISITN TRTN*VISITN TRTREG ANCAPOS AATSTAT / ddfm=kr; 
      repeated VISITN/subject=SUBJECT type=TOEP; 
      lsmeans TRTN*VISITN /cl diff=control("1"); 
   run;  
 
 
 
If GTI data are not normally distributed, the GTI change will be classified into two categories, 
for example, > 0 vs ≤0. The generalized linear mixed model with logistic link function will be 
used to analyze the dichotomized GTI data. The linear contrast will be similar to the primary 
analysis. 
7.3.1.2 Secondary Analysis 
Summary statistics including number, mean, standard deviation (SD), standard error of mean 
(SEM), minimum, median and maximum for individual components of the GTI, including Body 
Mass Index (BMI), glucose tolerance, blood pressure, lipids, steroid myopathy, skin toxicity, 
neuropsychiatric toxicity, and infection will be presented by treatment group for the ITT 
population. 
The number and percentage of subjects with “specific list” items, including all subjects with at 
least one specific list item, as well as each specific list item (endocrine, gastrointestinal, 
musculoskeletal, and ocular manifestations of glucocorticoid use) will be summarized by 
timepoint and treatment group.    
7.3.1.3 Subgroup Analyses 
Summary statistics including number, mean, standard deviation (SD), standard error of mean 
(SEM), minimum, median and maximum for GTI-CWS and GTI-AIS will be presented by 
treatment group at Week 13 and Week 26 for the following subgroups in the ITT population: 
1. Subjects receiving IV Rituximab background therapy 
2. Subjects receiving IV or Oral Cyclophosphamide therapy 
3. Subjects with PR3 ANCA positivity 
4. Subjects with MPO ANCA positivity 
5. Subjects with newly diagnosed AAV 
6. Subjects with relapsed AAV 
7. Subjects with renal disease at baseline 
8. Subjects without renal disease at baseline 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 39 
Version Date:  28 October 2019 
9. Subjects with Granulomatosis with Polyangititis (Wegener’s) 
10. Subjects with Microscopic Polyangitis 
11. Male Subjects 
12. Female Subjects 
13. Subjects in North America 
14. Subjects in Europe and Rest of World excluding Japan 
15. Subject in Europe 
16. Subjects in Japan 
7.3.1.4 Exploratory Analyses 
Exploratory analyses may be conducted to evaluate the relationship between GTI CWS and GTI 
AIS and the glucocorticoid cumulative dose and average daily dose over the first 26 weeks of the 
study by treatment group. 
7.3.2 Early Disease Remission 
The proportion of subjects with early remission, defined as BVAS of 0 at Week 4, regardless of 
receiving glucocorticoids, will be presented by treatment group for the ITT population. Summary 
by subgroup will also be provided. Early remission data will be analyzed similarly to the primary 
endpoint analysis. 
An exploratory analysis includes time to remission using the Kaplan-Meier estimate. For each 
subject, time to remission is defined as the time from first day of study medication dosing to the 
time when BVAS of 0 is achieved during the 52 week treatment period. For the subjects who did 
not achieve BVAS of 0, the subjects’ time to remission is censored at last time of BVAS 
assessment during the treatment period. Log-rank test will be used to test the difference of time 
to remission in two treatment groups. The median time to remission and its associated 95% CI 
will be provided for each treatment group. The hazard ratio and its 95% CI will also be provided.  
7.3.3 SF-36 v2 and EQ-5D-5L VAS and Index - Change from Baseline 
7.3.3.1 Primary Analysis 
The primary analysis of change from baseline over 52 weeks in the physical component score, 
mental component score, and eight domains of the SF-36 v2, and the visual analogue scale and 
index of the EQ-5D-5L will be performed in the ITT population using an MMRM with treatment 
group, visit, treatment-by-visit interaction, and randomization strata (IV rituximab, IV or oral 
cyclophosphamide, anti-PR3 or anti-MPO ANCA, and newly-diagnosed AAV or relapsed AAV) 
as factors, and baseline as covariate. Subjects will be considered as repeated measure units over 
visits. P-values, point estimates, and corresponding 95% confidence intervals will be estimated 
for the difference across 52 weeks using a simple contrast from the model. SF-36 v2 and EQ-5D-
5L are computed at Baseline, Weeks 4, 10, 16, 26, 39, and 52 during the treatment period. 
In the MMRM model, missing data will not be imputed. This analysis is unbiased under the 
missing at random (MAR) assumption. A Toeplitz covariance matrix will be used to model the 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 40 
Version Date:  28 October 2019 
within-subject variance-covariance structure for the model errors.  If the model does not 
converge using the Toeplitz covariance matrix, AR(1) covariance matrix will be used.  If 
convergence is still not met, then compound symmetry (CS) will be used. 
The code used to generate the MMRM analysis will be similar to the following: 
**********************************************************************************   
Note:  TRTN = randomized treatment group (numeric) 
                1 = Placebo + Standard of Care, 2 = Avacopan + Standard of Care 
       TRTREG = Standard of Care Treatment Regimen  
  *IV rituximab 
  *Cyclophosphamide followed by oral azathioprine [1] 
       ANCAPOS = ANCA Positivity:  PR3 vs MPO 
       AAVSTAT = AAV Status:  Newly diagnosed vs.relapsing disease 
       VISITN = Visit Number       RESP = Value of continuous response variable 
       BASERESP = Baseline value of response 
[1] IV and Oral Cyclophosphamide use will be combined due to the low number of 
subjects in the Oral Cyclophosphamide group 
**********************************************************************************   
 
 
ods listing close; 
    proc mixed data=MMRMDATA; 
      class SUBJECT TRTN VISITN TRTREG ANCAPOS AATSTAT; 
      model RESP= TRTN BASERESP VISITN TRTN*VISITN TRTREG ANCAPOS AATSTAT / ddfm=kr; 
      repeated VISITN/subject=SUBJECT type=TOEP; 
      lsmeans TRTN*VISITN /cl diff=control("1"); 
   run;  
7.3.3.2 Subgroup Analyses 
The subgroup analysis of change from baseline over 52 weeks in components of the SF-36 v2 
and EQ-5D-5L will be performed as described above for the subgroup analysis of  GTI for the 
ITT population (section 7.3.1.3).   
7.3.4 Relapses up to Week 52 
7.3.4.1 Proportion of subjects experiencing a relapse after achieving remission at Week 
26 and prior to Week 52 
The proportion of subjects experiencing a relapse after achieving remission at Week 26, and the 
time to relapse, will be summarized. The proportion of subjects will be calculated as the number 
of subjects experiencing a relapse after achieving remission at Week 26 divided by the number 
of subjects who have adjudicated remission at Week 26. The assessment of remission at Week 26 
and the relapse after Week 26 are both based on the assessment by the AC. 
7.3.4.2 Time to relapse after achieving remission at Week 26   
In subjects who achieved remission at Week 26, time to relapse will be analyzed by Kaplan 
Meier methodology and log rank testing of the differences between treatment groups. The time 
to adjudicated relapse  will be assessed from Week 26, independent of whether BVAS=0 was 
achieved at an earlier timepoint.  


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 41 
Version Date:  28 October 2019 
For subjects not achieving relapse on or before Week 52, time to relapse will be the time from 
the date of Week 26 BVAS assessment to the date of the last BVAS assessment during the 52 
week treatment, and is censored. 
The code used to generate the survival analysis will be similar to the following: 
**********************************************************************************   
Note:  TRTN = randomized treatment group (numeric) 
                1 = Placebo + Standard of Care, 2 = Avacopan + Standard of Care 
       TIME = Time to Remission at Week 26 to Relapse in Days 
       VISITN = Visit Number in Weeks 
**********************************************************************************   
proc lifetest data=SURVDATA method=km; 
    time TIME * censor(0); 
    strata TRTN; 
run; 
An exploratory analysis includes time to relapse from the first time point when BVAS of 0 was 
achieved. Time to relapse will be from the Kaplan-Meier estimate. For each subject, time to 
relapse is defined as the time from when BVAS = 0 was first achieved up to the time when a 
relapse occurred during the 52 week treatment period. For this analysis, BVAS = 0 and relapse 
will be based on the Adjudicators’ assessment of BVAS = 0 and relapse. For the subjects who 
did not relapse, the subjects’ time to relapse will be censored using the last time of BVAS 
assessment during the 52 week treatment period as the relapse date. Log-rank test will be used to 
test the difference of time to relapse in two treatment groups. The median time to relapse and its 
associated 95% CI will be provided for each treatment group. The hazard ratio and its 95% CI 
will also be provided. The adjudicated BVAS and adjudicated relapse assessments will be used 
in this analysis. 
7.3.5 eGFR (in Subjects with Renal Disease at Baseline) - Change from Baseline  
7.3.5.1 Primary Analysis 
The primary analysis of change from baseline over 52 weeks in eGFR (in subjects with renal 
disease at baseline) will be performed in the ITT population using an MMRM as described above 
for primary analysis of SF-36 v2 and EQ-5D-5L (section 7.3.3.1) with treatment group, visit, and 
treatment-by-visit interaction as factors, and baseline as covariate. eGFR is computed at 
Baseline, Weeks 1, 2, 3, 4, 7, 10, 13, 16, 20, 26, 32, 39, 45, and 52 during the treatment period. 
7.3.5.2 Subgroup Analyses 
If sample size permits, the subgroup analysis of change from baseline over 52 weeks in eGFR (in 
subjects with renal disease at baseline) will be performed using summary statistics as described 
above for the subgroup analysis of GTI for the ITT population (section 7.3.1.3). Change from 
baseline in eGFR over 52 weeks may be assessed based on baseline eGFR (<30, 30-59, >59 
mL/min/1.73 m2), if there are sufficient subject numbers in these subgroups.   


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 42 
Version Date:  28 October 2019 
7.3.6 UACR (in Subjects with Renal Disease at Baseline) – Percent Change from Baseline  
7.3.6.1 Primary Analysis 
The primary analysis of percent change from baseline over 52 Weeks in UACR (in subjects with 
renal disease at baseline and with albuminuria [UACR 10 mg/g creatinine] at baseline) will be 
performed using MMRM as described above for primary analysis of eGFR for the ITT 
population. To alleviate the skewness of the data, the UACR will be loge-transformed before 
entering into the MMRM analysis. Least squares mean differences between CCX168 and the 
control group in the change from baseline to Week 52 log(UACR) will be back transformed to 
obtain the estimate for the baseline-adjusted percent reduction from control in UACR. UACR is 
computed at Baseline, Weeks 1, 2, 4, 13, 26, 39, and 52 during the treatment period. 
7.3.6.2 Subgroup Analyses 
If sample size permits, the subgroup analysis of change from baseline over 52 Weeks in UACR 
(in subjects with renal disease at baseline and with albuminuria [UACR 10 mg/g creatinine] at 
baseline) will be performed using summary statistics as described above for the subgroup 
analysis of GTI for the ITT population (section 7.3.1.3). Percent change from baseline in UACR 
over 52 weeks will be assessed based on baseline UACR (<10 mg/g, 10-300 mg/g, >300 mg/g), 
depending on subject numbers in each subgroup.  
7.3.7 MCP-1:creatinine ratio (in Subjects with Renal Disease at Baseline) – Percent Change 
from Baseline  
7.3.7.1 Primary Analysis 
The primary analysis of percent change from baseline over 52 weeks in MCP-1:creatinine ratio 
(in subjects with renal disease at baseline) will be performed using MMRM as described above 
for UACR. Urinary MCP-1:creatinine ratio is computed at Baseline, Weeks 1, 2, 4, 13, 26, 39, 
and 52 during the treatment period.  
7.3.7.2 Subgroup Analyses 
The subgroup analysis of change from baseline over 52 weeks in MCP-1:creatinine ratio will be 
performed as described above for the subgroup analysis of GTI for the ITT population (section 
7.3.1.3).   
Urinary MCP-1:creatinine ratio will be log-transformed prior to analysis, similar to the UACR 
(section 7.3.6.1).    
7.3.8 VDI - Change from Baseline to Week 52 
7.3.8.1 Primary Analysis 
The primary analysis of change from baseline over 52 weeks in VDI will be performed as 
described above for primary analysis of SF-36 v2 and EQ-5D-5L (section 7.3.3.1) including 
incorporation of the baseline VDI score in the model. VDI is computed at Baseline, Weeks 26 
and 52 during the treatment period. The primary analysis is based on adjudicated data. 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 43 
Version Date:  28 October 2019 
A frequency distribution table will also be provided for the number and percentage of subjects in 
each of the following categories of change from baseline (0, 1, 2-3, and >3). 
7.3.8.2 Sensitivity Analysis 
A sensitivity analysis will be conducted to include the Investigator-assessed VDI data.  
7.3.8.3 Subgroup Analyses 
The subgroup analysis of change from baseline over 52 Weeks in VDI will be performed as 
described above for the subgroup analysis of GTI for the ITT population (section 7.3.1.3).  
7.3.8.4 Summary of Change from Baseline Categories 
Change from baseline in Adjudicated VDI scores will be categorized into the following groups: 
0, 1, 2-3, >3 and summarized at Week 26, Week 52, End of Treatment and Week 60.  van 
Elteren’s test will be used to compare the two treatment groups.  
 
 
**********************************************************************************   
Note:  TRTN = randomized treatment group 
              1 = Placebo + Standard of Care, 2 = Avacopan + Standard of Care 
       RESP = Value of response variable (Y/N) 
       TRTREG = Standard of Care Treatment Regimen  
  *IV rituximab 
  *Cyclophosphamide followed by oral azathioprine [1] 
       ANCAPOS = ANCA Positivity:  PR3 vs MPO 
       AAVSTAT = AAV Status:  Newly diagnosed vs. relapsing disease 
 
[1] IV and Oral Cyclophosphamide use will be combined due to the low number of 
subjects in the Oral Cyclophosphamide group 
**********************************************************************************   
The SAS code used will be similar to the following: 
 
  ods listing close; 
    proc freq data=VDI; 
      by VISITN; 
      tables TRTREG*ANCAPOS*AAVSTAT*TRTN*CHG / cmh alpha=0.05 scores=modridit 
          noprint; 
      ods output cmh=CMH_RMS;  * p-value for Row Mean Scores; 
     run; 
    ods listing; 
 
7.4 
8-week Follow-Up Period Data 
After the 52-week treatment period, there is an 8-week follow-up period during which subjects 
are not receiving any study treatment. Subjects visit the study centers at Week 60 for the final 
study visit. Data collected at the follow up visit will be listed by subject and summarized by 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 44 
Version Date:  28 October 2019 
treatment group. The number (and percentage) of subjects who have worsening of AAV (based 
on BVAS and relapse data) will be summarized by treatment group. No inferential statistical 
analyses will be conducted on the follow-up period data. 
8 
ANALYSIS OF SAFETY 
8.1 
Population 
All safety parameters will be summarized using the Safety Population. 
8.2 
Extent of Exposure 
Subject drug exposure will be calculated based on the study drug dispensing and return records 
(based on drug accountability). CCX168 plasma concentrations over the course of the study may 
also be used to assess compliance. The CCX168/placebo and prednisone/placebo compliance 
will be calculated comparing the study drug dispensed and the study drug returned. The study 
drug exposure (duration, total dose, and average daily dose) and compliance will be summarized 
and listed. If date of last dose is not available, the date of discontinuation from study will be 
used. 
Duration of exposure is defined as the date of the last dose of study medication minus the date of 
the first dose of study medication plus 1. Duration of exposure to study medication will be 
summarized with descriptive statistics and also in a contingency table for the safety population 
and presented by treatment group. Exposure data will be provided for the following intervals, 
defined to align with the efficacy endpoints: Days 1-29; Days 30-183; Day 184-365; Total Days 
1-183 and Total Days 1-365. 
Percent compliance to study drug will be calculated as follows: 
CCX168/placebo:  
Number of capsules taken / (6 x number of days in the randomized treatment period) x 100.  
For adolescents, the formula will be altered to be consistent with the number of capsules taken daily, 
e.g., if the CCX168 dose was 10 mg twice daily, the formula would be: 
Number of capsules taken / (2 x number of days in the randomized treatment period) x 100. 
Number of days in the randomized treatment period is the Week 52 visit date (or the early 
termination visit date) minus first dose date +1. 
Prednisone/placebo:  
Number of capsules taken / (number of expected doses in randomized treatment period*) x 100 
*The number of expected doses during the treatment period is based on the Prednisone/Matching 
Placebo schedule in the protocol. See Protocol Section 12.6.1, Tables 6 and 7, for further details.   
8.3 
Adverse Events 
An adverse event (AE) is considered treatment-emergent if the start date/time of the event is on 
or after the date/time of first dose of study drug through 56 days following the last dose 
administered during the randomized treatment period.  


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 45 
Version Date:  28 October 2019 
An overview of treatment-emergent adverse events (TEAEs) will be prepared that presents all 
TEAEs, serious adverse events (SAEs), TEAEs leading to study drug discontinuation, events 
related to study medication, glucocorticoid use, IV cyclophosphamide, oral cyclophosphamide, 
rituximab, azathioprine, or mycophenolate and TEAEs by maximum severity. 
Adverse events will be coded using MedDRA and TEAEs will be summarized by system organ 
class and preferred term and by preferred term, in descending order of frequency. Similar 
summaries by system organ class and preferred term will be prepared for TEAEs considered 
possibly related by the study investigators to study medication, glucocorticoids, 
cyclophosphamide, rituximab, azathioprine, or mycophenolate use, TEAEs by maximum 
severity, treatment emergent serious adverse events (TESAEs), possibly study treatment related 
TESAEs  and TESAEs leading to discontinuation of study medication. Adverse events will be 
listed by treatment group, including all available information of interest such as onset and 
resolution dates, study day of onset and resolution relative to first dosing day, duration, severity, 
seriousness, causal relationship to study medication per the investigator, glucocorticoids,  
cyclophosphamide, rituximab, azathioprine or mycophenolate use, action taken, and outcome. 
Separate listings will be provided for non treatment-emergent AEs and SAEs. Separate listings 
will be provided for treatment emergent deaths, TESAEs, TESAEs and TEAEs leading to 
discontinuation of study drug, TESAES and TEAEs leading to withdrawal from study, and 
TEAEs of special interest.  
TEAEs of special interest include infections, hepatic enzyme elevations, neutropenia and 
lymphopenia, and hypersensitivity/ angioedema. 
The subject incidence of infections, serious infections, severe infections (i.e., Grade 3+), and 
infections leading to subject withdrawal from the study will be summarized by treatment group. 
Infections will be identified by selecting terms with the Adverse Event System Organ Class of 
‘Infections and Infestations’.  
The subject incidence of adverse events potentially associated with liver injury will be 
summarized by treatment group – preferred terms in the category will include hepatic enzyme 
increased, alanine aminotransferase increased, aspartate aminotransferase increased, 
transaminases increased, liver function test increased, blood bilirubin increased, alanine 
aminotransferase abnormal, liver function test abnormal, hepatic function abnormal, 
hepatocellular injury, drug-induced liver injury, and similar. The list, finalized prior to 
unblinding, is presented in Appendix 15.3. Any events occurring during the 8-week follow-up 
period will be included in the CSR. Shift tables for increases in liver tests and CPK based on the 
Central Laboratory analyses  will be provided.  
For serious adverse events where the preferred term indicates elevated liver enzymes, the 
laboratory values may be from the local laboratories or hospitalizations and will not be 
represented in the shift tables. Therefore, individual case assessments will be presented for 
subjects with SAEs where the preferred term indicates an increase in liver enzymes. 
The subject incidence of adverse events associated with low WBC count, absolute granulocytes, 
neutrophils, or low lymphocytes will be summarized by treatment group – preferred terms in the 
category will include agranulocytosis, leukopenia, lymphopenia, neutropenia, febrile 
neutropenia, bone marrow failure, bone marrow toxicity, pancytopenia, white blood cell count 
decreased, lymphocyte count decreased, neutrophil count decreased, neutropenic sepsis, and 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 46 
Version Date:  28 October 2019 
similar. The list, finalized prior to unblinding, is presented in Appendix 15.4. Any events 
occurring during the 8-week follow-up period will be included in the CSR. 
For serious adverse events where the preferred term indicates neutropenia,  the laboratory values 
may be from the local laboratories or hospitalizations and will not be represented in the shift 
tables. Therefore, individual case assessments will be presented for subjects with SAEs where 
the preferred term indicates neutropenia. 
The subject incidence of adverse events associated with hypersensitivity/angioedema will be 
summarized by treatment group. Terms will be based on the Standardized  MedDRA Query for 
hypersensitivity. Hypersensitivity events caused by drugs or factors other than study drug 
(avacopan/placebo) will be excluded from this analysis. 
Exploratory analyses include TEAEs potentially associated with glucocorticoid use based on 
mechanism, consistent with The European League Against Rheumatism (EULAR) 
recommendations (van der Goes et al, 2010; Duru et al, 2013). These TEAEs, finalized prior to 
unblinding, are presented in Appendix 15.5. For this analysis, a by-subject listing will be 
provided and data will be summarized by treatment group by system organ class and preferred 
term. 95% Clopper-Pearson’s CIs and unconditional exact 95% CI for the difference in 
proportions (avacopan minus control) may be determined for these TEAEs.  
8.4 
Safety Laboratory Parameters 
Laboratory parameter results and changes from baseline will be summarized by visit. Summaries 
will be limited to values assessed at the Central Laboratory. Listings of laboratory values 
collected at local laboratories will be provided, but not summarized. Shift tables from baseline to 
subsequent study visits will also be generated based on the Central Laboratory measurements. 
Counts and percentages of laboratory values outside the normal reference range will be 
summarized by laboratory parameter, treatment group and visit.The denominator for percentages 
will be the number of subjects in the particular treatment group with measurement at a specified 
visit. Laboratory values outside the reference ranges will be flagged in the listings.  
The subject incidence of elevated laboratory values of ALT, AST, total bilirubin, alkaline 
phosphase, creatinine, and potassium, as assessed by the Central Laboratory, will be summarized 
by treatment group and Grade, as defined per Common Terminology Criteria for Adverse Events 
(CTCAE) Version 5.  Shift from baseline to highest CTCAE grade during the study period will 
also be produced for these laboratory parameters based on the Central Laboratory measurements. 
The same summary by treatment and CTCAE grade will be produced for subject incidence of 
elevated creatine phosphokinase (CPK), low neutrophils, low lymphocytes, low leukocytes, low 
hemoglobin, and low platelets.  Shift from baseline to highest CTCAE grade during the study 
period will also be produced for these laboratory parameters. A by-subject listing including all 
data for these laboratory parameters including CTCAE grade for subjects with any abnormality 
will be provided. 
A listing of subjects whose study drug were permanently discontinued due to adverse events or 
laboratory values will be produced. 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 47 
Version Date:  28 October 2019 
8.5 
Vital Signs 
Vital sign results and changes from baseline will be listed and summarized by study visit and 
treatment group.   
8.6 
ECG Parameters 
Abnormal ECG findings will be listed by treatment group and study visit, and clinical 
significance of abnormalities indicated. Shifts from baseline in overall interpretation (Normal vs. 
Abnormal) will be summarized by treatment group and overall with counts and percentages at 
each study visit. The denominator for percentages will be the number of subjects in the particular 
treatment group with measurement at a specified visit. 
8.7 
Physical Examinations 
Physical examination findings will be listed and summarized by treatment group and study visit, 
and clinical significance of abnormalities indicated. 
8.8 
Other Safety Parameters 
Analysis of change from baseline in the GTI is discussed in Section 7.3.1.   
8.9 
Pharmacokinetic and Pharmacodynamic Marker Analysis 
Individual plasma concentrations of CCX168 and significant metabolites will be listed, plotted, 
and summarized descriptively and graphically. PK parameters such as Cmax, Tmax, and AUC0-6hr 
will be calculated in adolescents for CCX168 based on plasma concentrations for samples 
collected on Day 1. Plasma levels of significant metabolites may also be determined and PK 
parameters calculated. Population PK modeling may be performed to calculate PK parameters.  
Plasma and urinary PD markers will be summarized and may be analyzed using methods 
analogous to the efficacy parameters. 
The relationship between PK parameters and renal function based on eGFR will also be 
evaluated. The data may also be used to evaluate the PK/PD relationship of CCX168 treatment. 
To this end, the change and/or percent change from baseline in eGFR, VDI, UACR, urinary 
MCP-1:creatinine ratio, or other biomarkers may be used as PD markers. 
Details of the PK and PD analysis will be described in a separate analysis plan and will be 
reported in a separate report. 
9 
DATA MONITORING COMMITTEE 
In addition to continuous safety monitoring by the Medical Monitor and clinical staff, an external 
Data Monitoring Committee (DMC) has been established to monitor the safety of subjects over 
the course of the study. The DMC consists of external physicians and a biostatistician. A DMC 
charter was developed before start of the study and the DMC functions according to the charter. 
The DMC has regular meetings, once every 3 to 6 months, depending on study enrollment rate. 
Ad hoc meetings may be scheduled if unanticipated safety events occur. After review of data at 
each meeting, the DMC makes recommendations about further conduct of the study. 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 48 
Version Date:  28 October 2019 
10 ADJUDICATION OF ENDPOINTS 
An Adjudication Committee (AC) has been established to perform a blinded, independent 
adjudication of the BVAS and VDI data. The AC is composed of individuals who are 
independent of the Sponsor, recognized experts in AAV, and expert in the use of BVAS and VDI 
in clinical trial design and operationalization. The AC operates under a charter, which provides 
detailed guidance
 
In addition to BVAS and VDI, the following endpoints will be adjudicated by the AC: 
1. Achievement of early disease remission at Week 4 (Secondary Endpoint) 
2. Achievement of disease remission at Week 26 (Primary Endpoint) 
3. Achievement of sustained disease remission at Week 52 (Primary Endpoint) 
4. Occurrence of relapse during the 52 week treatment period and follow up. 
Note that assessment of glucocorticoid use for the purpose of assessing (2) and (3) above is also 
performed by the AC.  
11 INTERIM ANALYSIS 
Safety data from the study will be summarized for review by the DMC at various points over the 
course of the study (see Section 9). The DMC charter includes details of these reviews. No Type 
I error adjustment will be made based on the DMC review of the data, since these reviews will 
focus on safety assessments. 
12 SAMPLE SIZE AND POWER CONSIDERATIONS 
The proportion of subjects in the control group achieving clinical remission at Week 26 is 
estimated to be ~60%, a blended proportion of 64% and 53% observed in the rituximab and 
cyclophosphamide/azathioprine groups, respectively, in the largest prior registration study in 
AAV (Stone et al, 2010). 
A non-inferiority margin of -20 percentage points has been derived for the difference between 
CCX168 and control groups, and a one-sided alpha level of 0.025. This non-inferiority margin is 
based on a thorough review and meta-analysis of all previous clinical trials conducted in subjects 
with AAV, as well as precedent (Stone et al, 2010). 
A sample size of 150 subjects per group (300 in total) is estimated to provide more than 90% 
power for the non-inferiority test. This sample size provides 90% power to detect approximately 
18% superiority in the proportion of subjects achieving clinical remission at Week 26 if the 
control group remission rate is 60%. 
The proportion of subjects in the control group with sustained remission at Week 52 is estimated 
to be ~45%, a blended proportion observed in a prior study comparing rituximab and 
cyclophosphamide/azathioprine in AAV (Specks et al, 2013). A sample size of 150 subjects per 
group (300 in total) is estimated to provide 85% power to detect approximately 18% superiority 
if the control group sustained remission rate at Week 52 is 45%. 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 49 
Version Date:  28 October 2019 
13 CHANGES FROM PROTOCOL–SPECIFIED STATISTICAL ANALYSES  
1. The protocol anticipates using the Glucocorticoid Toxicity Index version 1.0 (Miloslavsky et 
al 2016). Since the launch of this study, version 2.0 became available, which has distinct 
advantages over version 1.0, such as being validated in two patient cohorts (Ehlers et al 
2019a; Ehlers et al 2019b) and expressing glucocorticoid toxicity in a cumulative manner 
with the Cumulative Worsening Score as well as in a two-directional manner with the 
Aggregate Improvement Score. Therefore, a decision was made by the Sponsor, in 
consultation with the developers of the GTI, prior to completion of this study, to use version 
2.0 instead of version 1.0 for the final analysis. 
2. The protocol states the analysis for the primary endpoint would be based on the stratified 
Newcombe hybrid-score method for the common difference in proportions. The primary 
endpoint analysis will be based on the stratified Summary score test and estimate for the 
common difference in proportions. Summary score estimate of the common difference in 
remission rates (Agresti 2013, p. 231) will be determined by using inverse-variance stratum 
weights and Miettinen-Nurminen (score) confidence limits for the common difference in 
remission rates. Results comparing different stratified analysis methods show that the 
Summary score method provides robust results for the data from the RAVE study (Stone et 
al, 2010), which is similar to this study. 
14 REFERENCES 
1. Agresti A 2013. Categorical data analysis. 3rd Ed. Hoboken, NJ: John Wiley & Sons. 
2. Duru N, et al. 2013 EULAR evidence-based and consensus-based recommendations on the 
management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann 
Rheum Dis 72:1905-1913. 
3. Ehlers L, et al.  2019a Use of the Glucocorticoid Toxicity Index 2.0 in a longitudinal cohort 
of patients with systemic vasculitis (EULAR 2019). 
4. Exley AR, et al. 1997 Development and initial validation of the VDI. Arthritis Rheum 
40:371-380. 
5. Ehlers L, et al.  2019b Use of the Glucocorticoid Toxicity Index 2.0 in a longitudinal cohort 
of patients with systemic vasculitis (EULAR 2019). 
6. Miloslavsky EM, et al. 2016 Development of a Glucocorticoid Toxicity Index (GTI) using 
multicriteria decision analysis. Ann Rheum Dis 2016;0:1-4. doi:10.1136/annrheumdis-2016-
210002. 
7. Mukhtyar C, et al. 2009 Modification and validation of the Birmingham Vasculitis Activity 
Score (version 3) Ann Rheum Dis 68:1827–1832. 
8. Specks U, et al. 2013 Efficacy of remission-induction regimens for ANCA-associated 
vasculitis. N Engl J Med 369:417-427.  
9. Stone JH, et al. 2010 Rituximab versus cyclophosphamide for ANCA-associated vasculitis. 
N Engl J Med 363:221-232. 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 50 
Version Date:  28 October 2019 
10. Suppiah R, et al. 2011 A cross-sectional study of the Birmingham Vasculitis Activity Score 
version 3 in systemic vasculitis. Rheumatol 50:899-905. 
11. van der Goes MC, et al. 2010 Monitoring adverse events of low-dose glucocorticoid therapy: 
EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 
2010;69:1913-1919.  
15 APPENDICES 
15.1 Data Derivation Details 
15.1.1 BVAS 
Only symptoms/signs ascribed to the presence of active AAV (GPA or MPA) will be recorded 
and entered into EDC. For the Week 4 BVAS assessment, the disease activity present within the 
7 days prior to the visit was to be recorded. For all the other study visits, the disease activity 
present within the 28 days prior to the visit was to be recorded. 
AAV Organ Systems and Activity Items in BVAS 
There are 9 organ systems, plus an “Other” category in the BVAS. For study eligibility, a subject 
must have at least one major item, at least 3 minor items, or at least the two renal items of 
hematuria and proteinuria. If a subject has “other” items, not specified in the BVAS, these need 
to be discussed with the Medical Monitor before enrollment. The organ systems and items are 
provided in Table 3. Major items are indicated in bold italics. 
Scoring of BVAS 
The calculation of BVAS will be performed programmatically. A total score will be calculated 
from the individual organ system scores as described in Table 3. BVAS data recorded by 
investigators will be adjudicated, according to an adjudication charter, before data finalization 
and unblinding. The adjudicated data will be used in the final analysis. 
 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 51 
Version Date:  28 October 2019 
Table 3. BVAS Organ Systems, Individual Items and Scoring 
BVAS Items and Calculations 
Target Item 
Description 
General subscore 
The following items receive the respective scores provided and the score is the sum of these values but cannot 
exceed 3 (max score is 3 regardless if sum is above):  Myalgia (1), Arthralgia or arthritis (1), Fever >= 38 (2), Weight 
loss >=2 kg (2) 
Cutaneous subscore 
The following items receive the respective scores provided and the score is the sum of these values but cannot 
exceed 6 (max score is 6 regardless if sum is above):  Infarct (2), Purpura (2), Ulcer (4), Gangrene (6), Other skin 
vasculitis (2) 
Mucous membranes/eyes 
subscore 
The following items receive the respective scores provided and the score is the sum of these values but cannot 
exceed 6 (max score is 6 regardless if sum is above):  Mouth ulcers / granulomata (2), Genital ulcers (1), Adnexal 
inflammation (4), Significant proptosis (4), Scleritis / Episcleritis (2), Conjunctivitis / Blepharitis / Keratitis (1), 
Blurred vision (3), Sudden visual loss (6), Uveitis (6), Retinal changes (6) 
ENT subscore 
The following items receive the respective scores provided and the score is the sum of these values but cannot 
exceed 6 (max score is 6 regardless if sum is above):  Bloody nasal discharge / crusts / ulcers / granulomata (4), 
Paranasal sinus involvement (2), Subglottic stenosis (6), Conductive hearing loss (3), Sensorineural hearing loss 
(6) 
Chest subscore 
The following items receive the respective scores provided and the score is the sum of these values but cannot 
exceed 6 (max score is 6 regardless if sum is above): Wheeze (2), Nodules or cavities (3), Pleural effusion / pleurisy 
(4), Infiltrate (4), Endobronchial involvement (4), Massive haemoptysis / alveolar haemorrhage (6), Respiratory 
failure (6) 
Cardiovascular subscore 
The following items receive the respective scores provided and the score is the sum of these values but cannot 
exceed 6 (max score is 6 regardless if sum is above): Loss of pulses (4), Valvular heart disease (4), Pericarditis (3), 
Ischaemic cardiac pain (4), Cardiomyopathy (6), Congestive cardiac failure (6) 
Abdominal subscore 
The following items receive the respective scores provided and the score is the sum of these values but cannot 
exceed 9 (max score is 9 regardless if sum is above): Peritonitis (9), Bloody diarrhoea (9), Ischaemic abdominal 
pain (6) 
Renal subscore 
The following items receive the respective scores provided and the score is the sum of these values but cannot 
exceed 12 (max score is 12 regardless if sum is above): Hypertension (4), Proteinuria (4), Haematuria (6), Serum 
creatinine 125-249 (4), Serum creatinine 250-499 (6), Serum creatinine >=500 (8), Rise in serum creatinine >30% 
or fall in creatinine clearance >25% (6) 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 52 
Version Date:  28 October 2019 
BVAS Items and Calculations 
Target Item 
Description 
Nervous system subscore 
The following items receive the respective scores provided and the score is the sum of these values but cannot 
exceed 9 (max score is 9 regardless if sum is above): Headache (1), Meningitis (3), Organic confusion (3), Seizures 
(9), Cerebrovascular accident (9), Spinal cord lesion (9), Cranial nerve palsy (6), Sensory peripheral 
neuropathy (6), Mononeuritis multiplex (9) 
Other 
If RBC casts and/or glomerulonephritis is checked, it should be added to the Renal Organ System with a Score of 6.  
Haematuria is also in the Renal organ system (also given a score of 6).  Only one or the other should be included in 
the Renal System.   
If additional Other Items are checked the applicable organ system and whether the item is major or minor is 
indicated.  Minor items are given an score of 2 and Major items are given a Score of 4.  The maximum score within 
an organ system is still applicable. 
Total BVAS Score 
Sum of all individual scores described above (General + Cutaneous + Mucous membranes / eyes + ENT + Chest + 
Cardiovascular + Abdominal + Renal + Nervous System) 
Note:  Major items are indicated in bold italics. 
 
 
 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 53 
Version Date:  28 October 2019 
15.1.2 VDI 
The Vasculitis Damage Index (VDI) is for recording organ damage that has occurred in subjects 
since the onset of vasculitis. Damage is defined as the presence of non-healing scars and does not 
give any indication of current disease activity. Damage items in the VDI are often the direct 
result of previous disease activity (captured in the BVAS). Damage is defined as having been 
present or currently present for at least 3 months. It is therefore possible for abnormalities to 
have occurred in the past, not be currently present, but to still count as damage. 
Subjects often have co-morbidity before they develop vasculitis, which is not to be scored. 
Features of active disease are recorded using the BVAS, not the VDI. 
New subjects should usually have a VDI score of zero, unless: 
a. They have had vasculitis for more than three months of onset of disease, and 
b. The damage has developed or become worse since the onset of vasculitis. 
The VDI item list can only deteriorate or be stable over time (damage is defined as irreversible in 
this scoring system). For each item in turn, all features which have occurred since the onset of 
vasculitis are recorded, regardless of the cause. For specific events, such as GI surgery, damage 
can be scored as positive if the procedure was undertaken at least three months prior to the 
assessment (and also must have occurred after the onset of the disease). The same time frame is 
applied to all the damage items. If the subject is seen for the first time, and their vasculitis onset 
date is within three months of the assessment, then by definition, the subject cannot be recorded 
as having any damage. However, any features which are observed can be recorded as ascribable 
to damage after the arbitrary time of three months has elapsed. 
There are 11 organ systems in the VDI: 
1. Musculoskeletal 
a. Significant muscle atrophy or weakness 
b. Deforming / erosive arthritis 
c. Osteoporosis / vertebral collapse 
d. Avascular necrosis 
e. Osteomyelitis 
2. Skin/Mucous Membranes 
a. Alopecia 
b. Cutaneous ulcers 
c. Mouth ulcers 
3. Ocular 
a. Cataract 
b. Retinal change 
c. Optic atrophy 
d. Visual impairment / diplopia 
e. Blindness in one eye 
f. Blindness in a second eye 
g. Orbital wall destruction 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 54 
Version Date:  28 October 2019 
4. Ear, Nose & Throat 
a. Hearing loss 
b. Nasal blockage / chronic discharge/crusting 
c. Nasal bridge collapse / septal perforation 
d. Chronic sinusitis / radiological damage 
e. Subglottic stenosis (no surgery) 
f. Subglottic stenosis (with surgery) 
5. Pulmonary 
a. Pulmonary hypertension 
b. Pulmonary fibrosis 
c. Pulmonary infarction 
d. Pleural fibrosis 
e. Chronic asthma 
f. Chronic breathlessness 
g. Impaired lung function 
6. Cardiovascular 
a. Angina angioplasty 
b. Myocardial infarction 
c. Subsequent myocardial infarction 
d. Cardiomyopathy 
e. Valvular disease 
f. Pericarditis ≥3 months or pericardectomy 
g. Diastolic BP ≥95 or requiring antihypertensives 
7. Peripheral Vascular Disease 
a. Absent pulses in one limb 
b. Second episode of absent pulses in one limb 
c. Major vessel stenosis 
d. Claudication >3 months 
e. Minor tissue loss 
f. Major tissue loss 
g. Subsequent major tissue loss 
h. Complicated venous thrombosis 
8. Gastrointestinal 
a. Gut infarction / resection 
b. Mesenteric insufficiency / pancreatitis 
c. Chronic peritonitis 
d. Esophageal stricture / surgery 
9. Renal 
a. Estimated / measured GFR ≤50 
b. Proteinuria ≥0.5 g/24 hours 
c. End stage renal disease 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 55 
Version Date:  28 October 2019 
10. Neuropsychiatric 
a. Cognitive impairment 
b. Major psychosis 
c. Seizures 
d. Cerebrovascular accident 
e. 2nd Cerebrovascular accident 
f. Cranial nerve lesion 
g. Peripheral neuropathy 
h. Transverse myelitis 
11. Other 
a. Gonadal failure 
b. Marrow failure 
c. Diabetes 
d. Chemical cystitis 
e. Malignancy 
f. Etc. 
The number of positive items is added for the total VDI score. Any previously scored items on 
the VDI must be carried forward to subsequent visits. The VDI score cannot decrease over time. 
The calculation of VDI will be performed programmatically. 
15.1.3 Glucocorticoid Toxicity Index (GTI) 
The GTI was developed to quantitatively capture glucocorticoid toxicity and the glucocorticoid-
sparing ability of other therapies.  The index consists of components in Table 4: 
Table 4. Glucocorticoid Toxicity Index Version 2.0 Items with Scoring and Specific List Items 
Feature/Body System 
Item Weight 
Body Mass Index (BMI) 
Decrease of 5 BMI units 
-36 
Decrease of >2 but <5 BMI units 
-21 
No significant change in BMI (±2 BMI units) 
0 
Increase of >2 to <5 BMI units 
21 
Increase of 5 or more BMI units 
36 
Glucose tolerance 
Improvement in HbA1c AND decrease in medication 
-44 
Improvement in HbA1c OR decrease in medication 
-32 
No significant change 
0 
Increase in HbA1c OR increase in medication 
32 
Increase in HbA1c AND increase in medication 
44 
Blood pressure 
Improvement in BP AND decrease in medication 
-44 
Improvement in BP OR decrease in medication 
-19 
No significant change in blood pressure 
0 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 56 
Version Date:  28 October 2019 
Feature/Body System 
Item Weight 
Increase in BP OR increase in medication 
19 
Increase in BP AND increase in medication  
44 
Lipids 
Decrease in LDL AND decrease in medication 
-30 
Decrease in LDL OR decrease in medication 
-10 
No significant change in lipids 
0 
Increase in LDL OR increase in medication 
10 
Increase in LDL AND increase in medication 
30 
Steroid myopathy1 
Moderate weakness to none 
-63 
Moderate to Mild weakness 
-54 
Mild weakness to none 
-9 
No significant change 
0 
None to mild weakness 
9 
Mild to moderate weakness 
54 
None to Moderate weakness 
63 
Skin toxicity1 
Decrease in Skin Toxicity - Moderate to None 
-26 
Decrease in Skin Toxicity - Moderate to Mild 
-18 
Decrease in Skin Toxicity - Mild to None 
-8 
No significant change 
0 
Increase in Skin Toxicity - None to Mild 
8 
Increase in Skin Toxicity - Mild to Moderate 
18 
Increase in Skin Toxicity - None to Moderate 
26 
Neuropsychiatric (NP) toxicity1 
Decrease in NP Toxicity - Moderate to None 
-74 
Decrease in NP Toxicity - Moderate to Mild 
-63 
Decrease in NP Toxicity - Mild to None 
-11 
No significant change 
0 
Increase in NP Toxicity - None to Mild 
11 
Increase in NP Toxicity – Mild to Moderate 
63 
Increase in NP Toxicity - None to Moderate 
74 
Infection1 
No significant infection 
0 
Oral/vaginal candidiasis or uncomplicated zoster 
19 
Grade 3, 4 or 5 infection 
93 
1 See Section 12.5.1 of the protocol for definitions of steroid myopathy, skin toxicity, neuropathy, 
and infection. 
Weighting of Improvement and Worsening in Items of Glucocorticoid Toxicity 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 57 
Version Date:  28 October 2019 
As indicated by a review of Table 4, the GTI 2.0 permits an improvement in glucocorticoid 
toxicity to be accorded the same absolute weight as a worsening of glucocorticoid toxicity. The 
GTI 2.0 accomplishes this through the GTI-AIS (Aggregate Improvement Score).  The GTI-AIS 
scores improvement in GC toxicity the same as a corresponding worsening of GC toxicity.    
Example: 
An increase in the body mass index (BMI) more than 5 BMI units to a BMI of greater than 25 is 
associated with an increase in the GTI score of +36 points. Conversely, a decrease in BMI of 
more than 5 BMI units towards a normal BMI is associated with an improvement in the score of 
-36 points. 
Application of GTI Scoring 
The GTI will be measured at baseline, Week 13, and Week 26 in this clinical trial. Both the GTI-
CWS and the GTI-AIS will be calculated for each three-month interval, and then the interval 
scores are summed. If avacopan is effective at reducing glucocorticoid toxicity compared to the 
prednisone control group, both the GTI-CWS and the GTI-AIS will be lower in the avacopan 
treatment group than in the prednisone group.     
Scoring of Domains That Have Sub-Items (the Skin and Neuropsychiatric Domains) 
The Skin and Neuropsychiatric Domains both have Sub-Items: 
 For the Neuropsychiatric Domain, these are Insomnia, Depression, Mania, and Cognitive 
Impairment.   
 For the Skin Domain, these are Acneiform Rash, Easy Bruising, Hirsutism, 
Atrophy/Striae, and Erosions/tears/ulcerations.  
Scoring of these Domains differs according to whether one is calculating the GTI-CWS or the 
GTI-AIS: 
With the GTI-CWS, only worsening is scored. Only the Item with the highest weight is 
scored for any GTI interval with the GTI-CWS. As an example, if neither insomnia nor 
depression were present at the baseline visit but there is now mild Insomnia and moderate 
depression present at follow-up, then only the moderate depression is scored (+74 points).  
With the GTI-AIS, improvement as well as worsening can be recorded. Because it is 
conceivable that one Item might improve while another worsens, the Item of greatest 
improvement (highest absolute weight) and the Item of greatest worsening (highest 
weight) are recorded for given GTI interval.     
Scoring of Infections 
The GTI-CWS and GTI-AIS handle the scoring of infections differently, because these scores 
reflect reciprocal measures of GC toxicity: 
 In the CWS, the most severe infection in every GTI interval (usually three months) is 
scored.   
 In the AIS, only the most severe infection occurring over the course of the 26 weeks is 
scored. 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 58 
Version Date:  28 October 2019 
15.1.3.1 Items in the specific list 
The Specific List Items of the GTI are provided in Table 5.  
Table 5. Specific List Items of the GTI 
Feature/Organ System 
Specific List 
Body Mass Index 
Major increase in BMI (>8 units and above 24.9 kg/m2) 
Glucose Tolerance 
Diabetic retinopathy 
Diabetic nephropathy 
Diabetic neuropathy 
Blood pressure 
Hypertensive emergency (or posterior reversible encephalopathy 
syndrome) 
Posterior reversible encephalopathy syndrome 
Steroid myopathy 
Severe steroid myopathy or tendon rupture 
Skin toxicity 
Severe skin toxicity 
Neuropsychiatric toxicity 
Psychosis (hallucinations, delusions, or disorganized thought processes, 
occurring in the absence of mania, delirium, or depression) 
Glucocorticoid-induced violence towards self or others 
Other severe neuropsychiatric symptoms 
Infections 
Grade IV infection 
Grade V infection (death from infection) 
Endocrine 
Symptomatic adrenal insufficiency 
Gastrointestinal 
Perforation (occurring in the absence of regular nonsteroidal anti-
inflammatory drug use) 
Peptic ulcer disease confirmed by endoscopy (excluding H. pylori) 
Musculoskeletal 
Avascular necrosis 
Tendon rupture 
Insufficiency fracture 
Ocular 
Central serous retinopathy 
New onset or worsened elevation of intraocular pressure requiring 
treatment or change in treatment. 
Posterior subcapsular cataract (or history of the same) 
Explanations of Specific Items are provided below. 
Hypertensive emergency: The blood pressure has reached levels that are damaging organs. 
Hypertensive emergencies generally occur at blood pressure levels exceeding 180 mmHg 
systolic OR 120 mmHg diastolic, but can occur at even lower levels in subjects whose blood 
pressure have not been elevated before. Complications can include: stroke, loss of consciousness, 
memory loss, myocardial infarction, hypertensive retinopathy or nephropathy, aortic dissection, 
angina, pulmonary edema. 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 59 
Version Date:  28 October 2019 
Posterior reversible leukoencephalopathy syndrome (PRES): A clinical radiological entity. 
Clinical features may include headaches, altered mental status, seizures, and visual loss, 
depending on the affected neuroanatomy. Characteristic Magnetic Resonance Imaging (MRI) 
findings include vasogenic edema involving the white matter that predominantly affects the 
posterior occipital and parietal lobes of the brain, although other brain regions may also be 
affected. Confirmation by MRI is required as is exclusion of other potential causes (including 
hypertensive emergency). 
Severe glucocorticoid myopathy: Grade 3 or worse myopathic weakness or respiratory 
myopathic weakness attributable to glucocorticoid myopathy. 
Central serous retinopathy: a fluid detachment of macula layers from their supporting tissue. 
Requires formal ophthalmology examination, typically accompanied by optical coherence 
tomography and/or fluorescein angiography for diagnostic confirmation. 
Grade 4 infection: Life-threatening consequences (e.g., septic shock, hypotension, acidosis, 
necrosis). 
Diabetic nephropathy: Macroalbuminuria; i.e., a urinary albumin excretion >300 mg in a 24-
hour collection or a urinary protein: creatinine ratio >300mg/g. 
Diabetic neuropathy: Any of four types of peripheral neuropathy occurring in the setting of 
diabetes mellitus, namely: 1) a distal sensory polyneuropathy; 2) autonomic neuropathy 
(hypoglycemia unawareness, bladder or bowel problems, erectile dysfunction, and other 
autonomic nervous system issues); 3) diabetic amyotrophy (muscle infarction); or 4) 
mononeuritis (e.g., foot drop attributed to diabetic neuropathy). 
15.1.4 EQ-5D-5L 
Crosswalk value sets used in the calculation of the EQ-5D-5L Index Score are available for the 
following countries: Denmark, France, Germany, Japan, the Netherlands, Spain, Thailand, UK, 
US and Zimbabwe.  For countries not listed above, reference data will used according to the 
following: 
 
Country 
EQ-5D-5L Crosswalk Value Country Set  
US, Canada 
US 
Denmark, Sweeden 
Denmark 
France, Switzerland 
France 
Germany, Czech Republic, Austria 
Germany 
Japan 
Japan 
Netherlands, Belgium 
Netherlands 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 60 
Version Date:  28 October 2019 
Spain, Italy 
Spain 
UK, Ireland, Australia, New Zealand,  
UK 
 
15.2 Imputation for Missing/Partially Missing Adverse Event and Concomitant 
Medication Dates 
15.2.1 Incomplete Adverse Event Start Date: 
Partially missing AE start/stop dates will be imputed in the ADaM dataset for AEs, according to 
the rules below.  However, listings of AE data will present the date as is, with missing date 
components left blank. 
If the AE end date is complete with no missing year, month, or day, and a partially missing start 
date imputed by the rules below is after the AE end date, then the start date will be imputed by 
the AE end date. 
Missing day and month 
 If the year is the same as the year of the first dosing date, then the day and month of the 
first dosing date will be assigned to the missing fields. 
 If the year is prior to the year of first dosing date, then December 31 will be assigned to 
the missing fields. 
 If the year is after the year of first dosing, then January 1 will be assigned to the missing 
fields. 
Missing day only 
 If the month and year are the same as the year and month of first dosing date, then the 
first dosing date will be assigned to the missing day. 
 If either the year of the partial date is before the year of the first dosing date or the years 
of the partial date and the first dosing date are the same but the month of partial date is 
before the month of the first dosing date, then the last day of the month will be assigned 
to the missing day. 
 If either the year of the partial date is after the year of the first dosing date or the years of 
the partial date and the first dose date are the same but the month of partial date is after 
the month of the first dosing date, then the first day of the month will be assigned to the 
missing day. 
Missing day, month, and year 
 No imputation is needed.  The corresponding AE will be included as TEAE. 
15.2.2 Incomplete AE Stop Date: 
If the imputed stop date is before the start date, then the imputed stop date will be equal to the 
start date. 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 61 
Version Date:  28 October 2019 
Missing day and month 
 If the year of the incomplete stop date is the same as the year of the last dosing date, then 
the day and month of the last dosing date will be assigned to the missing fields. 
 If the year of the incomplete stop date is prior to the year of the last dosing date or prior 
to the year of the first dosing date, then December 31 will be assigned to the missing 
fields. 
 If the year of the incomplete stop date is prior to the year of the last dosing date but is 
the same as the year of the first dosing date, then the first dosing date will be assigned to 
the missing date. 
 If the year of the incomplete stop date is after the year of the last dosing date, then 
January 1 will be assigned to the missing fields. 
Missing day only 
 If the month and year of the incomplete stop date are the same as the month and year of 
the last dosing date, then the day of the last dosing date will be assigned to the missing 
day 
 If either the year of the partial date is not equal to the year of the last dosing date or the 
years of the partial date and the last dosing date are the same but the month of partial date 
is not equal to the month of the last dosing date, then the last day of the month will be 
assigned to the missing day 
15.2.1 Incomplete Start/Stop Dates for Prior/Concomitant Medications/Procedures 
Partially missing start/stop dates for prior/concomitant medications and partially missing start 
dates for prior/concomitant procedures will be imputed in the ADaM dataset for 
prior/concomitant medications/procedures. However, listings of prior/concomitant 
medications/procedures data will present the date as is, with missing date components left blank. 
For prior/concomitant medications, if the stop date is complete with no missing year, month, or 
day, and the partially missing start date imputed by the rule below is after the stop date, then the 
start date will be imputed by the stop date. 
Partially missing prior/concomitant medication/procedure start dates will be imputed by the 
earliest possible date given the non-missing field(s) of the date, if the partial dates are either 
before or after the date of the first dose of the study drug.  Otherwise, they will be imputed with 
the date of the first study drug dose. 
Partially missing prior/concomitant medication stop dates will be imputed by the latest possible 
date given the non-missing field(s) of the date. 
 
15.3 Preferred Terms of Adverse Events Potentially Associated with Liver Injury 
Drug-induced liver injury 
Hepatic function abnormal 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 62 
Version Date:  28 October 2019 
Hepatocellular injury 
Alanine aminotransferase increased 
Aspartate aminotransferase increased 
Blood bilirubin increased 
Hepatic enzyme increased 
Liver function test abnormal 
Liver function test increased 
Transaminases increased 
Hepatitis cholestatic 
15.4 Preferred Terms of Adverse Events Indicating WBC Count Decrease 
Agranulocytosis 
Bone marrow failure 
Bone marrow toxicity 
Febrile neutropenia 
Leukopenia 
Lymphopenia 
Neutropenia 
Pancytopenia 
Neutropenic sepsis 
Lymphocyte count decreased 
Neutrophil count decreased 
White blood cell count decreased 
15.5 Preferred Terms of Adverse Events Potentially Associated with Glucocorticoid-
Related Toxicity 
Blood and lymphatic system disorders 
Increased tendency to bruise 
 
Cardiac disorders 
Acute myocardial infarction 
Angina pectoris 
Cardiac failure 
Cardiovascular insufficiency 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 63 
Version Date:  28 October 2019 
Congestive cardiomyopathy 
Myocardial infarction 
Myocardial ischaemia 
 
Endocrine disorders 
Adrenal insufficiency 
Cushing's syndrome 
Cushingoid 
 
Eye disorders 
Cataract 
Cataract nuclear 
Glaucoma 
Ocular hypertension 
Open angle glaucoma 
Retinopathy hypertensive 
 
Gastrointestinal disorders 
Duodenal ulcer 
Gastritis 
Gastritis erosive 
Gastrointestinal disorder 
Pancreatitis 
Pancreatitis acute 
 
General disorders and administration site conditions 
Influenza like illness 
Oedema 
Oedema peripheral 
Peripheral swelling 
Systemic inflammatory response syndrome 
 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 64 
Version Date:  28 October 2019 
Infections and Infestations (for the main analysis, only serious infections will be included) 
Anal fungal infection 
Aspergillus infection 
Atypical pneumonia 
Bacteraemia 
Blister infected 
Body tinea 
Breast abscess 
Bronchiolitis 
Bronchitis 
Campylobacter gastroenteritis 
Candida infection 
Carbuncle 
Catheter site infection 
Cellulitis 
Chlamydial infection 
Clostridium difficile infection 
Conjunctivitis 
Conjunctivitis viral 
Cryptococcosis 
Cystitis 
Cytomegalovirus infection 
Dacryocystitis 
Device related infection 
Diarrhoea infectious 
Diverticulitis 
Ear infection 
Ear infection fungal 
Enteritis infectious 
Epstein-Barr virus infection 
Erysipelas 
Escherichia infection 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 65 
Version Date:  28 October 2019 
Escherichia urinary tract infection 
Eye infection 
Folliculitis 
Fungal infection 
Fungal skin infection 
Furuncle 
Fusobacterium infection 
Gastroenteritis 
Gastroenteritis viral 
Genital herpes 
Genitourinary tract infection 
Gingivitis 
Hepatitis B 
Herpes simplex 
Herpes zoster 
Hordeolum 
Infectious pleural effusion 
Influenza 
Laryngitis 
Latent tuberculosis 
Localised infection 
Lower respiratory tract infection 
Lower respiratory tract infection viral 
Lung infection 
Klebsiella test positive 
Meningitis 
Mucocutaneous candidiasis 
Nasopharyngitis 
Neutropenic sepsis 
Oesophageal candidiasis 
Ophthalmic herpes simplex 
Oral candidiasis 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 66 
Version Date:  28 October 2019 
Oral fungal infection 
Oral herpes 
Otitis externa 
Otitis media 
Otitis media acute 
Otitis media chronic 
Parainfluenzae virus infection 
Paronychia 
Periodontitis 
Pharyngitis 
Pharyngitis streptococcal 
Pneumonia 
Pneumonia bacterial 
Pneumonia cytomegaloviral 
Pneumonia haemophilus 
Post procedural infection 
Post procedural sepsis 
Pulpitis dental 
Pyuria 
Rash pustular 
Respiratory syncytial virus infection 
Respiratory tract infection 
Respiratory tract infection viral 
Sepsis 
Sinusitis 
Subcutaneous abscess 
Tinea cruris 
Tinea pedis 
Tinea versicolour 
Tongue fungal infection 
Tonsillitis 
Tooth abscess 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 67 
Version Date:  28 October 2019 
Tooth infection 
Tracheitis 
Upper respiratory tract infection 
Urethritis 
Urinary tract infection 
Urinary tract infection bacterial 
Urosepsis 
Varicella zoster virus infection 
Viral infection 
Viral rhinitis 
Viral sinusitis 
Viral upper respiratory tract infection 
Vulvovaginal candidiasis 
Vulvovaginal mycotic infection 
Vulvovaginitis 
Wound infection pseudomonas 
 
Injury, poisoning and procedural complications 
Hip fracture 
Humerus fracture 
Lower limb fracture 
Lumbar vertebral fracture 
Spinal compression fracture 
Tendon rupture 
Wrist fracture 
 
Investigations 
Blood cholesterol increased 
Blood glucose increased 
Blood potassium decreased 
Blood pressure increased 
Intraocular pressure increased 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 68 
Version Date:  28 October 2019 
Low density lipoprotein increased 
Waist circumference increased 
Weight increased 
 
Metabolism and nutrition disorders 
Central obesity 
Diabetes mellitus 
Diabetes mellitus inadequate control 
Dyslipidaemia 
Fluid retention 
Glucose tolerance impaired 
Hypercholesterolaemia 
Hyperglycaemia 
Hyperlipidaemia 
Hypertriglyceridaemia 
Hypervolaemia 
Hypokalaemia 
Type 2 diabetes mellitus 
 
Musculoskeletal and connective tissue disorders 
Muscle atrophy 
Muscular weakness 
Myopathy 
Osteonecrosis 
Osteopenia 
Osteoporosis 
 
Nervous system disorders 
Poor quality sleep 
 
Psychiatric disorders 
Affective disorder 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 69 
Version Date:  28 October 2019 
Agitation 
Anxiety 
Confusional state 
Depressed mood 
Depression 
Insomnia 
Irritability 
Libido decreased 
Major depression 
Mania 
Mental status changes 
Mood altered 
Nervousness 
 
Reproductive system and breast disorders 
Gynaecomastia 
Menorrhagia 
Metrorrhagia 
 
Skin and subcutaneous tissue disorders 
Acne 
Dermatitis acneiform 
Ecchymosis 
Hirsutism 
Skin atrophy 
Skin striae 
 
Vascular disorders 
Arteriosclerosis 
Hypertension 
Hypertensive emergency 
 


Statistical Analysis Plan 
 
Protocol Number: CL010_168 
Version Number: 2.0 
Page 70 
Version Date:  28 October 2019 
Preferred Terms may be clustered according to EULAR terms (defined below). 
Sponsor-defined GC-associated TEAE EULAR Terms and Cluster Designations 
Terms included in EULAR recommendations 
For analysis  
EULAR 
category/SOC 
EULAR event term 
Cluster designation  
Cardiovascular 
Dyslipidemia 
Dyslipidemia 
  
Edema 
Edema 
  
Ischemic CVD/atherosclerosis 
CVD 
Infectious 
Infections 
Infections 
Gastro-intestinal 
Peptic ulcer disease 
Peptic ulcer disease 
  
Pancreatitis 
Pancreatitis 
Psychological 
Mood disturbances 
Mood disturbance 
  
Psychosis 
Mood disturbance 
Endocrine, metabolic 
Diabetes/glucose intolerance 
Hyperglycemia 
  
Body weight and fat redistribution 
Body weight and fat redistribution 
  
Interference with hormone secretion 
Interference with hormone secretion 
Dermatological 
Skin atrophy 
Skin 
  
Acne, hirsutism, alopecia, bruisability 
Skin 
Musculoskeletal 
Osteoporosis 
Bone 
  
Osteonecrosis 
Bone 
  
Myopathy 
Myopathy 
Ophthalmological 
Cataract 
Ophthalmological 
  
Glaucoma (intra-ocular pressure) 
Ophthalmological